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Abstract 
Background: Multiple myeloma is an increasingly common disease, but there is little evidence 
about the change in symptoms and problems in more advanced stages. 
Aim: To describe the health-related quality of life (QOL) trajectories in multiple myeloma, and to 
evaluate the longitudinal validity of the Myeloma Patient Outcome Scale (MyPOS), a 
questionnaire to monitor QOL and palliative care concerns. 
Methods: A national, multi-centre, observational study comprising (1) a cross-sectional analysis 
merging data from two studies, and (2) a longitudinal study, recruiting patients at various stages 
of the disease. Demographic and clinical data was collected alongside QOL measures. Analysis: 
(i) prevalence of symptoms and independently associated factors with poor quality of life, (ii) 
latent growth mixture analysis of quality of life trajectories, (iii) longitudinal validity and 
reliability via Rasch analysis, Generalizability theory and responsiveness to change. 
Results: (i) Cross-sectional study: 557 patients reported a mean of 7.2 symptoms with the most 
common symptoms, pain, fatigue and breathlessness, being present in 61-78% of patients. 
General symptom level, pain, anxiety and depression, physical decline, age and phase of illness 
had significant independent associations with high palliative care concerns. 
(ii) Longitudinal study: Four classes of individual QOL trajectories were identified (n=224): 
declining HRQOL over 8 months, stable moderate to good QOL, improving QOL, and fluctuating 
poor QOL. Logistic regression analysis revealed general symptom level (OR = 1.28), pain 
(OR=1.03) and presence of clinically relevant anxiety or depression (OR=1.19) to be predictors 
for a declining or poor QOL trajectory. 
(iii) The MyPOS demonstrated good to excellent test-retest reliability. Rasch analysis identified 
limitations of suboptimal scale-to-sample targeting, resulting in floor effects. Responsiveness 
analysis yielded an MID of +2.5 for improvement and -4.5 for deterioration. 
Conclusions: People with myeloma have four main trajectories of QOL which can be predicted by 
symptoms and psychological concerns. These could be tested as triggers for additional palliative 
support. The MyPOS is a valid and reliable outcome measure to monitor these indicators in 
routine clinical practice. 
Table of contents 
- 4 - 
 
Table of contents 
 
Abstract ............................................................................................................................................ 2 
Table of contents .............................................................................................................................. 4 
List of tables ..................................................................................................................................... 8 
List of figures ................................................................................................................................... 9 
Acknowledgements ........................................................................................................................ 10 
Publications, presentations and other output .................................................................................. 11 
Research publications in peer review journals ....................................................................... 11 
Research presentations at scientific meetings ........................................................................ 12 
Published research abstract .................................................................................................... 13 
Other collaborations, contributions and output ...................................................................... 15 
Abbreviations ................................................................................................................................. 16 
1 Introduction ................................................................................................................................. 19 
2 Background ................................................................................................................................. 22 
2.1 Multiple myeloma ................................................................................................................ 22 
2.1.1 Epidemiology, clinical picture and disease course ........................................................ 22 
2.1.2 Palliative care and haematology .................................................................................... 25 
2.2 Quality of life and multiple myeloma .................................................................................. 33 
2.2.1 Definition and model of quality of life in multiple myeloma ....................................... 33 
2.2.2 Symptom burden and quality of life in multiple myeloma ........................................... 42 
2.2.3 Longitudinal assessment of quality of life in clinical practice .................................... 112 
2.2.4 Measurement of quality of life in multiple myeloma .................................................. 119 
2.3 Conclusions from the literature .......................................................................................... 122 
Table of contents 
- 5 - 
 
3 Aims and objectives .................................................................................................................. 124 
3.1 Aim .................................................................................................................................... 124 
3.2 Objectives .......................................................................................................................... 124 
4 Methods ..................................................................................................................................... 125 
4.1 Introduction ........................................................................................................................ 125 
4.2 Overview of study design and methodological considerations .......................................... 125 
4.3 Research questions and rationale for study phases ............................................................ 127 
4.3.1. Phase 1: Cross-sectional, secondary analysis ............................................................. 127 
4.3.2 Phase 2: Longitudinal analysis of the trajectory of quality of life in multiple myeloma
 .............................................................................................................................................. 132 
4.3.3 Phase 3: Regression analysis/prognostic model .......................................................... 140 
4.3.4 Phase 4: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale 
for individual patient-monitoring ......................................................................................... 142 
4.4 History of the study and development of the MyPOS ....................................................... 149 
4.5 Ethical issues ...................................................................................................................... 157 
4.5.1 Ethical approvals ......................................................................................................... 157 
4.5.2 Ethical considerations ................................................................................................. 158 
5 Results: The impact of symptoms and palliative care concerns on health-related quality of life in 
multiple myeloma: a multi-centre study ...................................................................................... 159 
6 Results: Longitudinal trajectories of quality of life in multiple myeloma and predictive factors
...................................................................................................................................................... 185 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS)
...................................................................................................................................................... 209 
8 Integration of findings and discussion ...................................................................................... 248 
8.1 Integration of findings ........................................................................................................ 248 
8.1.1 Symptom burden and trajectory of palliative care problems in multiple myeloma .... 249 
Table of contents 
- 6 - 
 
8.1.2 Risk factors for poor and deteriorating HRQOL in multiple myeloma ...................... 261 
8.1.3 Longitudinal validity and reliability of the MyPOS .................................................... 267 
8.1.4 Integration: Symptom burden, longitudinal changes of QOL and self-monitoring of 
quality of life in multiple myeloma ...................................................................................... 276 
8.2 Strengths and limitations of the study ................................................................................ 278 
8.2.1 Strengths and limitations relating to the secondary analysis ....................................... 278 
8.2.2 Strengths and limitations relating to the longitudinal study of changes of QOL ........ 279 
8.2.3 Strengths and limitations relating to the psychometric assessment of longitudinal 
validity and reliability .......................................................................................................... 287 
8.2.4 Ethical issues ............................................................................................................... 291 
8.3 Methodological contributions ............................................................................................ 292 
8.3.1 Recruitment and retention of participants in a longitudinal palliative care study ....... 292 
8.3.2 Latent growth mixture models for modelling heterogeneity in palliative care ........... 294 
8.3.3 Psychometrics for monitoring quality of life .............................................................. 298 
8.4 Clinical recommendations: Improving QOL assessment and palliative care involvement in 
multiple myeloma .................................................................................................................... 302 
8.4.1 The use of MyPOS in research .................................................................................... 302 
8.4.2 The clinical use of MyPOS (screening, assessment, monitoring) ............................... 304 
8.4.3 Recommendations for the integration of haematology and early palliative care 
involvement in the care of multiple myeloma ...................................................................... 312 
8.4.4 Training, resource and policy implications ................................................................. 319 
8.5 Areas for future research .................................................................................................... 322 
8.5.1 Further development of the MyPOS ........................................................................... 322 
8.5.2 Validation of the risk model and further observational research ................................ 325 
8.5.3 Using MyPOS to foster integration of haematological and palliative care in multiple 
myeloma ............................................................................................................................... 329 
Table of contents 
- 7 - 
 
8.6 Conclusion ......................................................................................................................... 337 
9 References ................................................................................................................................. 339 
10 Appendix A: Correspondence with the Research Ethics Committee: approvals and 
amendments ................................................................................................................................. 412 
11 Appendix B: Protocol for the study ........................................................................................ 432 
12 Appendix C: Ethical considerations in survey research .......................................................... 464 
13 Appendix D: Patient information sheet, consent forms .......................................................... 472 
Appendix D.1: Consent form, phase I ‘Pilot survey’ ........................................................... 472 
Appendix D.2: Consent form, Phase II ‘Patient Quality of Life Survey’ ............................ 474 
Appendix D.3: Consent form, phase II ‘Caregiver Quality of Life Survey’ ........................ 476 
Appendix D.4: Information leaflet, phase I ‘Pilot Quality of Life Survey’ ......................... 478 
Appendix D.5: Information leaflet, phase II ‘Patient Quality of Life Survey’ .................... 482 
Appendix D.6: Information leaflet, phase II ‘Caregiver Quality of Life Survey’ ................ 486 
14 Appendix E: Topic guide for piloting ..................................................................................... 490 
15 Appendix F: Questionnaire booklets ....................................................................................... 494 
Appendix F.1: Example questionnaire booklet from the Patient QOL Survey .................... 494 




List of tables 
- 8 - 
 
List of tables 
 
Table 1: Overview of prognostic factor studies of PROs in patients with haematological disease 
(based on (241)) ............................................................................................................................. 29 
Table 2: Longitudinal health-related QOL data in multiple myeloma (100%), (a) clinical trials, (b) 
stem cell transplantation samples (SCT), (c) observational studies. .............................................. 80 
Table 3: An overview of twelve systematic reviews of effectiveness of routine collection of PRO 
data ............................................................................................................................................... 113 
Table 4: Taxonomy of applications of PROs in clinical practice (taken from (38)) .................... 116 
Table 5: Overview of current initiatives using electronic patient-monitoring to support clinical 
oncological care (based on (453) and (454)). ............................................................................... 118 
Table 6: Comparison of the main myeloma-specific quality of life and symptom questionnaire 151 
Table 7: Comparison of prevalence of symptoms to MyPOS-reported prevalence* (point 
prevalence and 95% confidence intervals) ................................................................................... 251 
Table 8: Comparison of quality of life results from this study with existing studies (EORTC QLQ-
C30 instruments) .......................................................................................................................... 255 
Table 9: Comparison of the content and domain coverage of the main myeloma-specific quality of 
life and symptom questionnaires .................................................................................................. 268 
Table 10: Summary of hypotheses and results of longitudinal validity of the MyPOS ............... 272 
 
 
List of figures 
- 9 - 
 
List of figures 
 
Figure 1: Median survival according to age. Median overall survival in the group less than 65 
years of age was 42 months and 18 months in the group aged 65 years and older (65). ............... 23 
Figure 2: The Wilson & Cleary model of QOL (330) ................................................................... 36 
Figure 3: Modified version of the ICF model (taken from (333)) ................................................. 37 
Figure 4: Theoretical model of the QOL of people with multiple myeloma (357) ........................ 41 
Figure 6: Overview of the PhD study and integration of findings from different substudies ...... 126 
Figure 7: Overview of datasets used in the PhD project and outputs .......................................... 127 
Figure 8: Hypothesised growth model diagram for HRQOL changes over 8 months in patients 
with multiple myeloma. Square boxes: observed variables; circles: latent variables; directed lines: 
regression equations. .................................................................................................................... 139 
Figure 9: The original version of the Myeloma Patient Outcome Scale (MyPOS) before it was 
adapted to the IPOS format. All questions are preceded by “Over the past week…”. ................ 154 
Figure 10: The modified version of the MyPOS after adaptation to the IPOS format. ................ 155 
Figure 11: Norm comparison of QOL and symptom data from this study to the general and cancer 
population .................................................................................................................................... 253 
Figure 12: Overview of the PhD research study and integration of findings from different sub-
studies .......................................................................................................................................... 277 
Figure 13: Research opportunities of generalist and specialist palliative care in multiple myeloma 




- 10 - 
 
Acknowledgements 
My supervisors, Professor Irene Higginson, Dr Gao Wei and Professor Richard Siegert, have 
provided ongoing and invaluable support throughout my PhD. I am grateful for their excellent 
advice and encouragement over the last years. They challenged me in discussions, helped me to 
understand what this study is about and inspired my learning. 
I would also like to acknowledge and thank all the study nurses that helped with recruitment and 
data collection. In particular, I would like to thank Susanne de Wolf-Linder, Param Kaler and the 
late Caty Pannell. Without their efforts and continuing practical support recruiting patients and 
their family members would not have been possible. This study was supported by multiple sites 
throughout England and it is thanks to the numerous research nurses in those centres that many 
participants completed questionnaires and continued with the study. In particular I would like to 
mention Marilyn Tegon and Victoria Drew from the Bradford Royal Infirmary, Annette Fleet, 
Katy Parkes and Sara Hathaway from Burton Hospital, Nikki Evans, Tommy Brown, Janet 
Pinfield and Terri Burchett from Epsom Hospital, Jean Taylor, Lorna Dewar and Tina Hickey 
from Colchester Hospital, Rebecca Burt, Catherine Gibson and Jill Lindsey from Coventry 
University Hospital, Mary Everett and Alison Richards from Medway Hospital (who obtained the 
fastest Research & Development approval possible), Charlotte Mountain and Helen Preston from 
the Mid Yorkshire Hospital NHS Trust, Samantha Weller and Tania West from East Surrey 
Hospital, Christopher Gray from the Royal Free Hospital in London, and finally Yvette Ibbotson 
and Nicola Lunt from Macclesfield District General Hospital. 
I would also like to thank my colleagues on the project and at the Cicely Saunders Institute, 
particularly Clare Ellis-Smith, Pauline Kane, Marsha Dawkins, Joanna Davies, Clare Pearson, 
Barb Daveson, Fliss Murtagh, Claudia Bausewein, Catherine Evans and Tom Osborne for their 
support, advice and friendship. Some of them provided me with a home, a piano or breakfast.  
My thanks also go to the funders of this PhD study, Myeloma UK and St Christopher’s Hospice, 
London. They were inspired by the goal to improve the quality of life of myeloma patients and 
helped us to move forward into new areas. I want to thank all the participants in this study for 
their time and patience. Many have died meanwhile. I hope that the results of this study will help 
improve the care for patients with multiple myeloma in the future. 
This PhD would not have been possible without the ongoing love and encouragement of my 
family and friends who understood that going to England was the best opportunity of my life. My 
thanks go especially to my family, to Helen and Alex, Judith and Sebastian, and my partner Jakob 
Georg Heller. While being in England I lost both my grandparents and this PhD is dedicated to 
them. 
Publications, presentations and other output 
- 11 - 
 
 
Publications, presentations and other output 
 
Research publications in peer review journals 
Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. Prevalence 
of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. European 
Journal of Haematology 2016; 97(5): 416-429. 
Ramsenthaler C, Osborne TR, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. The 
impact of disease-related symptoms and palliative care concerns on health-related quality of life 
in multiple myeloma: a multi-centre study. BMC Cancer 2016; 16: 427. 
Schildmann EK, Groeneveld EI, Denzel J, Brown A, Bernhardt F, Bailey K, Guo P, 
Ramsenthaler C, Lovell N, Higginson IJ, Bausewein C, Murtagh FE. Discovering the hidden 
benefits of cognitive interviewing in two languages: the first phase of a validation study of the 
Integrated Palliative care Outcome Scale. Palliative Medicine 2016; 30(6): 599-610. 
Osborne TR, Ramsenthaler C, Schey SA, Siegert RJ, Edmonds PM, Higginson IJ. Improving the 
assessment of quality of life in the clinical care of myeloma patients: the development and 
validation of the Myeloma Patient Outcome Scale (MyPOS). BMC Cancer 2015; 15: 280. 
Osborne TR, Ramsenthaler C, de Wolf-Linder S, Schey SA. Siegert RJ, Edmonds PM, 
Higginson IJ. Understanding what matters most to people with multiple myeloma: a qualitative 
study of views on quality of life. BMC Cancer 2014; 14: 496. 
Daveson BA, Alonso JP, Calanzani N, Ramsenthaler C, Gysels M, Antunes B, Moens K, 
Groeneveld EI, Albers G, Finetti S, Pettenati F, Bausewein C, Higginson IJ, Harding R, Deliens 
L, Toscani F, Ferreira PL, Ceulemans L, Gomes B; PRISMA. Learning from the public: citizens 
describe the need to improve end-of-life care access, provision and recognition across Europe. 
European Journal of Public Health 2014; 24(3): 521-527.  
Simon ST, Bausewein C, Schildmann E, Higginson IJ, Magnussen H, Scheve C, Ramsenthaler 
C. Episodic breathlessness in patients with advanced disease: a systematic review. Journal of Pain 
& Symptom Management 2012; 45(3): 561-578.  
Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. What issues 
matter most to people with multiple myeloma and how well are we measuring them? A systematic 
review of quality of life tools. European Journal of Haematology 2012; 89(6): 437-457. 
Publications, presentations and other output 
- 12 - 
 
Simon ST, Ramsenthaler C, Bausewein C, Krischke N, Geiss G. Core attitudes of professionals 
in palliative care: a qualitative study. International Journal of Palliative Nursing 2009; 15(8): 405-
411. 
 
Research presentations at scientific meetings 
Ramsenthaler C, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. General symptom 
level, pain and anxiety predict declining health-related quality of life in multiple myeloma: a 
prospective, multi-centre longitudinal study. Palliative medicine 2016; 30(6): NP13. Presentation 
at the 9th World Research Congress of the European Association for Palliative Care, Dublin, 9 – 
11 June 2016. 
Ramsenthaler C, Pannell C, Kaler P, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. 
Symptoms and quality of life in multiple myeloma – a longitudinal study. Presentation at the 
National Cancer Research International Conference, Liverpool, 1 – 4 November 2015. 
Ramsenthaler C, Osborne TR, de Wolf-Linder S, Siegert RJ, Wei G, Edmonds PM, Schey SA, 
Higginson IJ. The Myeloma Patient Outcome Scale (MyPOS) – Longitudinal validity and 
reliability of a measure of quality of life for clinical use in patients with multiple myeloma. 
European Journal of Palliative Care 2015; 22: 19. Plenary talk at the 14th World Congress of the 
European Association of Palliative Care, Copenhagen, 8 – 10 May 2015.  
Osborne TR, Ramsenthaler C, de Wolf-Linder S, Pannell C, Siegert RJ, Edmonds PM, 
Higginson IJ. Development and validation of the Myeloma Patient Outcome Scale (MyPOS): A 
quality of life questionnaire for use in the clinical care of people with multiple myeloma. Quality 
of Life Research 2014; 23: 39. Presentation held at the 21st Congress of the International Society 
for Quality of Life Research, Berlin, 15 – 18 October 2014. 
Ramsenthaler C, Osborne TR, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. Quality of life 
in multiple myeloma. Presentation held at the Myeloma Patient Information Day & Conference, 
London 2013. 
Ramsenthaler C, Siegert RJ, Weatherall M, Bausewein C, Koffman J, Higginson IJ. Cognitive 
behavioural therapy (CBT) for panic and anxiety in chronic obstructive pulmonary disease - A 
systematic review. Palliative Medicine 2012; 26(6): OA29. Presentation at the 7th World Research 
Congress of the European Association of Palliative Care Conference, Trondheim, 7 – 9 June 
2012. 
 
Publications, presentations and other output 
- 13 - 
 
Ramsenthaler C, Geiss-Mayer G, Bausewein C, Simon ST. Core attitudes in palliative care: 
acceptance as the key element. Palliative Medicine 2010; 24(6): S35. Presentation at the 6th World 
Research Congress of the European Association of Palliative Care Conference, Glasgow, 10 – 12 
June 2010. 
 
Published research abstract 
Murtagh FEM, Ramsenthaler C, Firth A, Groeneveld E, Lovell N, Simon S, Denzel J, Bernhardt 
F, Schildmann E, Bausewein C, Higginson IJ. A brief, patient- and proxy-reported outcome 
measure for the adult palliative care population: validity and reliability of the Integrated Palliative 
Outcome Scale (IPOS). Palliative Medicine 2016; 30(6): NP11. 9th World Research Congress of 
the European Association for Palliative Care, Dublin, 9 – 11 June 2016 
Firth AM, Guo P, Groeneveld EI, Ramsenthaler C, Lovell N, Higginson IJ, Murtagh, FEM. Do 
palliative care patients and staff report the same main problems and concerns? A textual analysis 
of the opening questions on the Integrated Palliative care Outcome Scale (IPOS). Palliative 
Medicine 2016; 30(6): NP106. 9th World Research Congress of the European Association for 
Palliative Care, Dublin, 9 – 11 June 2016 
Ramsenthaler C, Siegert RJ, Gao W, Edmonds PM, Schey SA, Higginson IJ. Symptoms, quality 
of life and health care utilisation in multiple myeloma – a longitudinal study of predictive 
demographic and clinical factors. 20th Congress of the European Haematology Conference 
Vienna, 11 – 14 June 2015. Abstract number E1426. 
Ramsenthaler C, Osborne TR, de Wolf-Linder S, Pannell C, Kaler P, Siegert RJ, Gao W, 
Edmonds PM, Schey SA, Higginson IJ. Symptom prevalence, palliative care needs, and quality of 
life in multiple myeloma – a multicentre, cross-sectional study. European Journal of Palliative 
Care 2015; 22: P1-059. 14th World Congress of the European Association of Palliative Care, 
Copenhagen, 8 – 10 May 2015. 
Schildmann EK, Groeneveld I, Denzel J, Brown A, Bernhardt F, Bailey K, Guo P, Ramsenthaler 
C, Higginson IJ, Bausewein C, Murtagh FEM. Discovering the hidden benefits of cognitive 
interviewing in two languages: the first phase of a validation study of the Integrated Palliative 
Care Outcome Scale (IPOS). European Journal of Palliative Care 2015; 22: P1-062. 14th World 
Congress of the European Association of Palliative Care, Copenhagen, 8 – 10 May 2015. 
Publications, presentations and other output 
- 14 - 
 
Halley A, Ramsenthaler C. Is Gabapentin effective for uraemic pruritus? A systematic review. 
European Journal of Palliative Care 2015; 22: P1-035. 14th World Congress of the European 
Association of Palliative Care, Copenhagen, 8 – 10 May 2015. 
Ramsenthaler C, Kane PM, Siegert RJ, Gao W, Edmonds PM, Schey SA, Higginson IJ. 
Symptoms and biomedical factors in multiple myeloma – a systematic review and metaanalysis. 
Quality of Life Research 2014; 23: 67. 21st Congress of the International Society for Quality of 
Life Research, Berlin, 15 – 18 October 2014. 
Ramsenthaler C, Kane PM, Siegert RJ, Gao W, Edmonds PM, Schey SA, Higginson IJ. 
Symptoms and biomedical factors show who is at risk of poor quality of life and high cost in 
multiple myeloma. Journal of Palliative Care 2014; 30: 3. 20th International Congress on Palliative 
Care, Montréal, 9 – 12 September 2014. 
Ramsenthaler C, Osborne TR, de Wolf-Linder S, Siegert RJ, Wei G, Edmonds PM, Schey SA, 
Higginson IJ. Who is at risk of experiencing poor quality of life and high palliative care needs in 
multiple myeloma? Journal of Palliative Care 2014; 30: 3. 20th International Congress on 
Palliative Care, Montréal, 9 – 12 September 2014. 
Osborne TR, Ramsenthaler C, de Wolf-Linder S, Siegert RJ, Wei G, Edmonds PM, Schey SA, 
Higginson IJ. (2014). Development and validation of the Myeloma Patient Outcome Scale 
(MyPOS): a questionnaire to assess physical, psychological and health care palliative care needs 
for use in the clinical care of people with multiple myeloma. Journal of Palliative Care 2014; 30: 
3. 20th International Congress on Palliative Care, Montréal, 9 – 12 September 2014. 
Ramsenthaler C, Kane PM, Siegert RJ, Gao W, Edmonds PM, Schey SA, Higginson IJ. (2014). 
What are predictors of health-related quality of life and cost in multiple myeloma? A systematic 
review and meta-analysis. Palliative Medicine 2014; 28(6): 631. 8th World Research Congress of 
the European Association of Palliative Care, Lleida, 5 – 7 June 2014. 
Wolf-Linder S, Koffman J, Ramsenthaler C. Does erythropoietin improve cognitive symptoms 
in patients with cancer? A systematic review. Palliative Medicine 2014; 28(6): 595. 8th World 
Research Congress of the European Association of Palliative Care, Lleida, 5 – 7 June 2014. 
Ramsenthaler C, Bausewein C, Schildmann EK, Higginson IJ, Magnussen H, Scheve C, Simon 
ST. Experiences and characteristics of episodic breathlessness (EB) in patients with advanced 
disease - a systematic review. Palliative Medicine 2012; 26(6): P270. 7th World Research 
Congress of the European Association of Palliative Care Conference, Trondheim, 7 – 9 June 
2012. 
Publications, presentations and other output 
- 15 - 
 
Osborne TR, Ramsenthaler C, Higginson IJ. What is important to the quality of life of people 
with multiple myeloma? Implications for the design of quality of life questionnaires. Journal of 
Epidemiology and Community Health 2012; 66(Suppl1): A54. 56th Annual Scientific Meeting of 
the Society for Social Medicine, London, 12 – 14 September 2012. 
Ramsenthaler C, Scheve C, Bausewein C, Simon ST. Typical crises and needs in patients with 
advanced chronic obstructive pulmonary disease (COPD) or lung cancer in their last year of life – 
a literature scoping exercise. European Journal of Palliative Care 2011; 18: P 169. 12th Congress 
of the European Association for Palliative Care, Lisbon, 18 – 21 May 2011. 
Ramsenthaler C, Siegert RJ, Higginson IJ. A checklist for reporting factor analysis in palliative 
care research. COMPASS Collaborative Annual Scientific Meeting, Edinburgh, 14th April 2011. 
Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. Health related 
quality of life instruments for use in people with multiple myeloma: a systematic literature review. 
Haematologica 2011; 96(Suppl 2): 366. 16th Congress of the European Haematology Association, 
London, 9 – 12 June 2011. 
Ramsenthaler C, Geiss-Mayer G, Bausewein C, Simon ST. How to teach and learn core attitudes 
in palliative care. Palliative Medicine 2010; 24(6): S146. 6th World Research Congress of the 
European Association of Palliative Care Conference, Glasgow, 10 – 12 June 2010. 
Ramsenthaler C, Geiss G, Krischke N, Bausewein C, Simon ST. Core attitudes in different 
working fields. European Journal of Palliative Care 2009; 16: 201. 11th Congress of the European 
Association for Palliative Care, Vienna, 7 – 10 May 2010. 
Ramsenthaler C, Geiss G, Krischke N, Bausewein C, Simon ST. Definition and elements of core 
attitude in palliative care. European Journal of Palliative Care 2009; 16: 201. 11th Congress of the 
European Association for Palliative Care, Vienna, 7 – 10 May 2010. 
Simon ST, Ramsenthaler C, Geiss G. Basic attitudes of professionals in palliative care. Palliative 
Medicine 2008; 22(6): 548. 5th Research Congress of the European Association for Palliative 
Care, Dublin, 2008. 
 
Other collaborations, contributions and output 
Conference “Quality of life in multiple myeloma: recent international research and future 




- 16 - 
 
Abbreviations 
ANCOVA Analysis of covariance 
ANOVA Analysis of variance 
APCA African Palliative Care Association 
ASCT Autologous stem cell transplantation 
AUC Area under the curve 
CAT Computer-adaptive testing 
CI Confidence interval 
CML Chronic myeloid leukemia 
COSMIN Consensus-based standards for the selection of health status measurement 
instruments 
CRP C-reactive protein 
CSRI Client Services Receipt Inventory  
CTT Classical test theory 
DIF Differential item functioning 
ECOG Eastern Co-operative Oncology Group 
EMA European Medicines Agency 
EOL End-of-life care 
EORTC European Organization for the Research and Treatment of Cancer 
EQ-5D EuroQOL 5D 
ESAS Edmonton Symptom Assessment Scale 
FACT Functional Assessment of Cancer Therapy 
FDA Food and Drug Administration 
GEE Generalised estimating equations 
Abbreviations 
- 17 - 
 
GMM Growth mixture modelling 
GT Generalizability theory 
HADS Hospital Anxiety and Depression Scale 
HIV Human immunodeficiency virus 
HRQOL Health-related quality of life 
HSCT Haematopoietic stem cell transplantation 
ICF International Classification of Functioning, Disability and Health 
IG Immunoglobulin 
IL Interleukin 
IRT Item response theory 
ISOQOL International Society for Quality of Life Research 
LGCA Latent growth curve analysis 
MDASI M.D. Anderson Symptom Inventory 
MDS Myelodysplastic syndrome 
MDT Multi-disciplinary team 
MGUS Monoclonal gammopathy of unknown significance 
MID Minimally important difference 
MM Multiple myeloma 
MNAR Missing not at random 
MyPOS Myeloma Patient Outcome Scale 
NCCN National Comprehensive Cancer Center 
NHS National Health Service 
NICE National Institute of Clinical Excellence 
POS Palliative care Outcome Scale 
Abbreviations 
- 18 - 
 
PRO Patient-reported outcome 
PROMIS Patient-Reported Outcomes Measurement Information System 
QOL Quality of life 
RCT Randomised controlled trial 
RMSEA Root mean square error of approximation 
SCT Stem cell transplantation 
SEIQOL Schedule for the Evaluation of Individual Quality of Life 
SMM Smouldering myeloma 
SPC Specialist palliative care 
STAS Support Team Assessment Schedule 
TNF Tumour necrosis factor 
UK United Kingdom 










This study seeks to understand and compare the individual quality of life (QOL) and symptom 
trajectories of people with multiple myeloma over time and to explore the utility and acceptability 
of routine monitoring of QOL in this patient group. 
In the past 40 years, QOL has evolved as a construct that is used frequently as an endpoint in 
health services research (1), to evaluate the effectiveness of treatments and therapies, to guide 
patient-centred clinical care (2) and to help decision-makers in allocating resources (3). 
Particularly in oncology and haematology, where therapies such as bone marrow transplantation, 
chemotherapy, surgery and radiation can have lasting powerful and toxic effects on patients’ 
health, the study of QOL allows gauging the impact of the disease, treatment and side effects on 
the individual’s wellbeing. Multiple myeloma, an incurable cancer of the bone marrow, is 
characterised by pathological proliferation of monoclonal plasma cells leading to anaemia and 
marrow failure (4). It is currently the third most common haematological malignancy (5,6) with 
4,672 new cases diagnosed in the United Kingdom each year (7). As such, its impact on mortality 
and morbidity is high with an estimated average of 30 years of life lost in patients aged ≤65 (8). 
There is evidence that myeloma patients suffer from more symptoms and problems than patients 
with other haematological cancers (9). In addition, myeloma inflicts a high economic burden on 
individuals and society. Although it accounts for only a small percentage of all cancer types, cost 
for treating and managing the condition are among the highest compared to all cancers (10-13). 
As a consequence, measuring QOL alongside other patient-reported outcomes (PROs) in 
myeloma can help determine whether interventions and treatments are tolerable, acceptable, 
clinically beneficial and economically effective.  
Information on QOL not only helps in determining the effectiveness of interventions and bringing 
the patient perspective into clinical and health research, it also has prognostic value and therefore 
helps to identify those at risk of developing future adverse outcomes such as treatment failure or 
death. Prognostic indicators help inform patients and doctors about the future course of the 
disease, especially about the risk of deterioration, and can help select those patients in need for 
treatment or supportive care (14). The prognostic value of health-related quality of life (HRQOL) 
for predicting survival has been shown in cancer (15-18), as well as chronic and life-limiting 
conditions, such as heart failure (19), HIV (20) and chronic kidney disease (21). Recently, the 
prognostic value of QOL in myeloma has been demonstrated in two studies (22,23). Dubois and 
co-authors (2006) (23) reported that quality of life changed consistently with the clinical response 
that patients experienced to bortezomib treatment and that a model of fatigue together with more 
traditional predictors like clinical toxicity, albumin and platelet count was able to predict survival. 
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Strasser-Weipl and Ludwig (2008) (22) demonstrated the prognostic power of psychosocial QOL 
for survival.  
Despite the value that health-related QOL has demonstrated as an outcome, it is still rarely used in 
multiple myeloma. A recent systematic review found only 15 clinical trials that incorporated QOL 
as an endpoint (24). The main outcomes are response to treatment, time to progression, 
progression-free survival, duration of response, and overall survival (25,26). Despite myeloma 
being an incurable disease that places a high burden on patients and the health care system, and 
despite the existence of guidelines for supporting care (27) and guidelines for the use of PROs in 
haematology (28), PROs play a minor role in research and clinical practice. 
One reason why QOL assessment is not used is that its added value for clinical practice has not 
yet been shown. This might be partly due to the fact that good quality information on how QOL 
develops throughout the disease trajectory is scarce. To date, only a handful of studies have 
measured QOL at several points in the myeloma trajectory (23, 29-36). These studies usually 
focus on people that participate in treatment studies of novel chemotherapeutical agents or bone 
marrow transplantation. Most of these studies are cross-sectional in nature. HRQOL is measured 
only at one point in time before, during or after treatment (30,32,34,36). Follow-up is usually 
limited. Not all people with myeloma are eligible for these treatments. Thus, these studies do not 
yield representative results. No study to date has looked at the impact of the advanced stages on 
people’s well-being and needs. 
The second reason why HRQOL measures are not used in clinical practice might lie in the fact 
that most questionnaires measuring this construct have been developed for research. Overly long 
measures with results that are hard to interpret for patients and clinicians hinder clinical 
applicability. Recent initiatives have focused on presenting information from QOL measures to 
clinicians and measuring the impact on communication in the clinical encounter (37). This has 
shown limited results. One avenue that remains under-explored is directly providing patients with 
the information from these measures via self-monitoring. It has been suggested that this could 
help patient empowerment (38). Some studies have explored the effectiveness of self-monitoring 
for detecting adverse effects of chemotherapy and problems in patients with lung cancer, prostate 
cancer or cancer survivors (39-44). However, it is not well understood how best to aid self-
monitoring, how to feedback information in an appropriate way (39), and what measurement 
characteristics items need to have in order to allow tracking of individual changes.  
Therefore, this study aims to address both gaps that have been identified – following a natural 
sample of patients with multiple myeloma at various stages of the disease over time to describe 
the trajectory of symptoms, psychological distress and HRQOL over time and during the 
advanced stages of the disease. It aims at identifying predictors for poor HRQOL to help target 
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services at those at risk of developing these adverse outcomes. The study will also explore which 
items perform well in monitoring individual changes in QOL and thus inform which measures can 








2.1 Multiple myeloma 
2.1.1 Epidemiology, clinical picture and disease course 
Multiple myeloma is an incurable malignant type of bone marrow cancer arising from plasma cells, 
which form part of the immune system. In multiple myeloma these plasma cells become abnormal, 
proliferate and release only one type of paraprotein (usually immunoglobulin IgG, IgA, IgD, IgE) (45). 
IgG is present in 60% of cases, IgA in 20-25% and free light chain disease in 15-20% (4). Detecting 
this monoclonal immunoglobulin (M-potein) in the serum or urine usually leads to the diagnosis of the 
disease. The subtype free light chain disease is characterised by paraproteins accumulating in the 
kidneys, which causes kidney failure. The clinical features of the disease are in part determined by the 
rate of accumulation and the properties of the abnormal cells that are expressed (46,47). Myeloma 
belongs to the group of cancers known as plasma cell dycrasias, a heterogeneous group consisting of 
plasma cell leukemia, solitary plasmacytoma, chronic lymphocytic leukemia, malignant lymphoma, 
primary amyloidosis and others. Almost all multiple myelomas evolve from an asymptomatic pre-
malignant phase, referred to as monoclonal gammopathy (MGUS) (48), or a more advanced 
premalignant stage known as smouldering myeloma (SMM) (49). MGUS and SMM progress to 
myeloma at a rate of 1% (50,51) to 10% (52) per year, respectively. 
Multiple myeloma has unique features which sets this disease aside from other conditions. Myeloma 
usually presents with osteolytic bone lesions and their complications. Bone disease (destruction and 
remodelling) and bone pain are major causes of morbidity (53). Bone destruction may lead to 
hypercalcaemia and renal insufficiency. Other major clinical manifestations are anaemia and an 
increased risk of infection (54). Infection is the most common cause of death in this group. Treatment 
and management focuses on addressing these features and problems. 
Multiple myeloma is currently the third most common haematological malignancy in the UK (5,6,55) 
and accounts for 1% of all cancers (56,57). Each year 4,672 cases are newly diagnosed. Incidence 
rates remain stable with 6.9 per 100,000 new cases in men and 4.5 per 100,000 cases in women (58). 
Nonetheless, there are more people living with myeloma which is related to the ageing of the 
population in recent years (59). The disease is more common in older age groups and age is considered 
a risk factor for the development of the disease (58). This has shifted the median age at diagnosis from 
70 to 74 years (59,60). The disease is almost twice as common in Black African and Caribbean 
patients as in White patients (i.e. incidence rate of 13.1 per 100,000 in Black African men versus 6.7 
per 100,000 in Caucasian men (58)). 
Median survival has improved considerably in recent years with the introduction of high dose 




5 years for younger patients and 18 months for patients aged 65 and older (45). This is because new 
treatment options (such as autologous stem cell transplantation (ASCT) which can result in a 
temporary complete response and prolong survival) mostly benefit younger patients (≤65 years) (8). 
Phekoo et al. (2004) (65) demonstrated differential survival rates for patients for those younger and 
older than 65 years in a population study in the South Thames region, using data from the Thames 
Cancer registry. They found a statistically significant difference of 24 months between these two age 
groups (see Figure 1, reprinted from (65)). The authors concluded that in order to improve survival 
and outcomes for patients diagnosed with multiple myeloma, treatment options and adequate planning 
of health care services needs to take into account the different profile of these patients, with added risk 
of complications arising from treatment and comorbidities (65). 
 
Figure 1: Median survival according to age. Median overall survival in the group less than 65 
years of age was 42 months and 18 months in the group aged 65 years and older (65). 
 
The general goals of treatment include disease control, halting or reversing complications, extending 
survival and maintaining QOL (67-69). The extension of median survival time in multiple myeloma 
seen in recent years is largely attributed to more targeted therapies that result in a longer period of 
stable disease for patients, across all phases of treatment (70). Treatment approaches differ according 
to the group of active disease that the patient is experiencing. There are three categories: newly 
diagnosed (NDMM), stem cell transplant (SCT) and relapsed or refractory disease (RRMM) patients 
(71). Autologous stem cell transplant (ASCT), either in NDMM or as salvage therapy after relapse, is 
still the standard of care and first-line treatment for those under the age 65 (71,72). Increasingly, older 




(62). In ASCT treatment, patients receive induction therapy with either single or combination therapy 
of anti-myeloma agents, followed by maintenance therapy to prolong the period of complete or partial 
response (73-76). Especially lenalidomide maintenance has been shown to improve progression-free 
survival in younger (77,78) and elderly patients (79). The same is true for bortezomib (80). However, 
none of these strategies are recommended universally and therapy-related short-term and long-term 
side effects can curtail the length of maintenance regimens for patients (76,81). Transplant-ineligible 
patients receive combination therapy, consisting of 2-, 3- or 4-drug regimens usually containing 
melphalan and/or cyclophosphamide plus thalidomide or the new-generation drugs lenalidomide or 
pomalidomide (75,77,78,82). Disease response to these regimens is usually below that for transplant-
eligible patients (66). For RRMM, most second-line and third-line combination chemotherapies are 
used until the refractory disease stage is reached. The choice of treatment is based on comorbidity 
profile, age, persisting toxicities from previous treatments and regimen-related toxicities (71). In 
general, at first relapse 40-82% of patients achieve a response and half of these will enter a second 
plateau phase. With each subsequent relapse, further lines of treatment have a lower chance of 
inducing remissions and the treatment-free interval will be shorter for patients (71). The duration of 
the treatment-free interval has been shown to affect QOL in patients with multiple myeloma (83).  
Overall, the clinical picture together with the debilitating effects of various treatments show that QOL 
should be of primary concern to haematologists and their patients, especially given that multiple 
myeloma is still an incurable disease. Typical chemotherapy-related, short-term side effects entail 
nausea, vomiting, anorexia and diarrhoea (84,85), leukopenia resulting in general myelosuppression 
and immunosuppression with a large impact on social life and functioning in patients (84,85). 
Combined 3- or 4-drug regimens in particular yield more toxic effects than single agents (86-89). 
Some of these, particularly fatigue, anaemia, mood disorders and peripheral neuropathy, can have 
long-lasting effects on the patient’s QOL (88). Although supportive care is a major part of treatment 
guidelines for multiple myeloma, supportive care needs in this population have traditionally not 
received enough attention, with depression and anxiety being undertreated (34,90) and fatigue, pain 
and nutritional problems only treated episodically (91-93). Supportive care has been defined as the 
multi-professional attention to the individual’s multi-dimensional needs that should be available to all 
patients regardless of stage of illness or intention of treatment (94). 
The focus of supportive care offered, however, seems to be narrower. The scope of therapies ranges 
from administration of simple drugs (e.g. bisphosphonates) to full, multi-professional survivorship 
care (94). In multiple myeloma, mostly the treatment of specific disease- and treatment-related 
complications is seen within the scope of supportive care. In guidelines, medication and surgery 
treatment for bone disease, infection, anaemia, thrombosis, polyneuropathy and pain as well as renal 
and cardiovascular toxicity is listed under supportive care (75,95). The 2011 UK guidelines as well as 




side effects using a mechanism-based, pharmacological approach, with a brief mentioning of non-drug 
methods (27,96,97). However, optimal comprehensive care in myeloma needs to consider the wider 
problems and impact that disease and treatment have on patients and their families, to improve the 
awareness and appreciation of HRQOL in both active and inactive disease (71).  
Routine systematic assessment can help to monitor holistic needs. Although some of these approaches 
gradually play a more important role, current supportive needs assessment is confined to early 
myeloma stages (usually when patients enter their first treatment-free interval) (27,71). This might 
explain the generally low provision of palliative care in this population. This situation is also reflected 
in findings from studies that contrasted physicians’ beliefs about patients’ preferences regarding 
myeloma treatment with patient views (98,99). In one study, physician- rated mobility, side effects and 
effectiveness of treatment as the three most important attributes they thought that patients would value 
when making treatment decisions. This contrasted with patients’ opinions who valued breaks in 
therapy over side effects and mobility. For patients, particularly periods of not having to think of the 
disease and therapies allowing them to lead a normal life with as little side effects as possible were 
chosen as most important attributes of therapy in MM (98). Aside from poor communication and a 
narrow focus of supportive care approaches, there are several other reasons why myeloma patients 
underuse palliative care services. 
 
2.1.2 Palliative care and haematology 
Despite significant advances in the treatment of multiple myeloma and other haematological 
malignancies in recent years, cancers like myeloma remain incurable with patients dying either from 
the disease, its complications or its treatment. Despite all myeloma therapy being considered palliative 
to an extent (95,100), the needs of these patients at the end of life and particularly in the dying phase 
have not been described. The bulk of epidemiological studies suggests that these patients do not 
receive specialist palliative care (SPC) services at the end of life (101,104). In order to create an 
interface between palliative care and haematological care, it is necessary to first identify and 
understand the barriers concerning access and receipt of palliative care services. This will allow 
recommendations regarding appropriate interventions to achieve a better integration (105). 
Population trends in recent years have resulted in an increase in the number of people living with 
advanced, often multi-morbid disease in need of palliative care (106,107). The scale of the challenge 
requires system-level changes (108-110). This has led to a progressive increase of home palliative care 
programmes and other services (111), partly to achieve cost-effective end-of-life care outside the 
hospital (112) and partly meeting the preferences for dying at home (113,114). This population trend 
is also observed in those haematological malignancies mainly afflicting the elderly. Multiple myeloma 




referrals of haematological cancer patients to SPC services (115), the vast majority of studies point 
towards haematology patients remaining a distinct group in the hospital setting, with a high level of 
aggressiveness of care in the final days of life, increased use of technology and restricted carer access 
(101-103,116-121). Patients die on acute wards or in intensive care units (105,122,123). If referrals to 
palliative care occur, they do so very late in the illness trajectory (124-129). Furthermore, despite more 
than half of adult haematological patients eventually dying from their disease (130), palliative care and 
its role is poorly understood and integrated in this setting, partly due to the lack of evidence regarding 
the specific unmet palliative care needs in this group of patients (131-134). 
In summary, studies demonstrate a lack of early and honest discussions regarding preferred place of 
death and dying, inadequate care of prevalent symptoms and problems, and high levels of patient and 
family distress (135). Already in 2003, the Nationale Institute for Clinical Excellence recommended 
the integration of palliative care and haematological services, as did other organisations (104,136,137). 
Possible factors that account for shortcomings of care at the end of life have been identified in few 
qualitative studies from Australia and the United States (102,138,139). Multiple patient-related, 
clinician-related and system barriers exist (125,129,140). Main barriers to introducing specialist 
palliative care at the patient level include a perceived lack of palliative care needs among patients, the 
potential for cure or life prolongation and heightened expectations regarding treatment outcomes. 
Also, uncertainty and rapid disease trajectories in which a clear end-of-life phase cannot be easily 
recognised result in a lack of prognostic models to indicate appropriateness of palliative care 
(103,139,141-143). Clinician-related barriers comprise low acceptability of palliative care, the stigma 
associated with palliative care or equating palliative care with end of life care, thereby using an 
inflexible model of curative versus palliative care, and lack of palliative care skills (103,139,141-144). 
System-level barriers include general funding shortages, organisation of care that precludes integration 
and the lack of randomised controlled trials to support early integration for patients with 
haematological malignancies (103,139,141-144). In the following chapters, five barriers will be 
discussed in depth.  
 
2.1.2.1 Illness trajectory and characteristics of deaths in haematological malignancy 
Haematological cancers are a unique and heterogeneous group with considerable variability in disease 
characteristics, features, and treatment pathways and outcomes (136). The WHO recognises over 60 
different pathological subtypes (145). Especially the course of disease can vary widely, from 
aggressive and short trajectories to more chronic forms with frequent relapses requiring active 
treatment and management over a number of years (136). Even in the advanced haematological cancer 
population there is heterogeneity with profiles ranging from independent, ambulatory patients to those 




haematological disease groups, certain subgroups exist. In multiple myeloma, older patients (usually 
over the age 75) (147,148) may not tolerate high-dose therapies and have an increased risk of therapy-
related toxicities, resulting in shorter disease trajectories with different clinical features (149). 
Universally, haematological cancer patients experience unique complications like bone marrow 
insufficiency and chemotherapy-induced leukopenia (150). This leads to a high risk of infections that 
represent the major cause of death (123,132,137,151-153). In addition to the disease-related problems, 
further comorbid conditions and treatment-related side effects can enter the clinical picture and alter 
trajectories in the advanced stages (137). Significant symptom burden also arises from complications 
of bone marrow failure, e.g. fatigue, dyspnoea and bleeding, which can have a rapid onset and 
fluctuating course, especially in multiple myeloma  (154). 
Thus, the typical disease trajectory of myeloma and other haematological cancers differs from those in 
solid cancer patients. Cancer patients typically experience a prolonged period of preserved functional 
status followed by a period of marked decline during the last month of life (155-157). The disease 
trajectory in myeloma, on the other hand, may follow more that of chronic, organ failure diseases with 
intermittent periods of remission, relapse and the potential for sudden deterioration (145,152,158,159). 
These relapsing – remitting trajectories with a rapid onset of the dying phase create difficulties in 
determining the right time to engage specialist palliative care services and the transition to and 
involvement of such services is often left until late. This usually precludes care at home (105). In 
addition, haematology patients often require invasive care, such as transfusions and antibiotics, and 
may even in the advanced stages benefit from anticancer treatment (including chemotherapy and high-
dose steroids) (123,143,151-153,160,161). These sudden and uncertain transitions are barriers towards 
the integration of palliative care, particularly if palliative care is perceived to follow curative 
approaches to care instead of trying the early integration of both paradigms (162). 
 
2.1.2.2 Unpredictability and prognostic markers of end of life in haematology 
In the advanced cancer setting, prognostication is one of the most important tasks for the planning of 
treatment and initiation of appropriate care approaches (163). In haematological disease, due to the 
non-existence of an easily identifiable phase of advanced disease, accurate identification of life 
expectancy and progression of illness has historically been a critical issue (164). The default system is 
non-standardised clinician’s prediction of survival (163,165,166). However, this method is 
problematic because of its inherent bias towards overestimation of survival (167-170), leading to late 
referrals to palliative care and altering patients’ expectations of treatment (171). Oncologist-driven 
referral is only one approach to the identification of patients in need of palliative care. Automatic 
referral, involving the use of predefined criteria relating to patients’ diagnoses, prognoses and needs, is 




particularly Glare et al.’s (2011) (178) and Gomez-Batiste et al.’s (2013) (179) prognostication tools, 
having been empirically tested (180). In myeloma, decisions regarding treatment options are still 
subjective and largely based on the response to treatment, defined by the level of M-protein that can be 
detected after a course of treatment has been finished (26,181,182). Many prognostic factors have been 
proposed in myeloma, but none has been used consistently so far. 
Among the most widely studied factors are biomedical variables, in particular albumin, haemoglobin 
levels, cytokines, and treatment response. Also, some comorbidity indices and their role in 
prognostication have been explored. Albumin and C-reactive protein, although proposed as general 
prognostic markers, have limited utility in multiple myeloma due to being confounded with disease 
processes such as osteolytic lesions (183). Anaemia and reduced baseline platelet count also have 
limited prognostic value since anaemia is multifactorial and partly sustained by concurrent 
chemotherapy and chronic disease (184,185). Cytokines, in particular interleukin (IL)-6, have been 
linked to disease activity in myeloma (186), and may be correlated with the duration of disease-free 
survival (187,188). A relationship between symptom severity and IL-6 (189) and inflammation 
processes (190) reinforces these results. However, whether IL-6 or other cytokines have good 
diagnostic characteristics to also indicate the advanced stage, when patients have potential needs for 
palliative care, remains to be investigated. 
Currently, the majority of clinical predictions in myeloma care rely on a system that classifies the 
response to anti-myeloma treatment by evaluating the remaining amount of myeloma protein (26). 
Whether tumour response translates into survival benefits is an area of debate in the literature. 
Furthermore, its value as prognostic marker to indicate suitability for palliative care can be questioned. 
Tumour response, i.e. complete response, partial response, response duration and time to progression, 
as well as its linkage with biomarkers is not a useful substitute for patient outcomes (191). Particularly 
contested is the relationship between tumour response and QOL with some studies demonstrating a 
positive relationship and others not (192,193). Whether a responding patient experiences 
improvements in QOL is dependent on many additional factors not related to the biological response 
of the cancer per se. Although cancer progression is an important outcome, the need for palliative care 
relies more on the symptom and problem burden that patients experience, a burden that is not captured 
by these disease markers (23). Furthermore, the quality of response is also not a valid surrogate marker 
for survival (194), with particularly the depth of response (partial response versus complete response) 
not being uniformly related to survival time. 
Acknowledging the situation that multiple myeloma and similar blood cancers show rising incidence 
due to the aging of society (6,59,60), prognostic indices for evaluating comorbidity in these cancer 
groups are now available. The Charlson Comorbidity Index (195-200), the Freiburg Comorbidity 
Index (201) and the Palliative Prognostic Index (202-204) have been used in conjuncture with the 




indices are composed of performance status assessments coupled with a weighting mechanism to 
preferentially weigh different comorbid conditions predictive of mortality, for example renal 
impairment and lung disease as in the case of the Freiburg Comorbidity Index (207-209). Prior studies 
have shown comorbidity’s substantial impact on overall survival in several haematological cancers 
like myelodysplastic syndromes (210-212), acute myeloid leukemia (213,214) and in allogeneic stem 
cell transplantation populations (215). Some of these studies led to the conclusion that the presence of 
comorbidity can be more important than the disease itself in determining the advanced or dying phase 
(216). As these indices rely on the combination of comorbidity information with assessment of 
performance status, the role of performance status impairment as a possible prognostic factor for 
palliative care involvement needs to be determined. The Palliative Prognostic Index as well as the 
Palliative Performance Scale (203) have been shown to have good prognostic validity in the context of 
palliative care (217-219). However, these indices have only been tested in palliative populations which 
largely exclude haematological cancer patients. Since patients with multiple myeloma experience 
impairments in their physical functioning early on in the disease trajectory (7,220-222), the role of 
deteriorating performance status is questionable in this condition. 
Some successes have been achieved in the use of QOL and symptom measures to predict survival in 
haematological cancer patients. Evidence is accumulating for the independent prognostic role of PROs 
for predicting survival in the advanced disease setting (223,224). Symptoms that have been found to 
be independently associated with survival are: fatigue (225), pain (226), dysphagia (16), appetite loss 
and anorexia (227), cough (228) and general symptom burden (229). One study in mixed 
haematological and solid tumour patients reported stage of illness and drowsiness on the M.D. 
Anderson Symptom Inventory as factors independently associated with survival in multivariate 
analyses (230). Similar results for overall symptom burden have been found in routine monitoring 
programmes using the Edmonton Symptom Assessment Tool (231-235). Wider domains of HRQOL 
are also related to survival, with physical functioning being among the most commonly evaluated 
indicators (224,225,236-240). Very little research of this kind has been conducted in haematological 
malignancies. However, data from three studies explored relationships of QOL and survival in 
multiple myeloma (see Table 1).  










MM 92 EORTC QLQ-
C30 
Role, emotional, 
cognitive and social 
functioning 
Dubois et al. 
(2006) (23) 
MM 114 FACIT-Fatigue Fatigue 
Wisloff et al. 
(1997) (242) 



























108 MDASI Drowsiness 
Jerkeman et al. 
(2001) (245) 
Lymphoma 92 EORTC QLQ-
C30 
Global QOL 
Abbbreviations: MM: multiple myeloma, AML: acute myeloid leukemia, MDS: myelodysplastic syndrome, NHL: Non-
Hodgkin lymphoma, PRO: patient-reported outcome measure, EORTC QLQ-C30: European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire –Core30, FACIT: Functional Assessment of Chronic Illness Therapy, 
MDASI: M.D. Anderson Symptom Inventory, QOL: quality of life 
 
These studies point towards the potential role of PROs, particularly inventories combining symptoms 
with QOL domains, to provide indicators for the appropriateness of palliative care involvement. 
 
2.1.2.3 Unclear goals of care 
Advances in treatment options and new therapies tested in clinical trials frequently lead to 
overoptimism in haematologists regarding potential success of treatment in patients. One main 
concern of haematologists regarding early referral to palliative care is the fear to create confusion with 
respect to treatment goals. This might upset patients and families (105). However, this view loses sight 
of the fact that in multiple myeloma, essentially all treatment is given with a palliative intent (100). 
The intended goal of extending survival can compound the difficulty of re-examining situations of 
declining health (246). Moreover, advance care planning and discussions regarding preferences of care 
are often performed late (247). However, the absence of any plans to manage the wider physical and 
psychosocial distress arising from the cancer and its treatment result in the patient not being prepared 
for the possibility of progressive disease. This prevents patients to receive appropriate end-of-life care 
(248). Advance care planning, the process of communication between clinicians, patients and their 
families regarding wishes and preferences for care in the advanced and dying phase (249), is an 
understudied area of research in haematological disease. The only available evidence is for those 
undergoing haematopoietic stem cell transplantation (250-252). However, advance care planning is 
beneficial and desired in this group of patients and should be extended, particularly with regard to the 
unpredictable course of haematological disease and multiple myeloma in particular (253-259). 
 
2.1.2.4 Attitudes towards palliative care and lack of knowledge of palliative care 
The misconception that palliative care is only for patients at the end of life is a particularly strong 




Australian and US contexts, have shown differences in the conception of palliative care in solid 
tumour oncologists and haematologists. A study surveying attendants of a national oncological 
conference reported a higher proportion of oncologists referring patients early to palliative care than 
their haematologist colleagues. Reasons for non-referral being cited were wishing to control the 
disease process, the fear of creating the wrong conception that the haematologists had given up on the 
patient, or an inability to see how palliative care could benefit haematological patients with specific 
symptom control needs (162). Similar results were found in a mixed methods study exploring 
differences between the specialties in referral patterns (261). Haematologists emphasised different 
treatment goals, chemotherapy and preference for controlling palliative aspects of patient care 
themselves as the main barriers to a joint model of care (261). Although haematology care, like all 
fields of medicine, has the potential to offer generalist palliative care to its patients, the philosophical 
orientation towards cure may lead physicians and nurses in this setting to being more willing to accept 
a poor QOL and high symptom distress during intensive treatments, particularly HSCT or 
chemotherapy (262,263). The resistance to palliative care may result in unnecessary suffering of the 
patient and his or her family, as pointed out by McGrath and Holewa (158) who cited attitudinal 
barriers among the most important for the lack of integration.  
Another factor in the low utilisation of palliative care services among haematologists is the lack of 
awareness of what palliative care is, when it is appropriate to transition a patient to services and the 
possibilities of early integration and co-management (105). Hui and colleagues (2015) surveyed 
second year oncology fellows regarding their experiences of fellowship training and identified a lack 
of skills with regard to symptom management and advance care planning/communication (264). 
Another study by the same group showed that haematology specialists preferred the term supportive 
care over palliative care and the change in label to supportive care was perceived to result in higher 
proportions of newly diagnosed patients being referred (265). The lack of knowledge about palliative 
care in this group is probably linked to the lack of standardised referral criteria and the lack of 
evidence around optimal transition points and the effectiveness of co-management models of care 
(105). 
 
2.1.2.5 System barriers to the integration of palliative and haematological care services 
Partly, these barriers are related to structural problems within healthcare. Difficulties in the referral 
process include shortage of hospice beds and the high intensity of medical support that can preclude – 
at least in the American context – a referral to hospice services for haematological patients (150). 
Integration would also be aided by joint models of care being anchored into the delivery of care on a 




Palliative care focuses on achieving the best possible QOL at the same time as curative or life-
prolonging treatments (143). According to the new definition of the WHO (266), the active and 
multidimensional care of the patient and their family can integrate from point of diagnosis and 
continue during phases of remission to the end of life (and beyond, in the form of bereavement care). 
The palliative care philosophy emphasises that it is not the prognosis that determines suitability. 
Rather, unmet palliative care needs should determine who receives palliative care (90). Palliative care 
is further characterised by an interdisciplinary approach with the goal of providing care for all 
multidimensional problems (e.g. physical, psychological, social, spiritual or practical) (267). Benefits 
of palliative care have been demonstrated, including improvements in QOL (172,174), improved 
symptom management (268), diminished aggressiveness of care at the end of life (172,269,270), 
enhanced ability to meet preferences for place of care and place of death (271), reduced cost 
(269,272), and even improved survival (172). The improved survival observed in a study providing 
early outpatient palliative care to newly diagnosed patients with advanced non-small-cell lung cancer 
was possibly related to the avoidance of hospitalisations, better symptom management and treatment 
of depression in the last weeks of life (270). This evidence demonstrates that the earlier introduction of 
palliative care in the disease process can address some of the challenges around prognostication 
identified as important barriers for haematological cancer patients (132,273). 
At a basic level, early integration is influenced by the model of care, particularly by how well 
palliative care is embedded into oncology practices (274). A systematic review found different models 
of integration, ranging from simple linkage to coordination and full integration achieved when 
resources from oncology and palliative care were combined (275). Indicators for integration of 
palliative care with haematology could be the existence of interdisciplinary palliative/haematological 
teams or combined tumour boards, a simultaneous care approach, routine symptom screening, and 
palliative care guidelines and pathways (275). In multiple myeloma care, early integration of SPC 
could yield potential benefits through management of side effects and symptoms, longitudinal 
psychosocial support for patients and their families, and early conversations about preferences for 
care, prognostic understanding and advance care planning (276). However, fully integrated models of 
care are yet to be developed (143,277). 
Over the last few years, several organisation have called for the early integration of palliative care in 
oncology or haematology and specified guidance documents (278,279). Although recent 
haematological clinical guidelines recommend that palliative care clinicians have central roles in 
haematological care teams (136), only few initiatives have tested innovative models of care (135). 
Some pilot projects established palliative care services on haematopoietic transplant units in hospitals 
and found that this early introduction did not shorten survival or dismiss hope in patients but appeared 
to improve symptom burden (132). A small randomised controlled trial tested the home provision of 




in favour of home treatment (280). Another qualitative study provided blood products at a day hospice 
and explored patients’ views on this procedure. The majority of patients was in favour of receiving 
transfusions at the hospice day unit, mainly due to better access and parking facilities at the hospice 
(281). The only study that tried to establish a full palliative home care service for haematology 
patients in Italy reported a higher rate of home death and less hospitalisations at the end of life (282). 
However, since the pilot study included only 15 patients, the generalisability of the findings is a 
concern. 
Overall, the integration of palliative care and haematology remains an underdeveloped field. Current 
models of SPC provision and end-of-life care services are not geared towards supporting 
haematological patients. Numerous barriers, particularly around prognostication and attitudes towards 
palliative care, need to be addressed. Early integration and a paradigm shift towards standardised 
monitoring of symptoms and palliative care problems could help identify patients earlier in their 
disease trajectory. 
 
2.2 Quality of life and multiple myeloma 
 
2.2.1 Definition and model of quality of life in multiple myeloma 
With improvements in treatment and care for patients with myeloma the exploration of the impact of 
the disease on QOL becomes important. The field of QOL and health status assessment is relatively 
young. In the 1970s, the first generic assessment tools were developed (283). Prior measurement of 
patient-related variables was largely limited to measures of functional ability (e.g. Karnofsky 
Performance Scale (284)) that were taken to represent QOL (285). The term QOL was indexed in 
Medline in 1975 and since then the number of QOL publications has risen exponentially (286). 
Traditional endpoints in clinical trials assessed survival or progression-free survival, but gradually 
HRQOL has been introduced as a secondary outcome to inform treatment decision making in all 
health care and in multiple myeloma (285). After the introduction of the guidance on incorporation of 
patient-reported outcomes issued by the Food and Drug Administration in the US (287), the 
percentage of trials with secondary HRQOL endpoints has grown dramatically from 25% up until 
1994 to more than 75% currently (288). 
However, despite QOL permeating medical effectiveness research, the study of QOL is limited by a 
plethora of definitions of the term, which has led to the perception of QOL being an amorphous 
concept (289). Definitions of QOL within healthcare can be classified into three groups, based on their 
scope – definition that see QOL as a part of health care (290), definitions of QOL that look at the 




consisting of numerous domains important to the life of the individual (such as physical, 
psychological, social and spiritual wellbeing (292)). One of the most widely used definitions is the one 
by the World Health Organization (293). It states that quality of life is defined 
“as [an] individual’s perception of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, standards and 
concerns. It is a broad-ranging concept affected in a complex way by the person’s physical 
health, psychological state, level of independence, social relationships, and their 
relationships to salient features of their environment.” (p.1404) 
This definition recognises the subjectivity of QOL – it can only be understood from the patient’s 
perspective. It also indicates that an appropriate assessment can only be made by asking the person 
directly (294). The WHO definition also recognises the broader world individuals live in and the 
importance of assessing these wider domains. This is contrary to narrow definitions of HRQOL that 
focus solely on the effects of illness and treatment and do not take into account non-health related 
aspects (295). HRQOL has also traditionally been associated with a pathology model of health. 
HRQOL usually focuses on impairment in physical function and mental decline, an approach that 
disregards the dynamic nature of QOL (289). Following the WHO definition, values and expectations 
play a major role in making an assessment of QOL and wellbeing. This is in line with one of the 
earliest recognised definitions of QOL by Calman (296), who saw QOL determined by the gap 
between an individual’s hopes and expectations and the reality. The assessment of QOL can therefore 
change when individuals adapt to an illness or an event in their life (34,297-299). The subjectivity 
inherent in the term is sometimes perceived to render outcomes like QOL, in comparison to seemingly 
objective parameters like biomedical variables, less robust (300). 
The two definitions cited above define QOL as a term belonging to the individual. There is also a large 
philosophical debate about the societal, objective perspective of QOL and health and how the well-
being of whole nations can be captured in routinely collected indicators (301). These definitions are 
well beyond the scope of this thesis. However, it demonstrates that QOL is often used as a generic 
label or an umbrella term to cover a variety of concepts (302). Ferrans has proposed a taxonomy of 
definitions and conceptualisations of the term in the early 1990s. She defined six broad categories 
(303-305): normal life, social utility, happiness, satisfaction with life, achievement of personal goals 
and natural capacities. The taxonomy has since been extended to include utility, the preference-based 
health state evaluation common in economic analyses within treatment effectiveness research, and 
satisfaction with specific domains of life (306,307). Most QOL assessment tools occupy the middle 
range of collecting information on a broad array of domains hypothesised to be related to or indicate 




Depending on the conceptual model and the definition of QOL followed, measurement approaches can 
differ considerably. Although multidimensionality is mapped in most measurement theories, 
assessment instrument vary regarding the number of domains that are encompassed by the measure. 
The usual consensus regards physical, emotional, social, role functioning and overall QOL as the core 
domains (309). Depending on the instrument, core or disease-specific symptoms (as is the case mostly 
in disease-specific measures such as the EORTC QLQ-MY20 (221,310)) can complete the picture. 
Recently, the inclusion of existential and spiritual domains has been advocated (311). The coverage 
and comprehensive composition of measures is of importance when the clinical utility of these 
measures is concerned. A few distinctions play an essential role, particularly the distinction between 
the terms health-related quality of life and QOL or well-being, and the distinction between health 
status and health evaluation measures (295). HRQOL, as defined by some authors, equates with 
impairment and disability. The term is rooted in the tradition of functional assessment like in 
Karnofsky’s performance scale (284). It focuses on those aspects of life that can be affected by 
medical treatment, in particular functioning and role performance (312). As such, it does not represent 
QOL which is understood to be more consistent with well-being and reflect satisfaction with life and 
level of mood (313). Covinsky et al. (1999) (314) have shown that health status and QOL are distinct 
constructs (314,315). The assumption that a fully healthy life is identical with a high QOL can thus be 
challenged. The paradox of good QOL in the presence of significant health problems or even in the 
presence of very advanced disease makes this distinction the more pronounced (316,317). 
The second large distinction within QOL measurement is between measures that assess the status 
versus those that ask an evaluation of a problem from an individual (295). The WHO definition of 
QOL (293) that was referred to above shows both aspects – it asks for the individual’s perception of 
their position in life, which is a question of perceived status, but then asks how this corresponds with 
the individual’s standards, goals and expectation, which constitutes an evaluation. The wording within 
QOL definitions and conceptualisations as well as measurement tools is distinct in these groups. A 
status measures usually asks about the severity or the extent of a problem. Questions about how 
distressing a symptom or problem is or how much the individual is bothered by it are two typical 
wordings for evaluation measures. These distinctions matter as scores can differ markedly between the 
two types of measures even though measures may assess the same domain. Moderate to small 
correlations have been found between the SF-36 (health status) and the Quality of Life Index (health 
evaluation) in patients with HIV/AIDS (318) and between the EORTC QLQ-C30 and the FACT-G 
(319). 
The multidimensionality, subjectivity, and dynamic nature of the construct and the lack of a consensus 
as to its definition have led research into QOL to be perceived as ‘atheoretical’ (311). Fayers and 
Machin characterised QOL as an ill-defined term (320). No definition to date has identified the 




also a lack of debate as to a consensus (311). A review reported that at least 25% of authors of QOL 
publication did not define the term per se and a distinction between factors that may influence QOL 
and those that may reflect QOL was not made in half of the reviewed literature (321). The non-
universal inclusion of domains further renders QOL results incomparable (322-325). Conceptual 
models that guide research are needed to place QOL and its related concepts in a context and model 
the inter-relationships among them. A theoretical model or framework is defined as a model that 
includes the structure of the elements and their relationship within a theory and hence allows the 
formation of hypotheses about pathways and relationships among elements (326). A theoretical 
framework can thus enable conceptual clarity and make the term QOL useful within clinical practice. 
QOL research then is used to identify the causes of variation and how these can be altered. From such 
a theory, guidance on how to intervene and improve QOL or its aspects can be gleaned (327). It 
further links health outcomes with health care services and how decrements in QOL may translate into 
specific supportive care needs (328). 
Two systematic reviews have specifically identified those models of QOL that have been used in a 
health-related context. Bakas et al. (2012) (329) found that among models, Wilson and Cleary’s model 
of QOL (330) was the most widely used, alongside its revision by Ferrans and colleagues (303,331). 
The second most common model was the one by the International Classification of Functioning, 
Disability and Health (ICF) (332,333). This result was also confirmed by Taillefer and co-authors 
(321). These models define the domains that make up the concept and hypothesise causal relationships 
among these domains (330,334-336). Conceptual models of QOL can be classified into several 
categories (295,337), of which the three most important types of model are: mediated models, 
interactive models and adaptation models (295). 
 
a) Mediated models 
In this category belong models which hypothesise direct relationships among their elements. Wilson & 
Cleary (330) propose a model that links biological and physiological variables to QOL and its 
antecedents via a direct pathway (see Figure 2). 






Thus, fully mediated relationships exist among the variables that influence QOL. Biological and 
physiological variables only have an indirect impact on QOL via affecting symptom status which then 
affects functioning. Functioning in turn only has a mediated effect on QOL via general health 
perceptions. In recent years, researchers have begun to use these causal models for investigating 
HRQOL, but also to study whether the relationships between domains hypothesised in the model hold 
true when applied to oncological patients or populations with chronic or life-limiting conditions 
(315,338-341). 
 
b) Interactive models  
The ICF proposed a partially mediated model that allows for direct and indirect links between 
constructs. The conceptual model posits bidirectional links between body function and structures (i.e. 
symptoms that lead to impairments), activities (limitations in physical function, self-care, carrying out 
daily activities), and participation (i.e. restrictions in role and social functioning) (332). All three 
concepts can directly influence the outcome HRQOL or indirectly influence it by affecting one of the 
other elements. This model, like the Wilson and Cleary QOL model, also presumes an influence of 
more distal personal and environmental factors. These variables can only impact on the health 
condition by influencing one of the elements body function, activities or participation. The model is in 
line with the WHO’s definition of QOL (293). McDougall et al. (2010) (333) have proposed a 
modified version of the ICF model that includes QOL and contextual factors (see Figure 3). 






c) Adaptation models 
Adaptation models are all mediational models as they hypothesise influences or mediators that 
determine perceived QOL (289). These mediators are cognitive appraisal processes such as mastery, 
self-efficacy, perceived control over life and other cognitive processes (334). These models try to 
further characterise what was termed a general health perception in the model by Wilson & Cleary 
(330). One of the most prominent models is one linking stress, coping and adaptation theories and 
emphasises the relationship between the person and its characteristics and the environment which acts 
as a stressor (342), based on Lazarus & Folkman’s theory of stress and coping (343). Other examples 
of adaptation models are Zissi et al.’s model of QOL developed in individuals with severe mental 
health problems (334), and Sprangers & Schwartz’s model of adaptation/response shift (344). 
Of these models, the model by Wilson & Cleary (1995) (330) is the most widely used (321). This 
might be because the authors defined the levels contributing to QOL as the natural progression of 
assessments within health care. Biological factors, treatment status and clinical signs are directly 
observable by the clinician or can be measured in clinical tests. Functioning is assessed either by the 
patient or the clinician through self-report or standardised performance tests. The components that are 
more proximal to overall QOL, particularly general health perceptions and other mediating variables 
(e.g. adaptation processes), can only be assessed and reported by the patients themselves, making use 
of PROs. In fact, symptoms (the second distal element of QOL) also falls into this category. The 
model presents two levels of empirically testable hypotheses. One is about the sequence of elements 
which directly translates into the amount of correlation they might show to the outcome overall QOL. 
The second range of hypotheses relates to the mediation of elements within the model. The model 
indicates that more proximal elements are subject to greater mediation by personal and environmental 




can be used in clinical research and practice. First, the more proximal the measure to overall QOL, the 
smaller the effects from disease and treatment will be. This can also be an explanation for why ceiling 
effects are reached in measures. Furthermore, treatment will yield greater results the more severe the 
symptoms are in a patient (346). Empirical tests, usually in the form of structural equation modelling, 
have provided strong support for the model in a variety of illnesses, ranging from chronic conditions 
to potentially life-limiting illnesses and cancer (338,347-354). Some problems with the unidirectional 
sequence of elements have been identified early on, which led to a revision of the model by Ferrans 
and co-authors (331). They allowed bidirectional relationships between the elements leading to QOL 
and allowed mediating factors to also influence biological factors.  
Fayers (340) critiqued the model with regards to the complexity of relationships that are posited 
between the elements. How each element should be operationalised is not clear. He also points out that 
an important distinction is lacking in the theoretical model. Fayers and co-authors (1997,2002) 
(339,340) introduced the distinction between reflective/indicator and formative/ causative variables 
within a QOL framework. In a reflective model (355), variables or items in a questionnaire reflect the 
QOL level of a person. Causative variables are variables that directly cause or influence QOL. For 
example, a low QOL that leads to psychological distress, anxiety and depression may reflect the level 
of QOL (indicator variables), whereas the symptoms and functional limitations may have caused the 
low level of QOL in the first place and are thus causal variables (356). These distinctions need to be 
made clear in the arrows that link the boxes and also in how the respective variables are handled in the 
regression and factor analyses in psychometric validation. 
Which model performs best in multiple myeloma is currently unknown. The subject of how QOL is 
perceived and constructed as well as affected by influencing variables has only recently been studied 
in three qualitative studies. To date, there is no empirical test of different models of QOL in this 
disease or in the wider haematological literature. Osborne et al. (2014) (357) in a study using 40 semi-
structured interviews and two focus groups, asked patients with multiple myeloma how they would 
define QOL, what elements brought quality to the individual’s life and how myeloma had impacted on 
their QOL. Partly due to the health-related focus of the interview questions, participants raised over 80 
issues mainly related to their health. The resulting model that represents the relationships between 
overall QOL and its elements was eventually proposed to follow Wilson & Cleary’s model (330) (see 
Figure 4). Similar to this model, participants in the study perceived biological status, treatment factors 
and symptom status as less closely related to overall QOL. Moreover and in contrast to Ferrans’ 
revision (303,331), participants indicated a strong causal relationship of biological and treatment 
factors only if they led to symptoms which led to impairments in the subsequent elements of 
functional status and health perceptions (357). A difference to Wilson & Cleary’s original 
conceptualisation was observed in the role of general health perceptions, in particular expectations, 




functional status to QOL in a mediating mechanism, adaptation or spirituality formed the essence of 
QOL in some patients, thus acting as a reflective variable according to Fayers’ theory 
(339,340,351,356). Furthermore, health service factors and the satisfaction with received care were 
mentioned as directly influencing QOL, a further adaptation and new finding that led to a revision of 




Figure 4: Theoretical model of the QOL of people with multiple myeloma (357) 
 
 
Two other studies aimed to depict relationships between QOL and its elements. Baz et al. (2015) (358) 
elicited some specific impact of symptoms (particularly side effects of treatments) on daily activities, 
work, family and leisure activities and independence in myeloma. Similar to Osborne et al. (2014) 
(359), they described a direct impact of clinic visits and quality of care on HRQOL. In contrast to the 
Wilson & Cleary model, however, a direct influence of the disease not mediated through aspects of 
functioning was allowed, as was the direct influence of symptoms onto HRQOL. The model further 
did not distinguish between reflective and causative indicators (358). A similar situation arises in 
Zabora et al.’s model (360). Their study used expert and patient consultation for the derivation of 
guidelines for supportive care and thus does not constitute a genuine qualitative study. Rather than 
proposing a model that universally depicts the relationships between the elements influencing and 
reflecting QOL, the authors focused on mapping the temporal sequence of specific problems and how 
these influence QOL at different stages of the disease (360). The stages were defined as relating to 
treatment and ranging from diagnosis of pre-forms of myeloma over newly diagnosed patients to 




a conceptual rather than a theoretical framework and the authors fail to define the nature of 
relationships between the elements in the model. For subsequent QOL measurement development this 
poses a problem in deriving items for a QOL measure. 
To conclude, any research into quality of life should be clear about its definitions and the underlying 
conceptual or theoretical model that guides the research (307). Researchers need to distinguish 
between indicators and determinants of QOL (339,340,351,356). Little is known about whether the 
hypothesised interactions and relationships in the models hold true generally and specifically in real-
world samples of myeloma patients and whether these proposed interactions are an accurate 
representation of the interrelationships. Research into QOL therefore should clearly identify the 
theoretical model that guides the research and, if possible, try to test the hypothesised relationships 
among the constructs. In this PhD study, Osborne et al.’s definition and model of QOL in multiple 
myeloma is followed, with hypotheses regarding the differential influence of factors onto QOL being 
derived from the model (357). In the next section, literature regarding the symptom burden, QOL-
related problems and the longitudinal trajectories in multiple myeloma will be reviewed to provide a 
more fine-grained picture of the problems experienced by patients. 
 
2.2.2 Symptom burden and quality of life in multiple myeloma 
The clinical picture of multiple myeloma is that of a condition that presents with multiple debilitating 
symptoms and problems. These are either caused by the disease itself (like bone pain, infections, renal 
failure), are associated with treatment (like intensive chemotherapy, stem cell transplantation, 
maintenance therapy) or with side effects of these treatments (71). Patients are aware that the disease 
cannot be cured and will ultimately return, progress and lead to further problems and disabilities. In a 
qualitative study of patients living with relapsed myeloma, participants characterised the disease 
experience as living with uncertainty and enduring it (361). Dependent on the physical impact the 
disease had on their life and the coping mechanisms they used, patients were more or less able to 
adjust to this state of not knowing and not being able to plan the future due to the prospect of 
deterioration and living with the inevitability of relapse.  
Thus, the disease and its treatment have a profound impact on QOL. Despite the push within oncology 
to incorporate PROs and a patient-centred view in clinical trials and clinical decision making 
(287,362,363), HRQOL is not yet routinely assessed in myeloma clinical practice and research. A 
systematic review assessing the impact of HRQOL measurement on clinical practice in myeloma 
identified only 15 clinical trials published between 1996 and 2008 that used this outcome (24). The 
fact that HRQOL does not play a role in clinical practice is further supported by official guidance for 




focuses on prolongation of survival and the progression-free interval and response to therapy only 
(26). 
Only since 2010, attempts have been made to understand what these response categories mean in 
terms of patient experience. Ancaster et al. (2013) (83) examined how the treatment-free interval and 
its duration impacted on HRQOL. They showed that patients had better HRQOL during their first 
treatment-free interval (as opposed to treatment-free intervals after second line or third-line treatment) 
and that the length of the interval was associated with HRQOL (83). This is the only study so far in 
which the relationship between HRQOL and response has been studied in a nationally representative 
sample (364-366). Almost all information on HRQOL in myeloma is treatment-specific and does not 
reflect the treatment course or the whole disease trajectory (23,24,32,367). It is not apparent which 
factors of the disease and its treatment have the most impact on QOL and whether this impact changes 
when patients with myeloma enter a new phase in their disease (for instance the relapsed/progressive 
phase) (368). 
There is some evidence that people with myeloma suffer more symptoms and problems than those 
with other haematological cancers like leukemia and malignant lymphoma (9). The 45 patients in a 
cross-sectional survey of 470 haematological cancer patients in Denmark reported 5.6 symptoms on 
average, of which 2.3 were rated severe. They also reported the highest levels of pain, fatigue and 
constipation as well as limitations in role, physical and social function (9). The fact that myeloma 
patients have poorer QOL than the general population with severe symptoms and impairments in 
functioning was also demonstrated by Gulbrandsen et al. (2001) (32). To date, only a handful of 
studies have measured QOL at several points in the disease trajectory (23,29-36). These studies 
usually focus on people that participate in treatment studies of novel chemotherapeutical agents or that 
receive bone marrow transplantations. Most of these studies are cross-sectional in nature 
(30,32,33,36). 
Related to QOL is the assessment of the supportive care needs of this disease group. Only one study to 
date has assessed these needs in a sample of 134 patients living with myeloma (on average 5 years 
post diagnosis) (90). Unmet supportive care needs mainly centred on accessibility of health care 
services and information needs. The study also found moderate levels of QOL, with the most affected 
areas being physical, role and emotional functioning, pain, fatigue, dyspnoea, appetite loss, insomnia 
and constipation (90). However, it is unknown how these needs progress when patients enter the more 
advanced stages of the disease. As shown above, palliative care services are currently not provided to 
myeloma patients, despite existing guidelines (27,86). Areas of further research need to address the 
following gaps in the evidence (105,132): (a) identifying and describing the symptom patterns and 
levels of distress at different points during the illness trajectory, (b) describing the multidimensional 




whole disease trajectory, and (d) determining preferences of patients and family carers for end-of-life 
care.  
Describing symptom patterns in multiple myeloma, understanding how QOL and QOL-related 
problems change over time and which factors are related to poor QOL, possibly indicating the need for 
palliative care involvement, are objectives of this study. To inform data collection and analytical 
strategies of the main study, the following three areas were systematically reviewed prior to 
commencing and planning primary data collection: (1) symptom prevalence and prevalence of QOL-
related problems, (2) longitudinal changes in symptom prevalence and QOL in existing research 
studies, and (3) independently associated factors of QOL. Two of these were published as meta-
analyses in journals and these publications are reprinted in the following chapters. 
 
2.2.2.1 Prevalence of symptoms in patients with multiple myeloma – a systematic review and 
meta-analysis 
 
Article published in the European Journal of Haematology (369) 
Authors: Christina Ramsenthaler, Pauline M. Kane, Wei Gao, Richard J Siegert, Polly M. Edmonds, 
Steve A. Schey, Irene J. Higginson 
 
Due to copyright restriction, I have included the final manuscript that was submitted to the journal for 
publication but not the published article in layout. The final and published version may be accessed at 
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Objectives. Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, 
overall survival has improved in this group, yet there are no systematic reviews to understand the 
symptom profiles resulting from disease and treatment-related toxicities. We aimed to synthesise data 
on prevalence of symptoms in patients with MM.  
Methods. A systematic database and grey literature search was conducted in 6 databases. Random 
effects meta-analysis with inverse variance weighting to pool prevalence data was performed.  
Results. 36 studies were included of which 34 studies (N = 3,023) provided data for meta-analysis. 27 
distinct symptoms were reported, with the majority of studies focusing on pain (n=27), fatigue (n=19) 
and problems with functioning (n=15). The most prevalent symptoms were fatigue (98.8%, 95% CI 
98.1 – 99.2%), pain (73%, 39.9 – 91.7), constipation (65.2%, 22.9-92.2) and tingling in the hands/feet 
with 53.4% (0.4-99.7). The most common problems were decreased physical functioning (98.9%, 98.2 
– 99.3), decreased cognitive functioning (80.2%, 40 – 96.1) and financial difficulties (78.4%, 39.1 – 
95.4). These problems were present in newly diagnosed to advanced disease stage.  
Conclusions. Optimal quality of life and good symptom management in this incurable disease can only 
be achieved by routinely assessing symptoms throughout the disease trajectory.   
 







Multiple myeloma is the second most common haematological cancer in the UK with an annual 
incidence of 6.9 cases per 100,000 population (1). Cancer registries estimate that there are 4,040 new 
cases each year in the UK and 41,719 new cases in Europe (2). The incidence has increased in recent 
years, due to advances in treatment and overall ageing of the society (3). Despite these improvements, 
multiple myeloma remains an incurable disease and patients will eventually die from it or the 
consequences of its treatment. Estimates for the year 2016 range from 2,799 deaths in the UK to 
20,462 in Europe (2).  
The introduction of novel agents such as bortezomib and, lately, lenalidomide and pomalidomide (4, 
5), and the wide-spread use of high-dose melphalan with autologous stem cell transplantation (ASCT) 
as first-line treatment means that now more patients with multiple myeloma live with their illness for 
longer than in the past (4, 6). These new treatment agents have also resulted in a varied profile of 
adverse events and long-term treatment-related toxicities, among them most prominently treatment-
induced peripheral neuropathy (7, 8). Moreover, with multiple myeloma being a cancer primarily of 
older age, with a median age at diagnosis of 73 to 75 (9), co-morbid chronic and progressive diseases 
among all myeloma patients will also become more common. These trends bring with it that health 
care needs and the need for managing the various disease- and treatment-related problems become 
much more complex.  
Despite the extensive study of symptom burden in solid tumours, particularly in the advanced stages of 
disease (10–13), there has been little reliable and valid observational evidence on symptom burden in 
haematological diseases. To date, no systematic review focusing on haematological cancer populations 
has been published. A few non-systematic reviews describe burden in stem cell transplantation (SCT) 
samples, but mainly in form of quality of life with pooling of symptom prevalence a secondary 
objectives at best (14–16). This may be because only few prospective studies have documented the 
prevalence of symptoms in patients with haematological disease. A few notable exceptions employ a 
population perspective. These studies have reported a mean of 8.8 symptoms (17, 18), an average that 
is lower than that of 11 symptoms reported for advanced cancer (10) but sufficiently high to indicate 
substantial need for effective symptom management in this group.  
In this systematic review, rather than including all haematological cancers we focus on the symptom 
prevalence reported in multiple myeloma. Due to its more chronic nature and the cumulative toxicities 
that patients experience from multiple lines of treatment, the symptom burden can be profound (e.g. 
bone pain, fatigue, gastrointestinal symptoms, peripheral neuropathy) (19). Multiple myeloma can thus 




and outcome measurement tools have been developed for multiple myeloma, which makes the study 
of symptom prevalence more valid and reliable (20, 21). 
The aim of this systematic review is to synthesise the data on the point prevalence of symptoms and 
side effects as well as other health-related quality of life (HRQOL) problems and concerns in patients 
with multiple myeloma.  
 
Materials and methods 
Literature search and data extraction 
This systematic review and meta-analysis follows the recommendations from the PRISMA statement 
(22). We searched the following databases on 26th May 2016, to identify studies reporting symptom 
prevalence in multiple myeloma: Medline (from 1950), Embase (from 1980), PsycINFO (from 1806) 
(all via Ovid), CINAHL (from 1981, via Ebscohost), and the Web of Science (from 1900, via 
Thomson Reuters). The search strategy used a combination of medical subject headings (MeSH, 
exploded) and key words, adapted to individual databases, to search for the following concepts: 
“symptoms” AND “multiple myeloma” AND “prevalence”. The search strategy can be found in the 
Appendix. To account for database limitations, the search was supplemented by (a) identification of 
reports and grey literature in GoogleScholar, (b) search for conference abstracts in Web of Science, (c) 
a hand search of six relevant journals. Finally, we further searched the reference lists of all included 
studies and used citation tracking searches in Scopus (via Elsevier).  
Articles written in English, French, German, Italian and Spanish were considered for inclusion. Study 
inclusion criteria were: a) reporting data on symptoms and other problems using a validated or piloted 
self-report instrument for establishing symptom prevalence; b) for an adequate representation at least 
>30% of myeloma participants in the sample, including mixed haematological, cancer or palliative 
samples (Studies were also included if prevalence data was reported separately for the subgroup of 
myeloma patients in a study in which the overall proportion of multiple myeloma patients was less 
than 30%); c) original research of a quantitative design, including descriptive and analytical 
observational studies, quasi-experimental and experimental studies and secondary analyses of 
randomised controlled trials. Studies were excluded if they reported their findings in a language not 
included in the list above. Further exclusion criteria were studies using a case report/series design, 
systematic reviews and qualitative designs.  
One reviewer assessed titles, abstracts and full-texts. 30% of full-texts were assessed independently by 
a second reviewer. Data extraction using a standardised form and recording aims and characteristics of 
the study, the study population and its clinical characteristics (e.g. stage of disease, treatment history) 




investigator (I.J.H.). Methodological quality was assessed using two checklists, one for appraising the 
methodological quality of randomised controlled trials (23), and one assessing cohort studies and 
descriptive observational studies (24). Studies were checked for the likelihood of selection bias, 
confounding, study design, blinding and randomisation (for clinical trials), data collection methods, 
statistical analysis and reporting of withdrawals. Based on these criteria, studies were scored as weak, 
moderate or strong evidence (23, 25). Quality was assessed independently by a second reviewer. Any 
disagreement between reviewers was solved by consensus. 
Analytical methods and meta-analysis 
Prevalence figures were combined separately per symptom using meta-analysis, if comparability of 
study and patient characteristics in included studies permitted synthesis. Data were pooled using a 
random-effects model since some studies included samples not solely consisting of myeloma patients. 
Mixed samples represent a source of heterogeneity, making the estimation of several population point 
prevalence rates likely (26). Raw prevalence figures from included studies were logit transformed and 
synthesised using the inverse variance method. The final pooled logit was back transformed using the 
exponential function, resulting in pooled prevalence and 95% confidence intervals (27). For each 
symptom, if possible, two prevalence estimates were derived, one for mild to moderate symptom 
severity and one for severe symptom severity. For the quality of life subscales from the EORTC QLQ-
C30 questionnaire, the prevalence of a problem indicated on the respective subscale was determined 
using a cut-off of less than 66 for a mild problem and less than 34 as a severe problem (18). 
Heterogeneity was estimated using Cochran’s Q-statistic (28) at a significance level of 0.10. From this 
statistic, the I2-statistic was calculated with an acceptable level of heterogeneity being defined as I2 
equalling less than 70% (29, 30). We anticipated the following sources of heterogeneity: clinical 
diversity, stemming from inclusion of mixed samples and populations, methodological heterogeneity 
and heterogeneity from using different symptom assessment tools and classification systems.  
Subgroup analysis of disease stage and treatment group was planned, depending on presence of at least 
three studies per subgroup. Meta-analysis was performed using the metafor package (31) in the 
statistical programme R (32).  
 
Results 
The electronic database searches yielded 16,236 records. An additional 5 records were added after 
hand searches and grey literature searches. Thirty-six studies were included in the systematic review, 
with 34 studies contributing data to meta-analysis. Reasons for exclusion are shown in Figure 1. 




Clinical and methodological characteristics of included studies 
The characteristics of included studies are presented in Table 1. The majority of studies used cross-
sectional designs (n = 19). Four randomised clinical trials and four quasi-experimental studies were 
included. Almost an equal proportion of studies focused on SCT populations (n = 16) or 
chemotherapy/outpatient populations (n = 15). Three studies investigated new chemotherapeutic 
agents in an RCT. The setting was not reported in two studies. Of the 36 included studies only nine 
used determining symptom prevalence as the explicit aim. By far the most common HRQOL tool was 
the EORTC-QLQ-C30 used in 16 studies, either solely or in conjunction with its myeloma module 
(MY-20). Validated symptom assessment tools were the MDASI-BMT (n = 2) and the MDASI-MM 
(n = 2). Some studies used other HRQOL tools, such as the SF-36, SF-12 or measures from the FACT-
group. Some studies used single symptom measures like the Brief Pain Inventory or specific mental 
health assessments. Four studies used tools that had a purpose other than symptom assessment and five 
studies used no validated tools to ascertain symptom prevalence. The proportion of myeloma patients 
in included studies varied from as little as 4.8% (33) (those were studies that reported data separately 
on the myeloma subgroup and could therefore be included in the meta-analysis) to 100% in almost 
three quarter of the included studies (n = 25). Fifteen studies did not report the stage of disease. The 
remaining studies consisted of newly diagnosed patients (n = 9), with 12 studies including a proportion 
of advanced stages.  
[Insert Table 1] 
Methodological quality 
Twelve of the included studies obtained a low methodological quality score (see Table 1), 17 were of 
medium and seven were of high quality. The seven high-quality studies comprised the randomised 
controlled trials and those epidemiological observational studies with a focus on establishing symptom 
prevalence. Bias was introduced in original studies due to attrition in longitudinal designs, with little 
information on those participants lost to follow-up, and scant reporting of the recruitment process and 
clinical characteristics. Further problems were the absence of clear hypotheses and poor statistical 
analysis. 
Symptom prevalence 
27 symptoms were identified across the 35 studies (see Table 2). The four most prevalent symptoms, 
occurring in at least 50% of study participants, were fatigue, with a pooled prevalence of 98.8% (95% 
CI 98.1 – 99.2), constipation (66.5%, 23.5 – 92.8), pain (58.6%, 8.8 – 95.2), and tingling in the 
hands/feet (53.4%, 0.4 – 99.7). Fatigue, pain and constipation were also the three symptoms that, in 
samples of myeloma patients that were severely affected by these symptoms, reached pooled 
prevalence rates of >40% (59.7% severe fatigue, 45.2% severe constipation, and 44.7% severe pain). 




prevalence of 22.3% for depression (95% CI 0.3 – 96.2) to 35.7% (1.0 – 96.9) for anxiety. If only 
clinically relevant cases of anxiety and depression were considered, based on cut-off criteria, a pooled 
prevalence of 26.7% for anxiety and of 23.6% for depression was found. Pain, fatigue, sleep problems 
and depression were the symptoms the most frequently examined in included studies. 
[Insert Table 2] 
Prevalence of quality of life problems 
Decreased physical functioning, in the original studies determined by values of <66.7 on the EORTC 
subscale (18), was the most common HRQOL problem with a pooled prevalence of 98.9% (95% CI 
98.2 – 99.3%), followed by decreased cognitive functioning (80.2%, 40.0-96.1%), and financial 
difficulties with a pooled prevalence of 78.4% (39.1 – 95.4%). Decreased role, emotional and social 
functioning also had prevalence rates of >50%. Severely decreased role functioning and severe 
financial difficulties were problems with a pooled prevalence of 46.7% and 43.3%, respectively. The 
three subscales with the lowest pooled prevalence rates were severe disease symptoms, severe worry 
about dying or the future and severely decreased cognitive functioning. However, worry about 
dying/future and cognitive functioning both had higher prevalence rates when being of mild to 
moderate severity. 
Discussion 
27 distinct symptoms were reported in the 36 included studies of this meta-analysis of symptom 
prevalence in multiple myeloma. Most studies focused on pain (75%), fatigue (53.1%), and aspects of 
functioning (40.6%). Gastrointestinal symptoms, cognitive symptoms and psychological symptoms 
were assessed in a quarter to a third of studies. The most common symptoms were fatigue, pain, 
constipation, and peripheral neuropathy, present from 53.4% of patients to almost 100%. Further 
bothersome symptoms came from the psychological domain, as well as breathlessness and sleep 
problems. A pooled prevalence of nearly 25% was found for sexual dysfunction. Myeloma patients 
demonstrated severely decreased functioning in several domains, predominantly role and social 
functioning. Almost half of patients expressed worry about dying and the future and nearly 80% 
reported financial difficulties of which 43.3% were severe.  
These findings indicate that there is a large number of symptoms that occur frequently in high 
numbers of patients. These figures are comparable to symptom reviews in the general cancer 
population (12) and in advanced cancer patients, in which studies reported 11 to 56 distinct symptoms 
with the most prevalent symptoms being fatigue, lack of energy, pain, sleep problems and 
breathlessness (10–12, 65). Some of these reviews also investigated symptom severity, an analysis 
only indirectly achieved in this meta-analysis through the separate pooling of mild to moderate 




It remains challenging to analyse symptom prevalence over time in multiple myeloma. Some of the 
reported symptoms can have disease-related or treatment-related aetiologies. Only few studies 
presented longitudinal information on prevalence and inadequate power precluded meta-regression of 
variables such as treatment history and disease characteristics. However, analysing some of the 
symptoms that could be related to treatment toxicities and hence later stages of disease showed that 
not all of these confirm to this pattern. While neurotoxicity is reported in studies with mainly 
advanced patients in later stages of myeloma (19, 47, 51, 52), fatigue, sexual problems, and financial 
difficulties are present at all stages. Sexual problems in particular were also reported by patients with 
newly diagnosed disease pre-transplantation (58). The same was observed for financial difficulties, 
present in newly diagnosed samples, samples with mixed disease stages and studies reporting baseline 
evaluation of SCT patients (18, 42, 47, 48, 50,53, 54). A high prevalence of fatigue was also reported 
in these studies (17, 38, 60).  
This meta-analysis was a cross-sectional analysis of symptom prevalence. The longitudinal studies in 
this review all included mixed samples of SCT patients. In these studies, a general pattern of 
worsening of symptoms and functioning variables over the course of the transplantation process is 
reported, to either nadir (17) or to a point 2-3 months post transplantation (37, 39, 54), with the notable 
exception of depression and anxiety which were reported to not return to baseline levels and even rise 
after transplantation in one study (60). Nonetheless, the derivation of a general course of symptom 
prevalence is hampered by different assessments used in pre-, peri- and post-transplantation periods. 
What this data shows, however, is the high prevalence of problems and symptoms and the general 
burden that myeloma patients experience even at baseline and in the time period leading to 
transplantation. 
Methodological limitations 
Aggregating data on symptom prevalence in multiple myeloma was hampered by a number of 
methodological factors. The wide confidence intervals that were observed in the meta-analysis, in 
some cases spanning 99%, indicate high heterogeneity. First, this stems from the definition of each 
symptom depending on the method of assessment. Some studies used multi-item screening 
questionnaires with clinical cut-off criteria while others utilised single items. Second, studies differed 
in their design, the type of prevalence they assessed and sometimes even the numerator (number of 
events versus number of patients). Also, studies had different length of follow-up. Since comparability 
was not given, this data and the longitudinal change in symptom prevalence was not included in the 
meta-analysis. Third, patients at different stages of the disease were included, with stage often not 
reported. This might well affect the prevalence estimates for specific symptoms, in particular 
peripheral neuropathy and fatigue. As illness progresses, new symptoms emerge as side-effects of 
treatment. Fourth, some studies used non-validated measurement tools to ascertain symptom burden, 




predefined severity level. We did not mix these two groups in the meta-analysis. However, these 
factors could likely lead to systematic underreporting of symptoms. Lastly, the inclusion of mixed 
samples of haematological cancer could have distorted the symptom profile. Since we used tight 
inclusion criteria for the type of study and a language restriction, publication bias may have occurred. 
Although meta-analysis can improve the power of analysis by pooling results from small studies, some 
symptoms were reported in a small number only which diminishes the validity of the pooled estimates.  
Clinical implications 
Multiple myeloma is an example of an incurable haematological cancer in which, due to 
improvements in therapy, patients now live a comparably long time of 5-10 years (Kumar et al, 2008) 
with their disease.  New developments warrant insights into long-term toxicities and better patient 
management and care, especially towards the end of life (66). In 1996, a position statement was issued 
to advocate good symptom management, improving functioning and HRQOL alongside survival as the 
goal of effective cancer treatment (67). This also reflects patients’ experiences, who commonly cite 
QOL as one of their primary concerns, both at initial diagnosis as well as during later stages (68–70). 
Moreover, HRQOL has been shown to correlate with survival both in newly diagnosed (44, 64, 71) 
and in relapsed, refractory patients (72). Thus, symptoms provide meaningful information (73) and 
HRQOL yields prognostic information in conjunction with clinical markers (74). The challenge is the 
routine integration of collecting PRO information in the clinical setting. Routine collection of PROs 
has been shown to be feasible and efficient in SCT (75), approaches that could be translated to the 
myeloma setting.  
Conclusion 
This meta-analysis identified pain, fatigue and aspects of functioning as most common and 
burdensome symptoms in multiple myeloma. Some problems such as financial difficulties and sexual 
concerns, traditionally associated with later stages of disease, were present with a high prevalence 
even shortly after diagnosis or at the beginning of SCT. Awareness and studies of the symptom 
patterns over time may help optimise symptom management for patients with multiple myeloma. 
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(%) 95% CI I² (%) 
Pain 15 1882 58.6 8.8 – 95.2 12.0 
Severe pain 10 1136 44.7 2.2 – 96.7 24.7 
Bone aches 4 572 41.0 0 - 1 100.0 
Fatigue 13 1204 98.8 98.1 – 99.2 0.2 
Severe fatigue 7 620 59.7 12.9 – 93.7 11.2 
Weakness 3 264 21.6 0.1 – 99.7 100.0 
Tiredness 3 318 46.9 0.2 – 99.7 100.0 
Sleep problems 11 1075 34.5 3.8 – 87.4 100.0 
Severe sleep problems 4 245 32.1 1.9 – 92.1 36.6 
Feeling sick 2 254 13.5 0.0 – 100.0 37.9 
Dizziness 3 428 36.8 0.2 – 99.5 100 
Drowsiness 3 308 40.6 0.3 – 99.4 9.8 
Appetite loss 8 770 42.7 5.3 – 90.8 23.4 
Severe appetite loss 4 245 32.8 2.0 – 92.2 26.6 
Nausea 4 541 16.9 0.1 – 99.0 50.7 
Vomiting 2 109 9.5 0.1 – 99.4 12.0 
Nausea/vomiting 10 981 17.7 1.1 – 80.5 21.4 
Severe nausea/vomiting 4 245 2.7 0.1 – 59.7 2.2 
Diarrhoea 8 805 40.7 4.8 – 90.4 6.8 
Severe diarrhoea 4 245 21.1 0.8 – 89.9 5.7 
Constipation 7 639 66.5 23.5 – 92.8 13.2 
Severe constipation 4 245 45.2 4.6 – 93.4 17.9 
Breathlessness 7 540 36.6 3.3 – 90.7 36.3 
Severe breathlessness 4 245 33.0 1.8 – 92.2 17.0 
Cough* 1 253 42.0 23.9 – 60.0 - 
Mouth problems 7 1047 21.4 0.1 – 98.3 43.6 
Severe mouth problems* 1 154 17.1 1.4 – 35.6 - 
Problems remembering 3 281 42.6 0.1 – 99.9 100.0 
Difficulty paying attention* 1 100 8.0 1.3 – 29.1 - 
Tingling in hands/feet 4 481 53.4 0.4 – 99.7 98.3 
Severe tingling* 1 154 32.0 10.8 – 53.1 - 
Distress 4 379 27.8 0.0 – 100.0 100 
Anxiety 10 835 35.7 1.0 – 96.9 46.1 
Case of anxiety 8 720 26.7 0.2 – 98.4 100 
Depression 11 1028 22.3 0.3 – 96.2 86.4 
Case of depression 9 774 23.6 0.3 – 97.3 73.5 
Sexual problems 3 115 23.5 0.2 – 98.1 51.5 
Muscle cramps 2 176 6.9 0.0 – 99.5 21 
Peripheral edema 2 176 6.5 0.0 – 99.5 29 
Quality of life problems      
Decreased physical functioning 13 1424 98.9 98.2 – 99.3 0.5 
Severely decreased physical 
functioning 4 245 27.3 1.4 – 91.1 12.5 
Decreased role functioning 9 941 67.0 21.2 – 93.9 17.3 
Severely decreased role 
functioning 4 245 46.7 5.0 – 93.6 28.4 
Decreased emotional functioning 9 1005 57.7 12.5 – 92.9 10.4 
Severely decreased emotional 




Decreased cognitive functioning 5 577 80.2 40.0 – 96.1 3.3 
Severely decreased cognitive 
functioning 4 245 14.1 0.4 – 87.2 20.3 
Decreased social functioning 8 855 58.0 12.2 – 93.2 6.8 
Severely decreased social 
functioning 4 245 28.6 1.5 – 91.5 23.5 
Most severe disease symptoms 2 187 1.5 0.0 – 100.0 100 
Most severe side effects  3 219 15.1 0.0 – 99.5 7.4 
Worry about dying/future 6 569 49.7 1.1 – 98.9 16.4 
Severe worry about dying 3 341 11.9 0.0 – 100.0 43.6 
Problems with body image 3 228 41.3 0.1 – 99.7 13.5 
Financial difficulties 7 673 78.4 39.1 – 95.4 5.0 
Severe financial difficulties 4 245 43.3 4.2 – 93.1 6.9 
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Table S1. MeSH (Medical Subject Headings) terms and key words used in the systematic 
literature search. 
Concept    
Multiple 
myeloma 





plasm* cell myelom* 
myelomatosis 
exp Leukemia, Plasma 
Cell/ 
plasm* adj3 neoplas* 
 kahler* 
non-hodgkin*.mp. 









Hematopoietic Stem Cell 
Transplantation/ 
Stem Cell 
Transplantation/  Bone 
Marrow Transplantation/ 
Symptoms Symptoms  
Signs and symptoms/  
Signs 
"Quality of Life"/ 








Depressive disorders / 
Drowsiness  
Weakness  





Shortness of breath  
Breathlessness  











Constipation /  
Obstipation  
Diarrhea / 
Dry mouth  































Figure S1. Forest plot of the most common symptoms and problems in multiple myeloma with a 
pooled prevalence estimate of >50%. The final pooled logit was back transformed, resulting in 





















Table S2. Change in symptom prevalence and quality of life over time in included longitudinal 
studies 
Symptom Study Time point Prevalence 
Pain Anderson et al 2007 (17) Baseline 21.0 
  Conditioning 12.0 
  At transplant 11.0 
  At nadir 27.0 
  30 days post transplant 9.0 
 Coleman et al 2002 (38) Baseline  17.0 
  At transplant 9.2 
  6 days post transplant 26.4 
  12 days post transplant 8.1 
 Jones et al 2013 (21) Pre transplant 35.9 
  Post transplant 42.0 
 Sherman et al 2009 (60) Pre transplant 39.0 
  Post transplant 30.9 
Bone aches Jones et al 2013 (21) Pre transplant 18.0 
  Post transplant 19.0 
Fatigue Anderson et al 2007 (17) Baseline 29.0 
  Conditioning 22.0 
  At transplant 32.0 
  At nadir 55.0 
  30 days post transplant 34.0 
 Jones et al 2013 (21) Pre transplant 45.3 
  Post transplant 68.0 
 Sherman et al 2009 (60) Pre transplant 94.7 
  Post transplant 89.4 
Weakness Anderson et al 2007 (17) Baseline 14.0 
  Conditioning 13.0 
  At transplant 23.0 
  At nadir 52.0 
  30 days post transplant 31.0 
 Jones et al 2013 (21) Pre transplant 18.0 
  Post transplant 38.0 
Sleep problems Anderson et al 2007 (17) Baseline 8.0 
  Conditioning 34.0 
  At transplant 26.0 
  At nadir 39.0 
  30 days post transplant 14.0 
 Jones et al 2013 (21) Pre transplant 18.0 
  Post transplant 40.0 
Feeling sick Anderson et al 2007 (17) Baseline 5.0 
  Conditioning 9.0 
  At transplant 22.0 
  At nadir 42.0 
  30 days post transplant 9.0 
Drowsiness Jones et al 2013 (21) Pre transplant 16.0 





Appetite loss Anderson et al 2007 (17) Baseline 5.0 
  Conditioning 22.0 
  At transplant 34.0 
  At nadir 56.0 
 
 
30 days post transplant 
 
11.0 
Nausea/vomiting Anderson et al 2007 (17) Baseline 3.0 
  Conditioning 14.0 
  At transplant 25.0 
  At nadir 35.0 
  30 days post transplant 6.0 
 Coleman et al 2002 (38) Baseline  11.9 
  At transplant 35.6 
  6 days post transplant 33.3 
  12 days post transplant 9.2 
Diarrhoea Anderson et al 2007 (17) Baseline 2.0 
  Conditioning 5.0 
  At transplant 9.0 
  At nadir 34.0 
  30 days post transplant 2.0 
 Coleman et al 2002 (38) Baseline  1.2 
  At transplant 5.8 
  6 days post transplant 23.0 
  12 days post transplant 20.7 
Breathlessness Anderson et al 2007 (17) Baseline 10.0 
  Conditioning 6.0 
  At transplant 4.0 
  At nadir 16.0 
  30 days post transplant 8.0 
Mouth problems Anderson et al 2007 (17) Baseline 2.0 
  Conditioning 1.0 
  At transplant 0.0 
  At nadir 17.0 
  30 days post transplant 1.0 
 Jones et al 2013 (21) Pre transplant 8.0 
  Post transplant 57.0 
Distress Anderson et al 2007 (17) Baseline 17.0 
  Conditioning 9.0 
  At transplant 14.0 
  At nadir 20.0 
  30 days post transplant 10.0 
 Bergerot et al 2015 (33) Baseline 60.0 
 
 





Last day of 
chemotherapy 
0.0 
Anxiety Bergerot et al 2015 (33) Baseline 60.0 
 
 












 Pillay et al 2015 (54) Pre transplant 18.3 
  2-3 weeks post transplant 13.3 
  3 months post transplant 8.3 
 Sherman et al 2009 (60) Pre transplant 39.4 
  Post transplant 44.7 
Depression Anderson et al 2007 (17) Baseline 13.0 
  Conditioning 7.0 
  At transplant 7.0 
  At nadir 16.0 
 
 
30 days post transplant 5.0 
 
 Bergerot et al 2015 (33) Baseline 60.0 
 
 





Last day of 
chemotherapy 
0.0 
 Campbell et al 2011 (37) At hospital admission 23.0 
  At discharge 37.0 
  3 months post transplant 27.0 
  6 months post transplant 26.0 
  12 months post transplant 23.0 
 Pillay et al 2015 (54) Pre transplant 8.3 
  2-3 weeks post transplant 13.3 
  3 months post transplant 8.3 
 Sherman et al 2009 (60) Pre transplant 40.4 
  Post transplant 48.4 
Quality of life 




Pillay et al 2015 (54) Pre transplant 60.0 
 2-3 weeks post transplant 85.1 
  3 months post transplant 47.5 
 Sherman et al 2009 (60) Pre transplant 70.2 
  Post transplant 43.6 
Decreased role 
functioning 
Pillay et al 2015 (54) Pre transplant 23.3 
 2-3 weeks post transplant 70.2 
  3 months post transplant 35.0 
 Sherman et al 2009 (60) Pre transplant 57.5 
  Post transplant 67.0 
Decreased emotional 
functioning 
Pillay et al 2015 (54) Pre transplant 40.0 
 2-3 weeks post transplant 29.8 
  3 months post transplant 25.0 
 Sherman et al 2009 (60) Pre transplant 19.2 
  Post transplant 16.0 
Decreased social 
functioning 
Pillay et al 2015 (54) Pre transplant 1.7 
 2-3 weeks post transplant 6.4 
  3 months post transplant 2.5 
 Sherman et al 2009 (60) Pre transplant 2.1 





Erratum to: Prevalence of symptoms in patients with multiple myeloma – a systematic 
review and meta-analysis  
The following table presents the re-calculated meta-analytic results originally presented in Table 2 
on page 424 of the article. The decision to re-analyse the results was made after checking the 
results and forest plots of the original meta-analysis and noticing the biasing effect of small study 
estimates from Priscilla et al. (2011) (1) and Federico et al. (2013) (2). This was pointed out by 
the examiners of the thesis. The bias in the analysis should have been picked up before 
publication, as the forest plots presented in the supplementary appendix to the paper clearly show 
a problem with the pooling of individual prevalences. This was a learning point for me, to use 
visualisations of analysis results and how this can help to check results for common sense. 
The most likely cause for this bias was in the incorrect pooling of estimates under the random 
effects model using the generic inverse variance weighting technique applied within the SPSS 
macro provided by Lipsey & Wilson (2001) (3). Although the use of the SPSS macro is not fully 
detailed in the paper, it was in the thesis.Therefore, all meta-analyses of prevalence of symptoms 
and quality of life problems were re-calculated with forest plots redrawn using the ‘meta’ package 
in R (Schwarzer, 2015) (4). These results are presented in the following table. The forest plots 
originally presented in Figure S1 of the “Supplemental material” appendix are included 
subsequent to Table 2. For meta-analysis, the same technique of logit transformation was 
followed. However, confidence intervals are calculated using normal approximation as available 
within the R package meta. 
 
References: 
(1) Priscilla D, Hamidin A, Azhar MZ, Noorjan KON, Salmiah MS, Bahariah K. Quality of life 
among patients with hematological cancer in a Malaysian hospital. Medical Journal of Malaysia. 
2011; 66: 117-120. 
(2) Federico V, Cartoni C, Levi A, Meloni E, Gentilini F, Biagioli G, Finsinger P, Foa R, Petrucci 
MT. Evaluation of symptom assessment and health-related quality of life in MM patients 
followed in simultaneous care. Clinical Lymphoma, Myeloma & Leukemia. 2013; 14: 237. 
(3) Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks: Sage; 2001. 
(4) Schwarzer G. meta: General package for meta-analysis. 2015. Available at: https://cran.r-















Figure S1. Forest plot of the most common symptoms and problems in multiple myeloma. The 
































2.2.2.2 Longitudinal quality of life in multiple myeloma 
Although symptom prevalence has been studied in a variety of multiple myeloma samples and in 
various settings (369), and multiple myeloma is increasingly becoming a chronic cancer with 
many patients living years with their disease, longitudinal studies examining changes in QOL and 
its component parts are rare. Table 2 lists the available evidence from clinical trials, studies in 
ASCT populations and observational studies in multiple myeloma. All longitudinal evidence 
stemming from mixed populations was excluded since multiple myeloma is a unique blood cancer 
with a specific profile of QOL and symptom burden (27,88). 
Despite the call for inclusion of QOL as a standard secondary endpoint in clinical trials (287), 
HRQOL as endpoints were only included in a few randomised controlled phase II and phase III 
trials in multiple myeloma (see Table 2) (23,82,365,366,370-377). Almost all of these trials 
reported an improvement of QOL or its component scores over the course of treatment with single 
or combination drug anti-myeloma regimens. One exception is the phase III trial by Dimopoulos 
and coauthors (2013,2014) (373,374). The authors reported a worsening of physical functioning 
but improvement or stabilisation of general QOL in a sample of newly diagnosed multiple 
myeloma patients. It is not possible to extrapolate a common QOL trajectory from this data since 
clinical trial samples are usually selected according to narrowly defined eligibility criteria and 
may exclude elderly patients with comorbidities, a group that constitutes the majority of myeloma 
patients (58,145,147,148).  
Four studies followed newly diagnosed patients and patients with relapsed or refractory disease 
for up to 3 years after autologous stem cell transplantation (32,33,35,378). Except for the newest 
observational study by Wang and co-authors (2015) (379), all of these studies included a baseline 
pre-transplantation. Two studies utilised data from clinical trials and presented secondary, 
separate analyses of QOL data (32,378). Except for Sherman et al. (2009a,b) (33,35), they 
reported transient increases in symptom burden and QOL impairment that lasted a maximum of 
six months after the procedure (32,378). Campagnaro et al. (2008) (378) described an even earlier 
recovery of symptom burden after the nadir of counts was reached. Wang et al. (2015) (379), 
tracking prevalence of symptoms over a period of 3 to 9 months post ASCT, contradicted this 
finding by showing that more than a third of the sample experienced a continuously high 
symptom burden with several symptoms, among them fatigue, pain, peripheral neuropathy and 
bone aches. However, the authors did not describe corresponding QOL trajectories in their sample 
and focused on point prevalence at each assessment time point instead. Sherman et al. (2009a,b) 





Table 2: Longitudinal health-related QOL data in multiple myeloma (100%), (a) clinical trials, (b) 
stem cell transplantation samples (SCT), (c) observational studies. 
Study (year) Treatments/ sample 
QOL 
instruments QOL results 
(a) Clinical trials    
Verelst et al. (2011) 
(370) 
HOVON 49 trial 
MP (n = 168) vs MPT-
T (n = 165), NDMM 
QLQ-C30 
QLQ-MY24 
Equal improvement of QOL 
Waage et al. (2010) 
(371) 
NMSG trial  
MP (n = 175) vs MPT 
(n = 182), NDMM 
QLQ-C30 Equal QOL improvement in both arms 
Delforge et al. 
(2012) (365) 
VISTA trial 
MP (n = 338) vs 
VMP (n = 344), 
NDMM 
QLQ-C30 Better QOL with once-weekly 
bortezomib, initial deterioration and 
above-baseline levels post-tx 
Niesvisky et al. 
(2013) (372) 
UPFRONT trial 
VD (n = 100) vs 
VTD (n = 100) vs 
VMP (n = 100), 
NDMM 
QLQ-C30 Transient decrease in QOL in all arms 
during induction,  
improvement or stabilization during V-
maintenance 




MP (n = 154) vs MPR 
(n = 153) vs MPR + R-




Improvement of QOL during induction, 
thereafter stabilization of QOL, 
worsening of physical functioning 
Delforge et al. 
(2015) (366) 
FIRST trial 
Rd 18 cycles (n = 541) 
or continuous till PD 





Equal improvement for preselected 
domains: pain, fatigue, disease 
symptoms, physical functioning, global 
health scale 
Dubois et al. (2006) 
(23) 
SUMMIT-trial 
V monotherapy, If PD 
or stable disease after 







Fatigue scores improved in responders 
with a positive  correlation between 
QOL and Fatigue 
Lee et al. (2008) 
(375) 
APEX-trial 
V (n = 296) vs  
D (n = 302), RRMM 
QLQ-C30 
FACT-NTx 
With V better FACT-NTx scores and 
better QOL compared to D 
Hjorth et al. (2012) 
(376) 
NSMG trial 
In M-refractory: TD (n 
= 67) vs VD (n = 64), 
RRMM 
QLQ-C30 No QOL improvement over time in both 
arms 
Alegre et al. (2012) 
(377) 
MM-018 trial 




Improvement in future perspective 
score, no other significant changes in 
QOL 
Weisel et al. (2015) 
(82) 
MM-003 trial 
In V- and R refractory 
patients: Pom+Low 
dose Dex (n = 302) vs 





Favorable trends for 7/8 pre-selected 
QOL domains in Pom-Dex-group 
(global health, side effects of treatment, 
physical/ emotional functioning, pain, 
fatigue, health utility) 
(b) ASCT     
Campagnaro et al. 
(2008) (378) 
3 years 
64 NDMM and 
RRMM undergoing 
HDC + ASCT 
MDASI-BMT Symptom burden increase from baseline 
to nadir of counts, majority returning to 
baseline by Day 30 
Gulbrandsen et al. 
(2001) (32) 
3 years 
Secondary analysis of 
RCT HDC + ASCT (n 
= 334) 
QLQ-C30 Improvement in global QOL until 6 
months follow-up, only small trend 
towards better physical functioning at 3 
years, all domain scores improve after 6 
months except for emotional 
functioning 
Sherman et al. 
(2009a,b) (33,35) 
3 months 
Observational study of 
94 NDMM  
FACT-G 
FACT-BMT 
Deterioration of FACT-BMT and 
depression and life satisfaction scores 




Wang et al. (2015) 
(379) 
6 months 
Observational study 3 




35% in high symptom group throughout 
6 months follow-up, highest symptom 
ratings for fatigue, pain, numbness, 
bone aches and muscle weakness 
(c) Observational studies 







QLQ-C30 Small but significant deterioration in 
physical, role, emotional, cognitive, 
social funtioning 
Mols et al. (2012) 
(381) 
1 year 





Worsening of QOL, fatigue, 
nausea/vomiting, pain and dyspnoea 
over one year 
ASCT, autologous stem cell transplantation, D, dexamethasone, EQ-5D, EuroQOL -5D, FACT-BMT, Functional 
Assessment of Cancer Therapy Bone Marrow Transplantation module, FACT-G, Functional Assessment of Cancer 
Therapy General , questionnaire, FACT-NTx, Functional Assessment of Cancer Therapy chemotherapy-related side 
effects questionnaire, HDC, high dose chemotherapy, M, melphalan, MDASI-BMT, M.D. Anderson Symptom 
Inventory Bone Marrow Transplantation module, NDMM, newly diagnosed multiple myeloma, P, prednisone, PD, 
progressive disease, Pom, pomalidomide, QLQ-C30, EORTC quality of life questionnaire C30, QLQ-MY, EORTC 
quality of life questionnaire myeloma module, QOL, quality of life, R, Revlimid, RCT, randomised controlled trial, Rd, 
Revlimid maintenance, RRMM, relapsed refractory multiple myeloma, T, thalidomide, V, Velcade 
 
newly diagnosed multiple myeloma patients. They also reported a worsening of depression and 
anxiety over this time period. Again, generalising from ASCT populations to how QOL might 
change over time in multiple myeloma is difficult due to the selected nature of individuals in these 
studies (145). This is true for all treatment-defined samples (380). 
Only one observational study employing a population perspective was published by a group from 
the Netherlands using data from the Eindhoven Cancer Registry (381). In this prospective study, 
the EORTC QLQ-C30 together with its myeloma module was sent to 156 patients who had been 
diagnosed with myeloma from 1999 to 2010. Two questionnaire packs were sent one year apart to 
derive one-year follow-up scores of symptoms and disease-specific complaints. Statistically 
significant and clinically relevant (using minimal important differences, MIDs, derived by Kvam 
and co-authors (368,382,383)) worse scores, compared to a norm population, were observed on all 
QLQ-C30 subscales at both time points. For the analysis of changes over time, the final sample 
was considerably smaller (n = 80). Sixty-five up to 90% of patients reported a deterioration of 
functioning and/or symptom subscales with the most prominent worsening reported for fatigue, 
nausea and vomiting, pain and dyspnoea (381). The study demonstrates the considerable disease 
burden which is present for patients regardless their stage of disease or the time elapsed since 
diagnosis. 
To glean more information on how QOL scores change over time, results from the EORTC QLQ-
C30 and its subscales were graphed for all longitudinal studies listed in Table 2. These trajectories 
can be seen in Figure 5. The first figure shows all subscales from the EORTC QLQ-C30. Since 




panel shows trajectories of disease-specific subscales. These are interpreted differently, with 
higher values signifying more disease-specific symptoms and complaints in the different domains. 
Since financial difficulties have been reported as one of the major problems in multiple myeloma 
(358,384,385), the QLQ-C30 subscale ‘Financial difficulties’ was also graphed. Overall, general 
QOL and emotional functioning seem to be the domain with the most complaints over time, 
followed by physical functioning and social functioning. A worsening of functioning scores up to 
4 months is seen, with gradual but heterogeneous recovery of scores. A similar picture is present 
for disease-specific subscales, except for body image and future perspectives subscales. These 
show a high level of severity throughout. However, it must be kept in mind that this data largely 
stems from ASCT studies and randomised controlled trials and trajectories observed might be a 
direct reflection of treatment-related patterns. Synthesising information from these studies should 
be interpreted with caution because of the considerable heterogeneity within this comparison. 
Also, mean trajectories can obscure aberrant change scores and lead to the assumption of a more 
homogeneous picture with not much fluctuation despite the existence of subgroups that might 
experience a very different trajectory than the depicted mean trajectory (386). 
To sum up, the evidence on how QOL changes over time in multiple myeloma is scarce with only 
one study employing a true population perspective and remaining studies using treatment-defined 
samples. The study by Mols et al. (2012) (381) only used two time points and this does not 
provide a clear picture of the change in experiences of patients. QOL scores reflect the course of 
treatment with many patients seemingly reporting a recovery and improvement in QOL and its 
domains at month four to six post autologous stem cell transplantation. Evidence on changes in 
QOL in later stages of disease and the existence of subgroups within the relative heterogeneous 
group of myeloma patients have not been explored. For generalisability/external validity, a study 
is needed that does not recruit patients that are defined by the treatment regimen they receive. 
The last section within this chapter on symptom burden and QOL in multiple myeloma reviews 
the factors that are associated with a poor QOL in this disease. For this analysis, data from all 
studies reporting cross-sectional or longitudinal studies was pooled and regression or correlation 
coefficients between independent variables (demographic characteristics, clinical and disease 
characteristics, symptom burden, stage of illness etc.) and the outcome were subjected to a meta-





Figure 5: Comparison of findings from this study to QOL meta-analysis: severity of symptoms, QOL 
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Multiple myeloma is associated with a higher burden of disease than other haematological 
cancers. To target services towards those in need of support, we need to understand who is at risk 
of developing poor health-related quality of life (HRQOL). We conducted a summary-data meta-
analysis to systematically review, assess and analyse the strength of association between 
demographic, disease and treatment-related factors and HRQOL in multiple myeloma. We 
searched Medline, Embase, PsycINFO, Cinahl, Assia, the Cochrane library and NHS EED 
databases, journals and citations. Two independent raters reviewed abstract and full-texts. Meta-
analysis used Fisher’s z method for Pearson correlations (effect size), inverse variance weighting 
and random effects per factor. Of 15,083 references, 34 studies totalling 6,794 participants were 
included. The largest effect sizes were found for nutritional risk (r=-0.54, 95% CI -0.73 to -0.35), 
fatigue (r=-0.52, 95% CI -0.57 to -0.47), and pain (r=-0.45, 95% CI -0.5 to -0.39). Medium 
associations were reported for symptoms and physiological parameters, e.g. M-protein level, and 
cytokines. High hemoglobin was a moderate protective factor for HRQOL (r=0.39, 95% CI 0.33 
to 0.44). Demographic, disease- and treatment-related factors showed weak associations only, 
except for response to treatment (achieving at least a partial response: r = 0.29, 95%CI 0.24 to 
0.34). Early detection of those at risk for developing poor HRQOL should consider symptoms as 
well as biochemical factors and cannot focus on response to treatment or assessment of 
paraprotein alone. Regular measurement of symptoms can help screen for those with poor QOL. 
 






Multiple myeloma is the second most common hematological malignancy in the UK [1], an 
incurable cancer of the bone marrow that affects mainly older people, with a median age at 
diagnosis of 70-74 years [2]. As such, multiple myeloma is an example for the changing face of 
cancer, as a condition that may be managed as a chronic illness with a recurrent pattern of 
treatments followed by maintenance therapy [3]. Front-line treatment with high-dose 
chemotherapy and transplant has improved median survival for those under the age of 65 to five 
years or longer [1]. 
These improvements in survival time and duration of response have led to a need to evaluate and 
better understand patient-reported outcomes such as health-related quality of life (HRQOL), to 
capture benefits and adverse effects alongside traditionally used parameters such as response to 
treatment and toxicity profiles. There is evidence that HRQOL is substantially impaired in 
myeloma with patients suffering more symptoms and problems than in other haematological 
cancers [4] and through all phases of their disease [5]. HRQOL has also been shown to be a 
predictor for survival alongside clinical parameters [6]. In addition to the disease and its treatment 
affecting daily life, the economic burden of multiple myeloma is among the highest compared to 
all cancers [7], due to treatment, supportive and indirect societal costs.  
Identifying determinants of poor outcome can help target services to those individuals most at risk 
[8]. This can help to identify prognostic indicators and planning of early and preventive 
interventions. Focusing on what predicts poor HRQOL also helps to bring a patient-centred 
perspective into care in a condition that is long-lasting and incurable. To date, reviews examining 
correlates of QOL have focused either on treatment populations or mixed haematological samples 
[9-14], and have provided a narrative synthesis but have not determined the relative strength of 
association between determinants and outcomes. Therefore, there is controversy in the literature 
regarding the impact of various socio-demographic (e.g. age, ethnicity), disease (e.g. length of 
survival, phase of disease) and treatment factors (e.g. receiving specific types of chemotherapy) in 
terms of weak or inconclusive evidence [9,11,13].  
Knowledge of the factors that are associated consistently and strongly with the outcome poor 
QOL can help focus assessment in clinical trials and in routine clinical practice towards those 
variables that act as risk factors [15,16].  
The aim of this meta-analysis is to assess the strength of association between demographic, 
disease, treatment and psychosocial factors with HRQOL to understand which myeloma patients 







The design of this study is a systematic literature review with meta-analysis following the 
PRISMA guidance [17].  
Searches 
The online databases Ovid Medline, Embase, PsycINFO, Ebscohost CINAHL, ProQuest ASSIA, 
the Cochrane Library and Centre for Reviews and Dissemination NHS Economic Evaluations 
database were searched from their inception to March 2015. The search was supplemented by 
contacting authors, hand-searching bibliographies of reviews on HRQOL in myeloma [9-14], key 
journals (Quality of Life Research, European Journal of Haematology, Blood, Bone Marrow 
Transplantation, Biology of Blood and Marrow Transplantation, British Journal of Haematology, 
Psycho-Oncology), citation and reference searches and a Web of Science search for conference 
abstracts. Grey literature was not searched because the majority of ongoing studies could likely be 
identified through databases and searches for conference abstracts [18]. (For search strategy see 
Online Appendix A) 
Study selection 
Published studies were considered if they met the following eligibility criteria:  
(a) Adult (≥18 years) homogeneous or mixed samples including at least 50% of patients with 
multiple myeloma of all disease stages on- or off-treatment. This cut-off was used to ensure an 
adequate relevance and specificity of the results to myeloma; 
(b) Outcomes assessed being either HRQOL, measured by using a single global item, a subscale 
or a total score from a validated HRQOL measure. In addition, distress was included as a proxy 
for HRQOL in the systematic review but not the meta-analysis, measured by any validated tool; 
 (c) Statistical analysis producing an estimate of the association of the independent (IV) with the 
dependent variable (DV) HRQOL;  
(d) Studies could be of any quantitative or mixed-method design, except reviews or case 
studies/series; 
(e) There was a language restriction to English, German, Italian, Spanish and Portuguese.  
After de-duplication, titles and abstracts were independently reviewed by two reviewers (CR, PK) 
against the eligibility criteria. Full-texts and results from additional searches were screened by one 
reviewer only (CR). 
Data extraction and analysis  
Data on design and outcomes were extracted using a standardised and piloted Excel form. A 
checklist for prognostic factor studies was used to assess methodological quality [19,20]. The 
maximum quality score was further stratified into low (<45 points), medium (≥45 to <60), and 




two independent reviewers were resolved by consensus. Overall κ [22] was 0.76. Predictor 
variables were grouped for data synthesis following the theoretical framework for HRQOL by 
Wilson & Cleary [23]. Data analysis followed a two-stage approach. First, predictor variables and 
their outcomes were tabulated and analysed using data synthesis and vote-counting [24]. Vote-
counting also provides a more-fine-grained view of all predictors and their associations to 
subscales as well as total HRQOL scores. 
To enable direct comparison of correlations, the HRQOL subscales and total scores were 
transformed in the same direction with high scores always indicating good HRQOL (multiplying 
by -1 if necessary). The Pearson r was calculated as the effect size metric for the correlations 
between IVs and HRQOL (either total score or an average of reported domain scores if a total 
score was not provided). If possible, zero-order correlations were used to estimate effect sizes. 
Imputation of r from other statistical values (beta weights, odds ratios, p values or R2) was used if 
necessary [25,26]. In case authors reported that correlations were significant or non-significant an 
effect size of zero for non-significance and a p value of <0.05 for significance was assigned. This 
is seen as a conservative approach because the actual p values are likely to have been smaller. 
Estimation of effect sizes from values other than r was necessary in 2/5 of cases, reflecting the 
heterogeneity in quality of reporting in included studies. Correlation coefficients were 
transformed into Fisher’s z [25] for meta-analysis, back-transformed and plotted in a forest plot. 
Data from all studies was pooled per independent factor using inverse variance weighting and a 
random effects model (as more than one population effect size was likely to be estimated due to 
the heterogeneous nature of multiple myeloma). Weighted effect sizes were considered significant 
when the 95% confidence interval excluded zero. Effect sizes were categorised into a weak 
(r≤0.30), moderate (r=0.30-0.49) and large effect size (r≥0.50) [27]. Because of necessary 
independence of effect sizes in meta-analysis [25], each study could only contribute one effect 
size per independent factor. Heterogeneity could not be assessed due to no pooled overall effect 
being calculated. Rosenthal’s fail-safe N [28] was calculated for estimating publication bias using 
the formula x=k(average effect size/lowest mean r -1). A criterion effect size of r=0.10 was 
chosen. Publication bias was not present as the fail-safe N is less than five times the number of 
existing studies plus ten. 
For meta-analysis, the metafor package in R 3.0.1 and an SPSS Macro [25] were used. The forest 







The database search identified 16,886 articles and other sources yielded 5 further articles (see 
PRISMA flowchart in Figure 1). Of the 1,259 screened full-texts, the majority (n = 925) was 
excluded because of failure to report an association or not reporting HRQOL. 54 studies included 
samples of less than 50% of patients with multiple myeloma. 43 studies were included with 39 
presenting enough data for meta-analysis.  
Description of included studies 
Table 1 presents the study characteristics for HRQOL. The number of articles exceeds the number 
of studies as some studies were reported in more than one article. 39 studies reporting correlations 
with HRQOL included 7,391 participants and 7,082 myeloma patients. Of these studies, 21 were 
longitudinal in nature [29-48]. The pooled mean age across all studies was 60 with a range of 24 
to 91. 11 studies used mixed haematological samples with the lowest proportion of myeloma 
being 53% [49]. The majority of samples were on treatment, receiving stem cell transplantation 
[5,29-31,45-47,37-39,41,44,49-57], or chemotherapy [33-36,42,43,58-63] 
Methodological quality 
The detailed quality assessment of all included studies is presented in Online Appendix B. Owing 
to the high number of cross-sectional studies and conference abstracts, the median quality rating 
score was low to medium (Median=48.5). Nine studies scored high quality, 24 medium, and ten 
low quality. Bias was mainly associated with attrition, with little information on those participants 
lost to follow-up. Prognostic factor measurement was judged poorly because of absence of clear 
hypotheses. Statistical analysis was poor in some cases (i.e. univariate models in cases where 
multivariate models would have been more appropriate). 
Factors that influence HRQOL 
Factors associated with HRQOL were assessed in 34 studies. There was consistency in the choice 
of measurement tools to measure the outcome (see Table 1). The display of weighted correlation 
coefficients and their confidence intervals is shown in Figure 2 with values shown in Online 






















Records identified through database 
searching 
n = 16,886 
Medline = 5,068 
EMBASE = 8,130 
PsycINFO = 1,012 
CINAHL = 1,144 
Cochrane = 1,315 
ASSIA = 149 
























Additional records identified 
through other sources 
n = 5 
Records after duplicates removed 
n = 11,358 
Duplicates = 5,533 
Records screened 
n = 11,358 
Records excluded 
n = 10,099 
Full-text articles assessed for 
eligibility 
n = 1,259 Full-text articles excluded  
n = 1,216 
Reasons: 
Excluded-dissertation: 15 
Excluded –not correct design: 926 of which: 
   Review: 61 
   Only descriptive analysis: 213 
   Not correct outcome: 632 
   Outcome is survival: 20 
Excluded-not meet sample criterion: 276 
Excluded because sample >50% MM: 54 
Articles included in 
qualitative synthesis 
n = 43 
Studies included in 




























Figure 2 Pearson weighted correlations between all independent variables investigated in the 
included studies and the dependent variable HRQOL. Independent variables are grouped into 
demographic, disease-related, physiological, treatment-related factors, symptoms, emotional 
distress and psychosocial factors. The outcome HRQOL is scored in a way that a high score 
indicates better health status/quality of life, thus factors on the left hand side indicate risk factors 
for poor HRQOL and factors on the right-hand side indicate protective factors. 
 
Legend: ISS: International staging system, MCP-1: monocyte chemotactic protein 1, MM: 
multiple myeloma, NHL: Non-Hodgkin lymphoma; sTNF-R1: serum tumour necrosis factor-R1, 





Few of the demographic, disease-related, treatment-related, physiological, symptoms, emotional 
distress and psychosocial factors showed moderate to large associations to HRQOL. Demographic 
factors (age, gender, ethnicity etc.), disease factors (such as stage of disease, time since diagnosis, 
number of comorbidities) and psychosocial factors had zero to small correlations to HRQOL. For 
example, gender, ethnicity and weight/BMI were the only three demographic variables that 
emerged as weakly associated factors to better QOL in the meta-analysis. Female gender showed 
a low weighted correlation of r = 0.08 (95% CI: 0.03 to 0.13), ethnicity was estimated as r = 0.15 
(95% CI: 0.01 to 0.28).  
Poorer HRQOL was significantly associated with biochemical/physiological factors and 
parameters of disease activity such as M-Protein level, ß2-Microglobulin, C-reactive protein, 
serum creatinine, calcium and albumin and pro-inflammatory factors (IL-6, TNF-α, TNF-R1; r = -
0.09 to -0.38). Functional status, assessed using ECOG performance status, the only factor 
measured in seven studies with 1,464 participants, showed only a weak association to poorer QOL 
(r = -0.21, 95% CI: -0.27 to -0.16). The strongest negative association (r = -0.54, 95% CI: -0.73 to 
-0.35) was reported for nutritional risk, defined as change in weight change, change in food 
intake, difficulty eating and lower functional capacity [51]. Higher haemoglobin was moderately 
associated with better HRQOL (r = 0.39, 95% CI: 0.33 to 0.44).  
No disease-related factor reached moderate to high association. A weak to moderate relationship 
to HRQOL was found by response to treatment in five studies [31,32,44,46,47] with an r of 0.29 
(95% CI: 0.24 to 0.34, n=1,360). However, duration of response did not have a significant 
influence, with a large confidence interval mainly stemming from its differential impact on 
different domain scores. The only other significant association in this group was found for type of 
treatment with a negative weak impact on HRQOL (r = -0.19, 95% CI: -0.28 to -0.10, n=453). 
Receiving thalidomide was negatively associated with role, social and global quality of life 
(QOL).  
By contrast, symptoms had some of the highest correlations to global QOL (single item). The 
weighted correlation coefficient for fatigue was r = -0.52 (95% CI: -0.57 to -0.47, n=902). The 
second largest independent factor was pain/bone pain with a moderate association of r = -0.45 
(95% CI: -0.50 to -0.39, n=932). Poor appetite and difficulty in thinking/changing mental status 
had moderate weighted effect sizes. Weighted correlations for drowsiness, insomnia and 
breathlessness were in the weak range between -0.23 to -0.27 (see Figure 2). Effects were mainly 
observed on physical, social and global QOL. 
All three emotional factors, global distress, anxiety and depression were moderately correlated 
(ranging from r = -0.23 (95% CI: -0.30 to -0.16; n=749) with depression to r = -0.44 (95% CI: -




factors (religiousness, emotional control), cognitive appraisal of illness, coping (in the form of 
coping efficacy and positive/negative religious coping), and interpersonal factors (perceived 
social support, relationship cohesion) showed association in the non-significant to weak range. 
 
Discussion 
This is the first systematic review in haematology/oncology that used meta-analytical procedures 
to understand the relative impact of factors related to HRQOL in myeloma. Our review expands 
on the available evidence [9–14] for the importance of factors impacting on outcomes of HRQOL 
in multiple myeloma in three ways. (1) More factors, especially relating to disease activity have 
been included; (2) by computing effect sizes a direct comparison between factors allows an 
interpretation of their respective importance further than possible in a narrative synthesis; and (3) 
bias due to overlap between HRQOL and symptom scales present in the vote-counting approach 
was avoided by only considering correlations to global QOL items. The reported heterogeneity 
around traditionally examined risk factors such as demographic variables (age, gender, ethnicity, 
and educational background), disease or psychosocial factors [9–12] could therefore be resolved.  
Our analysis indicates that nutritional risk (in the form of weight loss, loss of lean muscle mass or 
reduced physical activity), fatigue and pain are the most important factors leading to poor 
HRQOL. Overall, these three indicators are more important than traditionally examined 
demographic risk factors (age, educational background) or stage of disease. A growing body of 
evidence supports the extent of fatigue in terms of its high prevalence and its impact on quality of 
life. Both fatigue and weight loss/anorexia-cachexia syndrome have been linked to shorter 
survival in the advanced, palliative stages of disease [75-77]. Thus, both variables could act as 
risk factors for low well-being and shorter survival in myeloma. Research in cancer patients 
points towards inflammatory processes (cytokines), anemia and metabolic status contributing to 
cancer-related fatigue alongside behavioural and well-being factors [76,78], which might explain 
the high correlations. Therefore, a focus on improving quality of life through addressing issues of 
fatigue and nutritional risk through counselling and behavioural interventions (like physical 
exercise) [79,80] could benefit those with particularly low quality of life in multiple myeloma. 
A small risk effect of ethnicity was shown for the Black African or Caribbean population in the 
UK having worse HRQOL. This finding supports the evidence of higher psychological morbidity 
and lower quality of life associated with an ethnic minority background from the United States 
[81]. 
Traditional endpoints of response to treatment were only weakly to moderately associated with 
HRQOL with correlation coefficients much smaller than those for symptoms. Overall, it is not 




impact on HRQOL [82,83]. We found that response to treatment and duration of response are not 
good proxy outcomes for HRQOL. Evaluation of patients in a clinical setting that only focuses on 
these criteria [84] will miss the patient-centred perspective and cannot reflect the impact that the 
disease and/or treatment have on the patient and his or her well-being. Outcomes like time to 
progression, progression-free survival, response and duration of response are currently the 
advocated primary outcome for phase III trials [82], a perspective that disregards the impact these 
treatments might have on the patient’s quality of life [85]. It has also prohibited the exploration of 
the linkage between HRQOL and survival, an avenue which showed prognostic significance in 
solid tumours [77,89,90]. This finding shows the need to assess HRQOL using patient-reported 
outcome measures in addition to biochemical monitoring of myeloma in a clinical setting. 
Clinically, the findings from the meta-analysis also imply that stage of disease, time since 
diagnosis and number of comorbidities [84] do not serve as good proxies for HRQOL. However, 
surveillance of biochemical parameters on their own (haemoglobin, calcium elevation, high serum 
creatinine, presence of bone disease and lactate dehydrogenase), prognostic factors for relapse and 
overall survival in myeloma [86] do show moderate correlations. The disconcordance between 
importance of biochemical and disease parameters is insofar surprising as staging systems for 
myeloma rely on the biochemical evaluation of disease [84]. Rather than the combined score, 
surveillance of these biochemical parameters may prompt clinicians to indicate the need for more 
thorough screening and assessment of quality of life. Recent electronic systems allow monitoring 
of HRQOL and adverse events for haematological patients receiving stem cell transplants or 
chemotherapy [15,16]. Screening and monitoring of HRQOL and symptoms would enable 
targeting supportive care services towards those in need and might help better symptom 
management, an avenue that warrants further exploration. 
Limitations  
The main limitation of this review concerns the inclusion of cross-sectional studies in a review of 
prognostic factors, which ideally relies on longitudinal research with a clear time-event pattern 
[87]. Hence, the results of the meta-analysis show the strength of association but not 
prognostication. However, exclusion of cross-sectional studies would have limited the 
generalisability of findings (see Appendix D). To counteract bias we refrained from calculating an 
overall pooled estimate. The review group opted for inclusion of studies that had at least 50% 
myeloma patients. 53 more studies had myeloma patients in the sample, but the majority less than 
5%. Also, a sensitivity analysis which excluded those studies with less than 100% myeloma did 
not alter the results of the meta-analysis. However, inclusion of mixed haematological samples 
resulted in associations between some factors and QOL being reported that might be important for 
a smaller part of myeloma patients, such as allografting [30].  
The heterogeneity in the assessment of independent variables and in the outcome (presentation of 




results, comparability of QOL measures was assumed [91]. This is debatable as health status 
measures might be different to measures of subjective well-being [88]. However, the effect sizes 
reported are robust and do not reflect the overlap of symptoms and quality of life outcomes, as 
only correlations between symptoms and overall quality of life (single item scale) were 
considered in the meta-analysis.  
The small number of studies per independent factor also counteracted the benefit of the meta-
analytic approach that can provide estimates of effect sizes not limited by issues of small sample 
size and power [25,92]. A power calculation revealed that in order to detect a weak to moderate 
effect of r = 0.20-0.30, a study with a significance level of 95% and a power of 80% would need 
119 participants. The smallest sample size in this review was 24 [38]. This might be the reason for 
some of the large confidence intervals and small correlations seen. Two fifth of correlation 
coefficients were imputed from other statistical information. Some authors argue against 
imputation of effect sizes from this data [91-93]. However, without imputation many factors could 
not have been considered. A conservative approach was followed throughout, and resulting 
correlation coefficients are most likely under-estimates of the real effect size. Lastly, bias might 
have been introduced by the independent second reviewer only reviewing the titles and abstract 
screening and quality assessment, but not the full-text screening and all of the data extraction. 
Conclusions  
In summary, nutritional risk, fatigue, pain and low haemoglobin are the most important risk 
factors for poor HRQOL in multiple myeloma. This meta-analysis highlights the need for good 
symptom management and patient-centred assessment alongside biochemical surveillance of 
disease progression to improve patient-monitoring, treatment and care.  Early detection of those at 
risk for developing poor HRQOL should therefore consider symptoms as well as biochemical 
factors and cannot focus on response to treatment and assessment of paraprotein alone. 
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Sample of full search strategies (used in Ovid Medline) (This search strategy was adapted to 
all the databases used in this systematic review) 
The search filter for myeloma was adapted from the Cochrane Haematological Malignancies 
group.1 Two search filters were combined and adapted for identification of HRQOL studies.2,3 
Search Block 1: Multiple myeloma  Search block 2: Quality of life 
exp Multiple Myeloma/ OR exp Plasmacytoma/ 
OR exp Leukemia, Plasma Cell/ OR exp 
Lymphoma, Non-Hodgkin/ OR exp 
Haematopoietic Stem Cell Transplantation/ OR 
exp Stem Cell Transplantation/ OR exp Bone 
Marrow Transplantation/ OR myelom$.mp. OR 
plasm?cytom$.mp. OR plasmozytom$.mp. OR 
plasm$ cell myelom$.mp. OR 
myelomatosis.mp. OR (plasm$ adj3 
neoplas$).mp. OR kahler$.mp. OR non-
hodgkin$.mp. OR nonhodgkin$.mp. OR (non 
adj2 hodgkin$).mp. OR NHL.ti. OR NHL.ab. 
OR autolog$.mp. OR auto-transplant$.mp. OR 
autotransplant$.mp. 
AND Quality of Life/ OR quality of life.mp. OR 
Value of Life/ OR Health Status/ OR Health 
Status Indicators/ OR health status.mp. OR 
Quality-Adjusted Life Years/ OR quality 
adjusted life.ti,ab. OR (qaly$ or qald$ or 
qale$).mp. OR qtime$.ti,ab. OR Treatment 
Outcome/ OR disability adjusted life.ti,ab. OR 
daly$.tw. OR Outcome Assessment (Health 
Care)/ OR  (HR-PRO or HRPRO or HRQL or 
HRQoL or QL or QoL).ti,ab. OR (health index* 
or health indices or health profile*).ti,ab. OR 
health utili$.tw. OR ((patient or self or carer or 
proxy) adj (appraisal* or appraised or report or 
reported or reporting or rated or rating* or based 
or assessed or assessment*)).ti,ab. OR 
((disability or function or functional or 
functions or subjective or utility or utilities or 
wellbeing or well being) adj2 (index or indices 
or instrument or instruments or measure or 
measures or questionnaire* or profile or profiles 
or scale or scales or score or scores or status or 
survey or surveys)).ti,ab. OR quality of 
wellbeing.tw.  
quality of well being.tw. OR qwb.tw. OR 


































Acaster (2013) 10·5 3 10 15 11·3 49·8 +/- 
Anderson (2007) 13·5 6 11·3 12·5 5·6 48·9 +/- 
Bartley (2014)  10·5 9 12·5 15 11·3 58·3 +/- 
Beguin (2013) 15 10·5 12·5 15 9·4 62.4 + 
Boland (2013) 9 0 12·5 15 3·8 40·3 — 
Booker (2007) 12 3 11·3 12·5 9·4 48·2 +/- 
Booker (2009) 10.5 3 11.3 12.5 9.4 46.8 +/- 
Campagnaro (2008) 13·5 7·5 10 12·5 7·5 51 +/- 
Coleman (2011) 12 0 12·5 15 7·5 47 +/- 
Delforge (2009) 10·5 0 4 10 7·5 23 — 
Delforge (2012) 13·5 6 12·5 15 13·3 60·3 + 
Delforge (2015) 13·5 6 12·5 15 13·3 60·3 + 
Dimopoulos (2014) 13·5 9 13·8 15 15 66·3 + 
Espinoza-Zamora 
(2015) 
10.5 6 10 15 5.6 47.1 +/- 
Frick (2004, 2006) 13·5 3 15 12·5 9·4 53·4 +/- 
Gulbrandsen (2001) 10·5 3 11·3 12·5 11·3 48·5 +/- 
Hung (2013) 12 3 10 15 5·6 45·6 +/- 
Jacobs (2007) 12 9 10 15 9·4 55·4 +/- 
Jones (2004) 13·5 1·5 7·5 12·5 15 50 +/- 
Jones (2013) 9 3 9·3 15 7·5 43·8 — 
Jordan (2010, 2013) 12 1·5 10 15 15 56 + 
Leleu (2013) 3 0 7·5 10 1·9 22·4 — 
Mendoza (2012) 9 0 11·3 15 15 50·3 +/- 
Molassiotis (2011) 15 0 11·3 10 13·1 49·4 +/- 
Pamuk et (2013) 1·5 0 2·5 7·5 3·8 15·3 — 
Pashos (2011, 2013) 7·5 0 6·3 7·5 3·8 25 — 
Paul (2015) 1·5 0 2·5 7·5 3·8 15·3 — 
Poulos (2001) 13·5 0 10 10 13·1 46·6 +/- 
Sherman (2003) 10·5 0 12·5 12·5 11·3 46·8 +/- 
Sherman (2004, 05) 15 10·5 12·5 12·5 13·1 63·6 + 
Sherman (2009a,b) 15 10·5 12·5 15 13·1 66·1 + 
Sherman (2012) 15 0 12·5 12·5 15 55 +/- 
Shi et al. (2015) 1·5 0 2·5 7·5 3·8 15·3 — 
Strasser (2008) 12 0 10 10 15 47 +/- 
Tuchman (2015) 10·5 0 12·5 12·5 11·3 46·8 +/- 
van der Poel (2015) 10·5 0 12·5 12·5 11·3 46·8 +/- 
Verelst (2011) 12 0 11·3 10 15 48·3 +/- 
Wang (2012) 4·5 0 10 15 1·9 31·4 — 
Wells (2009) 15 10·5 8·8 7·5 15 56·8 +/- 
Wisløff (2005, 
2007) 
10·5 0 10 10 15 45·5 +/- 







Table: Results of meta-analysis for health-related quality of life 







Younger age 12 1593 -0·04 -0·09 0·01 7 
Female gender 12 1615 0·03 0·02 0·08 2 
Ethnicity 3 280 0·07 -0·04 0·19 8 
Marital status 5 422 0·06 -0·08 0·19 3 
Education 5 653 -0·01 -0·09 0·06 3 
Employment 2 283 0·10 -0·01 0·22 1 
Income 2 195 0·06 -0·08 0·20 1 
Intelligence 1 101 0·05 -0·15 0·25 1 
Weight, 2 180 0·15 0·00 0·29 1 
Change in physical activity 1 24 0·36 -0·15 0·25 1 
Disease factors 
Disease type 1 101 -0·04 -0·24 0·16 1 
Stage 7 1607 0·00 -0·05 0·05 7 
Time since diagnosis 4 545 0·00 -0·08 0·09 3 
Comorbidity 3 356 -0·06 -0·16 0·05 1 
Skeletal disease/bone fractures 3 1585 -0·15 -0·20 -0·10 2 
Physiological factors 
M-protein level 1 92 -0·34 -0·56 -0·14 2 
ß2-Microglobulin 2 349 -0·25 -0·35 -0·15 3 
Hemoglobin 4 1010 0·39 0·33 0·44 9 
C-reactive protein 2 99 -0·38 -0·55 -0·21 6 
Serum calcium 2 778 -0·20 -0·27 -0·13 2 
Serum creatinine 1 92 -0·34 -0·56 -0·12 2 
Serum albumin 2 778 -0·18 -0·25 -0·10 4 
Lactate dehydrogenase 1 92 -0·31 -0·53 -0·09 2 
MCP-1 1 50 -0·31 -0·58 -0·03 2 
serum Tumor necrosis factor-R1 1 50 -0·38 -0·64 -0·11 3 
Tumor necrosis factor-alpha 1 36 -0·09 -0·43 0·25 1 
Interleukin 6 2 82 -0·29 -0·49 -0·09 3 
Performance status 7 1464 -0·21 -0·27 -0·16 6 
Nutritional risk 1 61 -0·54 -0·73 -0·35 4 
Change in fat mass 1 24 0·54 -0·18 0·90 1 
Treatment factors 
Response 5 1360 0·29 0·24 0·34 10 
Duration of response 1 256 0·18 -0·44 0·80 1 
Type of treatment 5 523 -0·24 -0·32 -0·16 4 
Duration of treatment 3 502 -0·04 -0·13 0·05 2 
Lines of treatment 1 32 0·00 -0·36 0·37 1 
Stem cell dose 1 56 0·00 -0·27 0·27 1 
Discontinuation of treatment 2 512 -0·12 -0·20 -0·03 1 










Infection 1 154 -0·16 -0·32 -0·00 1 
Symptoms 
Fatigue 8 902 -0·52 -0·57 -0·47 29 
Pain/bone pain 7 932 -0·45 -0·50 -0·39 20 
Dyspnoea 1 79 -0·23 -0·45 -0·01 1 
Nausea 1 79 -0·12 -0·34 0·10 0 
Poor appetite 1 79 -0·39 -0·59 -0·19 3 
Insomnia 3 318 -0·23 -0·33 -0·12 4 
Drowsiness 2 233 -0·27 -0·39 -0·15 3 
Difficulty thinking 2 233 -0·32 -0·43 -0·20 4 
Emotional distress 
Distress 5 757 -0·44 -0·50 -0·38 17 
Anxiety 6 792 -0·35 -0·41 -0·29 15 
Depression 6 749 -0·23 -0·30 -0·16 8 
Psychosocial factors 
Religiousness 3 411 0·17 0·07 0·26 2 
Emotional control 1 104 0·18 -0·02 0·38 1 
Personal meaning 1 104 0·09 -0·11 0·29 0 
Coping efficacy 1 104 0·04 -0·16 0·24 1 
Negative religious coping 2 307 -0·25 -0·35 -0·14 3 
Positive religious coping 2 307 0·07 -0·04 0·18 1 
Holding back 1 7 0·02 -0·22 0·26 1 
Social support 1 104 0·25 0·06 0·44 2 
Relationship cohesion 1 104 0·17 -0·02 0·36 1 




Forest plot of Pearson weighted correlations between all independent variables and the 
dependent HRQOL for longitudinal studies only.  
 
The outcome HRQOL is scored in a way that a high score indicates better health status/quality of life, thus factors on 





2.2.3 Longitudinal assessment of quality of life in clinical practice 
The importance of measuring not only the objective effects of cancer and its treatment but 
focusing on the patients and their perceptions of the illness, its effects and the effects of treatment 
have formed a central part of patient-centred care in the last 30 years (2,387). Almost thirty years 
ago, the term patient-reported outcome (PRO) was introduced by Paul Ellwood as a new 
technology of patient experience to transform medical care (388). Improvements in how patients 
feel and function was aimed to be seen as legitimate as clinical benefits and survival (389). PRO 
is an umbrella term to describe “any report of the status of a patient’s health condition that comes 
directly from the patient” (287, p.2). PROs include measurements that require patient input and 
comprise multidimensional QOL measures to focused, single-domain measures of symptom 
severity or impact (390). As such, PROs belong to the larger field of outcomes research, a 
scientific field that seeks to understand the final endpoints that matter to decision makers in health 
– patients, providers, and governments (362). These outcomes have been defined as the “five Ds” 
(391) – death, disease, disability, discomfort, and dissatisfaction. The latter three can only be 
evaluated from the patient’s perspective. However, a distinction is made between PROs that cover 
changes in the patient’s health status, and patient experience measures that cover satisfaction 
(392-394). 
Since the U.S. Food and Drug Agency adopted PROs in their guidance, HRQOL outcome 
measures have become an integral part of cancer clinical trials (287). The same trend can be seen 
in Europe where the European Organisation for Research and Treatment of Cancer group 
(EORTC) formed in 1984 and promoted their use, a mission that has been helped by developing 
the EORTC family of questionnaires that are among the most widely used QOL measures in 
clinical trials (1). Recent pooling of studies has enabled the development of item banks for the 
EORTC (395-398). Also, guidance on the use of HRQOL measures in clinical practice is 
available from the International Society for Quality of Life Research (ISOQOL) and the EORTC 
(399-401). 
Apart from using PROs in treatment effectiveness research, there has also been a push to use 
PROs in routine clinical practice. In medicine, the traditional way of assessing change and 
tracking the status of individual patients over time has been to focus on laboratory data and 
clinical tests (316). Whilst this information is useful, it does not give a complete picture and may 
miss important areas of unmet need, particularly in chronic and progressive disease (402). Several 
organisation, among them the FDA, clinical oncological societies and the ISOQOL have issued 
statements and guidelines establishing the importance of PROs as outcomes in clinical research 
and to guide decision making (287,403,404). This is hypothesised to help timely, patient-centred 




quality improvement (316). Especially in the UK, routine use of PROs has been helped by the 
initiative of the National Health Service (NHS) to routinely collect PROs, first in a few elective 
surgery disciplines but now expanded to many other conditions such as breast cancer (405,406). 
The USA have a nationally funded system of Patient-Reported Outcomes Measurement 
Information (PROMIS) that has provided PROs and QOL measures to the public via web-based 
applications (407-410). 
The rationale behind using these measures in routine clinical practice is that they are envisaged to 
help symptom identification and thereby patient satisfaction by improving patient-clinician 
communication (411). It improves the accuracy with which symptoms are assessed and can 
potentially safe time during clinic visits (412). Profound differences between patient-reported and 
clinician-assessed symptoms have been reported, calling into question the validity and reliability 
of clinician reports that are biased by underreporting and under-detection of symptoms (412-414). 
Use of HRQOL information can also guide clinical decision making (415). Twelve systematic 
reviews have tried to establish the effectiveness and impact that routine collection of PROs has on 
patients, providers and health organisations (see Table 3) (37,416-426). They conclude that there 
is mixed evidence for the impact of PROs for improving patient management and that 
heterogeneous results mainly stem from methodological problems and a lack of clarity around the 
intended use of PROs in clinical practice as well as the lack of theory behind their use and their 
implementation. 








studies Major conclusions 
Etkind et al. 
(2015) (37) 
To understand by which 
methods PROs are captured, 
transferred and their results fed 
back in palliative care 
populations and to determine the 
effect of PRO feedback on 
processes and outcomes of care. 
1985-
2013 
13 Scarce evidence for palliative 
care, most evidence from 
outpatient oncological 
populations. Strong evidence for 
the impact of PRO feedback on 
processes of care, but no large 
effects on outcomes of care (no 
effect on QOL and symptom 
burden, small to moderate effect 
on caregiver distress and patient 
distress/emotional burden).  
Howell et al. 
(2015) (416) 
The review focused on the 
identification of PROs used in 
routine cancer clinical practice, 
the impact on patient, provider, 





30 Mixed impact on patient 
outcomes: no significant results 
on patient satisfaction, positive to 
mixed results on perceived 
quality of care. 
Processes of care: good evidence 
for better patient-clinician 
communication, clinical decision 
making, symptom monitoring 















The review examined whether 
inclusion of PROs in routine 
clinical cancer practice 
improves patient outcomes, 
processes of care, and health 




24 Patient outcomes: effect sizes 
range from 0.01 to 0.75 for 
reduction of  symptom burden; no 
significant effect for QOL, 
d=0.15 to 0.42 for reduction of 
psychological distress, small to 
moderate effect for reduction of 
supportive care needs. 
Processes: Better patient-clinician 
communication, decision making, 
healthcare professionals’ 
awareness of outcomes, but no 
effect on higher referral rates to 
psychosocial care. 
Chen et al. 
(2013) (418) 
What are the impacts of 
composite measures of PROs 
collected on cancer patients 
during treatment with regards 
to: a) provider behaviour for 
improving care delivered, b) 
organisational change within 
health care settings, c) 
improving clinical outcomes for 
patients, d) improving patient 
experience of care. 
2000-
2011 
27 Strong evidence for well-
implemented PROs improving 
patient-provider communication 
and patient satisfaction, weak or 
non-existent evidence base for 
changes to patient management 
and improving health outcomes, 
changes to patient behaviour,  and 
quality improvement in 
organisation. 
Boyce et al. 
(2013) (426) 
To assess the impact of 
providing healthcare 
professionals with feedback on 
patient-reported outcome 
measures (PROMs). 
2012 17 Feedback at group-level: no 
statistical difference; only one 
study provided patient-level 
feedback and found an overall 
significant effect. 
Six studies found significant 
effects for subgroups of patients, 
PROs used as management tools 
and not for screening. 
Luckett et al. 
(2009) (419) 
To identify future strategies for 
interventions to impact patient 




6 Cluster RCTs are needed. More 
specific PROs should be used, 
improving the interpretability of 
feedback for both staff and 
patients is important. 
Valderas et al. 
(2008) (420) 
To summarise the best evidence 
regarding the impact of 
providing patient reported 
outcomes information to health 




28 Methodological concerns limit 
the strength of evidence. There is 
great heterogeneity of impact, 
context and interventions need to 





To synthesise the evidence for 
using publically reported 




40 Studies do not evaluate PROs as a 
means to facilitate patient care. 
The pattern of results suggests a 
general lack of clarity in the field, 
especially regarding appropriate 
goals for PROs and the 



















To assess the best available 
evidence on the value of routine 
HRQoL and needs assessment 
in: (1) improving the 
psychological care and outcome 
of people being managed in 
non-psychiatric settings and, (2) 
improving the quality of care 
and outcome of those with 
common mental disorders. 
1966- 
2000 
9 Impact on processes of care: 
increased recognition of 
psychological symptoms, but no 
impact on patient management 





To assess the impact on the 
process and the outcomes of 
care of feeding back information 
on perceived health status to 




21 Impact on processes of care 
(service utilisation, diagnosis, 
treatment and patient 
satisfaction), but no influence on 





To review the evidence for the 
effectiveness of using patient-
based measures of health in 
routine practice in improving 
the process and outcomes of 
individual patient care. 
1987-
1999 
13 Little evidence that use of PROs 
substantially changes patient 
management or improves patient 
outcomes. Implementation 
strategies need to be guided by 
theories of individual and 
organisational change to address 
barriers. 
 
To remedy this shortcoming, Greenhalgh et al. (2005) (427) have since applied a theory-driven 
approach for the use of HRQOL measures in clinical practice. They hypothesised mechanisms 
and paths through which the provision of information on QOL could lead to improved patient 
satisfaction and health outcomes for patients (38,427). One large area of concern that remains 
under-explored in studies was identified to be the area of feedback. Feedback was found to be 
given on a single occasion only with the recipient being the oncologist or doctor but not other 
health professionals like nurses, social workers, or the patients themselves. This was seen to be 
contrary to the reality of care in which a range of clinicians was involved (428), decision making 
occurred as a shared process between several clinicians and over several encounters with the 
patient (429). From this theoretical model the research group developed the following taxonomy 
of how PROs could be used in clinical practice (see Table 4).  
If PRO information is discussed between clinicians and patients individually, depending on who 
provided the data (the patients themselves or data was aggregated from a group of patients), this 
information can be used to directly influence assessment and care of the individual patient in the 
form of screening or monitoring. Group-level data is applied to the individual patient when 




clinicians is used for multi-disciplinary team meetings. At the national level, such aggregated data 
is used for population monitoring. Greenhalgh’s taxonomy (38) was built on the older conception 
by Sutherland & Till (1993) (431), who proposed three levels of decision making within the 
healthcare system at which PRO use could aid clinical utility and bring benefit: (a) micro-level 
decision making, concerned with decision making involving patients and health care 
professionals; (b) meso-level decision making, concerned with decisions about approaches to 
health care for a group of patients within regions; and (c) macro-level decision making, concerned 
with decisions for population benefit by policy makers and society. 
Table 4: Taxonomy of applications of PROs in clinical practice (taken from (38)) 
 Level of aggregation of PRO data 
Used at the clinician-
patient interface 











Population monitoring  
Assessing quality of care 
 
Some of the areas shown in the taxonomy have been more widely researched than others. The 
bulk of the evidence currently exists for screening (421-424), promoting patient-centred care 
(411,432), and decision aids (430,433); and only some studies exploring the capacity of PROs to 
facilitate communication within multi-disciplinary team meetings (434-437) and population 
monitoring (405,437-439). PROs have been adopted as quality improvement tools in the UK 
(405,440), America (441), Australia (442-444), Sweden (441) and other countries. 
Assessing the performance and quality of services is another role for aggregated PROs at the 
population level (440). This approach has been particularly followed in the setting of 
rehabilitation and long-term neurological conditions, with national databases/registries mandating 
input of PROs from each service to arrive at a national comparison of the quality of services and 
establishing benchmarks for the quality of care (442,443,445-447). This application of PROs is 
very much in line with Donabedian’s definition of outcomes within the quality of care framework 
(448). Outcome is defined as a change in the patient’s health status that can be attributed to 
preceding health care (448). This information allows an assessment of effectiveness and cost-
effectiveness of services, and – in the case of existing casemix classification variables (449) – can 
guide a direct comparison between services based on patient complexity and patient need. 




hypothesised to have a direct influence on HRQOL, but this relationship might be mediated by 
patient characteristics and patient preferences (431,448). Consequently, evidence for the 
effectiveness of PROs in improving service quality is weak (37,416-426). It can be expected that 
more applications of PROs at the national level will help to address these challenges. According 
to Donaldson (2008) (450), PROs are now a technology that has come of age, with translation into 
the healthcare system (use in clinical practice, post-market surveillance, cost-effectiveness) 
meaning PROs may soon become the standard of care. 
The area of longitudinal monitoring is particularly under-explored. Only few studies have used 
this application. There is some evidence from psychotherapy, in which one study has shown the 
effectiveness of longitudinal monitoring of PROs for predicting treatment failure or poor response 
to therapy (451,452). However, with the advent of new technologies and the more widespread use 
of the internet, electronic patient-monitoring is an avenue that should be explored more widely. 
The availability of user-friendly, electronic platforms or tablet computers has made it possible to 
standardise methods of PRO monitoring and using the data in real time. These systems also allow 
that alerts are sent to the clinic once scores indicate clinically relevant problems in certain areas. It 
also provides the opportunity to provide patients electronically with educational material tailored 
towards their needs (453). An overview of current systems using this approach in oncology and 
palliative care is given in Table 5. 
Although these new initiatives certainly facilitate the integration of PROs in clinical practice and 
address how monitoring could be established in a feasible way, gaps remain unaddressed. In fact, 
as can be seen in Table 5, most often results from QOL questionnaires are not given to the patient 
directly but remain with the clinician. Furthermore, these systems are held within clinics. In the 
United Kingdom a study has begun to prospectively monitor the HRQOL changes in cancer 
survivors. This study uses display of HRQOL information directly to the patient (470,471). This 
area needs further exploration. Specifically, it is not clear 
- what modifications to existing questionnaires are needed or which questions perform well 
in longitudinal monitoring, 
- which questions have sufficient discriminatory function to distinguish between subgroups 
of patients, 
- which questions have enough diagnostic power to indicate when a clinically important 
threshold is reached to send out an alert to the clinic for the patient to be seen, 
- which questions have high predictive validity and are indicative of subsequent poor 




- how results should best be fed back to clinicians and patients and which interpretation 
aids might be useful. 
Table 5: Overview of current initiatives using electronic patient-monitoring to support clinical 
oncological care (based on (453) and (454)). 
System University Population 












Web-based reporting from 
home; information to 
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in clinic;  
information to clinician 
Clinician only 
TellUs (465) Hospice 
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Milan, Italy Cancer 
patients 
Web-based or mobile 
phone reporting of cancer 





















Despite guidelines (399,401), the routine use of PROs has been slow to implement in clinical 
practice, in oncology as well as palliative care (400,472,473). Their optimal application is yet to 
be achieved (427). No system of routine PRO collection and especially longitudinal tracking of 
HRQOL is currently in place for multiple myeloma. Due to the relatively long median survival 
time, many patients classify as cancer survivors (474-477) and might benefit from self-
monitoring, especially during stable phases in which they do not receive treatments. This could 
help patient empowerment (38). This PhD study aims to describe the longitudinal trajectory of 




used to test which items perform best for the purpose of routine self-monitoring, thus indicating 
which variables might be validly and reliably monitored in multiple myeloma. 
 
2.2.4 Measurement of quality of life in multiple myeloma 
The previous section demonstrated some of the challenges of using PROs in clinical practice. The 
subjective nature, often leading to considerations of PROs as ‘soft’ endpoints, methodological 
limitations regarding the interpretation of scores of individuals, real-time data collection and 
missing data can pose barriers to the routine use of PROs. Particularly in the context of supportive 
and palliative care, clinical relevance and feasibility is of importance, meaning short and simple 
measures that are easy to score and interpret and that are able to assess change in individual 
patients over months and years (316). The clinical utility of a measure is determined by its 
measurement or psychometric characteristics (478). During the validation, particular emphasis 
needs to be placed upon making sure that the questionnaire works in the population in which it is 
intended to be used.  
In multiple myeloma, clinical applications of PROs can be manifold, aiding prognostication, 
monitoring response to treatment and prioritising problems or facilitating communication 
(38,316,479). Due to the often substantially reduced QOL in myeloma patients, some authors 
have called for making HRQOL assessment a normal part of clinical haematological care 
(32,34,35). Despite these demands, a systematic review identified 13 HRQOL instruments, none 
of which had been specifically validated for its clinical applicability (359). Most importantly, 
when contrasting available tools with results from qualitative studies identifying issues important 
to myeloma patients’ QOL (310,361,385,480-482), no instrument was comprehensive to all issues 
important to patients. This challenges the content validity and face validity of some of these tools. 
The EORTC QLQ-C30 (22,29-32,36,242,364,368,375,382,483-491) and QLQ-MY24/20 
(221,310) were the questionnaires which had undergone the most comprehensive psychometric 
evaluation. The other HRQOL questionnaires validated in myeloma were: the EORTC-QLQ-
High-dose chemotherapy module (HDC-19) (29,221,492), the FACT-G and anaemia (FACT-An) 
and bone marrow transplantation (BMT) modules (35,185,493,494), the Short Form-36 and SF-12 
(34,495-497), the SEIQoL (30,490), the EuroQOL-5D and 15-D (36,382), the Life Ingredient 
Profile (originally for leukemia patients) (498) and Ferrell’s Quality of Life Index (486). Most 
studies validated tools in clinical trial populations and not in clinically representative groups 
(359). There was considerable variation in the domains within the multi-dimensional HRQOL 





For defining clinical utility, areas of item development and item validation need to be taken into 
account. A clinically useful measure should have good content and face validity (316) and capture 
the core domains that patients find most important to their HRQOL. In multiple myeloma, a set of 
core symptoms comprising the most common symptoms that are either disease- or treatment-
related are essential for monitoring the disease status (e.g. asymptomatic patients versus patients 
with active disease) (26,61,71). These core symptoms should include pain, bone pain, and fatigue, 
but also gastrointestinal symptoms, symptoms of the neurologic and musculoskeletal systems and 
signs of bone marrow involvement, to cover the most common side effects of treatment 
(9,58,87,89,92,499-507). The HRQOL tool should cover symptom burden as the subjective 
evidence of disease observed by the patient (508,509). There is value in focusing on specific 
myeloma symptoms in some contexts, but there is also value in building a tool using common 
symptoms to enable cross-study comparisons with other conditions (510). A core set of 12 
common symptoms that affect most cancer patients has been defined in oncology (511). These 
two poles – the instrument covering only common symptoms or covering disease-specific 
symptoms – can be partly harmonised by using a core list of symptoms and adding disease-
specific symptoms at the end. Another option is to use free-text fields to add other symptoms and 
problems not contained in the fixed list (512). Since symptom management has been identified as 
one of the areas of need in multiple myeloma (369), accurate and psychometrically sound 
assessment of symptoms can form the first step in addressing this gap. 
Furthermore, a clinically useful tool should incorporate issues that diminish QOL but are seldom 
discussed in clinical consultations between patients and clinicians due to their embarrassing 
nature. These can comprise personal aspects of the illness experience such as anxiety, uncertainty 
and sexual function, but also cognitive problems (90,507,513). Underreporting and under-
detection of symptoms in clinical contexts that do not use patient self-report have been described 
in many studies (412-414). This does not only concern symptoms but also QOL problems (514-
516). 
Limited clinical utility of QOL instruments in multiple myeloma also stems from the fact that 
most of these tools are validated only in the early stages of disease but not in the advanced or 
palliative setting. The domains of QOL that are important to patients during later stages of disease 
most likely differ significantly from those at diagnosis or in stable disease (383). The exclusion of 
patients with relapsed disease or validating a HRQOL in clinical trial groups poses the additional 
problem of leading to a biased sample that is not clinically representative of the wider patient 
group (517). Combined with this aspect is the problem of QOL questionnaires in multiple 
myeloma mainly assessing health status (359). However, the presence or severity of a problem 
does not indicate how much that problem impacts on the patient’s QOL, as was detailed in the 




impact on QOL, even if biological and clinical parameters indicate that it should (518,519). The 
distinction, along with the theoretical model of QOL, ultimately becomes important when trying 
to identify targets for supportive care interventions in multiple myeloma. For example, going back 
to Fayers and coauthors’ distinction between indicator and causal variables (339,340,356), if 
symptoms are defined as causal variables, directly causing poor QOL, treatment would be directly 
targeted at the symptom. If, however, symptoms are indicator variables, treatment would need to 
be directed at other aspects of HRQOL, such as emotional well-being (520). These distinctions 
play a role in myeloma as some of the symptoms, in particular fatigue and depression, are 
reflective of QOL (indicator variables) while other symptoms may be causal variables (e.g. poor 
mobility) (357). This can be communicated via the scale that is used to assess these components 
(518,519). 
A related issue is the distinction between needs, satisfaction and HQOL. HRQOL surveys capture 
how well the patient is doing in several domains. Satisfaction measures focus on how well a 
particular clinician or organisation delivered healthcare (521). Another group of measures 
concerns supportive care needs (476,522-531). Needs are usually indicators of deficit and have 
been defined narrowly as the capacity to benefit from healthcare (532). This introduces the 
problem that wider aspects of HRQOL may not be seen as needs of the individual in case of 
healthcare not being able to address these areas of the patient’s experience (such as personal and 
environmental characteristics but also fatigue or difficult-to-treat symptoms) (533). A myeloma 
questionnaire asking about supportive care needs may thus not have clinical utility if these 
important areas are missed, leading to diminished content validity. Rather, it is for instrument 
developers to also provide guidelines for clinical management of these QOL-related symptoms 
and problems (531,534). Needs assessments have recently been used in myeloma care (535), but 
are usually conducted at one point in time. Since clinical utility entails using the HRQOL tool as 
an outcome measure and outcome measurement per definition requires longitudinal measurement 
(448), cross-sectional needs assessment forgoes aspects of change. It is longitudinal validity that 
helps the applicability of the measure in routine clinical practice. Only if changes can be validly 
and reliably tracked over time, HRQOL can function as an outcome measure. 
Based on the findings from the systematic review and qualitative study, the research group at the 
Cicely Saunders Institute developed the Myeloma Patient Outcome Scale (MyPOS), a HRQOL 
measurement tool particularly geared towards its use in routine clinical practice (see section 4.3) 
(384). The questionnaire was designed to address some of the shortcomings identified in the 
systematic review. For clinical applicability in particular, the MyPOS was designed to have good 
content and construct validity (357). This PhD study aims to validate this measure for longitudinal 




2.3 Conclusions from the literature 
What is known about quality of life in multiple myeloma? 
• Myeloma as an incurable disease places a high burden on patients. There is evidence 
that myeloma patients suffer from more problems and symptoms than patients with 
other haematological cancers. 
• There is a dearth of longitudinal evidence. Only four observational studies so far have 
measured changes in symptoms and HRQOL in patients receiving chemotherapy or 
stem cell transplants. There is no longitudinal information for patients receiving 
maintenance treatment or no treatment and no information on the impact on quality of 
life in the advanced, progressive stages of the disease. 
• Multiple myeloma is underserved by palliative care due to several barriers: the sudden 
death of patients and scarcity of prognostic indicators, attitudinal barriers in haemato-
oncologists that lead to late referrals and the lack of discussion regarding goals of care. 
Early integration of palliative care in multiple myeloma could be feasible if 
appropriate screening and monitoring of palliative care needs is introduced. 
What is new about this project? 
• This study follows a natural sample of patients at various stages of the disease and 
receiving different treatments over time. It will allow a description of the course of 
symptoms, HRQOL and psychological distress over time and in the advanced stages of 
myeloma.  
• The study aims to identify predictors for poor QOL and high palliative care concerns, 
which will allow the development of a model of prognostic indicators for palliative care 
involvement. 
• Recent attempts to incorporate PROs such as QOL into routine clinical practice have 
yielded mixed results. One avenue that has not been explored is monitoring QOL in 
multiple myeloma. For this, psychometrically robust items need to be selected which 
should satisfy more stringent criteria in order to measure individual changes validly and 
reliably.  
What is the clinical applicability of the results? 
• One barrier to the integration of supportive and palliative care services in multiple 
myeloma is the unpredictability of the illness trajectory which renders prognostication 




identification of trajectories and help determine whether these outcomes can be used to 
diagnose deterioration. Demographic, clinical and treatment-related predictors for poor 
QOL can help define the clinical profile of those in need of supportive or palliative care 
services and can help target therapies specifically to this group.  
• Knowledge of predictors for QOL will help identify those items or subscales that have 
high predictive validity in this patient group. Further item testing of the MyPOS can yield 
a small set of questions that could be used by patients themselves to monitor changes and 
could help direct them to support and services in a more timely manner. 
 
3 Aims and objectives 
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3 Aims and objectives 
 
3.1 Aim 
The aim of this study is to describe, understand and compare the individual QOL and symptom 
trajectories of people with multiple myeloma over time and to evaluate the validity of the 
Myeloma Patient Outcome Scale (MyPOS), a myeloma-specific questionnaire to measure QOL 
and palliative care concerns, for longitudinal patient-monitoring. 
 
3.2 Objectives 
1. To determine the prevalence and severity of common symptoms and problems in patients 
with multiple myeloma at various stages of their disease, specifically for those with relapsed 
or progressive disease, and to determine whether patients in the advanced stages of myeloma 
experience a different symptom and problem profile than patients in earlier stages. 
2. To determine demographic and disease characteristics that are associated with poor quality of 
life and high palliative care needs and evaluating whether general symptom burden has a 
stronger influence on poor QOL and/or high palliative care concerns than demographic and 
disease characteristics in a cross-sectional sample of myeloma patients. 
3. To identify the intra-individual change trajectories of QOL among multiple myeloma patients 
at various stages of disease over a period of 8 months. I hypothesise that four or five 
subgroups of individual QOL trajectories exist, defined by patterns of stability, improvement 
or deterioration and with a different initial level of QOL (good versus poor). 
4. To evaluate whether general symptom level and demographic as well as clinical 
characteristics help predict who experiences a deteriorating QOL or chronically poor QOL 
trajectory. 
5. To evaluate the validity and item quality of the MyPOS and its scale in myeloma patients at 
different stages in their disease trajectory in order to identify the items or subscales from an 
item pool that are the most reliable and valid for monitoring intra-individual changes in 
health-related quality of life in myeloma. 
6. To identify the items or subscales that have the best item characteristics, longitudinal 
reliability, validity (responsiveness to change) and for monitoring health-related quality of 







In this chapter, an overview of the methods used in this PhD study is presented. The detailed 
methods used for each component are described in their respective publications and chapters (see 
chapter 5, 6 and 7). The methods are further detailed in the study protocol that was prepared for 
the ethics application and can be accessed in Appendix B. The focus in this chapter is to give an 
overview and to describe the conceptual framework that links the three parts of this study. 
 
4.2 Overview of study design and methodological considerations 
In Figure 6, an overview of this PhD study is presented that shows how phases of this research 
interlink and how data from previous phases inform subsequent phases and are integrated to 
answer the objectives of this study. Figure 7 shows how datasets interlink. The heart of this PhD 
project is a longitudinal survey of symptoms and HRQOL in patients with multiple myeloma. The 
longitudinal study provides data both for modelling trajectories of HRQOL and for identifying 
predictors for poor QOL, thus answering the question of who is at risk of experiencing a 
deterioration in their health status. It also provides the main dataset for identifying those items 
from the MyPOS that are suitable for individual patient-monitoring. The model of predictors is 
built in several steps. Preliminary phases include systematic review and meta-analytical work to 
identify and understand the respective strength of variables influencing QOL in this condition. 
This initial model of predictors is supplemented by a review of the symptom burden and 
prevalence of HRQOL problems (presented in chapters 2.2.2.1 and 2.2.2.3, respectively). These 
models inform subsequent selection of variables in the regression analyses. A first model is built 
on the basis of a secondary dataset, involving a large naturalistic sample of multiple myeloma 
patients from multiple centres. For the secondary analysis, the dataset from the initial validation 
of the MyPOS is combined with the baseline dataset from the longitudinal PhD study. Methods 
for prioritising and selecting variables into the prediction model are detailed below. This model is 
then partly validated and extended by taking more variables from the longitudinal study into 
account. Also, the longitudinal trajectory of the outcome variable is modelled. Information from 
the regression analyses is finally integrated with the information on the suitability of items for 
longitudinal monitoring to develop a system of outcome variables to monitor in multiple 
myeloma. In this last step, a set of common, easy-to-measure variables is identified that could 


































































Figure 7: Overview of datasets used in the PhD project and outputs 
 
 
4.3 Research questions and rationale for study phases 
In the following sections, I present the rationale for the study phases and methods used. Detailed 
information with an overview of the methods of data collection and analytical approaches that 
were used in the study phases is given in the results chapters and the study protocol, Appendix B. 
Appendix D and Appendix F contain the study information leaflets, consent form templates and 
questionnaire booklets that were used in recruitment and data collection. 
 
4.3.1. Phase 1: Cross-sectional, secondary analysis 
The research questions for the first phase of this research study are: 
1. What is the prevalence and severity of symptoms and palliative care-related concerns in 
patients with multiple myeloma at various stages of their disease? 
2. Do patients in the advanced/progressive or refractory disease stage experience a different 
symptom and problem profile than patients in earlier stages? 
3. Which demographic, clinical and treatment-related factors are associated with a lower 
quality of life and more symptoms and problems? 
4. Do the general symptom level and specific symptoms have a stronger influence on health-




Since 5-year survival has increased from 24-32 months to 68 months in multiple myeloma, 
patients are now living longer with the complications of their illness, treatment-related short- and 
long-term toxicities and possible comorbid conditions (58). Clinical decision making should 
increasingly be driven by QOL-related concerns and it has been recommended that QOL 
assessment becomes part of routine care in this incurable condition (32,34,35). The systematic 
literature review of symptom burden in multiple myeloma (see section 2.2.2.1) yielded high 
prevalence rates for different symptoms, thus showing that patients face profound symptoms and 
emotional, social, and financial consequences associated with the cancer (536). However, it also 
became apparent that robust information on symptom prevalence is rare in myeloma, with mainly 
clinical trials or studies in mixed haematological SCT samples contributing data. There is also a 
paucity of studies focusing on the advanced stage. The burden of symptoms close to the end of 
life is therefore unknown. This study phase addresses this gap by determining symptom 
prevalence in patients at various stages of their disease. 
The research questions address objectives 1 and 2 (see chaper 3, Aims and objectives). This study 
phase focuses on the analysis of a combined dataset of two studies to give a cross-section of the 
prevalence of common symptoms and problems. Combining the dataset from the validation study 
of the MyPOS with the baseline of the longitudinal survey data from this PhD study resulted in a 
large dataset with enough power to answer the research question and to yield robust results for 
exploratory modelling of predictors (see 4.3.3, Phase 3 – Regression analysis/prognostic model). 
As the aims of the current analysis differ from the original aims of the MyPOS validation study, 
new questions will be asked of the data, and a secondary analysis will be performed (537-539). 
The use of secondary analysis has methodological, analytical and ethical implications. 
Simply put, secondary analysis is a set of research endeavours that uses existing data to answer 
research questions that may not have been proposed when the data was originally collected (540). 
Because many studies contain more data than is analysed in the primary study, and secondary 
analysis has the potential of yielding much higher sample sizes that are large enough to enable the 
investigator to draw meaningful conclusions, its use has been advocated for both quantitative and 
qualitative descriptive studies in palliative care (541,542). This approach is different from meta-
analytical studies in which effect sizes are estimated from means or count data in original studies, 
but a synthesis of estimates from original data is usually prepared under the same original aim. 
Descriptive studies, in which the portrayal of the characteristics of a group of patients, 
determining the frequency of events or the correlational, systematic investigation of relationships 
between variables are the key focus, lend themselves to secondary analysis. Secondary analysis 
can uncover aspects of a research problem that can lead to hypothesis revision or revision of 
existing measures (543,544) and the analysis of existing data can serve as a pilot study leading to 




baseline data from this longitudinal study with data already collected. This study phase provides 
data for the initial development and exploratory analysis of symptom prevalence and the 
correlational model of variables associated with poor QOL in myeloma. Both of these aspects 
inform the descriptive component of understanding trajectories of symptom burden and QOL in 
the longitudinal study, and forming the first phase in building a prognostic model of QOL 
predictors in the survey. This initial phase should not be considered a pilot study per se, as its aim 
is not simply testing study procedures, validity of tools, estimating the recruitment rate or 
estimating parameters needed for sample size calculation (546). Although it partly aims at 
providing the mean and variance estimates for sample size calculation in the longitudinal survey, 
it rather forms the initial step in a hierarchy of study phases to help model the factors associated 
with poor QOL that could potentially reveal targets for early palliative care intervention. This 
phase also serves the generation of hypotheses, particularly regarding the role of the general 
symptom level as an independent factor to explain poor or deteriorating QOL in multiple 
myeloma. 
Many approaches to secondary data analysis have been described (547). Among the most 
common are: taking a unit of analysis different than in the original study, studying a subsample, 
studying a different relationship between variables in the study (designating a new dependent 
variable), changing the method of analysis and analysing data that was collected but not analysed 
in the original study (547). This secondary analysis follows the latter three approaches with using 
the demographic, clinical and outcome data collected in the MyPOS validation study with three 
new dependent variables, the MyPOS total score, the EORTC QLQ-C30 global quality of life 
subscale and the EuroQOL EQ-5D Index score. The method of analysis was changed from 
establishing reliability and validity of the MyPOS to analysing prevalence and 
correlational/regression analysis. Thus, data that was collected but not analysed in the MyPOS 
validation study (e.g. the EQ-5D Index score, clinical information on staging of the disease and 
treatment details) is taken into account in this secondary analysis. 
Secondary analysis is a systematic method with procedural and evaluative steps. Like any 
research, the research question determines the research and analysis method (548). Hence, the 
first step in the process is developing the research questions. After identifying a suitable dataset, 
the next step is the evaluation of the dataset to ensure its appropriateness for the research topic 
(539,549-551). To make sure that the dataset addresses initial requirements, it is recommended to 
outline the original study, the process of data collection and the analytical processes applied to the 
data plus making processes regarding missing data transparent (552). The fit between the primary 
dataset and the research question is essential (552,553). To ensure congruency and quality of the 
resulting analysis, the following questions should be asked: (a) what was the purpose of the study, 




obtained (551). This framework can be extended by examining data collection techniques in the 
original study more closely to judge the internal validity (sample and measurement bias) and 
external validity (generalisability, representativeness). By evaluating (1) the definition of the 
target population and representativeness of the sample (i.e. sampling method), (2) the eligibility 
criteria, (3) strategies used to minimise selection bias, (4) methods to prevent study attrition, (5) 
characteristics of non-responders and drop-outs, (6) validity and reliability of the  data collection 
instruments, (7) controls used to minimise threats to measurement bias, and (8) procedures for 
handling missing data in the original research study, the scientific quality of the analysis can be 
described.  
Only one of the two primary datasets accessed for this secondary analysis was collected before the 
start of the longitudinal PhD study. The second dataset with which it is combined represents 
primary, original research. Dataset one was collected in the same population as dataset two, the 
baseline (cross-sectional) data from the longitudinal MyPOS study. In fact, data collection for the 
longitudinal study almost directly followed data collection for the MyPOS validation study in the 
participating centres. Data for both studies was partly collected in the same NHS trusts which 
resulted in study participants taking part in both studies. In case of duplicate ID numbers, newer 
data was kept in the analysis. Hence, the definition of the target population was the same in both 
studies, with the same sampling method (consecutive sampling) followed and thus with the same 
issues around representativeness. Consecutive sampling on the one hand aids representativeness 
by avoiding narrow eligibility criteria (as are necessary in clinical trials (554)), but also 
diminishes external validity by oversampling fitter patients that are more satisfied with the quality 
of services (147,555,556). Gate-keeping will also have affected data collection in both studies in 
the same way as there is an overlap in study personnel recruiting and collecting data in both 
studies. The MyPOS validation study was a three-year study, funded mainly by Myeloma UK, 
which aimed to develop and psychometrically validate a new, myeloma-specific quality of life 
measure. 380 patients with a confirmed diagnosis of multiple myeloma and not too ill, 
symptomatic or neutropenic to take part were recruited from 11 secondary and tertiary care 
centres in the United Kingdom. The study recruited consecutive patients whereby all available 
myeloma patients were screened for eligibility at every outpatient clinic or ward where 
recruitment was active. Data collection took place between May and August 2013. Participants 
who declined participation were asked for consent to record limited demographic details to judge 
the extent of sampling bias. Participants received a questionnaire that consisted of the following 
measures: Myeloma Patient Outcome Scale (MyPOS), EORTC QLQ-C30 and MY20 and the EQ-
5D-3L. Participants were given the option to complete the data collection instruments in the clinic 
or at home, returning them by post. Clinical data were collected by the research site staff, 




performance status. Data was analysed using exploratory and confirmatory factor analysis and 
examining construct validity in form of subgroup comparisons and correlational comparisons to 
other measures (384).  
The definition of the target population, criteria for inclusion and exclusion and strategies to 
minimise selection bias were the same in the two datasets (quality criteria 1-3 above). Methods to 
prevent study attrition were also comparable between the two datasets. In the MyPOS validation 
study, participants failing to return their questionnaires from home received a reminder phone call 
after one week. Since participants were given a pre-stamped envelope for returning questionnaires 
to the study centre, attrition was low in the MyPOS study. Only 21 of 401 recruited participants 
failed to return the questionnaire (see chapter 5). An even smaller proportion of withdrawals was 
observed in the baseline of the longitudinal survey. Furthermore, selection bias is low in both 
samples since a comparison of non-responders and withdrawals to the study population revealed 
no differences in demographic and clinical characteristics (384). Data collection instruments were 
selected on the basis of their status of having been validated with appropriate psychometric 
properties in the myeloma population. Regarding the outcome measures, QOL tools completely 
overlapped between the two studies, as did most other demographic and clinical characteristics. 
However, since the purpose of the MyPOS validation study was different from that of the 
secondary analysis, particularly regarding evaluating disease and treatment characteristics in their 
independent association to poor QOL, the analysis is biased towards patient-reported outcomes as 
many potential predictors such as haemoglobin level (483,557), albumin and creatinine levels 
(183), cytokines (186-188) or treatment response status (26,558), were not collected. Minimising 
measurement bias was achieved by training study site-personnel in study procedures. Some 
measurement biases, due to participants self-completing questionnaires without assistance, will 
not have been able to prevent. Procedures for handling missing data were detailed in the original 
analysis and consisted of returned questionnaires being checked by the investigator for missing 
items with subsequent phone calls to the participant to elicit an answer to the item. This strategy, 
although introducing a recall bias, resulted in a very low amount of missing data in outcome 
variables and symptom items. Demographic and clinical information were extracted from 
electronic patient records and carry a larger proportion of missingness, as high as 30% in the case 
of International Staging System (384). 
There are ethical considerations when carrying out any research which are relevant to a secondary 
analysis as well. These issues centre on confidentiality, non-maleficence and fidelity (553). One 
issue in particular, that of informed consent, needs specific consideration in this context. 
Secondary analyses of an existing dataset carry the risk of participants not having consented into 
this use of their data. In the MyPOS validation study, participants consented for their details to be 




anonymised form. The secondary research questions presented here were partly generated during 
the analysis of the MyPOS validation study and were related to the intention of the primary 
research, namely the description of the burden associated with QOL-related problems and 
concerns in this sample. Therefore, the judgment was made that the consent gained in the MyPOS 
validation study covered the goals of this secondary analysis. 
Overall, the MyPOS validation dataset represents a valid dataset for combination with the 
baseline data from the longitudinal survey and shows an appropriate fit for the purpose of the 
secondary analysis. The research participants and the population to whom the new set of research 
questions apply are congruent and this congruence extends toward the variables that were 
measured. The context in which the original data were obtained as well as the target population 
are also comparable. There are two main benefits of secondary data analysis, scientific advantages 
and functional advantages (547). Scientific advantages include the inclusion of more variables, 
the ability to survey a more diverse sample and possibility of more advanced statistical techniques 
(559,560). This secondary analysis allowed the exploration of symptom burden and QOL in 
different disease phases and how demographic and clinical variables are related to the outcome, 
thereby generating and testing hypotheses for the analysis of longitudinal trajectories. Functional 
advantages include cost-effectiveness, through combining existing datasets and yielding a large 
sample size sufficient for robust analyses which might otherwise not be feasible 
(539,549,550,559,561). The main limitation of secondary analysis, collection of original data 
usually serving a different purpose and the investigator having no control over the data collection 
process, is mitigated by the investigator being involved in the study design and data collection in 
both studies. The dataset was easily accessible and the investigator knew the types of variables 
and type of sample as well as other design issues which increased the fit between the new research 
questions and the original data. 
 
4.3.2 Phase 2: Longitudinal analysis of the trajectory of quality of life in multiple 
myeloma 
One of the main aims of this study is to examine the quality-of-life experience of individuals 
living with multiple myeloma over time, considering the core components of symptoms, wider 
palliative care-related problems and concerns, and coping/adaptation processes. It is also studied 
how these components interlink with patient characteristics. The first objective is to describe 
trajectories of the illness experience in this patient group. Second, the co-variation of the 
components of QOL, particularly aspects of symptoms and functioning, is described, with an 





The research questions are: 
1. What is the prevalence and severity of symptoms and palliative care-related concerns in 
patients with multiple myeloma over time and when during the observation period is 
symptom burden and burden from palliative care-related problems highest? 
2. Does the patient-reported quality of life experience of this cancer change over time? 
3. Are there distinct groups of individual change trajectories within the overall QOL 
trajectory, so that individuals can be characterized by a change trajectory showing the 
typical course of QOL for a small, homogeneous group? It was hypothesised to find 
classes of stable/chronic QOL that would vary by the level of QOL (intercept), either 
being low, moderate or high. It was also assumed to find classes of QOL experience 
characterized by an improving or deteriorating trajectory (slope). Further, the existence of 
a class of potentially fluctuating course of QOL was hypothesised. 
In addition, this study also develops a large and comprehensive dataset on burden of care and 
associated costs, as well as information from informal caregivers on their health, the patient’s 
health and well-being and their perceived caregiver burden. However, these variables are not 
analysed in the present PhD study and will be the subject of future publications from this project. 
Symptoms, HRQOL and other variables are assessed longitudinally using an analytic postal 
survey method with follow-up data collection every two months for patients with multiple 
myeloma. This study uses a panel sample (follow-up of the same population) and recruits 
participants from 12 secondary and tertiary hospitals in England. The advantages of longitudinal 
designs lie in their ability to capture change and to examine these changes in relation to patient 
characteristics. It is the only design that allows the establishment of temporal relationships 
between independent factors and outcomes (562). Due to the observational nature of this study, 
results are more representative of the underlying population than evidence from experimental 
studies with more strictly defined eligibility criteria (554). 
Understanding symptoms and other aspects of the illness experience over time has shown to be 
one of the main study designs to address those gaps in the palliative care evidence that are needed 
to inform how health and social services can best provide care to individuals with a life-limiting 
diagnosis. Improvements in the management of multiple myeloma mean that patient live with 
their disease for longer, thus experiencing accumulated symptoms and problems from myeloma 
itself and its treatment. Knowing about the progression of these QOL-related symptoms and 
problems over time allows better targeting of assessments, review times and referrals to 




can inform follow-up. If a large enough sample is recruited, subgroup analyses can help determine 
distinct trajectories of QOL experience in multiple myeloma and thus identify who is at risk of 
experiencing poor subsequent outcomes. Consideration of trajectories of symptoms and QOL 
problems can help with advance care planning, by helping to anticipate likely physical and 
psychological needs (563). The need for advance care planning is particularly high in the group of 
myeloma patients, due to this disease being life-limiting from the start of treatment, yet being 
subject to the pervasive culture of cure that precludes palliative care involvement (105). Knowing 
about the progression of the disease and about indicators of times of high need could help 
clinicians initiate discussions about end-of-life issues and patient preferences earlier. Ultimately, 
it could prevent unnecessary aggressive treatment at the end of life (564). Knowing about the 
likely trajectory of symptoms and problems also helps patients and their clinicians to make 
informed decisions about treatment and may be empowering to patients and their families (565). 
Understanding symptom trajectories is also the prerequisite for developing interventions and 
evaluating their effectiveness (566-568). The longitudinal measurement of HRQOL in multiple 
myeloma in particular can shed light on early intervention targets that could help improve long-
term HRQOL impairment, as well as the potential of PROs to act as predictors for long-term 
mortality (569). From these predictive models, further interventions specifically targeting patients 
at risk of deterioration and possibly the early integration of palliative care into haematological 
care could be developed (189).  
In palliative care, most of the information on patients’ and carers’ experiences and needs at the 
end of life is derived from cross-sectional studies rarely using PROs (259,570,571). The 
longitudinal studies available in palliative care research usually examine the period immediately 
before death (259,572-577), but there have also been publications of trajectories at early stage 
disease (578) and at treatment transition points (572). However, this information can only partly 
be transferred to multiple myeloma. In palliative care, much attention has been given to the 
functional decline that accompanies cancer. Three types of common trajectories have been 
described for three disease groups: a trajectory with steady levels of functioning up until a clear 
terminal phase for cancer, a trajectory with gradual decline, punctuated by acute exacerbation 
with subsequent recovery to a level below prior functional ability for organ failure; and a 
trajectory with prolonged and gradual decline which is typical for frailty and dementia (157). 
However, functional status can only be regarded a proxy for QOL. Its popularity partly stems 
from the fact that chemotherapy trials use functional status. Lynn and Lunney’s model was 
developed using cross-sectional data taken at different time points (157). Therefore one cannot be 
sure that these trajectories reflect the experiences of individual patients over time. Moreover, 
since the myeloma population has aged and treatments have evolved, concomitant comorbid 




following the typical course of cancer. The model also assumes homogeneity of trajectories for 
different aspects of QOL. Murray and co-authors have shown that different trajectories for 
subdomains of QOL may well exist that are not related to physical wellbeing. They described a 
trajectory of spiritual distress that followed a course of several peaks at diagnosis, at recurrence 
and in the terminal stage (579). They also mapped psychological and social trajectories. Thus, 
mapping not only the overall mean trajectory of QOL but obtaining a more fine-grained picture 
can help identify those patients within the myeloma population that would benefit from palliative 
care involvement. Such data could help with the early integration of palliative care alongside 
curative treatments and replace the idea that palliative care is confined to the last few weeks of 
life (equating with end–of-life care) (565). The palliative care approach could support people with 
chronic progressive illnesses much earlier and over many years.  
In this PhD study, multidimensional trajectories will be plotted. Therefore, this study aims to 
recruit a diverse sample including a spectrum of disease trajectories (shorter/longer, stable, 
fluctuating and deteriorating), with changes in QOL due to cancer, treatment, comorbid health 
problems, with periods of relapse and refractory disease. This will provide a broad dataset with 
data applicable to the wider population affected by multiple myeloma and possibly similar 
chronic, incurable haematological cancers (like myelodysplastic syndrome (MDS), chronic 
myeloid leukemia (CML) or follicular lymphoma). Longitudinal studies require a careful 
definition of the groups for study and a careful selection of variables for measurement (580,581). 
This study recruits a consecutive sample from out- and inpatient clinics. By recruiting patients 
that are in secondary and tertiary care, a more representative sample can be gained than studying 
treatment populations only (83,147). The timing of the repeated survey points should occur when 
changes are expected. This is difficult to realize as the population of myeloma patients is diverse 
(see Background Chapter 2.1). No concrete guidelines exist for the timing of HRQOL 
measurements. A study in non-small lung cancer patients advised a three-week interval for QOL 
assessment (582). Other guidelines (583,584) for timing of measurement in oncology mainly 
focused on advanced, palliative samples and therefore advise up to weekly data collection to 
counteract the high attrition that can be expected in that population. However, patients with 
multiple myeloma have a median survival of several years. To strike a balance between capturing 
changes and keeping participants engaged with the study, bi-monthly data collection is proposed 
as appropriate.  
Selection of variables for measurement is based on a prior cross-sectional survey of the same 
population and those measures that have been validated in multiple myeloma have been chosen 
for this study (359). Postal surveys require least effort for the participants and are among the 
cheaper alternatives for costly longitudinal studies (581). However, response rates need to be high 




from poor recruitment and retention (585). In designing methods of approaching potential 
participants and study procedures like telephone support and postal surveys in this study, results 
from qualitative studies that used semi-structured interviews to identify the views on taking part 
in longitudinal research and the preferred methods of approaching and contacting study 
participants (585,586) have been taken into account. Furthermore, in its pilot phase this study 
used qualitative interview methodology to explore the best methods of recruitment and 
longitudinal follow-up. The topic guide for these interviews is shown in Appendix E. After 
conducting and analysing five interviews from purposefully sampled patients, no changes to the 
proposed methods for the longitudinal component of this PhD study were needed. Therefore, no 
further interviews were conducted and we proceeded to the next phase of research. 
The longitudinal modelling framework consists of two components: within-person change and 
inter-individual or between-person change. The former answers the question how symptoms and 
QOL dimensions of each study participant change over time. The latter answers the question of 
what predicts differences in the symptom and QOL trajectories among individual participants 
(587). Thus, the analysis separates the descriptive mapping of trajectories from the relational and 
analytical part, the examination of associations among explanatory variables and trajectories 
(587). The two main benefits of longitudinal analysis are its capacity to understand individual 
within-person relationships while at the same time providing the opportunity to test hypotheses at 
multiple levels of analysis (588). The fundamental tenet of longitudinal analysis is that these two 
elements need to be separated in the analysis. Relationships that are observed at the within-person 
level need not mirror those observed at the between-person level of analysis. Hypotheses for both 
levels should be formulated separately (589).  
Collins (2006) (590) and Collins & Graham (2002) (591) define three elements of any 
longitudinal modelling framework: the theoretical model of change and the temporal design used 
to observe the change phenomenon, both of which need to be reflected in the statistical model of 
change. The first element, the theoretical model of change consists of a clear statement about the 
nature of the change phenomenon that is observed. This concerns a description of the shape of 
change (stable, rising, curvilinear or fluctuating), a possible cyclical nature of change, and which 
time-invariant and time-varying covariates may predict change. The temporal design involves 
decisions about the timing, frequency and spacing of observations in the longitudinal study (591). 
These decisions presuppose the statistical model that is chosen for analysing longitudinal change 
in individuals (590). Since multiple myeloma is a heterogeneous disease as to the clinical 
manifestations of disease-related problems and as to the treatment pathways that patients 
experience, in this PhD study both the observation of within-person stability and within-person 




heavy a burden on study participants, yet trying to capture outcomes often enough to detect 
significant stages of change in a sequential process of change (591). 
In terms of the statistical model of change, one goal of this research study is to adequately capture 
the variation within and between individuals. Instead of establishing a general developmental 
trajectory for all participants in the study, understanding change within the individual and 
establishing intra-individual variability is the primary interest (592). Most often, trajectory studies 
focus on establishing an average change trajectory for the entire group by first plotting individual 
trajectories of all participants, then estimating an average/mean trajectory from the mean 
symptom or QOL scores at each time point. However, given the conflicting results of those few 
studies having examined changes in QOL in multiple myeloma (see section 2.2.2.2), one can 
presuppose considerable heterogeneity within the QOL trajectories of multiple myeloma patients. 
Inconsistencies in the conclusions of these longitudinal studies, ranging from reporting decreases 
in psychological symptoms and QOL-related problems (31,35) to studies concluding substantial 
worsening or deterioration (381,593), may stem from the fact that analysis of change made use of 
mean symptom or QOL scores for the entire sample. Conventional approaches to modelling the 
longitudinal course assume that individuals are sampled from the same underlying population and 
that a single growth trajectory can describe the entire sample. These approaches are usually 
known as random-coefficient or mixed linear regression models (594-596), sometimes also 
described as multi-level or hierarchical models (597). In these models, although each participant 
is assumed to have his or her own unique trajectory, a single group, fixed coefficient is computed 
to index the average rate of change for the entire sample (386). Between-subject covariates are 
then introduced into the model, either as fixed covariates (e.g. demographic variables, baseline 
variables) or time-varying random covariates (e.g. time-varying physiological variables or 
psychological/coping variables). Although this is a very flexible and robust method for analysing 
change that allows imbalanced data (measures not collected at the exact same time point for each 
participant) with missing values (594-596), it disregards the existence of potential subgroups 
whose trajectory may be significantly different from the overall estimate. Moreover, covariates 
are further assumed to affect the trajectories of all individuals in the same way, an assumption that 
might not hold true in myeloma, a disease in which certain predictors may only be relevant for 
certain patients at different stages in their disease (598).  
These problems in statistical longitudinal modelling have been captured in the distinction between 
person-centered and variable-centered analytical methods (599). Variable-centered approaches 
such as random-coefficient models, other models like generalized estimating equations for non-
parametric data (600) focus on describing relationships among variables. The aim of such 
analyses is usually to understand relationships between independent and dependent variables. 




mixed effects models and focus on relationships among individuals, with the goal being the 
classification of a heterogeneous group into distinct subgroups based on a homogenous individual 
response pattern (601,602). This results in the analysis separating classes of groups of individuals 
that are characterised by a common pathway of QOL-related problems. Person-centered 
approaches are therefore better suited to address individual differences in patterns of change over 
time (603). These models are known as latent growth curve analysis (LGCA) (601,602), or in the 
presence of within-class variance on growth parameters (slope and intercept), as growth-mixture 
modelling (GMM) (601,604). In an LGCA model, two types of hypotheses can be posited. The 
first set of hypotheses usually concerns the number of latent classes, i.e. distinct subgroups, within 
the heterogeneous population on the outcome that one is measuring. For the multiple myeloma 
population, hypotheses can be formed about classes that represent stable QOL, improving or 
deteriorating QOL and fluctuating QOL trajectories. In addition to assumptions about the slope of 
the change, hypotheses can also focus on the intercept parameters, i.e. positing high or low values 
of QOL. The second set of hypotheses then concerns time-invariant or time-variant variables that 
predict membership in a specific class of QOL change. Variables can be selected that reflect 
different levels of factors, for example individual factors (such as demographic or clinical 
characteristics) or system-level factors (such as health service provision or treatment variables) 
(605,606). It is at this step at which a theoretical model of QOL and its influencing factors can be 
brought into the analysis, by selecting and hierarchically entering covariates representing the 
different levels of the QOL model. This approach essentially uses elements of variable-centered 
approaches like structural equation modeling (607). The results are separate growth models for 
each latent class, each with a unique set of estimates of influences from independent variables 
(608). 
The latent growth curve model that is tested in the longitudinal component of this PhD study can 
be depicted in the following way (Figure 8). The growth factor (slope) and intercept parameter 
(estimated baseline value of the outcome, i.e. high or low levels of QOL) (eta 0 and eta 1 in 
Figure 8) are modelled to capture changes for the time intervals two, four, six and eight months (t0 
to t4). The probability of class membership is adjusted for independent variables (ECOG 




Figure 8: Hypothesised growth model diagram for HRQOL changes over 8 months in 
patients with multiple myeloma. Square boxes: observed variables; circles: latent variables; 
directed lines: regression equations. 
 
Several alternative statistical approaches that could be used to model change in this sample were 
initially explored at the time of planning the longitudinal study, but eventually discarded once the 
nature of the sample (large enough sample and moderate attrition) became apparent. In the initial 
stages of this research, the usually small sample sizes common in palliative care research (609) 
led to proposals of using graphical methods to depict trajectories (587), or using aggregated 
measures that summarise repeated assessments into a single measure (610). This can either be 
done by calculating the area under the curve (AUC) (610) or event history analysis (Q-Twist, an 
approach that calculates the time until deterioration of QOL for each individual in the sample 
(611)). Summary measures of change can then be subjected to the conventional methods of 
regression analysis or ANOVA to identify independently associated variables (610,612). 
However, although summarizing longitudinal change for each subject into a single numeric index 
can be a powerful method if presented with small sample sizes, longitudinal modelling that takes 
into account the fact that successive QOL assessments by the same person are auto-correlated are 
stronger. A technique that can analyse the heterogeneity within individual trajectories of QOL 





4.3.3 Phase 3: Regression analysis/prognostic model 
Research questions: 
1. What are the demographic and clinical (disease and treatment-related) predictors of poor 
outcomes as defined by experiencing a poor or deteriorating quality of life? 
2. Do the general symptom level and PROs have a stronger influence on health-related 
quality of life than demographic and disease (biomedical and treatment) factors? 
3. Is the model of predictors robust? 
In this study, a system of prognostic predictors is to be developed through a series of regression 
analyses. First, potential variables for inclusion into the multivariable models are explored in a 
meta-analysis (see chapter 1.2.2.3). This initial model is then tested on the cross-sectional, 
secondary dataset and refined and partly validated in the longitudinal dataset. 
Within epidemiology and medicine, regression modelling and the investigation whether particular 
variables are prognostically or diagnostically important and associated with an outcome enables 
the prediction of patient pathways. Since disease causation is always multifactorial, multivariable 
models are advised (613-618). Normally, the term prognosis is defined narrowly as the probable 
course and outcome of a health condition over time (619), as the investigation of causes of disease 
progression, prediction of mortality risk in individuals or prediction of individual response to 
treatment (620). In this PhD it is used in a wider sense to include outcomes other than survival 
and to shed light on deteriorating QOL as an indicator for palliative care involvement. Altman & 
Royston (614) have used the term more loosely to include other outcomes than survival as well. 
Although there are similarities between prognostic and aetiologic research, predicting outcomes 
does not focus on explaining their cause (14,621). Hence, this PhD study uses a simple 
longitudinal approach without following a cohort design to evaluate cause and effect (581). 
Prognostic modelling studies have been used in medicine to understand the course of health-
related conditions, to examine specific risk factors in their association with prognosis, to develop 
and validate statistical models of risk and to help tailor treatment decisions to the individual 
patient (622,623). This information can be used when communicating information about disease 
and treatment to patients and families, to create clinical risk groups or as stratification models of 
disease severity (614). It is this latter use that is intended in this PhD study, identifying patient-
reported variables that can be used to indicate deterioration in QOL and increase in palliative care 
needs. 
Prognostic model building falls into two categories: predictive and explanatory models 




model structure or causal pathways among predictors (613). Model fit indices and prediction error 
are the main criteria for judging model adequacy (613). Explanatory models, however, are mainly 
concerned with hypothesis generation and with identifying the factors that predict a certain 
outcome without focusing just on which particular set of multiple variable produces the best 
model (614,619). The multivariable model that is built in this study for predicting deteriorating 
QOL falls into the latter category. This decision also relies on the fact that predictive models are 
often limited to data-dependent model building strategies only (626), with very little consideration 
of subject-matter knowledge. Statistical modelling in these contexts uses stepwise procedures for 
variable selection, whereby the choice of variables in the model is based on sequential hypothesis 
testing of individual predictors in an automated procedure (627). These procedures tend to yield 
overoptimistic models with too many variables included. This model of predictors for 
deteriorating QOL, however, is partly built from theory (330,357).  
The second, often overlooked aspect of model building is the one of validating the model. 
Validation contains the two general aspects of accuracy (the degree to which prediction matches 
outcomes) and generalisability, the ability of the model to hold true in a different sample of 
patients (628,629). Validating the accuracy of a model entails the comparison of observed and 
predicted event rates for groups of patients (calibration), and distinguishing between future 
outcomes of a group of individuals (discrimination) (618,630). Both approaches rely on using the 
model in a new sample. This is problematic in multiple myeloma since follow-up until 
development of the outcome can take long. Mean survival time has increased in recent years 
(61,62). Therefore, in keeping with the data sources and the scope of the current study, internal 
validation and temporal validation procedures are used to validate the model, rather than 
validating it in a separate sample (614). Establishing generalisability of the set of predictors in a 
different population is a task for future research. Internal validation usually involves data-splitting 
into an exploratory and a confirmatory data set (631). Several ways of establishing these test and 
training sets have been proposed of which the most common way is to use a random sample. 
However, random splitting constitutes a weak procedure and tends to yield imprecise estimates 
(614,632). An alternative is temporal validation, evaluating the performance of a model on 
subsequent patients from the same centres (633). In this study, temporal validation is used by 
building the initial model on the combined datasets of the MyPOS validation study and the 
longitudinal PhD study, then validating it taking the temporal course of HRQOL in myeloma into 
account.  
Different phases have been defined in prognostic research studies. The earliest conception of 
phases was proposed by Altman & Lyman (1998) (634). They distinguished three phases, 
exploratory studies that are hypothesis generating, exploratory studies that attempt to use an 




(e.g. disease progression), and confirmatory studies attempting to validate a priori cut-off values 
on prognostic markers to define groups of high and low risk (634). This initial model was 
subsequently extended and reformulated in the guidelines for prognostic factor research published 
by the same research group (14). In this model, the authors distinguish between developmental 
studies, validation studies and impact studies. Developmental studies entail identification of 
important predictors within multivariable prognostic models with calibration and discrimination 
and internal validation techniques (635). Validation studies are studies that test the model’s 
performance in new participants, usually comprising temporal validation and generalisability 
studies to discriminate groups of patients on the risk factors identified in the model (14,629). 
Impact studies finally use the prognostic model at the bed-side and try to quantify whether the 
model improves decision making and patient outcome in clinical practice (14). This PhD study 
only covers the developmental stage, with model identification and internal validation procedures, 
by building the model over three subsequent study phases – the systematic review and meta-
analysis of factors associated with QOL in multiple myeloma (see section 2.2.2.3), the cross-
sectional study (chapter 5), and the longitudinal survey (chapter 6). Further validation processes 
should entail a prospectively planned pooled analysis of individual patient data and eventually 
using the model in routine clinical practice for confirmatory and impact studies of its 
performance. 
 
4.3.4 Phase 4: Longitudinal validity and reliability of the Myeloma Patient Outcome 
Scale for individual patient-monitoring 
Research questions: 
1. How does the MyPOS after its conversion to the format of its core module, the Integrated 
Patient Outcome Scale, perform psychometrically in terms of item quality, construct 
validity, and reliability? 
2. Is the MyPOS reliable over time, both when measuring changes and stability in groups of 
patients and in individual patients? 
3. Can the MyPOS validly reflect important changes in the individual multiple myeloma 
patient over time and can the minimally important difference both for patients that 
improved and for those that deteriorated be determined? 
4. Is the MyPOS an acceptable instrument to monitor changes in symptoms and quality of 




Measurement is central to clinical practice, medical and health research. Measurement forms the 
basis for diagnosis, prognosis and evaluation of results of interventions. Especially in the context 
of palliative care and progressive disease, with its focus on whole-person care and patient-
centredness, capturing the personal and social context of disease and including the wider factors 
impacting QOL is important. QOL measures are accepted as outcome measures in clinical 
research but less so in clinical practice (316). There are unique challenges when using QOL tools 
in clinical practice. These challenges concern: selecting appropriate measures, analysing data, 
providing feedback on scores to clinicians and patients, interpreting results and using results in 
clinical decision making (316,442,443). Rather than introducing the Myeloma Patient Outcome 
Scale in a wide-spread fashion in routine haematological practice, this PhD study focuses on 
establishing whether the MyPOS is suitable and of high enough quality for such an application. 
In clinical research, the quality of inferences made in clinical trials is dependent on the soundness 
of the outcome measures used. Both the FDA and the EMA have specified minimum criteria for 
the psychometric quality of health outcomes scales (287,636,637), albeit only for application in 
clinical trials. The other two prominent sources for guidelines of instrument properties are the 
Scientific Advisory Committee of the Medical Outcomes Trust (638,639) and the COSMIN 
guidelines (640). All these sources differ slightly as to the attributes of measurement quality they 
define as essential. Central to all classifications are concepts of validity, usually split into the 
components content and face validity, construct validity and criterion validity, reliability, 
responsiveness (longitudinal validity), interpretability, and cultural and language adaptations 
(638-640). What is often lacking in these catalogues are explicit criteria for what constitutes good 
measurement. With the notable exception of Terwee et al. (2007) (641), no evaluative cut-off 
values are specified for different attributes. Moreover, Higginson and Carr (2001) (316) point out 
that these lists of measurement properties are geared towards an application in clinical research. 
Validation of outcome measures in clinical practice, however, necessitates an exploration of 
certain features that make a questionnaire easy to use in this context. Clinical utility entails 
features such as respondent burden, assessing floor and ceiling effects to evaluate whether the 
instrument is applicable in the target population, and responsiveness of scores for individual 
patients and not just groups of individuals (316,642).  
Another feature of these guidelines is that they assume that the same set of quality criteria applies 
to all types of health outcome measures, a notion that Kirshner & Guyatt (1985) (643) refute by 
defining different purposes of measurement use in health care. The authors distinguish between 
discriminative, predictive and evaluative measures. Discriminative and predictive scales are used 
for screening and diagnostic purposes, usually to distinguish between individuals or groups and to 
identify those at risk for developing a certain outcome (643). Evaluative indices, on the other 




locate QOL measure within the latter category. Uniquely, they point towards the application of 
evaluative and predictive indices for the individual patient (and not solely for a group of patients), 
and it is in this context that screening and monitoring benefit clinical practice. Screening is the 
process of systematically searching for preclinical disease and classifying people according to 
their risk of presenting with a certain health problem or being at risk of experiencing a certain 
outcome (644). Screening programs usually relate to risk factors for chronic conditions. Within 
healthcare of cancer and chronic diseases, the early detection of recurrence of cancer (645,646) 
and emotional distress (647) usually constitute the largest screening applications. Similar to 
screening is the application of monitoring or surveillance, whereby repeated assessments of 
biological or health status parameters are used to track changes and patterns in key domains in a 
group of patients (648). Both applications of measurement work at the local level, i.e. in screening 
all newly diagnosed patients for emotional distress, or are used in the form of population 
monitoring as core epidemiological functions within public health (648). 
When used for the individual patient, the question of accuracy and scientific quality of measures 
becomes paramount. However, as this application has not been popular within the field of health 
outcomes research, which has traditionally focused on comparing groups of patients on outcome 
measures within effectiveness research or for comparisons of health care delivery systems (283), a 
definition of what constitutes a set of necessary criteria for a health outcome measure to fulfil in 
order to be applied at the individual patient level is still lacking. The only work with an explicit 
focus on the evaluation of health status measures for purposes of individual patient-monitoring 
was published by McHorney & Tarlov in 1995 (649). They conducted a head-to-head comparison 
of five prominent QOL measures and specified measurement standards inclusive cut-off criteria 
that define the measure’s suitability for individual monitoring. Essential are six criteria: (i) 
interpretability of scores, (ii) assessing the full range of underlying constructs across different age 
groups, diagnoses, severity and comorbidity, (iii) minimal floor and ceiling effects, (iv) 
reproducibility and minimal measurement error over time for individual patients, and (v) 
sensitivity to clinical change. The authors also recommend more stringent benchmarks for 
measurement errors to fit the longitudinal use of measures, thus asking for higher reliability or 
accuracy of scores, as high as 0.90 to 0.95 (649,650). Kirshner & Guyatt (1985) (643) defined 
similar criteria for psychometric properties applicable to evaluative measures. They emphasised 
the need for responsive measures that assess the construct of interest in sufficient gradations to 
register change (643). In addition to longitudinal construct validity, they also defined stable intra-
subject variation as the second important criterion for evaluative measures.  
Since there is no agreed framework for evaluating whether outcome measures are fit for the 
purpose of individual, longitudinal monitoring, it is proposed to use new psychometric methods to 




Tarlov (649). I suggest to use Generalizability theory, Rasch analysis and new methods for 
determining individual minimally important differences. 
For establishing test-retest reliability of the measure the approach of Cranford et al. (2006) (651) 
will be followed. The authors used Generalizability theory (GT), an extension of classical test 
theory, to study dynamic change in emotional processes. Their approach developed in response to 
studying evolving emotional states and self-regulation via diary studies that require frequent self-
reports of participants (652). Monitoring evolving concepts frequently poses challenges in its own 
right, usually due to respondent burden and the need to keep measures short (653). Brevity of 
measures results in psychometric challenges, particularly regarding reliability (654). This 
sacrifices redundancy which usually improves reliability, as well as sacrificing coverage of the 
full conceptual range of a construct of interest. Reliability in psychometric terms is formally 
defined as the ratio of signal variance to the total variance (655). Systematic change variation is 
often small compared to random measurement error variation and the reliability of change 
assessment hence becomes a question of detecting a small signal among high amounts of noise. 
Generalizability theory (656) offers an answer to that challenge by providing a much more fine-
grained picture than just systematic variance and error/random variance (657). Within the GT 
approach, the variance of a set of scores is partitioned into its component parts and their 
interactions, along with an error component (658). Cronbach et al. (1972) (659) introduced the 
theory of generalizability to make it possible to assess multiple sources of measurement error. 
These error components consist of person variation (due to changes within the person), item 
variation and time variation. All possible interactions between these components are also explored 
(person by time variance, item by time variance, person by item variance and error) (658). 
Cranford et al. (2006) (651) then composed a set of four reliability indices using different 
combinations of these variance components to estimate various forms of reliability (for formulae 
see chapter 7). Via these four indices it is possible to judge the reliability of a measure on an 
average day, and to judge how well the measure discriminates between different persons on a 
given day. Finally, it is possible to assess how well a measure captures changes over time (651). 
Interpretation of these reliability indices follows the common guidelines (641). Different methods 
of assessing the reliability of within-person change have emerged in recent years (651,660), but 
Cranford and co-authors’ method has been found to be the most applicable to the situation of 
assessing the reproducibility of the MyPOS for individual patient-monitoring. It is also the only 
approach that provides the estimation of how well a measure such as the MyPOS can discriminate 
between persons with different levels of the attributes/dimensions to be measured. 
The reliability of the MyPOS is also assessed using the differential item functioning (DIF) 
approach first proposed by Hobart et al. (2009) (661). DIF analysis uses the Rasch measurement 




whole measure, Rasch analysis indicates reproducibility at the individual item levels and thus 
allows to satisfy the objective to assess which individual items are suitable for monitoring. The 
Rasch model was proposed by the Danish mathematician Georg Rasch in 1960 (662). Classical 
test theory confounds the performance of the scale with the measurement of people (661). In 
Rasch analysis, estimates of item and person parameters are separated which allows the 
assessment of quality of individual items that is not sample-dependent. One way of assessing the 
reproducibility of single items within the MyPOS is to conduct a DIF analysis. Via a two-way 
ANOVA of standardised residuals across the continuum of QOL and levels of QOL in the sample, 
the invariance of items can be quantified (661). There are two types of DIF which indicate 
different breaches of the principle of invariance. First, a significant time effect, also known as 
uniform DIF, shows that an item is not stable across time points. Second, non-uniform DIF 
(significant interaction between class intervals and time) indicates that there is general misfit of 
the item across the whole measurement continuum (661). Both uniform and non-uniform DIF will 
be assessed for all MyPOS items. 
Classical test theory (CTT) and Rasch measurement are both measurement theories that underpin 
the psychometric evaluation of rating scales (663). Measurement theories describe how numbers 
on a rating scale relate to the constructs they seek to measure (663). CTT represents a relatively 
simple theory that posits that a person’s score on a scale (the observed score) is the sum of the 
unobservable true score of that person on the trait that is measured (i.e. QOL or pain) and an 
associated measurement error (655,664). The major critique of CTT is its general weakness as a 
theory that cannot be tested (665). The parameters of the theory (the true score and the 
measurement error) cannot be determined in a way other than through the observable score and 
thus they cannot be evaluated for their accuracy (664,666). This leads to several problems, chief 
among them the problem that the assumptions of CTT are easily satisfied by datasets, even if they 
are not true (664,666). More pronounced is the problem that parameters cannot be determined 
with confidence and only ordinal raw scores can be analysed. Likert-type rating scales thus never 
generate interval measurement which has a direct negative effect on comparisons of scores 
between individuals and deriving meaning of a score for the individual per se. With ordinal 
scores, confidence intervals are too wide to allow this application (667). Moreover, all 
information in CTT on the validity and reliability of the scale pertains to the whole score and is 
sample-dependent. Thus, results obtained in samples of relatively well patients cannot be 
transferred to palliative care samples (316). One elegant solution that addresses these 
methodological problems is using latent trait theories such as the Rasch model. Rather than 
developing a model that best fits the data, the Rasch model defines measurement, so that data are 
fitted to the model to see if they meet the model’s expectations (668). The Rasch model posits that 




item location and the respondent location on a linear scale. Applied to health measurement scales 
this means that the response to an item is determined by (a) the QOL status of the person and (b) 
the level of health status impairment represented by the item. Questionnaires that meet the 
requirements of the Rasch model have interval scaling properties, meaning that patients are more 
likely to endorse items assessing less severe QOL problems (item difficulty or location) when 
they experience few symptoms and limitations that would negatively impact on their QOL (person 
ability).  
Not only does the Rasch model allow an analysis of the individual items within the scale, its 
results are also sample-independent and show where along the measurement continuum the 
questionnaire is situated. Thus, more information than through simple analysis of floor and ceiling 
effects can be gained. The question can be answered whether the items fit the population which 
they target. In CTT analysis of scale targeting, floor and ceiling effects are considered to be 
present if more than 15% of respondents achieve the lowest or highest possible score (649). This 
indicates that items either asking about mild or severe/extreme levels of the construct are missing 
at either end of the scale. Floor or ceiling effects diminish the content validity of a scale and 
reduce reliability, since patients at the lower or upper level cannot be distinguished. This in turn 
affects responsiveness because changes cannot be measured at these ends of the spectrum (667). 
Within Rasch analysis, more information on the targeting of the scale is available. Fit statistics 
(mean location scores) for persons and items should be centering on zero (668), which indicates a 
well-targeted measure. In addition, a person-item location diagram which maps item locations to 
person locations allows an assessment whether the scale spans the entire range of person locations 
(thus all levels of QOL – from no problems/good QOL to severely impaired QOL) (512). A 
further technique within the Rasch framework is to use DIF (see reliability analysis above). DIF 
signals that different groups within the sample respond in a different manner to items. A 
consistent, systematic difference in the responses is called uniform DIF, which suggests splitting 
the item for these groups. If disease severity or phase of illness are variables producing DIF, then 
this could be an indication for a scale such as the MyPOS to work differently in these groups 
(668). 
The shift in focus and the growing interest in using QOL results at the individual patient-level is 
especially driven by the need to track changes in QOL and symptoms over time (432,454,669). 
Responsiveness analysis use QOL data that was assessed repeatedly over time and can thus make 
use of the time course and differences in QOL scores from time point to time point (650). 
However, results usually apply to a group of patients. The sensitivity of change or responsiveness 
to change of individual scores has received less attention in the methodological literature (641). In 
these analyses, what might constitute a meaningful change for an individual certainly differs from 




as the indicator of meaningful change as “the smallest difference in score in the domain of interest 
which patients perceive as beneficial and which would mandate, in the absence of troublesome 
side effects or excessive costs, a change in patient management” (p.408). Reviews have defined 
methods to assess this MID in HRQOL, mainly splitting approaches into anchor-based and 
distribution-based methods (671,672). Distribution-based methods rely on effect sizes (673-675), 
the standard error of measurement (676,677), the responsiveness index (678) and the reliable 
change index (679). Distribution-based approaches usually represent statistically rather than 
clinically significant change. Anchor-based approaches use an external criterion to determine the 
significance of change in global QOL or well-being, usually a global change rating that is 
completed by the patient (680). Alternatively, significant clinical events (e.g. laboratory or 
physiological measures, treatment benefit) or ratings by clinicians are used (650). A review of 
possible approaches is presented in Crosby et al. (2003) (672). 
Methodological challenges concerning determining clinically relevant change centre around a 
variety of methods being proposed with an overall lack of consensus regarding definitions and 
methodological approaches (672,681). Furthermore, the MID can be determined at the group or 
individual level (682). This is determined by the anchor. However, this distinction is often not 
taken into account (683). Moreover, the interpretation of MID values at the individual level is 
accompanied by uncertainties. MID values at the individual level are immensely influenced by 
scale reliability and measurement precision (684). Although this is a well-known fact and QOL 
questionnaire are subject to lower reliability values due to their multidimensionality (672), 
oftentimes the same thresholds for relevant changes are proposed for individual-level as for 
group-level applications (685,686). Vet and co-authors (2010) (683) have proposed a way to 
visualise the uncertainty around MID values, not just using a 95% confidence interval but 
evaluating whether the MID value exceeds the measurement error. Thus, thresholds of statistical 
significance are brought together with thresholds of clinical significance (687). The Amsterdam 
group used this approach to compare MIDs on the EORTC QLQ-C30, showing that at least 
moderate to large changes derived from distribution-based methods need to be defined in order to 
measure change reliably at the individual patient level (683,688). For the evaluation of 
responsiveness of the MyPOS subscales, methods to determine responsiveness at the individual 
patient-level and methods of displaying uncertainty and confidence intervals around these MIDs 
pioneered by Vet et al. (2010) (683) are used. 
Finally, information from phase 3 will be integrated with the results from phase 4 of this analysis. 
In phase 1 and 2, the cross-sectional and longitudinal analysis, data sets of variables potentially 
influencing QOL are collected. In a series of regression models, a prognostic model of variables 
related to poor or deteriorating QOL identified. The psychometric perspective in phase 4 




multiple myeloma from a measurement perspective. Both analyses try to answer the same 
question, but use different approaches to help identify targets for screening and monitoring in 
myeloma.  
 
4.4 History of the study and development of the MyPOS  
This longitudinal study on quality of life in multiple myeloma represents the last phase in a 
programme of research started at the Cicely Saunders Institute at King’s College London in 2010. 
Prior to this year, Myeloma UK, the largest patient-led charity for multiple myeloma operating in 
England and Scotland, had announced to fund a five-year research programme to improve the 
wellbeing of myeloma sufferers, with the aim to directly inform the healthcare policy-making 
process and leading to improvements in the clinical care of patients. They were particularly 
interested to understand which factors impact on QOL and wanted to fund the development and 
validation of myeloma-specific instruments to assess QOL in clinical practice. The Cicely 
Saunders Institute offered special expertise in the development of measures in populations in 
which outcome measurement can be a challenge due to their advanced disease stage. The Support 
Team Assessment Schedule (STAS) and the Palliative care Outcome Scale (POS) were among the 
first outcome measures to be developed for palliative care (689). Many versions for different 
conditions (multiple sclerosis, dementia, renal disease etc.) are now available, with a considerable 
number of culturally adapted and translated versions (for example the APCA African POS (689)). 
The newest iteration is the Integrated Palliative Care Outcome Scale (IPOS) (819), which 
integrates 15 years of work in the development of the POS measure and represents a refined 
patient- and proxy (staff-reported) version of the POS.  
The first step in the Myeloma-UK funded research project was a systematic literature review 
(359) to identify instruments that were developed and validated for use in patients with myeloma. 
Subsequently, two more questionnaires were published, the Functional Assessment of Cancer 
Therapy – Multiple Myeloma (FACT-MM) (513), which is in its initial development phase, and 
the M.D. Anderson Symptom Inventory – Multiple Myeloma (MDASI-MM) (690). The review 
identified no tool specifically developed for clinical use (359). Subsequently, a qualitative study 
explored the meaning of QOL in this group and also explored participants’ views on existing 
QOL tools, their utility, breadth of coverage of the construct and views on their acceptability 
(357). A theoretical model of quality of life in multiple myeloma was derived from that data. 
These findings were used to develop a prototype version of the Myeloma Patient Outcome Scale 
(MyPOS). Since developing a new tool in the presence of existing instruments to measure a 
construct in a patient group needs to be well-argued, it was decided to modify an existing 




decided to adapt the Palliative Care Outcome Scale (POS) since this was the only tool that was 
initially developed with a specific focus on use in clinical care and its scaling considered the 
impact of symptoms and problems rather than the status of these problems (512). The POS also 
offered items that had been designed specifically for a more advanced population, a feature that 
the new tool for clinical use in myeloma needed to have. Items for the prototype version were 
derived from the qualitative work, the theoretical model of QOL in myeloma, and existing 
questionnaires identified in the systematic review (357). The initial 33-item version, using a 
combination of structured and open items (with 10 items taken from the POS and 23 newly 
written items), was pre-tested in cognitive interviews with twelve participants. The refinement 
was conducted in two stages, with a first rewording of questions being undertaken after an initial 
round of six interviews and further six interviews, after which 2 items were removed because of 
redundancy. The formatting was also changed (384).  
The 27-item version of the MyPOS was then tested for validity and reliability in a multi-centre 
sample of 380 patients. Results of these analyses, combined with further results from the 
longitudinal validation study, are shown in Table 6. In this table, the MyPOS is further compared 
to the other two most prominent disease-specific HRQOL tools, the EORTC QLQ-MY20 
(221,310) and the MDASI-MM (690). Structural validity testing of the MyPOS yielded three 
subscales, Symptoms & Function, Emotional Response and Healthcare Support. Construct 
validity was further tested using hypothesis testing/subgroup comparisons and 
convergent/discriminant validity comparison to other measures. MyPOS scores behaved as 
hypothesised with higher scores (worse QOL) in those with active disease, those receiving 
chemotherapy and those with a poorer ECOG performance status. Reliability testing was confined 
to assessment of internal consistency which was high (alpha = 0.89), given that the MyPOS is a 
multi-dimensional, clinical measure.  
After the initial validation and before the set-up and application to the ethics committee had been 
completed for the longitudinal survey, the Palliative care Outcome Scale was transformed to the 
Integrated Palliative care Outcome Scale (IPOS). This measure builds on 15 years of development 
work of the POS and its extensions. It combines the most important elements of the original 10-
item palliative care measure with a symptom list stemming from the POS-S symptom measure 
(819). Further cognitive interviewing work from the development of the African POS (689) 
regarding item and response option wording was also incorporated. The IPOS has undergone 
psychometric testing including cognitive interviewing in phase 1, to assess content/face validity 
and acceptability (818), and full construct validity as well as test-rest and inter-rater reliability 
assessment (819). To aid the harmonisation of the different measures of the POS family, it was 





Table 6: Comparison of the main myeloma-specific quality of life and symptom questionnaire 
Measurement 
domain 




M. D. Anderson Symptom 
Inventory – Multiple 
myeloma (690) 
No of items 33 50 26 
Content validity Based on existing questionnaires 
and over 70 qualitative 
interviews with MM patients 
with different disease stages for 
item generation, cognitive 
testing with 12 MM patients 




patients for item 
generation, cognitive 
testing with MM 
patients 
Literature search and 
informal interviews with 
clinicians and researchers 
for item generation, 
cognitive testing with 20 
MM  
Construct validity  
Structural 
validity 
Initial exploratory factor 
analysis found three subscales, 
subsequent confirmatory factor 
analysis confirmed subscale 
structure 
Multi-trait scaling 






High correlations with QLQ-
C30 global QOL scale, and with 
physical, role, cognitive, social 
function and MY-20 disease 
symptoms and side effects. 
MyPOS Emotional subscale 
correlated highly with QLQ-C30 
emotional function and QLQ-
MY20 future perspectives. No 
correlation between MyPOS 
Healthcare support and any 
subscale on the EORTC. 
Moderate 
correlations between 
global QOL scale on 
QLQ-C30 with all 
items on QLQ-
MY24, except for 
social functioning 
Moderate to strong 
correlations of MDASI 
severity subscale with QLQ-
C30 subscales; activity-
related interference subscale 
strong correlation to 
physical function subscale 
on the QLQ-C30, MDASI 
symptom subscales 
correlated well with QLQ-
MY20 disease symptoms 





MyPOS total scores higher 
(worse QOL) in those with 
newly diagnosed or relapsed 
versus stable disease 
MyPOS total scores higher in 
those receiving chemotherapy 
versus those not on treatment 
MyPOS Symptoms and 
Function subscale higher in 









status at baseline 
associated with 
disease symptoms, 
side effects and 
body image 
subscales 
Patients with good 
performance status 
significantly lower MDASI-
MM subscales, also on MM-
specific symptom items, 
large effect sizes for 




Cronbach’s alpha 0.89 Cronbach’s alpha 
0.92 




Excellent test-retest reliability 
(>0.90) and moderate to good 
reliability for screening and 

















M. D. Anderson Symptom 
Inventory – Multiple 
myeloma (690) 
Responsiveness Moderate to strong correlation 
to external change question, 
reliable identification of those 
that improved, remained stable 
or deteriorated with 
misclassification only in case of 
deterioration (results from this 
PhD study) 
Improvement over 







decreases over time 
in disease 
symptoms, side 
effects and body 
image subscales in 
those achieving at 
least a partial 
response 
Difference scores between 
patients whose ECOG 
performance status 
worsened and those with 
stable/improved 
performance status were 
significant for each MDASI-
MM subscale  
Increases in all subscales 
and some single items 7 






Total score: MID of 2.5 for 
improvement and 4.5 for 
deterioration; MIDs for all 





Floor effects for nausea, 
vomiting, diarrhoea, poor 
appetite, sore/dry mouth, 
drowsiness, tingling in hands 
and feet and Healthcare support 
subscale (results from this PhD 
study) 
Some items skewed 
but full range of 
responses 
Healthcare support 
scale (4 items) 
removed due to 
ceiling effects 
– 
Acceptability Acceptability and burden from 
patient interviews 
Mean time to complete 7 
minutes 
Percentage of missing items 
minimal overall 




the POS to the new IPOS format, with disease-specific items being listed in a modular approach 
after the core-IPOS items. Thus, the MyPOS was adapted to the new IPOS format. The changes 
are detailed in Figures 9 and 10. Figure 9 reproduces the original MyPOS version that was used in 
the initial validation study (384), Figure 10 details the changes that were made to adapt the 
MyPOS to the general IPOS format. These changes were as follows: 
• Item 2, a-l (original version): This symptom list was extended by two symptoms, Poor 
appetite and Drowsiness, that are incorporated in the symptom list of the IPOS. 
Furthermore, the symptom list was reordered to fit the general ordering of symptoms in 
the IPOS. The MyPOS original item “Fatigue or lack of energy” was reworded to 
“Weakness or lack of energy” as in the IPOS symptom list, as was the original MyPOS 




results from cognitive interviewing regarding the use of technical jargon or the ambiguity 
of the item phrasing (818). The symptom list now contains all the symptoms contained in 
the original IPOS and two further myeloma-specific symptoms, Tingling in the 
hands/feet and Difficulty remembering things, two symptoms that were mentioned as 
important by patients in the qualitative and development work to the original MyPOS 
(357,384). 
• Page 2 of the new MyPOS contains all generic IPOS items. Three of these seven items, 
Patient anxiety, Depression and Information needs, had already been part of the original 
MyPOS and were thus moved from their original place to the newly formed second page. 
The four items Family anxiety, Feeling at peace, Sharing feelings with family/friends and 
Practical matters are items from the IPOS. The ordering of items follows the order in the 
IPOS (819). 
• All myeloma-specific items contained within the original MyPOS were moved to a third 
page. These items consist of the specific impact of myeloma on activities & participation, 
emotional well-being and of questions regarding the quality of care. No further changes 
to the item wording or response options were made for these items. 
All data collection in the longitudinal survey regarding palliative care concerns and myeloma-




 Figure 9: The original version of the Myeloma Patient Outcome Scale (MyPOS) before it was 
adapted to the IPOS format. All questions are preceded by “Over the past week…”. 
1 What are your main problems or concerns at 
the moment? 
[Open question with three empty boxes for respondent to complete, 
numbered 1-3] 
2 Below is a list of symptoms, which you may 
or may not have experienced.  For each 
symptom please tick one box that best 
describes how it has affected you over the past 
week: 






























b Fatigue or lack of energy 
c Shortness of breath 
d Diarrhoea 
e Constipation 
f Nausea (feeling like you are going to be sick) 
g Vomiting (being sick) 
h Mouth problems 
i Poor mobility 
j Tingling in the hands and / or feet 
k Difficulty remembering things 
l Please list any other symptoms not mentioned 
above, and tick one box to show how they 
have affected you over the past week: 
[Three boxes beneath symptoms list for respondent to add 
additional symptoms, numbered 1-3] 
3 Have you been able to carry out your usual 
activities without help from others? 
Yes, as 
much as I 
wanted 
Most of the 
time 
Sometimes Occasionally 
No, not at 
all 
4 Have you been able to pursue your hobbies 
and leisure activities? 
5 Have you been able to spend quality time with 
family and friends? 
6 Have you been worrying about your sex life? 
No, not at 
all 
Occasionally Sometimes 




7 Have you been feeling depressed? 
8 Have you been feeling anxious or worried 
about your illness or treatment? 
9 Have you been worrying about infections? 
10 Have you been worrying about your physical 
appearance? 
11 Have you been worrying about your financial 
situation? 
12 Have you been worrying that your illness will 
get worse? 




Most of the 
time 
Sometimes Occasionally 
No, not at 
all 
14 Are you able to contact your doctors or nurses 
for advice if needed? 
15 Do your doctors and nurses show a good 
standard of knowledge skill when treating 
you? 
16 Do your doctors and nurses show care and 
respect when treating you? 
17 Do you have enough information about your 












18 Do you have enough information about what 

















Figure 10: The modified version of the MyPOS after adaptation to the IPOS format.  
1 What are your main problems or concerns at the 
moment? 
[Open question with three empty boxes for respondent to 
complete, numbered 1-3] 
2 Below is a list of symptoms, which you may or may not have experienced.  For each symptom please tick one box 
that best describes how it has affected you over the past week: 
a Pain Not at 
all 
Slightly Moderately Severely Over-
whelming-
ly 
b Shortness of breath 
c Weakness or lack of energy 
d Nausea (feeling like you are going to be sick) 
e Vomiting (being sick) 
f Poor appetite 
g Constipation 
h Sore or dry mouth 
i Drowsiness 
j Poor mobility 
k Diarrhoea 
l Tingling in the hands and / or feet 
m Difficulty remembering things 
n Please list any other symptoms not mentioned 
above, and tick one box 
[Three boxes beneath symptoms list for respondent to add 
additional symptoms, numbered 1-3] 
3 Have you been feeling anxious or worried about 
your illness or treatment? 
No, not 
at all 




4 Over the past week, have any of your family or 
friends been anxious or worried about you? 
5 Have you been feeling depressed? 
6 Have you felt at peace? 
Yes, 
always 





No, not at 
all 
7 Have you been able to share how you are 
feeling with your family or friends? 
8 Have you had as much information as you 
wanted? 
9 Have any practical matters resulting from 
















10 Have you been able to carry out your usual 









No, not at 
all 
11 Have you been able to pursue your hobbies and 
leisure activities? 
12 Have you been able to spend quality time with 
family and friends? 
13 Have you been worrying about your sex life? We would like you to answer this question whether or not you 
are sexually active. If you would prefer not to answer please tick 
here: 
 Have you been worrying about infections 








15 Have you been worrying about your financial 
situation? 
16 Have you been worrying that your illness will get 
worse? 









No, not at 
all 
19 Are you able to contact your doctors or nurses for 
advice if needed? 
20 Do your doctors and nurses show a good standard 
of knowledge skill when treating you? 
21 Do your doctors and nurses show care and 
respect when treating you? 
22 Do you have enough information about your 
illness and treatment? 
Response options – impact 






Bolded items are new items from IPOS 
Bolded items in italics are IPOS items that 
had already been part of the original 
MyPOS. These were moved to the second 
page. 
Remaining original MyPOS items were 




I was the research assistant on the MyPOS project and took part in the systematic review work, 
the qualitative study and the development and validation of the MyPOS. I worked on recruitment 
of participants, conducting data collection, analysing data and publication of the research findings. 
The dataset from the multi-centre MyPOS validation study was used in the secondary analysis of 
this PhD research study, forming a part of phase 1, cross-sectional analysis of symptom burden 
and quality of life in multiple myeloma and initial modelling of predictors for poor quality of life 
in this patient group. The validation study of the MyPOS was cross-sectional in nature and 
precluded the assessment of longitudinal validity (sensitivity to change/responsiveness analysis 
with derivation of the MID) and reliability (test-retest reliability in particular). To achieve full 
clinical utility (316) of the instrument, it was necessary to recruit a clinically representative 
sample to study measurement characteristics over time. Also, there was a need to understand and 
improve the illness experience of people with myeloma throughout the whole disease trajectory, 
into stable phases and after relapsed/during refractory disease. To date, as shown in section 
2.2.2.2, only a handful of studies have measured HRQOL at several points in time, usually before, 
during and post-treatment. Large, naturalistic studies are missing (95). The need for a longitudinal 
study that would identify predictors for poor HRQOL and could therefore help to prognosticate 
when prominent problems in different domains of HRQOL would make the involvement of 
palliative care beneficial to these haematological cancer patients, was also identified by St. 
Christopher’s Hospice London. They funded this PhD study from May 2011 onwards, using a 
grant endowed by a former patient with multiple myeloma for the improvement of QOL in this 
condition. I developed the application to the funder, together with the chief investigator Irene J. 
Higginson and the Quality of Life in Multiple Myeloma group at the Cicely Saunders Institute, 
consisting of Dr. Richard Siegert (psychometrics and statistical lead, replaced by Dr. Gao Wei, 
the second supervisor of this PhD study after Dr Siegert changed post in 2012), Dr Steve Schey 
(clinical lead for haematology) and Dr Polly Edmonds (clinical lead for palliative care). I 
developed and lead the application for ethical and local approval in the participating NIHR/NHS 
trusts. I also recruited participants for the first phase, piloting of methods, of the longitudinal 
study. The recruitment for the longitudinal survey was completed by the research nurses in all 
participating centres, with the exception of recruitment taking place at King’s College Hospital 
and Guy’s Hospital, London, two trusts in which this tasks was shared between two research 
nurses and me. Prior to recruitment, I held a training session for each participating site to train 
study-site staff in the standard operating procedures for this study. Once participants had 
completed and returned their first questionnaire, I performed follow-up contact via letter and 
phone calls and subsequent data collection. Data entry, data analysis and interpretation as well as 
publication was also performed and led by me. As part of the dissemination of findings to a wider 
audience, a successful conference was run on 31st March 2016 at the Cicely Saunders Institute. 




talks focusing on routine monitoring of outcomes in this patient group, were presented to an 
audience of clinicians (both from the fields of haematology and palliative care), researchers and 
students and patients and their families. Further dissemination involved international conferences 
and dissemination through patient-led charities like Myeloma UK (for a list of publications, talks 
and poster presentation see section “Publications, presentations and other output”, page 10). 
 
4.5 Ethical issues 
4.5.1 Ethical approvals 
The cross-sectional dataset used in secondary analysis was derived from the validation study of 
the Myeloma Patient Outcome Scale. Research Ethics Committee approval was granted by the 
South East London REC-3 (REC reference number 10/H0808/133). Local research governance 
approvals were obtained for all participating sites taking part in this multicenter study. These were 
Bradford Teaching Hospitals NHS Foundation Trust, Colchester Hospital University NHS 
Foundation Trust, Epsom and St Helier University Hospitals NHS Trust, Guy’s and St Thomas’ 
NHS Foundation Trust, King’s College Hospital NHS Foundation Trust, Maidstone and 
Tunbridge Wells NHS Trust, Mid Yorkshire Hospitals NHS Trust, Northampton General Hospital 
NHS Trust, Pennine Acute Hospitals NHS Trust, St Christopher’s Hospice London, Surrey and 
Sussex Healthcare NHS Trust, University Hospital Coventry and Warwickshire NHS Trust, 
Weston Area Health NHS Trust, and Wye Valley NHS Trust. All patients were screened by a 
member of their clinical team before being approached. Written informed consent was obtained 
from every participant. Data collection was voluntary and took part at a time and place convenient 
to the participant. Completed questionnaires were screened for issues needing immediate clinical 
attention and, if necessary, consent was thought from participants to alert their primary clinical 
team to these issues (distress protocol).  
The longitudinal, multicenter study involving patients with multiple myeloma and their informal 
carergivers was approved by the Central London Ethics Committee (REC reference number 
13/LO/1140). Site-specific local approvals were received from Bradford Teaching Hospitals NHS 
Foundation Trust, Burton Hospitals NHS Foundation Trust, Colchester Hospital University NHS 
Foundation Trust, East Cheshire NHS Trust, Epsom and St Helier University Hospitals NHS 
Trust, Guy’s and St Thomas’ NHS Foundation Trust, King’s College Hospital NHS Foundation 
Trust, Medway NHS Foundation Trust, Mid Yorkshire Hospitals NHS Trust, Royal Free London 
NHS Foundation Trust, Surrey and Sussex Healthcare NHS Trust, and University Hospital 
Coventry and Warwickshire NHS Trust. The study received approval for adoption onto the 




Sponsorship of the project was provided by King’s College London and King’s College Hospital 
NHS Foundation Trust. A minor amendment for change in questionnaire booklet layout was 
approved by the ethics committee in April 2014. The correspondence with the ethics committee, 
amendment and approvals are included in Appendix A.  
 
4.5.2 Ethical considerations 
Ethical considerations are detailed in the study protocol for ethics, available in Appendix B. A 
detailed discussion of the ethical issues around longitudinal survey research in palliative care was 
prepared for the application to the research ethics committee. This discussion is provided in 
Appendix C, Ethical considerations in survey research. 
 
5 Results: The impact of symptoms and palliative care concerns on health-related quality of life in 
multiple myeloma: a multi-centre study 
159 
 
5 Results: The impact of symptoms and palliative care concerns on 
health-related quality of life in multiple myeloma: a multi-centre study 
 
In this chapter, I present the results of the cross-sectional, secondary analysis of symptom burden 
and factors associated with health-related quality of life in multiple myeloma. The objectives of 
this study were: 
(a) To determine the prevalence and severity of common symptoms and problems in patients 
with multiple myeloma at various stages of their disease, specifically for those with 
relapsed or progressive disease. 
(b) To determine whether patients in the advanced stages of myeloma experience a different 
symptom and problem profile than patients in earlier stages 
(c) To determine which demographic and disease characteristics were associated with a lower 
quality of life and more symptoms and problems, testing the hypothesis whether general 
symptom level and specific symptoms had a stronger influence on HRQOL than disease 
characteristics 
The article was published in BMC Cancer in July 2016 (691). 
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Figure S1. Myeloma Patient Outcome Scale (MyPOS). All questions are preceded by “Over the 
past week…”. 
1 What are your main problems or concerns at 
the moment? 
[Open question with three empty boxes for respondent to complete, 
numbered 1-3] 
2 Below is a list of symptoms, which you may 
or may not have experienced.  For each 
symptom please tick one box that best 
describes how it has affected you over the past 
week: 






























b Fatigue or lack of energy 
c Shortness of breath 
d Diarrhoea 
e Constipation 
f Nausea (feeling like you are going to be sick) 
g Vomiting (being sick) 
h Mouth problems 
i Poor mobility 
j Tingling in the hands and / or feet 
k Difficulty remembering things 
l Please list any other symptoms not mentioned 
above, and tick one box to show how they 
have affected you over the past week: 
[Three boxes beneath symptoms list for respondent to add 
additional symptoms, numbered 1-3] 
3 Have you been able to carry out your usual 
activities without help from others? 
Yes, as 
much as I 
wanted 
Most of the 
time 
Sometimes Occasionally 
No, not at 
all 
4 Have you been able to pursue your hobbies 
and leisure activities? 
5 Have you been able to spend quality time with 
family and friends? 
6 Have you been worrying about your sex life? 
No, not at 
all 
Occasionally Sometimes 




7 Have you been feeling depressed? 
8 Have you been feeling anxious or worried 
about your illness or treatment? 
9 Have you been worrying about infections? 
10 Have you been worrying about your physical 
appearance? 
11 Have you been worrying about your financial 
situation? 
12 Have you been worrying that your illness will 
get worse? 




Most of the 
time 
Sometimes Occasionally 
No, not at 
all 
14 Are you able to contact your doctors or nurses 
for advice if needed? 
15 Do your doctors and nurses show a good 
standard of knowledge skill when treating 
you? 
16 Do your doctors and nurses show care and 
respect when treating you? 
17 Do you have enough information about your 












18 Do you have enough information about what 
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Table S1. Prevalence and severity of myeloma-specific symptoms and problems (MyPOS) in 557 
multiple myeloma patients 
   
Prevalence 95% CI Not at all (0) 
Slight (1) or 
Moderate (2) 






 M SD n (%)  n % n % n % % 
Symptoms            
Pain 1.35 1.05 398 (71.5%) 67-76% 152 27.3 321 57.7 77 13.8 1.2 
Breathlessness 0.99 0.99 339 (60.9%) 57-65% 214 38.4 295 52.9 44 7.9 0.8 
Fatigue 1.75 0.99 488 (87.6%) 85-90% 66 11.8 366 65.7 122 21.9 0.6 
Nausea 0.44 0.78 163 (29.3%) 25-33% 391 70.2 150 26.9 13 2.4 0.5 
Vomiting 0.15 0.51 56 (10.1%) 7-13% 496 89.0 49 8.8 7 1.3 0.9 
Poor appetite 0.61 0.88 218 (39%) 35-43% 337 60.5 196 35.1 22 3.9 0.5 
Constipation 0.67 1.00 213 (38.3%) 34-42% 340 61.0 174 31.3 39 7.0 0.7 
Sore or dry mouth 0.58 0.89 207 (37.3%) 33-41% 344 61.8 183 32.9 24 4.4 1.1 
Drowsiness 0.97 0.89 353 (63.4%) 59-67% 198 35.5 330 59.2 23 4.2 1.1 
Poor mobility 1.46 1.15 398 (71.5%) 68-75% 156 28.0 287 51.5 111 20.0 0.5 
Diarrhoea 1.46 1.15 129 (23.2%) 20-27% 414 74.3 117 21 12 2.2 2.5 
Tingling in hands/feet 0.96 1.06 304 (54.6%) 50-59% 249 44.7 247 44.4 57 10.2 0.7 
Difficulties remembering 0.86 0.92 314 (56.5%) 52-61% 237 42.5 287 51.6 27 4.9 1.1 
Problems with/ Worry about...           
Usual activities 1.2 1.2 342 (61.4%) 57-66% 212 38.1 244 43.8 98 17.6 0.5 
Pursuing hobbies 1.64 1.5 366 (65.7%) 62-70% 187 33.6 191 34.3 175 31.4 0.7 
Spending quality time with 
family/friends 
0.87 1.16 252 (45.3%) 41-50% 302 54.2 186 33.4 66 11.9 0.5 
Sharing feelings with family 0.89 1.2 245 (45%) 41-49% 304 54.5 168 31.1 77 13.9 1.5 
Sex life 0.46 0.9 132 (23.7%) 20-28% 376 67.5 109 19.6 23 4.1 8.8 
Feeling depressed 0.78 0.96 269 (48.3%) 44-53% 285 51.2 242 43.5 27 4.8 0.5 
Feeling at peace 2.38 1.14 439 (78.9%) 76-82% 110 19.8 345 62.1 94 16.8 1.3 
Anxious  about 
illness/treatment 
1.1 1.05 360 (64.7%) 60-69% 193 34.6 298 53.5 62 11.2 0.7 
Family anxious/worried 
about patient 
1.23 1.14 369 (66.1%) 62-70% 179 32.2 284 50.9 85 15.2 1.7 
Infection 0.74 1.04 233 (41.8%) 38-46% 320 57.5 190 34.1 43 7.7 0.7 
Physical appearance 0.67 1.00 214 (38.4%) 34-43% 341 61.2 176 31.6 38 6.8 0.4 
Financial situation 0.61 1.07 170 (30.6%) 28-35% 385 69.1 122 21.9 48 8.7 0.4 
Illness worsening 1.32 1.19 384 (68.9%) 65-73% 172 30.9 291 52.2 93 16.7 0.2 
Coping  with 
illness/treatment 
0.71 0.85 289 (51.8%) 48-56% 265 47.6 261 46.8 28 5.0 0.5 
Contacting doctors/nurses 0.31 0.67 127 (22.7%) 19-27% 427 76.7 115 20.6 12 2.1 0.5 
Skill/Knowledge of 
doctors/nurses 
0.21 0.53 98 (17.6%) 15-21% 457 82.0 93 16.7 5 0.9 0.4 
Respect from doctors and 
nurses 
0.10 0.39 48 (8.6%) 6-11% 507 91.0 46 8.2 2 0.4 0.4 
Having enough information 
about illness/treatment 
0.37 0.89 98 (17.6%) 15-21% 455 81.7 73 13.1 25 4.5 0.7 
Information about what 
might happen in the future 
0.86 1.29 193 (34.6%) 31-39% 356 63.9 104 18.7 89 15.9 1.4 
Addressing practical matters 
resulting from illness 
0.5 0.97 142 (25.5%) 22-29% 405 72.8 106 19.0 36 6.5 1.7 
MyPOS Total score 21.5 13.4 range: 0-61         
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Table S2. Univariate associations of symptoms with EORTC QLQ –global quality of life scale, 
EQ5D index and visual analogue (VAS) scale scores and the Myeloma Patient Outcome Scale 
total score, using linear regression with bootstrapping (1000 samples)  
 QL2 EQ5D index EQ5D VAS MyPOS total score 
Variable Coefficient 
(95% CI) p 
Coefficient 
(95% CI) p 
Coefficient 
(95% CI) p 
Coefficient 















































































<0.001 n/a n/a 7.73 
(5.98, 9.48) 
<0.001 
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Erratum 
Unfortunately, the original version of this article [1] contained an error. In Table 3, Outcome data 
scores for total sample and comparison of symptoms and palliative care needs across disease 
phases, there was an error in the calculation of the EORTC QLQ-MY20 subscale “Disease 
symptoms” and “Side-effects of treatment”. In both cases, the printed mean and median values of 
both subscales are too high. These two symptom subscales were erroneously calculated using the 
syntax for functioning subscales. The corrected mean and median values for “Disease symptoms” 
and “Side-effects of treatment” for the complete sample and the three subgroups of newly 
diagnosed, treatment-free interval / stable disease and progressive, relapsed disease have been 
corrected in Table 3 (see corrected version below, corrections are in red).  
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6 Results: Longitudinal trajectories of quality of life in multiple 
myeloma and predictive factors 
 
In this chapter, I present the longitudinal trajectories of symptom burden and quality of life in 
multiple myeloma, based on five measurement time points over a period of eight months. The 
primary aim of this study was to identify the intra-individual change trajectories of quality of life 
among multiple myeloma patients at various stages of disease over a period of 8 months.  
It was hypothesised that four or five different trajectories of QOL would be found.  
Hypothesis 1a: It was expected to find classes with stable QOL; low, moderate or high. It was 
assumed that some patients would experience a stable, good QOL, and others would experience 
moderate or poor levels of QOL throughout the observation period, which would be chronic. 
Hypothesis 1b: Classes with changes in QOL level – either improving or deteriorating QOL – 
were expected.  
The second aim was to evaluate whether the general symptom level and demographic as well as 
clinical characteristics help determine in particular those with a deteriorating QOL or chronic poor 
QOL trajectory.  
Hypothesis 2a: It was expected that a high symptom burden along with a later/more advanced 
disease stage, a higher comorbidity level and a lower ECOG performance status would predict 
inclusion in classes with poor or deteriorating QOL trajectories.  
Hypothesis 2b: It was hypothesised that the high symptom burden would act as a mediator in 
predicting inclusion in trajectories of poor chronic or deteriorating QOL. 
The article presented was submitted to PlosMed in November 2016. The main article text 
formatted in the style of the journal is presented, followed by supplementary material that was 
submitted to the journal as an online appendix. 
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Objective: To identify which patients might benefit from early integration of palliative care, by 
identifying trajectories of health-related quality of life (HRQOL) and symptoms over time, and 
determining which demographic and clinical characteristics predict declining or poor HRQOL.  
Design: Prospective, longitudinal cohort study. 
Setting: Inpatient and outpatient haematological or chemotherapy units at 14 hospitals in 
England. 
Participants: Multiple myeloma at all stages (newly diagnosed, first line or second line treatment, 
early or later treatment-free interval, refractory disease).  
Main Outcome Measure: In addition to demographic, clinical, treatment information and 
standardised HRQOL and psychological aspects, the Myeloma Patient Outcome Scale (MyPOS) 
measured palliative care concerns. 
Results: Between February and August 2013, 238 patients were recruited, on average 3.5 years 
(SD: 3.4) post-diagnosis. Latent mixture growth models identified four HRQOL trajectories. 
Classes 3 and 4 represent trajectories of stable poor HRQOL or declining HRQOL over an eight 
months period. The strongest predictors of poor outcome at the end of follow-up were general 
symptom level (OR: 1.3, 95% CI: 1.0 to 1.6, p = 0.028), presence of clinically relevant anxiety 
(OR: 1.2, 95% CI: 1.0 to 1.4, p = 0.019), and presence of pain (OR: 1.02, 95% CI: 1.0 to 1.1, p = 
0.018), all being more predictive than demographic or clinical characteristics. 
Conclusion: General symptom level, pain and presence of anxiety predict declining HRQOL in 
multiple myeloma. Identification of patients with palliative care needs should focus on assessing 
patient-reported symptoms and psychosocial well-being for identifying those at risk of 
deterioration.  
Keywords: Multiple myeloma, Health-related quality of life, Palliative Care Outcome Scale, 
Symptom burden, Quality of life, Palliative care 




Due to the ageing of populations and the rising incidence of cancer, health care systems will face 
a growing number of people at the end of life in need of palliative care. The WHO estimates that 
around 8 million people die of cancer worldwide, of which a substantial number will have 
palliative care needs [1]. With treatment options and the introduction of novel anti-cancer agents, 
the lives of cancer patients have been lengthened, which in turn has changed the cancer trajectory, 
resulting in chronic disease patterns. This changing face of cancer has also altered the role of 
palliation and specialist palliative care (SPC) services are now advocated to be integrated with 
treatment of curative intent [2-4]. 
One such cancer is multiple myeloma (MM), an incurable haematological malignancy of the bone 
marrow and one of the most common haematological cancers with incidences of 3.29 to 4.82 per 
100,000 population [5,6]. MM is primarily a disease of older age with a median age at time of 
diagnosis of 73 years and almost 40% of patients being 75 years or older [7,8]. This has 
implications for treatment options and survival time, as the most intense options such as stem cell 
transplantation are only accessible to younger patients. Myeloma results in bone destruction, bone 
marrow failure and renal impairment [9]. Throughout their disease trajectory, patients suffer from 
a variety of symptoms, some resulting from advancing disease, some being treatment side effects 
such as neuropathies [10]. There is evidence that myeloma patients suffer more symptoms and 
problems than other cancers [11]. Unlike solid cancers, where relatively high levels of functioning 
are maintained up until a distinct and short period of terminal decline [12], haematological 
malignancies often follow no such clear pattern. Trajectories rather show entry, re-entry 
characteristics, with periods of intensive antineoplastic regimens that may continue until the end 
of life, hospitalisations due to treatment complications, interspersed with stable, treatment-free 
intervals [13-15]. Death follows a period of rapid decline or arrives suddenly during exacerbations 
[16,17]. These characteristics make determination of palliative status and referral to SPC difficult 
in this patient group. Indeed, haematologists in Australia and the UK have expressed insecurities 
regarding when referral is appropriate [17,18]. 
Therefore, haematological cancer patients still miss out on SPC, as evidenced by a meta-analysis 
showing that the number of referrals to SPC is much lower in this cancer group than in solid 
tumours [19]. A meta-analysis investigating place of death (often used as a proxy for quality of 
end of life care) in haematological cancers showed that patients with a haematological cancer 
have 2.25 times the odds of dying in hospital [20,21]. Even if SPC is initiated, it is often done too 
late in the disease trajectory [20,21]. However, early integration of palliative care as a new model 
can only be achieved by knowing which patients are in need of such receipt of care. Several 
prognostic indicators for predicting patient survival and therefore initiation of palliative care have 
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been developed, based on clinical features, laboratory data, and response to treatment [22-24]. 
However, one of the most interesting findings in recent years has been the evidence for the 
independent prognostic role of patient-reported outcomes [25]. Patient’s experience of disease, 
symptoms and treatment-related side effects can provide clinically meaningful information on 
prognosis in multiple myeloma [26-28]. This could help identify those with poor quality of life 
(QOL) that would benefit from early palliative care involvement.  
In this study we sought to determine (a) how symptoms common in multiple myeloma and 
HRQOL change over time, (b) what demographic and clinical characteristics predict declining 
health-related quality of life. Specifically, it was hypothesised that we would identify four or five 
different trajectories of QOL, characterised by stability or fluctuation and the initial level of QOL 
that was experienced by patients (good, moderate or poor HRQOL). It was also expected to find 
classes of QOL experiences with either an improving or a deteriorating QOL course. It was 
further expected that a high symptom burden together with a more advanced disease stage, higher 
comorbidity level and a lower Eastern Cooperative Oncology Group (ECOG) performance status 
would predict inclusion in classes with poor or deteriorating QOL.  
 
Methods 
For this multi-centre, longitudinal prospective study, patients with multiple myeloma were 
recruited from both inpatient stem cell transplantation units and outpatient haematology clinics or 
chemotherapy day care centres in 14 secondary and tertiary hospitals in England, United 
Kingdom, from February to August 2013. The study protocol and procedures were approved by 
the Central London Research Ethics Committee (study ref number: 13/LO/1140). Further local 
Research and Development approvals were obtained from all 14 participating NHS hospital trusts. 
The study was conducted according to the principles expressed in the Declaration of Helsinki. All 
participants were given full information regarding the study, signed to indicate their consent, and 
could withdraw at any time without giving reasons or withdrawal affecting their medical 
treatment. All information was kept confidential. 
Participants and procedures 
Consecutive patients were screened by a member of the clinical team for eligibility according to 
study entry criteria at all the participating sites. Eligibility criteria were designed to identify 
people at various stages of their disease rather than focusing on a cohort at the end-of-life. 
Eligibility criteria were: adult patients with confirmed diagnosis of multiple myeloma that had 
been disclosed to the patient, and capacity to give informed written consent. Patients who were 
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too unwell, distressed or symptomatic to participate were excluded, as were patients with severe 
neutropenia or for whom myeloma was not the most important health problem. 
All patients screened eligible were asked permission by the clinical staff to being approached by a 
study nurse or research assistant, who explained the study and obtained written consent. At this 
point the research nurse or researcher also completed the demographic information sheet. The 
study questionnaires were either completed during the clinic visit or at home with patients being 
supplied a pre-paid envelope for returning the questionnaire to the institute. Subsequent 
questionnaires were sent via mail to patients, with a pen, a sweet and a self-addressed, pre-
stamped envelope provided for return. Participants received one written reminder and an 
additional second telephone reminder if they did not return their questionnaire within two weeks. 
Patients were followed, if possible, if they moved to a nursing home, hospital, or hospice. We 
sought information about any deaths that occurred. 
Among the disease details, the date of diagnosis and the immunoglobulin type (Ig) were extracted, 
alongside time since diagnosis and stage according to the International Staging System (ISS) [29]. 
The current phase of illness was classified as newly diagnosed (pre-treatment or undergoing first-
line treatment), stable disease (watch and wait or receiving maintenance treatment with no 
evidence of disease progression) or relapsed/progressive disease (second line therapy or above, 
lack of response or progression on treatment or receiving palliative care) [30]. Treatment details 
were recorded [22]. 
Measurements 
Participants were followed up for a period of eight months from baseline. They completed postal 
surveys every two months for a total of five assessments. Questionnaires that were administered 
assessed their generic or disease-specific QOL and symptom burden – the Myeloma Patient 
Outcome Scale MyPOS [31], the European Organisation for the Research and Treatment of 
Cancer (EORTC) QLQ-C30 [32] and its myeloma module MY20 [33]; the Hospital Anxiety and 
Depression Scale for measuring depression and anxiety [34], and a mastery of illness scale [35]. 
Comorbidities [36] and performance status [37] was also assessed directly from the patient. Table 
1 presents a short description of each outcome measure. The MyPOS is shown in Figure S1. The 
MyPOS and the symptom list within the EORTC QLQ-C30 and QLQ-MY20 were used to assess 
general symptom level and 15 common symptoms in myeloma [39]: pain, bone pain, weakness, 
drowsiness, breathlessness, nausea, vomiting, constipation, diarrhoea, sore/dry mouth, poor 
mobility, tingling in the hands/feet, problems remembering, sleeplessness, and poor mobility. If 
these symptoms were scored mild/moderate to extreme severe/severely on the instruments, they 
were coded as ‘present’ and added to form a general symptom level score. This score was further 
categorised as low (1-5 symptoms), moderate (6-8 symptoms) and high (9-15 symptoms).  
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Table 1. Data collection and questionnaires for outcome collection 
 Measure Description and scoring 
Symptom status 
and palliative care 
problems 
MyPOS [31] 33-item questionnaire with 15 disease- and treatment-
specific symptoms, 13 myeloma-specific quality of life 
items, 5 generic items about palliative care concerns  
Module of Palliative Care Outcome Scale [41] 
Three subscales: Functioning and symptoms, 
Emotional response, Healthcare support (information 
and satisfaction with care) 
5-point Likert scale (0 – not at all to 4 – overwhelming) 
Possible range of 0-132 for total score (higher score 
means more symptoms/problems) 
Health-related 
quality of life 
EORTC QLQ-
C30 [32] 
30-item generic health-related quality of life 
questionnaire 
Five functional scales (physical, role, emotional, social, 
cognitive functioning), six symptom scales (fatigue, 
nausea/vomiting, pain, dyspnoea, constipation, appetite 
loss, sleeping problems, financial difficulties), one 
global health status/ quality of life scale 
4-point Likert scale (1 – not at all to 4 – Very much), 
except for two 7-point global health status/quality of 
life items 
Transformation of all scales to 0-100 scale (41) 
High scores on functional scales and global quality of 
life scales represent high level of functioning/quality of 
life 




20-item add-on module of disease-specific symptoms 
and functional impact for multiple myeloma, added 
onto the EORTC-QLQ-C30 
Two symptom subscales (disease symptoms and side-
effects of treatment), two functional subscales (body 
image and future perspectives) 
4-point Likert scale (1 – not at all to 4 – Very much) 
Transformation of all scales to 0-100 scale 
High scores on functional scales represent high levels 
of functioning. High scores on symptom scales 







14-item measure to diagnose depression and anxiety in 
non-psychiatric hospital samples. 
Depression and anxiety subscale consist of 7 items each 
4-point Likert scale from 0 (no problem) to 3 
(maximum distress) 
Range of total score from 0 to 21 on each subscale. 
Cut-offs for the presence of clinically relevant anxiety 
or depression defined as ≥ 8 on each subscale (42,43) 
Mastery of illness Global Mastery 
Scale (35) 
7-item scale to measure the impact of disease and 
treatment on perception of self  and perceived 
control/mastery over illness 
5-point Likert scale ranging from 1 (strongly disagree) 
to 5 (strongly agree) 
4 items need to be reversed scored to form a total score 
of 35. 





In order to detect a difference between subgroups in an independent, two-tailed t-test with 80% 
power, at a significance level of 5% and assuming a moderate effect size of 0.5-0.6 of change on 
the total MyPOS score, the estimated total sample size is 64 to 90. Allowing for attrition of 25-
30% over the course of one year, 113-117 patients needed to be recruited to the study.  
Descriptive statistics (mean, standard deviation, percentages, medians and interquartile ranges for 
categorical data) were calculated. Prevalence of symptoms over time was determined as point 
prevalence with 95% confidence intervals at each time point. Objective 1, determining change in 
QOL over time was established via latent class growth analysis (LGCA) [44]. Repeated measures 
of a continuous variable are used to identify classes with a categorical latent variable that 
represent homogeneous subgroups within the sample [44]. A trajectory class thus consists of a 
group of patients sharing a common course of HRQOL. The outcome that was modelled was the 
total MyPOS score for each patient. LGCA analysis follows several analytical steps [45]: First, 
different growth functions (linear, quadratic, piecewise) for modelling general slope growth were 
tested in a growth model without classes, to test which growth function would provide the best fit 
to the data. Second, the optimal number of classes was tested with within-class variance on 
growth parameters (slope) freely estimated [45]. Decisions on the number of classes of HRQOL 
trajectories were based on fit indices, in combination with clinical interpretability of the classes 
[46]. The mean class trajectories of the total MyPOS scores and all individual patient trajectories 
were plotted for each graph.  
To identify predictors for poor HRQOL, we ran ordinal logistic regression models with the 
proportional odds assumption. A poor HRQOL outcome was defined as reporting a low level of 
HRQOL throughout the study period or reporting deteriorating MyPOS scores over the eight 
months period, based on the classes of HRQOL trajectories found in the latent class growth 
modelling. We first tested bivariate associations between the outcome variable and potential 
predictors (including demographic, clinical information, general symptom level and psychological 
symptoms) using nominal regression. Those predictors found to be significant at the 0.2 level in 
bivariate analyses were included in multivariable models. 
The main analysis included non-missing data only. Missing data in LGCA were addressed using 
Full Information Maximum Likelihood (FIML) [47]. Regression analyses were repeated on 
multiple imputed data for sensitivity analyses. Three methods of imputation were used: (a) last 
observation carried forward (LOCF), (b) imputation of the median value for each single item, 
stratified by disease stage of the individual, and (c) multiple imputation [48]. Results from 
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sensitivity analyses are reported in Table S4. All analyses were conducted using SPSS v22 [49], 
except for LGCA which was conducted in MPlus 7.31 [50]. All statistical tests used a 0.05 two-
tailed alpha level of significance. 
 
Results 
Demographic and clinical characteristics 
The mean age of the sample was 68.5 (SD 10.5), with 87 women (36.6%) and with an average 
disease duration of 39 months (0 to 24 years, 95% CI: 34.2 – 44.1). A quarter of patients had lived 
longer than 5 years with myeloma (20.6%). According to phase of illness, most were in a stable or 
plateau phase (53.1%). 48.7% were in a later treatment phase, receiving second line treatment or 
higher with 35.7% having received at least two lines of treatment. According to the ECOG 
performance status, one quarter had at least moderate to severe disability – with 20.2% being 
unable to work or bedridden. The mean Charlson Comorbidity index was 4.9 (95% CI: 4.7 – 5.1). 
Clinical characteristics are shown in Table 2. 
Table 2. Demographic, clinical and treatment characteristics of 238 multiple myeloma patients  
Variables 238 MM patients 
Age (years), mean (SD) 68.5 (10.5) 
Men, N(%) 147 (61.8) 
Married, N(%) 170 (71.4) 
White, N(%) 220 (92.4) 
Education level, N(%)  
Secondary school 137 (57.5) 
Technical qualification 52 (21.8) 
University 41 (17.3) 
Working, N(%) 41 (17.2) 
Type of myeloma, N(%)  
IgA or IgG 180 (78.6) 
Light chain disease 39 (16.4) 
Other 9 (3.8) 
ISS stage at diagnosis, N(%)  
I 68 (28.6) 
II 41 (17.2) 
III 52 (18.6) 
Time since diagnosis (in months), mean (SD) 39.1 (38.2) 
Disease stage, N(%)  
Newly diagnosed 38 (15.9) 
Stable/plateau 128 (53.8) 
Relapsed/progressive/refractory disease 72 (30.3) 
Treatment phase, N(%)  
Newly diagnosed 3 (1.3) 
First-line treatment* 35 (14.7) 
First treatment-free interval* 79 (33.2) 
Second-line treatment 31 (13.0) 
Second treatment-free interval 41 (17.2) 
Later phase 49 (20.6) 
Currently receiving treatment, N(%) 118 (49.6) 
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Active therapy 80 (33.6) 
Maintenance therapy 38 (15.9) 
Current MM treatment, N(%)  
Bortezomib or Carfilzomib 46 (19.3) 
Lenalidomide 48 (20.2) 
Thalidomide/Pomalidomide 27 (11.3) 
Alkalyting agent (Cyclophosphamide, Melphalan, Bendamustine, Vincristine) 45 (18.9) 
High-dose steroids 73 (30.7) 
Other (Interferon, Situximab, Fluradabine, Vorinostat) 9 (3.8) 
Those with current treatment receiving combination therapy 70 (29.4) 
Past MM treatment, N(%)  
Bortezomib or Carfilzomib 96 (40.3) 
Thalidomide/ Lenalidomide/ Pomalidomide 179 (75.2) 
Alkalyting agent 179 (75.2) 
High-dose steroids 194 (81.5) 
Doxorubicin 22 (9.2) 
Other (Interferon, Situximab, Fluradabine, Vorinostat) 4 (1.7) 
Bisphosphonates 105 (44.1) 
Radiotherapy 31 (13.0) 
Intensity of received treatments, N(%)  
Chemotherapy only 111 (46.7) 
Chemotherapy and HSCT 76 (31.9) 
Two or more HSCT 15 (6.3) 
Lines of treatment received*, mean (SD) 1.5 (1.2) 
ECOG performance status, N(%)  
0 Fully active 79 (33.2) 
1 Restricted 104 (43.7) 
2 Unable to work 33 (13.9) 
3 or 4 – Limited self-care/bed-bound 15 (6.3) 
Charlson comorbidity index, mean (SD) 4.9 (1.5) 
ECOG: Eastern Cooperative Oncology Group performance status, HSCT: haematopoietic stem cell 
transplantation, IgA: Immunoglobulin A, IgG: Immunoglobulin G, ISS: International Staging System for 
multiple myeloma, ISS I: Serum β2 microglobulin < 3.5 mg/L and Serum albumin ≥ 3.5 g/dL, ISS II: not 
ISS I or ISS III, ISS III: Serum β2 microglobulin > 5.5 mg/L [29]. 
*Initial induction and HSCT were counted as one single line of treatment. Likewise, if during a line of 
treatment the anti-myeloma therapy was changed due to unresponsiveness or side effects, this was still 
counted as one line. If active treatment was followed by maintenance treatment, active and maintenance 
were counted as one line. A treatment-free interval was defined by not receiving active or maintenance anti-
myeloma therapy, whereas supportive therapies (e.g. bisphosphonates or anti-anaemia treatment) were 
possible.  
 
A total of 250 patients were recruited and consented into the study, with 238 patients completing 
questionnaires at baseline. 199 participants completed time point 2 (83.6%), 171 completed time 
point 3 (71.8%), 150 completed time point 4 (63%) and 125 (52.5%) completed the last time point 
5 questionnaire. Of the 113 patients lost to follow-up, 9 had died, 17 had been feeling too unwell 
to continue with the study, 2 had moved, and 88 had given no reason to discontinue the study. 12 
questionnaire had been lost in the mail (see Figure S2). 
 
6 Results: Longitudinal trajectories of quality of life in multiple myeloma and predictive factors 
195 
 
Prevalence of common symptoms over time  
Table 3 presents the percentages of patients reporting each symptom as moderate, severe or 
overwhelming on the MyPOS and on the EORTC QLQ-C30/MY20 at each time point. At 
baseline, over half of patients reported fatigue (52.1%) and 40.3% reported moderate to 
overwhelming pain. One third of patients reported anxiety (31.1%). About one fourth of patients 
reported moderate to overwhelming breathlessness (20.2%), drowsiness (26.1%), Tingling in the 
hands or feet (26.1%) and sleeping problems (24.4%). The frequency of moderate to 
overwhelming symptoms subsequently decreased over time with an increase seen at the last 
assessment, 8 months post-baseline.  
 
Table 3. Percentages of patients with symptoms at moderate to overwhelming levels across five 
time points 






































































































































































a Symptom taken from the MyPOS. 
b Symptom taken from the EORTC QLQ-C30. 
c Symptom taken from the EORTC QLQ-MY20. 
6 Results: Longitudinal trajectories of quality of life in multiple myeloma and predictive factors 
196 
 
Trajectories of quality of life in multiple myeloma 
The adequacy of fit of several growth functions, including linear, piecewise, and quadratic growth 
factors was tested for each of the three QOL outcomes with the linear growth function providing 
the best fit in each model. Table S3 contains the fit indicators for the number of latent classes in 
QOL trajectories in LGCA analysis. Across the models, a 4-class and 5-class solution worked best 
with values for the BIC and AIC decreasing for these models compared to models with smaller or 
higher numbers of classes (see Table S3). Among the two, the BIC and entropy values as well as 
the Bootstrap Likelihood ratio test supported the four-class solution. The four-class solution was 
chosen based on the better BIC, entropy and likelihood test values, better clinical interpretability 
and better class group sizes than seen in the 5-class solution.  
Figure 1 Four trajectories of HRQOL (MyPOS) (Solid line: Estimated unadjusted mean growth 
curve; grey line: individual trajectories) 
 
216 participants contributed enough data at all time points to enter trajectory analysis. Figure 1 
shows the four trajectories of QOL and palliative care concerns. The first trajectory (n=57, 26.4%) 
followed a pattern of slightly improving QOL, with an initial medium level of symptoms and 
problems (M = 36.7, SD = 10.8 at T1), and subsequently decreasing over 8 months to a lower 
level of symptoms (M = 28.6, SD = 10.1 at T5). Most of the sample (n=122, 56.5%) fell under a 
pattern of stable, good QOL, starting from an already high QOL baseline level at T1 (M = 14.9, 
SD = 7.6) and showing only minute differences over the 8 months follow-up (M = 15.1, SD = 8.5 
at T5). The third class (n = 24, 11.1%), termed stable, poor QOL, was characterised by generally 
high symptom burden/palliative care concerns throughout the follow-up period (M = 55.1, SD = 
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9.9 at T1 to M = 53.1, SD = 13.5 at T5) and experiencing a much lower baseline QOL than all 
other classes. In the fourth class (n = 13, 6%), termed deteriorating QOL, participants experienced 
relatively medium initial levels of QOL (M = 20.6, SD = 8.4 at T1) with subsequent stark 
decreases in QOL, particularly from T3 to T5 (M = 54.9, SD = 12.3 at T5). 
Sample characteristics of MyPOS trajectories 
Table 4 presents the demographic and clinical characteristics of participants per MyPOS 
trajectory class. Multinomial regression models showed significant associations between 
trajectory class and the demographic factors occupational status and the clinical characteristics 
ECOG performance status and intensity of prior treatments. More participants in class 1, slightly 
improving QOL, and class 2, stable good QOL, were working when comparing observed with 
expected frequencies. Participants with a trajectory of poor or deteriorating QOL (classes 3 and 4) 
were experiencing a poorer ECOG performance status, but had less intensive treatments than 
expected, compared to members of other classes. 
 
Table 4. Multinomial logistic regression analysis of sample characteristics (demographic, clinical 
















Age (years), mean (SD) 64.8 (11.3) 69.7 (10.1) 67.1 (11.5) 71.9 (6.3) 138.5 .401 
Men, N(%) 36 (63.2) 82 (67.2) 13 (54.2) 6 (46.2) 3.7 .298 
Married, N(%) 46 (80.7) 87 (71.3) 16 (66.7) 9 (69.2) 2.9 .409 
White, N (%) 50 (87.7) 114 (93.4) 22 (91.7) 13 (100) 3.7 .292 
Education level, N(%)     11.3 .501 
Secondary school 28 (7) 63 (51.6) 16 (66.7) 10 (76.9)   
Technical 
qualification 
12 (21.1) 29 (23.8) 5 (20.8) 3 (23.1)   
University 11 (19.3) 26 (21.3) 2 (8.3) 0 (0)   
Working, N(%) 12 (21.1) 24 (19.7) 2 (8.3) 0 (0) 7.7 .049 
Disease stage, N(%)     6.5 .365 
Newly diagnosed 13 (22.8) 13 (10.7) 2 (8.3) 1 (7.7)   
Stable/plateau 26 (45.6) 73 (59.8) 14 (58.3) 8 (61.5)   
Progressive/palliativ
e disease 
17 (29.8) 34 (27.9) 8 (33.3) 4 (30.8)   
Type of myeloma, N(%)     6.5 .689 
IgA or IgG 40 (70.1) 92 (75.5) 20 (83.3) 12 (92.3)   
Light chain disease 10 (17.5) 21 (17.2) 3 (12.5) 1 (7.7)   
Other 4 (7) 4 (3.3) 0 (0) 0 (0)   
ISS stage at diagnosis, 
N(%) 
    7.7 .262 
I 12 (21.1) 38 (31.1) 8 (33.3) 1 (7.7)   
II 11 (19.3) 22 (18) 2 (8.3) 4 (30.8)   
III 13 (22.8) 25 (20.5) 7 (29.2) 4 (20.8)   






    43.7 .000 
0 Fully active 15 (26.3) 50 (41) 3 (12.5) 6 (46.2)   
1 Restricted 25 (43.9) 61 (50) 6 (25) 3 (23.1)   
2 Unable to work 13 (22.8) 6 (4.9) 7 (29.2) 2 (15.4)   
3/4 limited self-care 
or bedbound 
2 (3.5) 3 (2.5) 7 (29.2) 2 (15.4)   
Charlson Comorbidity 
Index, mean (SD) 
4.5 (1.6) 5 (1.4) 5 (1.6) 5.2 (1.2) 28.3 .246 
Lines of treatment, 
median (IQR) 
1 (1-2) 1 (1-2) 1 (1-2) 1 (1-2.5) 18.5 .422 
Time since diagnosis in 
months, mean (SD) 
34.5 (34.9) 40.8 (39.7) 44.1 (47) 35.5 (28.7) 8.9 .440 
Currently on treatment, 
N(%) 
38 (66.7) 64 (52.5) 15 (62.5) 6 (46.2) 4.3 .231 
Type of current 
treatment, N(%) 
    10.8 .095 
None 18 (31.6) 58 (47.5) 9 (37.5) 7 (53.8)   
Active therapy 24 (42.1) 33 (27) 12 (50) 2 (15.4)   
Maintenance therapy 14 (24.6) 29 (23.8) 3 (12.5) 4 (30.8)   
Intensity of received 
treatments, N(%) 
    16.7 .054 
None 12 (21.1) 12 (9.8) 2 (8.3) 1 (7.7)   
Chemotherapy only 18 (31.6) 59 (48.4) 13 (54.2) 9 (69.2)   
Chemotherapy and 
stem cell transplant 
26 (45.6) 49 (40.1) 9 (37.5) 3 (23.1)   
 
Regression analysis: predictors of poor and deteriorating quality of life 
For determining which baseline characteristics predict a poor outcome in multiple myeloma 
patients, we first entered those variables found in univariate regression analysis to be significant 
into the multivariable model. The model was then trimmed to contain only those significant in 
multivariable analysis and adjusted for general symptom level (total number out of 15 symptoms 
experienced by each participant) (see Table 5). Experiencing a trajectory of poor or deteriorating 
QOL was predicted by baseline pain (OR = 1.2, 95% CI: 1.1-1.3, p = .042), presence of clinically 
relevant HADS anxiety (OR = 1.2, 95% CI: 1.0 – 1.4, p = .019) and HADS depression (OR = 1.2, 
95% CI: 1.0 – 1.4, p = .040). Compared to the reference group of ECOG performance status 0 
(Fully active), participants with poor or deteriorating QOL had lower odds of being in the ECOG 
performance status group 2 (ambulatory but unable to carry out work activities) (OR = 0.2, 95% 
CI: 0.1- 0.9, p = .042). 
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Table 5. Results of multivariable logistic regression models of predictors for joint poor QOL 
(class 3) and deteriorating QOL (class 4), n = 37 







Constant -4.3 1.4 9.7 0.013 - - .002 
ECOG 0 (reference) - - 6.9 - - - .076 
ECOG 1 -0.3 0.9 0.1 0.8 0.1 4.4 .752 
ECOG 2 -1.7 0.8 4.2 0.2 0.1 0.9 .042 
ECOG 3 and 4 -0.5 0.9 0.4 0.6 0.1 3.3 .551 
General symptom level 0.3 0.2 4.5 1.3 1.1 1.6 .035 
Fatigue -0.1 0.1 0.4 0.9 0.9 1.0 .551 
Pain 0.2 0.1 4.2 1.2 1.1 1.3 .040 
Breathlessness 0.1 0.1 1.3 1.1 0.9 1.1 .256 
Drowsiness -0.4 0.5 0.9 0.7 0.3 1.6 .349 
Anxiety 0.2 0.1 5.5 1.2 1.0 1.4 .019 
Depression 0.1 0.1 4.2 1.2 1.0 1.4 .040 
 
Discussion 
This study is the first to describe and compare the longitudinal patterns of change in QOL and 
palliative care concerns in patients with multiple myeloma. We successfully investigated the 
heterogeneity in the course of HRQOL trajectories across an 8-months study period and 
determined four classes of trajectories. To capture the breadth of the QOL experience of MM 
patients, we did not restrict our sample to a specific group of patients on chemotherapy or newly 
diagnosed patients eligible for first-line treatment. Within all QOL trajectories, the two largest 
classes (class 1, 26.4%, and class 2, 56.5%) were characterised by improving and stable, good 
HRQOL. Notably, MM patients in class 1 showed a much lower intercept than patients in class 2, 
indicating that they experienced poor HRQOL at the beginning of the observation period and then 
substantially improved over the course of 8 months. The initial intercept of class 2 was much 
higher, suggesting that this group started with a better QOL and remained relatively stable in the 
next months. In comparison, patients in classes 3 (11.1%) and 4 (6%) experienced either a poor 
QOL throughout the 8 months observation period or, as in class 4, showed the most severe 
trajectory of deteriorating QOL. Class membership was not associated with stage of disease. 
Thus, experiencing a stable trajectory of QOL or a course of improving QOL was not associated 
with being in a stable, treatment-free interval or with recovering from first- or second-line 
treatment. Rather, members of trajectory classes 3 and 4 were those with higher general symptom 
levels, a higher pain level, a poor ECOG performance status (unable to carry out work activities), 
and with clinically relevant levels of anxiety and depression. 
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Strengths and limitations 
Our observational study is based on a large, representative sample of patients with multiple 
myeloma that were sampled from different settings and at different stages of their disease. This 
lends greater representativeness to the findings than possible in treatment-defined samples [51] or 
clinical research samples that are usually composed of more carefully selected individuals and 
oversample younger patients with less comorbid disease [52]. The drawback of this methodology 
is that patients were consecutively enrolled in the participating centres, resulting in a convenience 
sample. The outpatient setting and possible gate-keeping from recruiting staff might have resulted 
in a higher proportion of patients with stable disease and a lower symptom burden having been 
included in this study. The group for which predictors were modelled, consisting of patients with 
poor or deteriorating QOL, was comparably small to the larger classes of improving and stable, 
good QOL. This will have reduced analytical power [46]. Latent class growth models for HRQOL 
only included baseline predictors. Time-varying covariates were not included in the model due to 
the comparably small sample size. Other covariates that were not included in the model may have 
influenced the HRQOL trajectories. In particular, information on response to treatment [22] and 
important biomedical variables such as albumin, C-reactive protein [52], haemoglobin levels [53], 
and possible cytokines [54,55] might have altered the number and odds ratios yielded in the 
logistic regression analysis. Future research needs to investigate the relationship between patient-
reported outcomes like symptoms and QOL and these biomedical variables and their respective 
strength for indicating deteriorating disease and potential need for palliative care involvement. 
Findings of this study need to be validated in larger samples and specifically in a study with a 
longer follow-up period during which more patients progress through intervals of high-dose 
treatment and stable, treatment-free phases to see the evolution of QOL. 
Comparison with other research 
Longitudinal studies are rare in multiple myeloma. Most of the evidence on QOL is presented as 
secondary endpoint data in clinical trials or in longitudinal studies of patients receiving 
haematopoietic stem cell transplant populations [54-57]. Only one longitudinal observational 
study using a population perspective could be identified [10]. Mols et al. (2012) [10] assessed 
myeloma-specific QOL at two time points with the EORTC QLQ-C30 and its myeloma MY20 
module. They described a generally poor QOL compared to an age- and gender-matched 
normative sample. Worsening of symptoms such as pain, peripheral neuropathy, drowsiness, but 
also psychosocial problems such as worries about the future and about dying, was observed. 
However, in this registry-based study only two measurement points, one year apart, were used to 
evaluate the mean trajectory of QOL. Studies of SCT populations [54-57], on the contrary, report 
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an increase in QOL over the course of the first two years after transplantation. Only depression 
and life satisfaction have been reported as persistent areas of concern [56].  
In our study we observed a large heterogeneity in the QOL trajectories that was not captured in 
the mean change in QOL over time. Compared to the available longitudinal evidence, our findings 
highlight that within an average trajectory of stability or improvement, subgroups of patients exist 
whose QOL trajectories differ substantially from the overall course. The logistic regression 
analysis identified five variables, general symptom level, pain, anxiety, depression and ECOG 
performance status as significant predictors of poor or deteriorating QOL in MM. This result is 
similar to multivariable regression analyses in two recent, observational cross-sectional studies in 
myeloma [58,59]. Jordan and co-authors determined symptom burden in 154 MM patients [59]. 
Fatigue and bone pain were the most frequent symptoms and were strongly associated with global 
QOL, as were depression, general symptom level, disease duration and being currently on 
treatment. Also, a study of stable but advanced stage MM patients identified pain and fatigue as 
the most frequent symptoms, impacting negatively on physical functioning [58]. Similarly, these 
studies did not identify clinical factors such as comorbidities or type of treatment as significantly 
associated factors for QOL. The importance of physical functioning, symptoms and psychosocial 
distress and their higher predictive power compared to disease parameters have been 
demonstrated in three studies prognostic studies [26-28]. For example, psychosocial QOL scales 
were associated with overall survival, whereas none of the disease parameters (ISS stage, 
creatinine, LDH, M-protein level and albumin level) explained a substantial proportion in the 
overall variability of QOL parameters [27]. 
Policy implications and conclusions 
Despite recent guidelines pleading the access of haematological cancer patients to palliative care 
services due to the high symptom burden in this group [10,11], these patients, particularly more 
chronic haematological malignancies such as multiple myeloma, miss out on SPC [19-21]. 
Reasons are the unpredictability of the disease trajectory with the potential for sudden 
deterioration and death as well as attitudinal barriers resulting from equating palliative care with 
end of life care [17,18]. Our findings demonstrate that in order to reach haematological cancer 
patients early enough during times of high palliative care needs, the model of care needs to 
change. The result of a subgroup of patients consistently experiencing poor or deteriorating QOL 
calls for early identification of these patients and early integration of palliative care alongside 
anti-myeloma treatment regimens [16]. In particular, possible targets that indicate suitability for 
palliative care involvement are patients that experience a high general symptom level, high levels 
of psychosocial distress, pain and low physical functioning. In order to identify these patients in 
clinical practice, routine monitoring of symptoms and QOL is warranted. 
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Figure S2. Study flow chart 
Number screened 524 Ineligible 120 
  Feeling too unwell 36 
  No english 26 
  No capacity 5 
  No confirmed diagnosis  38 
  Myeloma not main problem 15 
Number approached 404 Not recruited 154 
  Not interested in study 73 
  Feeling too unwell 8 
  Too short of time 25 
  Participating in other study 21 
  No reasons given 27 
Number recruited 250 Not returned questionnaire 12 
  No longer interested in study 0 
  Feeling too unwell 3 
  Died 1 
  No reason given 8 
Completed first questionnaire 238  
Completed second questionnaire 199 Lost in post 2 
 (83.6%) feeling too unwell 6 
  died 2 
  too burdensome 3 
  no reasons given 26 
Completed third questionnaire 171 Lost in post 5 
 (71.8%) feeling too unwell 3 
  died 2 
  moved 1 
  no reasons given 19 
Completed fourth questionnaire 150 Lost in post 5 
 (63.0%) feeling too unwell 5 
  died 4 
  moved 1 
  no reasons given 12 
completed fifth questionnaire 125 died 1 
 (52.5%) no reasons given 31 
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Table S3. Fit indices for the general growth mixture models of the baseline value and probability 
of class membership 
# Log likelihood Par BIC aBIC AIC Entropy 
BLRT 
p-value Group sizes (n) 
2 -2744.59 13 5559 5517 5515 .750 .000 52/164 
3 -2733.55 16 5553 5502 5499 .764 .000 52/153/11 
4 -2724.23 19 5550 5490 5486 .758 .013 13/122/57/24 
5 -2716.26 22 5550 5481 5476 .756 .000 56/115/22/13/10 
6 -2711.73 25 5557 5478 5473 .734 .098 29/30/11/18/115/13 
Note: Best fit indicators are in bold. 
Abbreviations: LogL Log-Likelihood statistic, Par: Number of free model parameters, BIC: 
Bayesian Information Criterion, ABIC: sample-size adjusted Bayesian information criterion, AIC: 
Akaike information criterion, BLRT: boot-strapped likelihood ratio test, MyPOS: Myeloma 




Table S4. Results of sensitivity analyses: complete case versus weighted imputation and multiple 
imputation 
 Complete case Weighted imputation Multiple imputation 
 OR p OR p OR p 
Constant 0.013 .002 0.055 .003 0.055 .003 
ECOG 0 
(reference) 
- .076 - .445 - .078 
ECOG 1 0.8 .752 1.8 .451 0.8 .753 
ECOG 2 0.2 .042 0.3 .025 0.2 .040 
ECOG 3 and 4 0.6 .551 1.3 .766 0.6 .620 
General 
symptom level 
1.3 .035 1.4 .049 1.4 .024 
Fatigue 0.9 .551 1.01 .048 1.0 .552 
Pain 1.2 .040 1.1 .045 1.2 .039 
Breathlessness 1.1 .256 1.0 .389 1.1 .256 
Drowsiness 0.7 .349 1.0 .826 0.7 .349 
Anxiety 1.2 .019 1.2 .037 1.2 .037 
Depression 1.2 .040 1.2 .038 1.2 .038 
 
 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
209 
 
7 Results: Longitudinal validity and reliability of the Myeloma Patient 
Outcome Scale (MyPOS) 
 
In this chapter, I present the last empirical part of this PhD study, the longitudinal psychometric 
analysis of the MyPOS with specific focus on its item quality for longitudinal individual 
monitoring, its responsiveness to change and its test-retest reliability. The objectives of this part 
were: 
a) To evaluate the validity and item quality of the MyPOS and its scale in myeloma patients at 
different stages in their disease trajectory,  
(b) to determine the reliability of the MyPOS over time (test-retest reliability) within a 
Generalizability framework,  
(c) to determine the responsiveness and clinical significance of changes in quality of life scores 
and subscale scores and estimate the minimal important change (MID), both for patients who 
deteriorated and improved, and  
(d) to explore the acceptability of frequent self-monitoring of HRQOL. 
The article presented was submitted to Quality of Life Research in April 2016. The main article 
text formatted in the style of the journal is presented, followed by supplementary material that 
was submitted to the journal as an online appendix. 
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Purpose. The Myeloma Patient Outcome Scale (MyPOS) was developed to measure quality of 
life in routine clinical care. The aim of this study was to determine its longitudinal validity, 
reliability, responsiveness to change and its acceptability.  
Methods. This 14-centre study recruited patients with multiple myeloma. At baseline and then 
every two months for 5 assessments, patients completed the MyPOS. Psychometric properties 
evaluated were: (a) confirmatory factor analysis and scaling assumptions, (b) reliability: 
Generalizability theory and Rasch analysis, (c) responsiveness and minimally important 
difference (MID) relating changes in scores between baseline and subsequent assessments to an 
external criterion, (d) determining the acceptability of self-monitoring. 
Results. 238 patients with multiple myeloma were recruited. Confirmatory factor analysis found 
three subscales, criteria for scaling assumptions were satisfied except for gastrointestinal items 
and the Healthcare support scale. Rasch analysis identified limitations of suboptimal scale-to-
sample targeting, resulting in floor effects. Reliability indices were good for monitoring quality of 
life over time (R = 0.42 to 0.98). Responsiveness analysis yielded an MID of +2.5 for 
improvement and -4.5 for deterioration. 
Conclusions. The MyPOS demonstrated good longitudinal measurement properties. It can be 
used in routine clinical care to monitor symptoms and changes in health-related quality of life and 
therefore guide patient care. The new psychometric approaches should be used for testing validity 
of monitoring in clinical settings. 




Cancer is a major public health concern, being the second leading cause of death worldwide [1]. 
With the aging of the society, cancer incidence is rising [2,3]. Despite advances in treatments, 
many cancer patients still face long disease trajectories and incurable disease. Multiple myeloma, 
an incurable cancer of the bone marrow and the second most common haematological malignancy 
[4], exemplifies this changing face of cancer. Many myeloma patients experience a more chronic 
disease trajectory, coping with gradually progressing disease, interspersed with intervals of stable 
disease with minimal or maintenance treatment but lasting effects of high-dose chemotherapy 
[5,6]. This longer disease trajectory of cancer and the intensive treatments have led to a need to 
evaluate patient-reported outcomes in addition to traditional monitoring, such as response to 
treatment and toxicity profiles, in this condition. 
Patient-reported outcomes primarily comprise symptoms and health-related quality of life 
(HRQOL). Incorporating longitudinal assessment into routine clinical practice has shown benefits 
such as better symptom control, improved patient-clinician communication and satisfaction with 
care [7,8]. In trials, serial assessment of HRQOL incorporates the patient’s experience while 
monitoring treatment safety and efficacy [9]. It also aids prognosis in chronic conditions and in 
haematological malignancy [10-12]. 
Despite these benefits, few measures are designed for monitoring HRQOL in routine clinical 
settings [13,14]. A systematic review of 13 generic and disease-specific HRQOL measures in 
multiple myeloma [13], found no single tool developed or validated for this purpose. 
Consequently, the Myeloma Patient Outcome Scale (MyPOS), a questionnaire to measure 
disease-specific HRQOL and palliative care concerns, was developed and validated in a cross-
sectional sample of 380 community and inpatient myeloma patients in the United Kingdom (UK) 
[15]. However, the clinical utility of the MyPOS in form of longitudinal validity and reliability 
[16-19] still needs to be established. 
The psychometric criteria for longitudinal monitoring validity are still ill-defined. Traditional 
psychometrics and associated guidelines focus on usages of assessment or screening [20-22]. The 
notable exception is McHorney’s study of individual patient-monitoring in which the following 
criteria were proposed [23]: (i) practical features (brief measures, easy administration, easy score 
interpretation), (ii) breadth of health measured (variety of health concepts with assessing the full 
range of health from disability to well-being), (iii) depth of health measured (minimal floor and 
ceiling effects), (iv) precision for cross-sectional assessment (precise reliability estimates, e.g. 
Cronbach’s alpha, with small standard error of measurement) (v) precision for longitudinal 
monitoring (high reproducibility/test-retest reliability with small standard error of measurement), 
and (vi) validity (satisfactory convergent/divergent validity, high responsiveness/sensitivity to 
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clinical change and definition of individual patient application, e.g. screening, monitoring, 
decision-making, tested). The authors also recommend more stringent benchmarks for 
measurement errors to fit the longitudinal use of measures [23]. Building on this work, we 
propose to extend McHorney et al’s framework by incorporating new psychometric approaches, 
particularly Rasch analysis [24,25] and Generalizability theory [26-28], to further test some of 
their six quality criteria for longitudinal monitoring applications. Particularly Generalizability 
theory has been used successfully in psychological studies that monitored emotional changes [46]. 
Both techniques are suitable since they address the limitations of classical test theory (CTT) by 
providing individual item information, information on item invariance and person-level indicators 
that help understand floor and ceiling effects, understanding sources of measurement error, and 
the ability for discriminating among different patient groups (i.e. disease severity) [24,25,28,29]. 
In particular, we propose to extend analysis for criteria (iii), depth of health measured, (iv) 
precision for cross-sectional assessment, and (v) precision for longitudinal monitoring by using 
person-item targeting in Rasch analysis to further understand floor and ceiling effects (iii), and to 
use the variance decomposition method for forming reliability indices beyond simple test-retest 
reliability, to understand how reliable the use of an instrument is in the situation of screening 
HRQOL at one point in time, monitoring HRQOL over time and detecting change over time (iv 
and v, [46]).  
We aim to examine the longitudinal validity and reliability of the MyPOS. The objectives were: 
(a) to evaluate the validity of the MyPOS and its scale in myeloma patients at different stages in 
their disease trajectory, (b) to determine the reliability of the MyPOS over time (test-retest 
reliability) within a Generalizability framework, (c) to determine the responsiveness and clinical 
significance of changes in quality of life scores and subscale scores and estimate the minimal 
important change (MID), both for patients who deteriorated and improved, and (d) to explore the 
acceptability of frequent self-monitoring of HRQOL. 
Methods  
Study design and participants 
This multi-centre, prospective longitudinal study recruited patients with multiple myeloma at 
different disease stages. Patients were enrolled in the study from March 2014 until July 2015. 
Inclusion criteria were: older than 18 years, confirmed diagnosis of multiple myeloma that had 
been disclosed to the patient, and capacity to give informed written consent. Patients who were 
too unwell, distressed or symptomatic to participate, as judged by their clinical team, were 
excluded, as were patients with severe neutropenia or for whom myeloma was not the most 
important health problem. Patients were recruited from 14 hospital trusts in the United Kingdom, 
both from secondary and tertiary centres. Study procedures followed the guidelines of the 
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Helsinki Declaration. Ethical and research governance approvals were obtained from the Central 
London Ethics Committee (13/LO/1140) with further local Research and Development approvals 
from all participating National Health Service (NHS) hospital trusts. 
Procedures  
Consenting patients were invited to complete questionnaires at baseline and then every two 
months for a total of five assessments and a maximum follow-up time of 8 months post-baseline. 
The first questionnaire was given to patients when they attended outpatient clinics. Subsequent 
questionnaires were sent via mail, with a self-addressed, pre-stamped envelope provided for 
return, a pen and a sweet to boost participation [30]. Patients were followed, if possible, if they 
moved to a nursing home, hospital, or hospice. We sought information about any deaths that 
occurred. 
Questionnaires 
Participants completed the Myeloma Patient Outcome Scale [15]. The MyPOS is a module of the 
Palliative Care Outcome Scale (POS) [31-33], extended by myeloma-specific concerns. It 
comprises a list of 13 symptoms and 20 quality of life or palliative care concerns items. Items are 
scored on a 5-point Likert scale ranging from 0 ‘not at all’ to 4 ‘overwhelmingly’ and summed to 
form a total score (total possible score: 132). A higher total MyPOS score indicates more 
problems. Content and construct validity of the MyPOS have been established in a clinically 
representative sample [15,34].    
To evaluate the responsiveness and minimal important change on the MyPOS, an independent 
question to assess the degree of change was used. This global rating of change question (GRC) 
[22,36] asked ‘Has your overall quality of life changed since the first time you completed this 
questionnaire?’, with patients indicating whether their quality of life had got worse, stayed the 
same, or had improved. The GRC question was part of each follow-up assessment. 
The questionnaire sent at the third assessment contained three open-ended questions to explore the 
acceptability of frequent self-monitoring. The questions concerned the suitability of the MyPOS 
for monitoring quality of life, the potential usefulness of monitoring quality of life and how 
results could be used by patients and clinicians.  
Statistical analysis 
Table 1 provides an overview of analyses methods per objective, following the McHorney et al 
framework [23], and details the criteria that were used for establishing fit and validity/reliability. 
All quantitative data analyses were conducted in SPSS v.22 [52], lavaan package in R [53] and 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
215 
 
partial credit Rasch models were run in RUMM2030 [54]. Patients with three or more missing 
MyPOS questionnaires at the follow-up time points were excluded from statistical analyses. If 
more than 50% of responses within a scale were missing from one questionnaire, it was removed 
from the analysis. Missing data in the confirmatory factor analysis were imputed using a multiple 
imputation approach [37]. Responsiveness analyses and Rasch analysis used a complete case 
analysis without imputation of missing data. 
For construct validity (objective 1), re-evaluating the subscale structure defined in the initial 
validation [15] was necessary due to the sample-dependency of CTT approaches [55]. 
Confirmatory factor analyses contrasting three models to find best fit of the data were used: (i) a 
unidimensional model (one factor) solution, (ii) three factor solution replicating the solution from 
the initial validation [15] with symptom and functioning items loading on one factor, separate 
from factors emotional response and healthcare support, and (iii) an adapted three-factor solution 
with all functioning items loading onto the emotional response factor, resulting in three subscales 
Symptoms, Functioning and Emotional response, and Healthcare support. Scaling assumptions of 
the total MyPOS score, subscale scores and individual item scores were evaluated using Rasch 
analysis. A partial credit Rasch model was fitted to each subscale, Symptoms (13 items), Emotions 
(17 items) and Healthcare Support (3 items), separately. Floor/ceiling effects and distribution of 
item responses were checked using descriptive statistics and Rasch analysis (person-location 
maps). Presence of floor or ceiling effects is indicated in the person-location map by mean item 
location scores not matching the whole range of person locations at the lower or upper end of the 
scale [57]. This indicates either items missing from the measure to represent very good or poor 
HRQOL, or indicates that the sample used for evaluation of the measure is not well-targeted to 
comprise all levels of severity that the MyPOS measures [44]. For establishing the test-retest 
reliability and invariance of the MyPOS (objective 2) for participants that indicated they did not 
experience a change in their condition over time, the Generalizability theory framework was used 
[26-28]. Four generalizability coefficients [46] were computed (see Table 1). Item invariance was 
further tested using Rasch analysis following Hobart et al’s [55] approach using differential item 
functioning (DIF). DIF is an indicator of items not performing in a stable/invariant way since the 
expected values on the item are not the same for all subgroups in the sample (i.e. groups of 
different disease severity or functional ability) [55]. Objective 3, establishing the responsiveness 
to change and the minimal important difference for the MyPOS, followed guidelines by Guyatt 
[50] and used a combination of anchor-based, distribution-based approaches. For responsiveness, 
we used the GRC to identify patients that experienced change over time, with categories 
improved, unchanged and deteriorated to examine the differences in mean score changes between 
each time point and baseline (T2 to T1, T3 to T1, T4 to T1, T5 to T1). We determined ROC 
curves separately for improvement and deterioration (improved vs. stable or deteriorated vs. 
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stable) for total MyPOS score and the three subscale scores. For objective 4 we analysed 
participant’s written comments in the open-ended questions of the MyPOS using thematic 
analysis [51]. 
Table 1 Overview of measurement properties and criteria for assessing longitudinal validity and 
reliability 
 
Measurement property Statistical methods 
Objective 1: Further validity of the MyPOS 
Maximum-likelihood 
confirmatory factor analysis 
[37] 
Goodness-of-fit indices: 
a) Chi2/df > 2 [38] 
b) Comparative fit index (CFI) of ≥ 0.90 [39] 
c) Root mean square error of approximation (RMSEA) of ≤ 0.60, 90% 
confidence interval 0.05 to 0.08 [39] 
d) Non-normal fit index (NNFI) of ≥0.95 or normal fit index (NFI) of ≥0.95 
[39] 
Checks of unidimensionality for Rasch scaling via principal component 
analysis and independent t-tests [40,41]: 
a) RMSEA <0.08 [42] 
b) CFI >0.90 [43] 
c) Tucker-Lewis Index (TLI)>0.90 [39] 
Floor and ceiling effects via 
descriptive and Rasch 
analysis 
• Data completeness and distribution of item responses 
• >10% missing from lower or upper end of the scale [16] 
• Rasch analysis: Scale-to-person targeting, the ability of the scale to cover 
the whole range of person estimates, shown on the person-item threshold 
distribution map [44] 
Scaling assumptions via 
Rasch analysis: 
• Fit to the Rasch model 
• Fit of individual items 
• Person fit 
• Reliability 
• Response options 
• Redundant items 
• Fit to the Rasch model: Non-significant Χ2-test [44] and RMSEA <0.2 [39]. 
However, large sample size can inflate the Χ2 value and increase the 
likelihood of identifying misfit [39]. 
• Individual item fit: Fit residual range -2.5 to +2.5 [44]. The residuals 
indicate the level of agreement between the observed and expected 
responses with perfect fit being given if a mean residual is zero with a 
standard deviation falling between -1 and +1. Positive fit indices above 
+2.5 show misfit to the model, negative fit indices below -2.5 indicate 
redundancy of items. Item characteristic curves were examined for 
graphical item fit. 
• Person fit: Same criteria as item fit. 
• Reliability: Person Separation Index (measure of internal consistency in 
Rasch analysis) ≥ 0.70 [45] 
• Response options: Category probability curve maps for each item examined 
for disordered answer options, signifying ambiguous labelling or 
abundance of response options. 
• Redundant items: Residual correlation matrix, identifying pairs of items 
with high correlation coefficients (≥0.3) [44] 
 
Objective 2: Test-retest reliability/item invariance of the MyPOS 
Test-retest reliability using 
Generalizability theory 
Restricted maximum-likelihood variance decomposition (VARCOMP) with 
participants and interaction terms as random factors and items and days as 
fixed factors. The variance associated with each component of variation, 
systematic between-person differences in mean item levels, true within-
person change over time, idiosyncratic item responses and random 
measurement error, is partitioned [27,28]. These variance estimates are used 
to form indices of the reliability for discriminating between-persons 
(between-person differences) and within-person change. 
Four generalizability coefficients (all >0.5 [46]): 
• R1F: Reliability of assessment/screening (Is the MyPOS reliable at each 
assessment?) 
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• R1R: Reliability of discrimination (Can the MyPOS reliably distinguish 
between persons over time?) 
• RKF: Test-retest reliability (Is the MyPOS reliable over time?) 
• Rc: Within-person reliability of change (Can the MyPOS assess change in 
one person over time?) 
It should be noted that determination of test-retest reliability within 
Generalizability theory is a model-based approach that derives reliability 
indices from variance decomposition as an alternative way to intra-class 
correlation coefficients. Analysis of test-retest reliability was based on the 
subgroup of stable patients as indicated by the global rating of change 
(“unchanged” – see Objective 3, Responsiveness). 
Item invariance using Rasch 
analysis 
Differential item functioning (DIF) via a two-way ANOVA of standardised 
residuals with Bonferroni correction for type I error [47]; assessing whether 
item mean scores showed significant change over all five assessments [44] 
• Significant interaction between class interval (level of quality of life) and 
time indicates a non-uniform DIF and an unstable, unreliable item. 
Objective 3: Responsiveness and minimal important difference (MID( for MyPOS 
Responsiveness GRC to categorise patients into: 
(a) improved overall QOL 
(b) deteriorated overall QOL 
(c) unchanged 
Differences in mean score changes between each time point and baseline 
were assessed and graphed. The adequacy of the anchor was assessed via 
Spearman correlation [17]. 
MID: Anchor-based 
approach 
• Receiver-operating characteristic curve (ROC) to determine optimal cut-off 
points separately for improvement and deterioration, according to GRC 
ratings [48].  
• MID: cut-off point on ROC for which the sum of percentages of false-
positive and false-negative classifications [(1-sensitivity or true positive 
rate) + (1-specificity or false positive rate)] is smallest [36]. 
• Significance of the area under the curve with a p-value >0.5 indicates 
changes on the MyPOS scores are associated with the gold standard GRC 
criterion [36]. 
• Graph of distribution of change scores, MIDs and 95% CIs [49]. 
MID: Distribution-based 
approach 
• Standard deviation at baseline used to estimate MID [50] 
• Following Cohen’s criteria [84], small changes (0.2 x SD), moderate 
changes (0.5 x SD) and large changes (0.8 x SD) were computed. A 
moderate effect size change was designated as the MID [50]. 
Objective 4: Acceptability of monitoring 
Acceptability Thematic analysis of responses to open-ended questions about views on self-
monitoring and data feedback were analysed using thematic analysis [51]. 
 
Results  
Characteristics of patients and questionnaire completion 
250 patients were recruited of whom 238 completed the questionnaire at baseline. Mean age was 
68.5 (range: 34-92 years), mean time post diagnosis was 3.3 years with 139 (25.5%) patients who 
had been living with myeloma 5 years and longer (see Table 2). 199 participants completed time 
point 2 (83.6%), 171 completed time point 3 (71.8%), 150 completed time point 4 (63%) and 125 
(52.5%) completed the last time point 5 questionnaire. Of the 113 patients lost to follow-up, 9 had 
died, 17 had been feeling too unwell to continue with the study, 2 had moved, and 86 gave no 
reason for discontinuing the study. 12 questionnaires were lost in the mail. 
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At baseline, 3.3% of responses in returned questionnaires were missing. The number of missing 
responses reduced over time: 1.2% at time point 2, 0.7% at time point 3, 0.7% at time point 4 and 
0.9% at last follow-up time point. 
Table 2 Demographic and clinical characteristics of 238 patients with myeloma included in the 
study 
Variable  
Age, Mean ± SD (range) 68.5 ± 10.5 (range 34-92) 
Men, N(%) 147 (61.8) 
Married, N(%) 170 (71.4%) 
White background, N(%) 220 (92.4%) 
Education level, N(%)  
Secondary school 137 (57.5) 
Technical qualification 52 (21.8) 
University 41 (17.3) 
Working, N(%) 41 (17.2%) 
Type of myeloma, N(%)  
IgA or IgG 180 (78.6%) 
Light chain disease 39 (16.4%) 
Other 9 (3.8) 
ISS stage at diagnosis, N(%)  
I 68 (28.6%) 
II 41 (17.2%) 
III 52 (18.6) 
Time since diagnosis (in months), mean 
(SD) 
39.1 (38.2) 
Disease stage, N(%)  
Newly diagnosed 38 (15.9) 
Stable/plateau 128 (53.8) 
Relapsed/progressive/refractory disease 72 (30.3) 
Currently receiving treatment, N(%) 118 (49.6) 
Active therapy 80 (33.6) 
Maintenance therapy 38 (15.9) 
Intensity of treatments received, N(%)  
Chemotherapy only 111 (46.7) 
Chemotherapy and HSCT 76 (31.9) 
Two or more HSCT 15 (6.3) 
Lines of treatment received, mean (SD) 1.5 (1.2) 
ECOG performance status, N(%)  
0 Fully active 79 (33.2) 
1 Restricted 104 (43.7) 
2 Unable to work 33 (13.9) 
3 or 4 – Limited self-care/bed-bound 15 (6.3) 
Charlson comorbidity index, mean (SD) 4.9 (1.5) 
General symptom level (MyPOS), N(%)  
0 3 (1.3%) 
1 – 5 70 (29.4%) 
6 – 8 65 (72.3%) 
9 – 15 
 
92 (38.7%) 
Mean number of symptoms, Mean ± SD 7.4 ± 3.6 
Total MyPOS, Mean ± SD 26.0 ± 16.8 
Note: Initial induction and HSCT were counted as one single line of treatment. Likewise, if during a line of 
treatment the anti-myeloma therapy was changed due to unresponsiveness or side effects, this was still 
counted as one line. If active treatment was followed by maintenance treatment, active and maintenance 
were counted as one line. A treatment-free interval was defined by not receiving active or maintenance anti-
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myeloma therapy, whereas supportive therapies (e.g. bisphosphonates or anti-anaemia treatment) were 
possible. 
Abbreviations: ECOG, Eastern Cooperative Oncology Group performance status; HSCT: haematopoietic 
stem cell transplantation; IgA, immunoglobulin A; IgG: immunoglobulin G; ISS: International staging 
system for multiple myeloma; MyPOS, Myeloma Patient Outcome Scale; SD, standard deviation. 
 
Confirmatory factor analysis of the MyPOS and Rasch scaling 
Confirmatory factor analysis 
Factor analysis confirmed a three-factor structure but with functioning items now loading onto the 
Emotional response factor (solution iii). The fit indices indicated a satisfactory model fit. 
Although the X2 test was significant, the RMSEA (0,056; 90% CI 0.050 – 0.063) and the CFI 
(0.942) were satisfactory. When compared to the uni-dimensional solution, the three-factor 
solution performed best. The three factors together explain a total of 42.2% of the variance with 
the three subscales explaining 28.1, 7.2, and 6.9%, respectively. All items loaded above 0.40 on 
their respective subscales, except item 12 (“Tingling in the hands/feet, 0.378) and item 29 
(“Worry about sex life”, 0.189) (see Supplemental Table 1).  
Rasch analysis 
Overall fit of the data to the Rasch model for each subscale was given (see Supplemental Table 
2). The range of item locations and item thresholds logits for all three subscales indicated that 
items mapped out a measurement continuum. The Symptom subscale had the widest range of item 
locations from       -1.16 to +1.92 logits. The Healthcare support subscale had a range of item 
thresholds from a maximum of -3.07 to +5.28 logits. Regarding individual item fit, item 12 
‘Tingling in hands/feet’ was the only item showing misfit in the Symptoms subscale with a fit 
residual of +2.68. In the Emotional response subscale, three items (‘Sharing feelings with 
family/friends’, ‘Worry about sex life’, ‘Information about the future’) showed misfit to the Rasch 
model (fit indices ranged from +2.52 to +3.16). All items in the Healthcare support subscale fitted 
the Rasch model (see Table 3). Examination of graphical fit via item characteristic curves 
confirmed good fit to the Rasch model for 30/33 items, except for ‘Tingling in the hands/feet’, 
‘Worry about sex life’ and ‘Information about future’ (see Supplemental Figure 1). These show a 
slight under-discrimination, indicating difficulties to stratify participants according to different 
levels on the latent variable HRQOL. 
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Regarding item response options, thresholds were ordered for 12/33 items, but for 21/33 items the 
5-point scale did not work in a linear way (see Supplemental Table 2). For ten of these items, 
people appeared to have difficulty discriminating between the last two to three categories, thus 
distinguishing a moderate problem from a severe or overwhelming one. For 11 items, people 
seemed to have difficulty discriminating between the first two categories (‘not at all’ and 
‘slight’/’moderate’). Fit for all items improved after removing extreme persons and rescaling the 
MyPOS items showing misfit and disordered thresholds to a 3-point Likert scale by combining 
categories “A little” and “Moderate”, and combining “Severe” and “Overwhelming”, the two 
highest response categories. After rescoring, all items on the Symptom subscale showed ordered 
thresholds. In the emotional subscale, item 19 (Having enough information about the illness”)  
and  item 33 (“Having enough information about what might happen in the future”) retained 
disordered thresholds, as did item 32 (“Doctors/nurses show care & respect”) on the Support 
subscale. Chi-square test statistics and the person separation index did not improve on this last 
subscale after rescoring and the Support subscale does not fit the Rasch model. 
Some item redundancy was present for seven pairs of items that had residual correlations 
exceeding r<0.30 (3% of total correlations). The following item pairs showed potential 
redundancy: Nausea-Vomiting (r = +0.37), Feeling at peace-Depression (r = +0.36), Sharing 
feelings with family-Family anxiety (r = -0.39), Hobbies-Usual activities (r = +0.36), Worry about 
illness worsening-Anxiety (r = +0.35). Two pairs of items in the Healthcare support subscale 
correlated highly: Contacting doctors for advice – Knowledge of staff (r = -0.82) and Contacting 
doctors for advice-Doctors showing respect (r = -0.55).  
 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
223 
 
Figure 1 Targeting of the sample (person-item location distribution maps) for the three subscales 
Symptoms (first panel), Emotional response (second panel), and Healthcare Support (third panel) 






Subscale Emotional response (17 items) 
 
Subscale Healthcare support (3 items) 
 
 
Note: The figure shows the distribution of person measurements (upper histogram) against the distribution 
of item locations (lower histogram). People are located along a continuum of low quality of life (left-hand 
side) to better quality of life (right-hand side). Items are located relative to their difficulty: easier items 
(representing lesser impact on quality of life) on the right-hand side, and the most difficult items (required 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
224 
 
for a better quality of life) on the left-hand side. People outside the scales measurement range (-2 to +2 
logits) indicate suboptimal scale-to-scale targeting. A ceiling effect is seen when the person locations on the 
left-hand side do not cover the item locations below, meaning items not discriminating in the portion of the 
sample with high quality of life. 
Floor and ceiling effects 
For most items, all response options were endorsed. However, 10/33 items (‘Nausea’, ‘Vomiting’, 
‘Poor appetite’, ‘Sore or dry mouth’, ‘Diarrhoea’, ‘Drowsiness’, ‘Tingling in the hands/feet’, and 
three items in the Healthcare support subscale) had floor effects with participants not using the 
two highest levels. These were also the items with the most skew. Up to 18/33 items had 
percentages of >50% of participants choosing the option ‘Not at all’. The MyPOS total score and 
subscale scores showed a normal distribution except for the Healthcare support subscale which 
demonstrated skew > 2.5 at each time point. 
In Rasch analysis, 14 person fit residuals exceeded the recommended range of -2.5 to +2.5 (-3.68 
to 3.55); implying that approximately 6% of people gave responses not in keeping with expected 
scores. Scale-to-scale targeting was suboptimal. Figure 1 shows the person estimation-item 
location distribution for the three MyPOS subscales. The sample covers the bulk of possible item 
locations on the MyPOS Symptom. Some mistargeting exists for the Emotional response 
subscale. The scale did not cover the sample in the Healthcare support scale, indicating floor 
effects. 
 
Reliability of the Myeloma Patient Outcome Scale 
The Person separation indices implied good sample separation and high reliability (Table 3), 
except for the Healthcare support subscale consisting of only three items. This was confirmed by 
values of Cronbach’s alpha that did not exceed a lower bound of 0.795.  
Variance decomposition shows that the largest component is error variance. Next, variance is due 
to participants experiencing change between assessments (Table 4), reflected by high between-
person variation and interaction terms for person x time and indicating that participants 
experienced different HRQOL trajectories over the period of eight months. The generalizability 
coefficients (Table 4) show that (a) reliability of screening was reasonable to good (RIF 0.55 to 
0.73), (b) discrimination was lower (RIK <0.50), except for the Healthcare support scale, (c) test-
retest reliability of the MyPOS was excellent (RKF > 0.90), (d) MyPOS can reliably measure 
change in individual patients over time (RC >0.60), except in the Healthcare support subscale (RC 
= 0.42).  
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
225 
 
Table 4 Variance partitioning of MyPOS total and subscale scores and Generalizability reliability 
coefficients  





 var % var % var % var % 
Person 0.11 12.5 0.097 12.7 0.177 17.1 0.05 20.0 
Time point 0.143 16.2 0.164 21.4 0.108 10.4 0.005 2.0 
Item 0.004 0.5 0.003 0.4 0.006 0.6 0.001 0.4 
Person x time point 0.2 22.7 0.178 23.3 0.202 19.5 0.021 8.4 
Person x item 0.083 9.4 0.066 8.6 0.143 13.8 0.087 34.8 
Time point x item 0.007 0.8 0.006 0.8 0.009 0.9 0 0.0 
Error 0.334 37.9 0.251 32.8 0.393 37.9 0.086 34.4 
Total 0.881 100.0 0.765 100.0 1.038 100.0 0.25 100.0 
Standard error of 
measurement 
6.9 3.2 4.9 1.1 
 







Total MyPOS 0.553 0.233 0.970 0.642 
Symptoms subscale 0.587 0.218 0.974 0.680 
Emotions subscale 0.632 0.338 0.978 0.607 
Healthcare support  0.734 0.591 0.986 0.423 
*Test-retest reliability is based on patients who indicated their QOL as stable on the global rating 
of change. 
Item invariance via DIF analysis identified the items ‘Constipation’, ‘Drowsiness’, ‘Diarrhoea’ in 
the Symptom subscale as unstable over time. In the Emotional response subscale, only the item 
‘Worry about infections’ showed DIF. None of the items in the Healthcare support subscale 
showed DIF (see Supplemental Table 3). 
Responsiveness of the Myeloma Patient Outcome Scale 
The total MyPOS score correlated moderately with the global rating scale (GRC, anchor) at every 
time point (range: r=0.312 to r=0.482). 125 participants contributed data for all five time points. 
Equal numbers of participants experienced a change in quality of life for the better or the worse, 
but the majority (about 60%) experienced no change (see Supplemental Table 4). Figure 2 shows 
the plotted change scores across time points. Except for the Healthcare support subscale, all mean 
change scores and corresponding confidence intervals indicated an improvement in MyPOS 
scores when patients classified themselves as overly improved, and a worsening of MyPOS scores 
when participants described their general quality of life as deteriorated.  
Table 5 lists the optimal cut-off points (MIDs). For patients who reported they had improved, the 
MID for the total MyPOS score was 2.5. The subscale MIDs were 1.5 for Symptoms, 4.5 for 
Emotional response and 0.5 for Healthcare support. MIDs for deterioration were similar to those 
for improvement, with an MID of 4.5 for the total score and MIDs of 2.5, 3.5 and 0.5 for the 
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subscale scores. The range of MIDs is much larger derived from the distribution-based approach, 
with estimates ranging from a minimum of 3.4 to 13.4 in the total score and 0.3 to 9 in the 
subscale scores (Table 5). Further examination of mismatch between the two methods and 
uncertainty around the MID revealed greater misclassification for improvement than for 
deterioration (see distribution graph for total MyPOS, Supplemental Figure 2). The area under the 
ROC curve predicting improvement or deterioration was significantly greater than 0.5 (p < 0.01) 
for the total MyPOS change score and all subscale scores except the Healthcare support subscale.  
  
Figure 2 Responsiveness of the total MyPOS change score over 8 months post baseline 
 
Note: A negative change score on the total MyPOS denotes an improvement in quality of life 
Acceptability of frequent self-monitoring for patients  
46% of participants thought the MyPOS to be a feasible tool for monitoring symptoms and 
problems/concerns over time. 23.9% of patients did not believe it was acceptable to complete the 
MyPOS regularly before clinic visits. 30% of responses were missing due to drop-out at this time. 
Concerns about acceptability fell into two categories: (a) those who thought it unfeasible to 
monitor changes because their condition changed on a daily basis and a questionnaire could not 
capture these minute alterations; and (b) those who felt that their clinical team monitored their 
condition regularly and a questionnaire would duplicate information. Linked to both of these were 
concerns regarding overall burden, especially when receiving treatment within a clinical trial with 
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regular data collection, and associated cost. Positive statements included the belief that 
monitoring would help to focus on the symptoms and problems over time, something which these 
patients felt was often disregarded or overlooked in consultations: “It would help the patient to 
focus on their treatment, difficulties and problems. We are not always aware that some problems 
and side effects are related to medication and treatment and try to ignore them.” (Female 
participant with relapsed disease) 
 








In the CTT and Rasch psychometric analysis, the MyPOS, a disease-specific measure of quality 
of life and palliative care concerns in multiple myeloma, presented as having adequate construct 
validity and reliability for certain subscales and items. For example, in the Rasch analysis items 
mapped out a measurement continuum in all three subscales. In terms of suitability for 
longitudinal monitoring, it had excellent test-retest reliability as well as reliably measuring change 
and being responsive. The MyPOS was able to discriminate between subgroups of patients 
longitudinally. However, some symptom and health care support items with floor effects, 
suboptimal scale-to-scale targeting and disordered thresholds point towards areas for revision. 
These revisions in particular concern the third subscale, Healthcare support, which overall had 
very substantial floor effects in the items, high inter-item correlations and thus item redundancy. 
Further targets are items in the Emotional Response subscale, particularly items 15 (“Family 
anxiety”) and 18 (“Sharing feelings with family/friends”), item 14 (“Anxiety”) and item 28 
(“Worry about illness worsening”), item 21 and 22 (“Usual activities”/”Hobbies”) and items 19 
(“Information about illness/treatment”) and 33 (“Information what might happen in the future”). It 
is worth exploring whether the MyPOS could be shortened by removing redundant items, which 
might also improve model fit in the factor analysis, and whether a two-factor structure (after 
removal of the Healthcare Support items) provides a better fit to the data. 
Any revisions of the MyPOS must weigh information on psychometric quality with 
considerations of clinical utility of the item in the clinical context [63]. Revisions need to balance 
considerations regarding content validity, clinical usefulness and applicability of the item and take 
item quality into account. A systematic review [13] identified 13 HRQOL instruments validated 
in myeloma, most of them generic in nature (EORTC QLQ-C30, EQ-5D and 15D, FACT-G, SF-
36/12). This poses a problem as generic questionnaires do not include disease-specific concerns 
and symptoms and are therefore less suited for validly reflecting patient experience [18]. The 
MyPOS was subsequently developed following extensive patient interviews to close the gaps in 
item coverage identified in other HRQOL instruments, and to operationalise disease-specific 
HRQOL according to a conceptual model developed from these qualitative interviews [34].  
We argue further that for clinical applicability, considerations of test-retest reliability and 
responsiveness to change for enabling the valid monitoring of patients in clinical practice are 
paramount. However, this information is often not available for disease-specific tools in multiple 
myeloma. For example, an MID was only determined for the EORTC QLQ-C30 and the two 
health state measures EQ-5D and 15D [58,59]. Subsequently, two new disease-specific tools, the 
MDASI-MM [60] and the FACT-MM [61], have been developed, but their validation has not yet 
been completed or has not included longitudinal validity testing to date. Another aspect lacking 
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from validation studies is the investigation of scaling quality. One notable exception is a study 
exploring Mokken scaling stability of the EORTC QLQ-C30 across different subpopulations of 
myeloma [62]. However, this analysis did not provide in-depth information on each item and did 
not look at item stability in a longitudinal context. For the MyPOS we provide both information 
on scaling quality and longitudinal validity.  
Regarding possible revisions of the MyPOS, the measurement aim needs to be considered. For 
example, floor effects in gastrointestinal symptoms may be observed for most of the sample of a 
relatively stable myeloma population not currently undergoing anti-cancer treatment or receiving 
maintenance treatment only [79]. However, they are important symptoms to monitor for the 
clinician to make adjustments to the treatment plan should they suddenly become severe [69-
71,86]. Inspection of the person-item threshold maps shows that it is not the items in the measure 
that do not cover the whole spectrum but rather the sample that did not target all the item 
difficulty locations. Similarly, floor effects are commonly seen in HRQOL and health satisfaction 
measures that are constructed with the intention of being applicable to a wide range of disease 
severity levels [64-66]. This is even true for disease-specific scales and was observed in the field-
testing of the EORTC QLQ-MY24 [67], subsequently revised to 20 items. Floor effects in 
healthcare support items may reflect the finding that respondents have more positive experiences 
with the healthcare they received affecting their willingness to participate in studies from the 
outset [68]. However, while revision of the scale helped improve the fit of items in the Symptoms 
and Emotional Response subscale, the Healthcare Support subscale remained to have very poor 
fit. Removal of this subscale might help improve overall fit of the MyPOS.response scale 
adaptations should be performed after further qualitative, cognitive interview work [57,72]. 
Another option is to extend the range of item difficulties to cover all levels of severity and impact 
of myeloma on HRQOL by constructing item banks and computer adaptive testing [73].In our 
analysis we tried to combine the perspectives of traditional psychometric approaches 
(confirmatory factor analysis, responsiveness and MID) with modern item response theory for 
evaluating the stringent criteria proposed by McHorney et al [23] for longitudinal individual 
patient monitoring. Using the new approaches addresses shortcomings of CTT such as validating 
only total scores instead of single items in a measure and yielding sample-dependent results [29]. 
The benefits of Rasch analysis include item-level statistics and information on how items can be 
improved to fit the application in a specific sample [35]. Furthermore, generalizability theory [26-
28] allows an exploration of sources of variation in item scores, which leads to establishing 
various reliability indices to distinguish different scenarios of use, i.e. using HRQOL measures for 
screening (single application) or for monitoring (application to track outcomes over time in an 
individual). This extends the limited exploration of test-retest reliability in CTT approaches [22].  
The new psychometrics are proposed as extensions to the original operationalisations of 
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measurement quality criteria that were proposed by McHorney et al [23] in their seminal paper. 
They can potentially offer additional information on sources of floor & ceiling effects and, due to 
Rasch analysis yielding information on the full range of the construct being measured, sources of 
problems with the coverage of constructs and diverse patient groups. The same is true for 
Generalizability analysis that provides a fine-grained picture of sources of measurement error 
beyond the random measurement error and can therefore help understand problems with precision 
of measurement in the cross-sectional and the longitudinal application [27,28]. However, 
especially the latter approach to reliability assessment and the indices proposed by Cranford et al 
[46] are limited by not being used widely in the literature which makes their interpretation 
difficult. For example, it is not clear whether thresholds for acceptable ICC estimates as proposed 
by McHorney et al [23] are applicable for the screening, discrimination and reliable change index 
proposed in this paper [46]. Further research is needed to explore this issue. Moreover, we used 
Cranford et al’s [46] method in a situation of a less intensive longitudinal design, with far less 
frequent measurement than was employed in their diary study. Therefore, the analysis of sources 
of variation stemming from different time points is not as detailed as in their original analysis. 
Applying the framework of quality criteria for individual patient-monitoring to the MyPOS yields 
the following assessment of its suitability for this application. Regarding (i) practical features, 
survey administration is well below 15 minutes [15], however, the number of items is rather high 
for a clinically applicable tool [18]. The analysis of breadth of health measured (ii) yields good 
dimensionality of the measure and coverage of all aspects of disease-related QOL according to the 
theoretical model [15], however, scale revisions indicated by low factor loadings, item 
redundancy and poor fit of the Healthcare Support subscale call for further exploration of 
dimensionality. Criterion (iii), the depth of health measured, was partially fulfilled with floor 
effects showing in 10/33 items and person-item targeting analysis within Rasch modelling 
suggesting further analysis in more severely affected samples. Criteria (iv) and (v) pertaining to 
reliability were assessed slightly differently by extending suggested analyses of Cronbach’s alpha 
for cross-sectional reliability and test-retest reliability by Rasch analysis and Generalizability 
theory, and by omitting standard error of measurement as a quality criterion. Although the actual 
size of the coefficient that should be obtained is unclear, the rigorous criterion for reliability 
(>0.95) set by McHorney et al [23] was achieved for all subscales in longitudinal analysis, but not 
for cross-sectional reliability (screening & discrimination application, Cronbach’s alpha). Validity 
(vi) in terms of cross-sectional construct validity and responsiveness to change yielded good 
sensitivity to change values. Further convergent and divergent validity assessment is reported in 
the initial validation of the MyPOS [15]. 
One of the most important features that makes a scale suitable for monitoring purposes is its 
responsiveness to change [19]. Our MIDs for improvement and deterioration were smaller than 
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the MIDs reported by Kvam and colleagues for the EORTC QLQ-C30 for patients with multiple 
myeloma [59]. Their MIDs range from 6-17 points for improvement and 12-27 points for 
deterioration, a small to medium change [59]. This discrepancy might arise from the different 
nature of the QLQ-C30, a generic measure, with absolute higher values of meaningful change 
[74-77]. The large baseline standard deviations and the amount of misclassification that was seen 
imply that not enough patients in our sample experienced a substantial change and that there 
further exists imprecision in the anchor in classifying participants into improved and deteriorated. 
This is a commonly reported problem with the ROC-curve based method of MID [49,78] which, 
as a diagnostic approach, would require a bias-free and precise gold-standard anchor. However, in 
the absence of guidance regarding construction of global rating scales this situation might not 
easily be rectified. 
The first limitation of our study is the use of consecutive enrolment, resulting in a convenience 
sample. The strength lies in its greater clinical representativeness that counteracts the effect of 
sampling younger and fitter patients if validation is part of a clinical trial [79,80]. However, since 
we recruited from outpatient clinics or day centres, we potentially missed patients feeling too 
unwell to participate in a longitudinal survey. This was the first study to use Generalizability 
theory. This approach for evaluating sensitivity to change normally requires frequent assessments 
[46]. However, due to patient burden this was not feasible. The reliability coefficients may be an 
underestimation of the true longitudinal reliability of the MyPOS. Furthermore, since this 
approach is relatively new, there are no guidelines as to the size of the coefficients. Confirmatory 
factor analysis used the DWLS approach to account for non-normality and the ordinal nature of 
the response scale in the MyPOS. However, although this approach has been reported as robust in 
samples of above 200, a caveat is its use in situations were missing data is missing not at random 
[85]. Baseline data was used for confirmatory factor analysis with missingness likely not due to 
systematic item nonresponse or non-random mechanisms. However, low factor loadings of some 
items might be due to systematic bias, i.e. for item 24 “Worry about sex life”, with effect on 
model fit. Different groupings of functioning items on subscales in the reported factor analysis 
compared to the initial factor analysis reported in Osborne et al. [15] are most likely due to 
changing descriptive labels of the rating scale of the symptom items to adapt the MyPOS to the 
overall item and scaling format of the IPOS [31], of which it is a module. In the adapted version 
of the MyPOS, the rating scale for the symptoms only lists the severity of impairment but not the 
added descriptor “impaired activity or concentration”. This change might have affected other 
aspects of construct validity, which likely necessitates a re-validation of aspects of construct 
validity of the symptom subscale. For the anchor-based MID approach, there is no consensus for 
the amount of categories and the exact phrasing of the global rating scale of change. Authors have 
used 3-point [83] to 15-point scales [81]. We tried to balance the potential lack of sensitivity of 
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fewer response options with the need to arrive at a valid measurement of change presenting only 
so many levels which patients can adequately discriminate. Since we asked patients to compare a 
change in their condition always to the first assessment, recall bias may have affected at least part 
of the sample. Furthermore, the wording of the rating scale might not present a valid global 
assessment of change in quality of life as operationalised in the multi-dimensional, disease-
specific MyPOS. The validity of the global rating of change as a criterion for anchor-based 
derivation of the MID is further pulled into question by the relatively low correlation between 
anchor and change scores and the MID not exceeding the SEM in all subscales. 
Conclusion 
This analysis supported the responsiveness and test-retest reliability of the MyPOS, using a multi-
centre outpatient sample of patients at different disease stages. Additional derivation of the MID 
for use in individual patient care and exploration of valid anchors of global change are needed. 
Modifications to the scoring format and potential removal of the Healthcare Support subscale may 
be warranted, subject to further testing. The study was the first to apply Generalizability theory to 
establish test-retest reliability and stability of scores in frequent measurements in medicine.  
Funding 
This work was supported by grants from Myeloma UK, St Christopher’s Hospice London, UK, 
and the National Institute of Health Research (NIHR) UK (Professor Irene Higginson holds a 
Senior Investigator Award and leads a theme in the South London Collaboration for Leadership in 
Applied Health Research and Care (CLAHRC)). The funder of the study had no role in the study 
design, data collection and analysis, decision to publish, or preparation of the manuscript. The 
corresponding author had full access to all the data and had responsibility for the decision to 
submit for publication. The views expressed in this publication are those of the author(s) and not 
necessarily those of the NHS, the National Institute for Health Research or the Department of 
Health. 
Conflicts of interest 
All authors declare that they have no conflicts of interests. 
Ethical approval 
All procedures performed in studies involving human participants were in accordance with the 
ethical standards of the institutional and/or national research committee and with the 1964 
Helsinki declaration and its later amendments or comparable ethical standards. Ethical and 
research governance approvals were obtained from the Central London Research Ethics 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
234 
 
Committee (reference number: 13/LO/1140) with further local Research and Development 
approvals obtained from all participating NHS hospital trusts. These collaborating centres were 
Bradford Teaching Hospitals NHS Foundation Trust, Burton Hospitals NHS Foundation Trust, 
Colchester Hospital University NHS Foundation Trust, East Cheshire NHS Trust, Epsom and St 
Helier University Hospitals NHS Trust, Guy’s and St Thomas’ NHS Foundation Trust, King’s 
College Hospital NHS Foundation Trust, Medway NHS Foundation Trust, Mid Yorkshire 
Hospitals NHS Trust, Royal Free London NHS Foundation Trust, Surrey and Sussex Healthcare 
NHS Trust, and the University Hospital Coventry and Warwickshire NHS Trust. These 
collaborating and supporting organisations were not involved in planning the study or preparing 
the manuscript. 
Informed consent 
Informed consent was obtained from all individual participants included in the study. 
Author’s contributions 
CR detailed methods for the study, led the application for ethical approvals, collected the data, 
planned and conducted the data analysis and drafted the manuscript, supervised by IJH, GW and 
RJS. IJH led the application for funding for this programme of work, which included this study, in 
collaboration with SAS, RJS and PME, and acted as senior researcher overseeing the project and 
publications. All authors contributed to the preparation of the manuscript and read and approved 
the final manuscript. 
 
References 
[1] World Health Organisation. (2015). Cancer. Fact sheet No. 297. Resource document. World Health 
Organisation. http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed 03 March 2016. 
[2] Siegel, R.L., Miller, K.D., Jemal, A. (2016). Cancer statistics 2016. CA Cancer Journal for Clinicians, 66(1), 7-
30. 
[3] Malvezzi, M., Caroli, G., Bertuccio, P., Rosso, T., Boffetta, P., Levi, F., et al. (2016). European cancer mortality 
predictions for the year 2016 with focus on leukaemias. Annals of Oncology, 27, 725-731. 
[4] Phekoo, K.J., Schey, S.A., Richards, M.A., Bevan, D.H., Bell, S., Gillett, D., et al. (2004). A population study 
to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. British 
Journal of Haematology, 127(3), 299-304. 
[5] Niscola, P., Tendas, A., Giovannini, M., Scaramucci, L., Perrotti, A., Fabritiis, P., et al. (2015). Caring for 
terminal patients in haematology: the urgent need of a new research agenda. Supportive Care in Cancer, 23(1), 
5–7. 
[6] Gleason, C., Nooka, A., Lonial, S. (2009). Supportive therapies in multiple myeloma. Journal of the National 
Comprehensive Cancer Network, 7(9), 971-979. 
[7] Velikova, G., Booth, L., Smith, A.B., Brown, P.M., Lynch, P., Brown, J.M., et al. (2004). Measuring quality of 
life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. 
Journal of Clinical Oncology, 22(4), 714-724. 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
235 
 
[8] Detmar, S.B., Muller, M.J., Schornagel, J.H., Wever, L.D.V., Aaronson, N.K. (2002). Health-related quality-of-
life assessments and patient-physician communication: a randomized controlled trial. Journal of the American 
Medical Association, 288(23), 3027-3034. 
[9] U.S. Department of Health and Human Services, Food and Drug Administration. (2009). Guidance for industry: 
Patient-reported outcome measures: Use in medical product development to support labelling claims. Food and 
Drug Administration. Resource document. http://fda.gov/downloads/Drugs/…/Guidances/UCM193282.pdf. 
Accessed 04 April 2016. 
[10] Viala, M., Bhakar, A.L., de La Loge, C., van de Velde, H., Esseltine, D., Chang, M., et al. (2007). Patient-
reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. Journal of 
Clinical Epidemiology, 60(7), 670-679. 
[11] Gotay, C.C., Kawamoto, C.T., Bottomley, A., Efficace, F. (2008). The prognostic significance of patient-
reported outcomes in cancer clinical trials. Journal of Clinical Oncology, 26(8), 1355-1363. 
[12] Efficace, F., Cartoni, C., Niscola, P., Tendas, A., Meloni, E., Scaramucci, L., et al. (2012). Predicting survival in 
advanced hematologic malignancies: do patient-reported symptoms matter. European Journal of Haematology, 
89, 410-416. 
[13] Osborne, T.R., Ramsenthaler, C., Siegert, R.J., Edmonds, P.M., Schey, S.A., Higginson, I.J. (2012). What issues 
matter most to people with multiple myeloma and how well are we measuring them? A systematic review of 
quality of life tools. European Journal of Haematology, 89(6), 437-457. 
[14] Kvam, A.K., Fayers, P.M., Hjermstad, M., Gulbrandsen, N., Wisloff, F. (2012). Health-related quality of life 
assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on 
treatment recommendations. European Journal of Haematology, 83(4), 279-289. 
[15] Osborne, T.R., Ramsenthaler, C., Schey, S.A., Siegert, R.J., Edmonds, P.M., Higginson, I.J. (2015). Improving 
the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the 
Myeloma Patient Outcome Scale (MyPOS). BMC Cancer, 15, 280. 
[16] Terwee, C.B., Bot, S.D.M., de Boer, M.R., van der Windt, D.A.W.M., Knol, D.L., Dekker, J., et al. (2007). 
Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical 
Epidemiology, 60(1), 60: 34-42. 
[17] Terwee, C.B., Dekker, F.W., Wiersinga, W.M., Prummel, M.F., Bossuyt, P.M. (2003). On assessing 
responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. Quality of Life 
Research, 12, 349-362. 
[18] Higginson, I.J., Carr, A.J. (2001). Measuring quality of life: Using quality of life measures in the clinical 
setting. British Medical Journal, 322(7297), 1297–1300. 
[19] Higginson, I.J. (2007). Quality criteria valuable with slight modification. Journal of Clinical Epidemiology, 
60(12), 1315. 
[20] Mokkink, L.B., Terwee, C.B., Patrick, D.L., Alonso, J., Stratford, P.W., Knol, D.L., et al. (2010). International 
consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-
reported outcomes: results of the COSMIN study. Journal of Clinical Epidemiology, 63, 737–745. 
[21] Nunally, J.C., & Bernstein, I.H. (1994). Psychometric theory. New York: McGraw Hill. 
[22] de Vet, H.C.W., Terwee, C.B., Mokkink, L.B., Knol, D.L. (2011). Measurement in medicine: a practical guide. 
Cambridge: Cambridge University Press. 
[23] McHorney, C.A., Tarlov, A.R. (1995). Individual-patient monitoring in clinical practice: are available health 
status surveys adequate. Quality of Life Research, 4, 293–307. 
[24] Rasch, G. (1960). Probabilistic models for some intelligence and attainment tests. Copenhagen: Danish Institute 
for Education Research. 
[25] Rasch, G. (1966). An item analysis which takes individual differences into account. British Journal of 
Mathematical and Statistical Psychology, 19(1), 49–57. 
[26] Shavelson, R.J., & Webb, N.M. (1991). Generalizability theory: A primer. Newbury Park: Sage Publications. 
[27] Brennan, R.L. (2001). Generalizability theory. New York: Springer. 
[28] Cronbach, L.J., Gleser, G.C., Nanda, H., Rajaratnam, N. (1972). The dependability of behavioral 
measurements: Theory of generalizability for scores and profiles. New York: Wiley. 
[29] Hobart, J.C., Cano, S.J. (2007). Rating scales as outcome measures for clinical trials in neurology: problems, 
solutions, and recommendations. The Lancet Neurology, 6, 1094–1105. 
[30] Bowling, A. (2002). Research methods in health: Investigating health and health services. Buckingham: Open 
University Press. 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
236 
 
[31] Hearn, J., Higginson, I.J. (1999). Development and validation of a core outcome measure for palliative care: the 
palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Quality in Health Care, 8(4), 
219–227. 
[32] Bausewein, C., Le Grice, C., Simon, S.T., Higginson, I.J. (2011). The use of two common palliative outcome 
measures in clinical care and research: a systematic review of POS and STAS. Palliative Medicine, 25(4), 304–
313. 
[33] Collins, E.S., Witt, J., Bausewein, C., Daveson, B.A., Higginson, I.J., Murtagh, F.E.M. (2015). A Systematic 
Review of the Use of the Palliative Care Outcome Scale and the Support Team Assessment Schedule in 
Palliative Care. Journal of Pain & Symptom Management, 50(6), 842-853. 
[34] Osborne, T.R., Ramsenthaler, C., de Wolf-Linder, S., Schey, S.A., Siegert, R.J., Edmonds, P.M., Higginson, I.J. 
(2014). Understanding what matters most to people with multiple myeloma: a qualitative study of views on 
quality of life. BMC Cancer, 14, 496. 
[35] Tennant, A., McKenna, S.P., Hagell, P. (2004). Application of Rasch Analysis in the development and 
application of quality of life instruments. Value in Health, 7 (Suppl 1), S22-S26. 
[36] de Vet, H.C.W., Bouter, L.M., Bezemer, P.D., Beurkens, A.J. (2001). Reproducibility and responsiveness of 
evaluative outcome measures. Theoretical considerations illustrated by an empirical example. International 
Journal of Technology Assessment in Health Care, 17(4), 479–487. 
[37] Schafer, J.L. (1997). Analysis of incomplete multivariate data. London: Chapman & Hall. 
[38] Ullman, J.B. (2001). Structural equation modeling. In B.G. Tabachnick, L.S. Fidell (Eds.), Using multivariate 
statistics (pp. 676-780). Boston: Allyn & Bacon. 
[39] Hu, L., Bentler, P.M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: conventional 
criteria versus new alternatives. Structural Equation Modeling, 6(1), 1–55. 
[40] Smith, E.V. (2002). Detecting and evaluating the impact of multidimensionality using item fit statistics and 
principal component analysis of residuals. Journal of Applied Measurement, 3, 205–231. 
[41] Tennant, A., Pallant, J.F. (2006). Unidimensionality matters! (A tale of two Smiths?). Rasch Measurement 
Transactions, 20(1), 1048–1051. 
[42] Browne, M.W., Cudeck, R. (1993). Alternative ways of assessing model fit. Sociological Methods & Research, 
21, 230-258. 
[43] Bentler, P.M. (1990). Comparative fit indexes in structural models. Psychological Bulletin, 107(2), 238–246. 
[44] Tennant, A., Conaghan, P.G. (2007). The Rasch Measurement Model in Rheumatology: What is it and why use 
it? When should it be applied, and what should one look for in a Rasch paper. Arthritis & Rheumatology, 57(8), 
1358–1362. 
[45] Andrich, D. (1982). An index of person separation in latent trait theory, the traditional KR20 index, and the 
Guttman scale response pattern. Education Research & Perspective, 9, 95–104. 
[46] Cranford, J.A., Shrout, P.E., Iida, M., Rafaeli, E., Yip, T., Bolger, N. (2006). A procedure for evaluating 
sensitivity to within-person change: can mood measures in diary studies detect change reliably. Personality & 
Social Psychology Bulletin, 32(7), 917–929. 
[47] Hagquist, C., Bruce, M., Gustavsson, J. (2009). Using the Rasch model in nursing research: An introduction and 
illustrative example. International Journal of Nursing Studies, 46, 380–393. 
[48] Deyo, R.A., Centor, R.M. (1986). Assessing the responsiveness of functional scales to clinical change. An 
analogy to diagnostic test performance. Journal of Chronic Diseases, 39, 897–906. 
[49] de Vet, H.C.W., Ostelo, R.W.J.G., Terwee, C.B., van der Roer, N., Knol, D.L., Beckerman, H. (2007). 
Minimally important change determined by a visual method integrating an anchor-based and a distribution-
based approach. Quality of Life Research, 16, 131–142. 
[50] Guyatt, G.H., Osoba, D., Wu, A.W., Wyrwich, K.W., Norman, G.R. (2002). Methods to explain the clinical 
significance of health status measures. Mayo Clinic Proceedings, 77, 371-383. 
[51] Green, J., Thorogood, N. (2009). Generating and analysing data. In J. Green, N. Thorogood (Eds.), Qualitative 
Methods for Health Research (pp. 93-122). London: Sage. 
[52] IBM Corporation. (2013). IBM Statistics for Windows, Version 22.0. Armonk: IBM Corporation. 
[53] Arbuckle, J.L. (2013). AMOS, Version 22.0. Chicago: SPSS. 
[54] Andrich, D., Sheridan, B., Luo, G. (2010). RUMM2030: a windows program for the analysis of data according 
to Rasch Unidimensional models for measurement. Perth: RUMM Laboratory Pty Ltd. 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
237 
 
[55] Hobart, J.C., Cano, S.J. (2009). Improving the evaluation of therapeutic interventions in multiple sclerosis: the 
role of new psychometric methods. Health Technology Assessment, 13, 1-177.  
[56] Ramp, M., Khan, F., Misajon, R.A., Pallant, J.F. (2009). Rasch analysis of the Multiple Sclerosis Impact Scale 
MSIS-29. Health & Quality of Life Outcomes, 22(7), 58. 
[57] Pallant, J.F., Tennant, A. (2007). An introduction to the Rasch measurement model: An example using the 
Hospital Anxiety and Depression Scale (HADS). British Journal of Clinical Psychology, 46(1), 1–18. 
[58] Kvam, A.K., Fayers, P.M., Wisloff, F. (2010). What changes in health-related quality of life matter to multiple 
myeloma patients? A prospective study. European Journal of Haematology, 84(4), 345–353. 
[59] Kvam, A.K., Fayers, P.M., Wisloff, F. (2011). Responsiveness and minimal important score differences in 
quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the 
generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. European Journal of 
Haematology, 87(4), 330–337. 
[60] Jones, D., Vichaya, E.G., Wang, X.S., Williams, L.A., Shah, N.D., Thomas, S.K., et al. (2013). Validation of 
the M. D. Anderson Symptom Inventory multiple myeloma module. Journal of Hematology & Oncology, 6, 13. 
[61] Wagner, L.I., Robinson, D., Weiss, M., Katz, M., Greipp, P.R., Fonseca, R., Cella, D. (2012). Content 
development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of 
qualitative and quantitative methods for scale construction. Journal of Pain & Symptom Management, 43(6), 
1094–1104. 
[62] Ringdal, K., Ringdal, G.I., Kaasa, S., Bjordal, K., Wisloff, F., Sundstrom, S., Hjermstad, M. (1999).  Assessing 
the consistency of psychometric properties of the HRQoL scles within the EORTC QLQ-C30 across 
populations by means of the Mokken Scaling Model. Quality of Life Research, 8, 25–43. 
[63] Juniper, E.F., Guyatt, G.H., Streiner, D.L., King, D.R. (1997). Clinical impact versus factor analysis for quality 
of life questionnaire construction. Journal of Clinical Epidemiology, 50, 233–238. 
[64] Williams, B., Coyle, J., Healy, D. (1998). The meaning of patient satisfaction: an explanation of high reported 
levels. Social Science & Medicine, 47(9), 1351-1359. 
[65] Taenzer, P., Bultz, B.D., Carlson, L.E., Speca, M., DeGagne, T., Olson, K., et al. (2000). Impact of 
computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer 
outpatients. Psycho-oncology, 9(3), 203–213. 
[66] Rosenthal, G.E., Shannon, S.E. (1997). The use of patient perceptions in the evaluation of health-care delivery 
systems. Medical Care, 35 (11 Suppl), NS58-NS68. 
[67] Cocks, K., Cohen, D., Wisloff, F., Sezer, O., Lee, S., Hippe, E., et al. (2007). An international field study of the 
reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of 
life of patients with multiple myeloma. European Journal of Cancer, 43(11), 1670-1678. 
[68] Rubin, H.R. (1990). Patient evaluations of hospital care. A review of the literature. Medical Care, 28 (9 Suppl), 
S3-S9. 
[69] Basch, E., Artz, D., Dulko, D., Scher, K., Sabbatini, P., Hensley, M., et al. (2005). Patient online self-reporting 
of toxicity symptoms during chemotherapy. Journal of Clinical Oncology, 23(15), 3552–3561. 
[70] Basch, E., Iasonos, A., Barz, A., Culkin, A., Kris, M.G., Artz, D., et al. (2007). Long-term toxicity monitoring 
via electronic patient-reported outcomes in patients receiving chemotherapy. Journal of Clinical Oncology, 
25(34), 5374–5380. 
[71] Frodin, U., Borjeson, S., Lyth, J., Lotfi, K. (2011). A prospective evaluation of patients' health-related quality of 
life during auto-SCT: a three-year follow-up. Bone Marrow Transplantation, 46(10), 1345–1352. 
[72] Bergh, I., Kvalem, I.L., Aass, N., Hjermstad, M.J. (2011). What does the answer mean? A qualitative study of 
how palliative cancer patients interpret and respond to the Edmonton Symptom Assessment System. Palliative 
Medicine, 25(7), 716-724. 
[73] Rose, M., Bjorner, J.B., Gandek, B., Bruce, B., Fries, J.F., Ware, J.E. (2014). The PROMIS Physical function 
item bank was calibrated to a standardized metric and shown to improve measurement efficiency. Journal of 
Clinical Epidemiology, 67(5), 516-526. 
[74] Bombardier, C., Melfi, C.A., Paul, J., Green, R., Hawker, G., Wright, J., Coyte, P. (1995). Comparison of a 
generic and a disease-specific measure of pain and physical function after knee replacement surgery. Medical 
Care, 33(4 Suppl), AS131-AS144. 
[75] Katz, J.N., Larson, M.G., Phillips, C.B., Fossel, A.H., Liang, M.H. (1992). Comparative measurement 
sensitivity of short and longer health status instruments. Medical Care, 30(10), 917–925. 
[76] Kazis, L.E., Anderson, J.J., Meenan, R.F. (1989). Effect sizes for interpreting changes in health status. Medical 
Care, 27(3), S178-S189. 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
238 
 
[77] Patrick, D.L., Deyo, R.A. (1989). Generic and disease-specific measures in assessing health status and quality 
of life. Medical Care, 27(3), S217-S232. 
[78] de Vet, H.C.W., Terluin, B., Knol, D.L., Roorda, L.D., Mokkink, L.B., Ostelo, R.W.J.G., et al. (2010). Three 
ways to quantify uncertainty in individually applied "minimally important change" values. Journal of Clinical 
Epidemiology, 63(1), 37–45. 
[79] Mols, F., Oerlemans, S., Vos, A.H., Koster, A., Verelst, S., Sonneveld, P., et al. (2012). Health-related quality 
of life and disease-specific compaints among multiple myeloma patients up to 10 yr after diagnosis: results from 
a population-based study using the PROFILES registry. European Journal of Haematology, 89, 311-319. 
[80] Smith, A., Roman, E., Howell, D.A., Jones, R., Patmore, R., Jack, A. (2009). The Haematological Malignancy 
Research Network (HMRN): a new information strategy for population based epidemiology and health service 
research. British Journal of Haematology, 148, 739-753. 
[81] Quittner, A.L., Modi, A.C., Wainwright, C., Otto, K., Kirihara, J., Montgomery, A.B. (2009). Determination of 
the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory 
symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway 
infection. Chest, 135, 1610–1618. 
[82] Tennant, A., Pallant, J. (2012). The root mean square error of approximation (RMSEA) as a supplementary test 
statistic to determine fit to the Rasch model with large sample sizes. Rasch Measurement Transactions, 25, 
1348-1349. 
[83] Yost, K.J., Eton, D.T. (2005). Combining distribution- and anchor-based approaches to determine minimally 
important differences: the FACIT experience. Evaluation & the Health Professions, 28, 172–191. 
[84] Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Hillsdale, N.J.: Laurence Erlbaum. 
[85] Muthén , B.O, du Toit, S., Spisic, D. (1997). Robust inference using weighted least squares and quadratic 
estimating equations in latent variable modeling with categorical and continuous outcomes. Unpublished 
manuscript. https://www.statmodel.com/download/Article_075.pdf, Accessed 11 April 2017. 
[86] Abernethy, A.P., Wheeler J.L., Zafar S.Y. (2010). Management of gastrointesintal symptoms in advanced 
cancer patients: the rapid learning cancer clinic model. Current Opinion in Supportive & Palliative Care, 4(1), 
36-45. 




Longitudinal validity and reliability of the Myeloma Patient Outcome scale was established 
using traditional, generalizability and Rasch psychometric methods  
 
Christina Ramsenthaler, Wei Gao, Richard J. Siegert, Stephen A. Schey, Polly M. Edmonds, Irene 
J. Higginson 
 
7 Results: Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) 
240 
 
Supplemental Table 1 Factor loadings of the MyPOS and fit statistics for confirmatory factor 
analysis 
Item no. Description Symptoms Emotions Support 
1 Pain .638   
2 Shortness of breath .529   
3 Fatigue .697   
4 Nausea .563   
5 Vomiting .451   
6 Appetite loss .629   
7 Constipation .532   
8 Mouth problems .442   
9 Drowsiness .645   
10 Poor mobility .695   
11 Diarrhoea .333   
12 Tingling .358   
13 Remembering .560   
14 Anxiety  .772  
15 Family anxiety  .614  
16 Depression  .715  
17 At peace  .775  
18 Sharing feelings  .480  
19 Information  .457  
20 Practical matters  .397  
21 Usual activities  .674  
22 Hobbies  .686  
23 Quality time  .670  
24 Sex  .149  
25 Infections  .392  
26 Appearance  .495  
27 Finances  .374  
28 Illness  .704  
29 Coping  .773  
30 Advice   .616 
31 Knowledge   .877 
32 Care and respect   .851 
33 Future  .383  
 Variance explained 28.1% 7.2% 6.9% 
Confirmatory factor analysis 
χ
2
 p-value <0.0001 
χ
2/ df 2.213 
CFI (>0.90) 0.794 
NFI (>0.95) 0.682 
NNFI (>0.95) 0.779 
RMSEA (95% CI) (<0.06) 0.073 (0.067-0.078) 
Abbreviations: CFI, comparative fit index; df, degrees of freedom; NFI, normal fit index; NNFI, 
non-normal fit index; RMSEA, root mean square error of approximation; MyPOS, Myeloma 
Patient Outcome Scale. 
Note: Thresholds for fit indices are indicated in brackets. 
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Supplemental Table 2 Rasch model fit for each subscale with item and person location fit 
statistics 
 
Measurement characteristic Symptom subscale 
(13 items) 
Emotional response 
subscale (17 items) 
Healthcare support 
subscale (3 items) 
Item locations    
Mean (SD) 0 (0.858) 0 (0.348) 0 (0.774) 
Range -1.16 to 1.92 -0.69 to 0.41 -0.69 to 0.83 
Thresholds    
Range -2.49 to 5.62 -2.19 to 1.86 -3.07 to 5.28 
Fit residuals: Mean (SD) -0.102 (1.191) 0.175 (1.66) 0.170 (0.338) 
Skewness 0.812 0.353 -0.221 
Person measures    
Mean (SD) -1.824 (1.101) -1.195 (1.058) -4.086 (1.484) 
Range -4.89 to 0.63 -4.33 to 0.69 -4.74 to 8.42 
Fit residuals: Mean (SD) -0.203 (0.875) -0.159 (1.163) -0.183 (0.621) 
Skewness 0.345 -0.176 -0.146 
Person separation index 0.804 0.834 0.127 
Overall fit    
X
2
 65.651 143.74 11.887 
p-value 0.005 0.001 0.065 
RMSEA (90% CI) 0.054 (0.038, 0.067) 0.088 (0.074, 0.100) 0.064 (0.049, 0.076) 
Note: RMSEA was calculated according to the formula √ Max ([(X2/df)-1/(N-1)], 0) [82].  
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Supplemental Figure 1 Item characteristic curves for all 33 MyPOS items 
Item characteristic curves plot responses predicted by the Rasch model (curve) and observed 
responses for all the different levels of quality of life and palliative care concerns in multiple 
myeloma (the measurement continuum). The available responses are 0 ‘not at all‘, 1 ‘slight‘, 2 
’moderate‘, 3 ’severe‘ and 4 ‘overwhelming‘. The observed mean scores are plotted according to 
levels of quality of life with the participants with the lowest quality of life represented on the left-
hand side and those with the highest observed level of quality of life represented on the right-hand 
side. Poor graphical fit to the Rasch model is apparent when the plotted observed means (dots) do 
not follow the continuous line. Items 12 ‘Tingling in the hands/feet‘, 24 ‘Worry about sex life’ 
and 33 ‘Information about future’ show a slight under-discrimination (also indicated by the 
positive fit residual for these items which is >2.5), in which participants with a higher level of 
quality of life report more difficulty with these areas than would be expected by the Rasch model, 
and participants with a lower quality of life report less difficulty with these items than would be 
expected.  
 
1 Pain 2 Breathlessness 
 
3 Fatigue 4 Nausea 
 
5 Vomiting 6 Poor appetite 
 












10 Poor mobility 
 
11 Diarrhoea 12 Tingling in hands/feet 
 
13 Difficulties remembering  
 
 
SUBSCALE EMOTIONAL FUNCTIONING 
14 Anxiety 15 Family anxiety 
  
16 Depression 17 Feeling at peace 
  
18 Sharing with family/friends 19 Information 






20 Practical matters 
 
 
21 Usual activities 
  
22 Hobbies 23 Quality time 
  
24 Worry about sex life 25 Worry about infections 
  
26 Worry about physical appearance 27 Worry about finances 
  
28 Worry about illness worsening 29 Coping with illness/treatment 
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SUBSCALE HEALTHCARE SUPPORT 
30 Advice from doctors/nurses 31 Knowledge of doctors/nurses 
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Supplemental Figure 2 Distribution (expressed in percent) of changes in scores on the total 
Myeloma Patient Outcome Scale for patients with multiple myeloma who report an important 
improvement (left-hand side) or an important deterioration (right-hand side) in their quality of life 
compared to those who reported no important change at time point 5. The ROC point indicates the 
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8 Integration of findings and discussion 
 
8.1 Integration of findings  
This thesis presents some of the first evidence relating to the symptom burden and palliative care 
concerns over time in patients with multiple myeloma. It therefore addresses the gap of 
insufficient longitudinal data on HRQOL in this patient group, focusing in particular on those 
patients with advanced disease. By using a new statistical method of analysing trajectories it was 
possible to understand the considerable heterogeneity in changes in HRQOL in multiple myeloma 
and to identify a group of patients that experienced deteriorating or poor QOL. The six factors 
general symptom burden, presence of severe fatigue and pain, poor ECOG performance status 
(ECOG group 2 or higher) and presence of clinically relevant anxiety and depression were 
identified as baseline predictors of poor or deteriorating QOL.  
For the monitoring of individual symptom burden and QOL over time, a newly developed 
myeloma-specific questionnaire was used, the MyPOS. The second aim of this thesis was to test 
its validity, reliability and acceptability for monitoring symptom burden and palliative care 
concerns, thereby not only describing these aspects over time but developing ways of tracking 
changes in these outcomes validly and reliably, so that the measure can be used in routine clinical 
practice. This thesis is unique in investigating the question of longitudinal monitoring both from a 
measurement/psychometric and a prognostic research perspective. Particularly regarding the 
properties that show suitability of an instrument for longitudinal monitoring, this work proposed 
and investigated a set of new psychometric criteria. By integrating the findings from the 
longitudinal QOL study with information on the psychometric quality of the measure for this 
application, it is possible to build a model of factors with prognostic value, thereby allowing the 
identification of variables and items that are targets for monitoring.  
It is proposed that these variables can indicate who would benefit from palliative care and 
possibly early integration of palliative care. As was shown in the introduction (section 2.1.3), 
haematological cancer patients are often seen late in their disease trajectory or not referred at all to 
specialist palliative care services. Ultimately, the clinical implication of the evidence is that for 
early referral to palliative care, a paradigm shift from prognosis/survival models to models of 
need incorporating PROs needs to happen in multiple myeloma care. Only routine monitoring of 
symptom burden and QOL-related aspects can help identify those needs. At the end of this 
chapter, these implications are discussed in detail. The following sections present some more in-
depth discussion of aspects that were not reviewed in the articles presented as chapters 5, 6 and 7 
of this thesis. I then focus on the methodological discussion of strengths and weaknesses of this 
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research and suggest ways of applying the findings in clinical research, and in haematological and 
palliative care clinical practice. 
 
8.1.1 Symptom burden and trajectory of palliative care problems in multiple 
myeloma 
The first three objectives of this study centred on assessing symptom severity, palliative care 
concerns and health-related quality of life in patients with multiple myeloma both cross-
sectionally and longitudinally. Determining which factors were associated with a poor or 
declining HRQOL was part of both studies, first building a model of predictors in a secondary 
analysis of a large sample involving data from the initial validation study of the MyPOS and the 
baseline data from the longitudinal survey. This model of predictors was refined and validated in 
the longitudinal survey, showing a stronger influence of symptom-related than disease- or 
treatment-related factors. 
Observational research, particularly research involving patients with advanced disease at relapsed 
or refractory stages, is rare in multiple myeloma. In the systematic review of QOL evidence in 
myeloma (see chapter 2.2.2.3), only a handful of genuine observational studies employing a 
population perspective and aiming to describe QOL in this population could be located. Most of 
these studies are cross-sectional in their design and involve mixed samples. Four recent studies, 
one involving 154 outpatients with multiple myeloma (598), one focusing in particular on the 
influence of length of stable disease phase on disease- and treatment-related symptoms (83), and 
one involving survey data of myeloma patients and their main caregivers sampled through 
Myeloma UK (90), provide a perspective on QOL that is not defined by a specific anti-myeloma 
or supportive care treatment that is tested in a clinical trial. Additionally, Boland’s study (2013) 
(593), albeit its small sample size (n=32), represents the only study including advanced patients, 
therefore presenting data applicable to the palliative care sector. Despite multiple myeloma now 
being a disease characterised by a long and chronic disease trajectory (62,73,692,693), providing 
opportunities to monitor QOL over time as patients progress through treatment lines and 
treatment-free intervals (and thus sharing characteristics of the typical trajectory of non-cancer 
conditions such as chronic obstructive pulmonary disease or heart failure (157,694)), longitudinal 
changes in the QOL of myeloma patients are seldom described. Mols et al. (2012) (381) coupled a 
QOL survey with registry-based monitoring but used only two measurement time points, one year 
apart. The remaining evidence stems from studies using samples of SCT patients that are usually 
followed over the period of one year (31,35,36,490,695,696), with one exception of monitoring 
for 36 months (31). However, since SCT is first-line treatment in those under the age of 75 
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(75,96,697), these studies do not represent the wider myeloma population because they involve 
mainly younger and fitter patients with less advanced disease (145,698).  
The general symptom level of myeloma patients varies widely, depending on sample 
characteristics. In this cross-sectional study, patients reported a mean of 7.2 out of 15 potential 
symptoms on the MyPOS, with one third of the sample reporting 6 – 8 symptoms and nearly 40% 
being highly symptomatic with 9-15 symptoms. These proportions did not change much over the 
study period of eight months. The mean number of symptoms was much higher than in the 
general population which reports a median of 3-4 symptoms (699). It was higher than in a cross-
sectional study of mixed haematological cancer patients, including 54 individuals with multiple 
myeloma, in which a mean number of 5.6 symptoms was reported, 2.3 of which were severe (9), 
and a similar study in a smaller sample (700). The fact that this sample was composed of a third 
of advanced patients is also apparent when comparing the proportion of moderately and severely 
symptomatic patients to Jordan et al.’s (2014) (598) sample composition. While the percentage of 
moderately symptomatic patients is comparable to Jordan’s study (598), the percentage of 
severely symptomatic patients exceeds the proportion in their sample by 10%.  
A more fine-grained comparison of how the findings from this study relate to the available 
research on symptom prevalence in multiple myeloma is provided in Table 7. Here, results from 
this survey are compared to the point prevalence and confidence intervals determined in the meta-
analysis presented in chapter 2.2.2.1. In comparison to all studies in myeloma and mixed 
haematological cancer populations, the most striking differences in symptom prevalence existed 
for pain, breathlessness and gastrointestinal symptoms. Pain with a prevalence of 70.8% in this 
study was much higher than the pooled prevalence ascertained in the meta-analysis (44.5%, 95% 
CI 34.4 to 54.9%). The difference was even higher for breathlessness. Here, we found almost 
twice the prevalence than in the systematic review (60.2% versus 32.6%, respectively). A marked 
higher prevalence of gastrointestinal symptoms (constipation, appetite loss, diarrhoea), however, 
was reported in the systematic review. This difference probably reflects the divergent composition 
of the sample, with a comparably smaller proportion of patients being on active chemotherapy or 
anti-cancer treatment and a far smaller proportion of patients undergoing haematopoietic stem cell 
transplantation (HSCT) in this study. Gastrointestinal symptoms are common side effects of these 
treatments (701). The prevalence of fatigue, on the contrary, was again higher in this study than in 
the review (59.3% compared to 86.8% in this study). The proportion of patients with severe 
fatigue is also twice as high as the pooled estimate in the systematic review (59% versus 20.7%). 
These marked differences, together with the slightly higher prevalence of memory problems and 
the much higher prevalence of breathlessness in this sample point towards age and comorbidity as 
possible influencing factors. Elderly people in general are more likely to report comorbid 
conditions. In the case of multiple myeloma, lung impairment can be a consequence of disease-
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related processes or secondary to treatment (207). It has been shown to be an important risk factor 
for mortality, possibly confounded by poor functional status (206,207,209,702). This also shows 
that the sample recruited in this study is different from clinical trial samples on which the 
prevalence estimates from the systematic review are based. 
 
Table 7: Comparison of prevalence of symptoms to MyPOS-reported prevalence* (point prevalence 
and 95% confidence intervals) 
Symptoms This study n 
Prevalence 
review 
Pain 70.8 (67.0 – 74.6) 1882 44.5 (34.4 – 54.9) 
Severe pain 46.3 42.1 – 50.4) 1136 25.9 (18.2 – 35.6) 
Breathlessness 60.2 (56.1 – 64.3) 245 32.6 (17.9 – 51.8) 
Severe breathlessness 27.3 (23.6 – 31.0) 253 25.1 (5.0 – 67.9) 
Fatigue 86.8 (83.9 – 89.6) 1204 59.3 (44.8 – 72.3) 
Severe fatigue 59.0 (54.9 – 63.1) 620 20.7 (11.1 – 35.4) 
Nausea/Vomiting 28.9 (25.1 – 32.7) 981 13.3 (3.2 – 41.5) 
Severe nausea/vomiting 11.4 (8.8 – 14.0) 245 9.2 (0.5 – 66.9) 
Appetite loss 16.0 (12.9 – 19.1) 770 23.1 (11.4 – 41.1) 
Severe appetite loss 7.3 (5.1 – 9.5) 245 25.7 (6.5 – 63.2) 
Constipation 38.0 (33.9 – 42.0) 639 39.1 (24.3 – 56.3) 
Severe constipation  17.3 (14.2 – 20.4) 245 21.3 (9.0 – 42.5) 
Mouth problems 36.9 (32.9 – 41.0) 1047 22.5 (13.8 – 34.5) 
Severe mouth problems† 13.7 (10.8 – 16.6) 154 17.1 (1.4 – 35.6) 
Drowsiness  26.2 (22.6 – 29.9) 308 32.5 (14.0 – 58.9) 
Severe drowsiness 10.7 (8.1 – 13.3)  -  - 
Poor mobility †† 70.8 (67.0 – 74.6) 1424 43.2 (33.3 – 53.6) 
Severely decreased  48.1 (44.0 – 52.3) 245 8.6 (2.8 – 24.0) 
Diarrhoea 23.0 (19.5 – 26.5) 805 9.5 (2.1 – 33.9) 
Severe diarrhoea 9.3 (6.9 – 11.7) 245 15.3 (1.4 – 70.3) 
Tingling in hands/feet 54.2 (50.1 – 58.3) 451 42.7 (29.0 – 57.7) 
Severe tingling 27.5 (23.8 – 31.2) 154 32.0 (10.8 – 53.1) 
Problems remembering 55.8 (51.7 – 59.9) 281 37.0 (21.3 – 55.9) 
Severe problems 21.6 (18.2 – 25.1)  -  - 
Case of anxiety 13.9 (11.0 – 16.8)  26.4 (19.1 – 35.3) 
Case of depression 11.9 (9.2 – 14.6)  20.8 (13.4 – 31.0) 
*Pooled prevalence rates are reported in a meta-analysis, see background section, page 65 
†Only one study 
††Item only included in MyPOS, comparable to items of physical functioning, therefore 
compared to physical functioning subscales 
 
Overall, when comparing results of this study to the wider literature, the type and prevalence of 
symptoms in this study closely resembled that of previous reports. However, the pattern of 
symptom prevalence was different. In the meta-analysis, the most prevalent symptoms were 
fatigue, pain,  poor mobility, tingling in the hands/feet (peripheral neuropathy) and constipation. 
The top five prevalent symptoms in this study were fatigue 86.8% (95% CI: 83.9-89.6%), pain 
70.8% (67-74.6%), poor mobility 70.8% (67.0-74.6%), breathlessness 60.2% (56.1-64.3%), and 
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problems remembering 55.8% (51.7-59.9%). Tingling in the hands/feet placed sixth with a 
prevalence of 54.2%. These results do not differ greatly from general reviews of symptom burden 
in non-cancer conditions, solid tumours and particularly advanced cancer. The triad pain, 
breathlessness and fatigue, for instance, has been found in well over 50% of both cancer and non-
cancer conditions at the end of life (703). These symptoms are thus considered universal. The 
estimates in multiple myeloma are well comparable to the solid cancer population 
(484,566,704,705). Particularly the high prevalence of pain and breathlessness is comparable to 
rates reported in the very advanced and palliative cancer population (122,536,566,705). These 
findings underscore the considerable burden of myeloma patients that is not confined to the later 
stages of disease, but already apparent in newly diagnosed patients. Particularly the high 
prevalence of pain is striking since the lower use and lower referral rates to palliative care services 
(151,706) is sometimes argued as appropriate because of the lower pain profile of patients with 
haematological cancer (122,707,708). What these findings reveal, however, is a burden similar if 
not exceeding the burden reported in general cancer (704), thereby refuting this traditionally held 
believe (709). When comparing findings of this study with findings from studies including 
haematological cancer populations referred to SPC services, it becomes apparent that the 
argument of a different and lower symptom profile applies to some leukemia and lymphoma 
patients. In acute leukemia, although presenting with a comparable median number of symptoms, 
patients reported a much lower prevalence of pain (275). This was also found in an outpatient 
SPC population (710), including lymphoma patients. Pain did not make the list of the five most 
frequent symptoms. This finding points towards the heterogeneity inherent in the haematological 
cancer population. Multiple myeloma may show a different pattern of complexity in symptoms, of 
dependency and functional decline. Overall the pattern is more common to the one seen in non-
malignant organ failure conditions. Patients with multiple myeloma may be comparable to certain 
haematological conditions that similarly affect the elderly (i.e. chronic myeloid leukemia, 
myelodysplastic syndrome). These differences in the trajectory towards the end of life between 
haematological conditions are not well understood and most likely add to the barriers regarding 
palliative care involvement. 
Johnsen and co-authors in their study from 2009 (9) concluded that patients with multiple 
myeloma reported a consistently higher symptom burden and more QOL problems than other 
haematological cancer patients. Some studies in myeloma that included QOL data also included 
normative comparisons to general populations or cancer populations (9,22,35,90,485,490,495). To 
better understand how multiple myeloma patients compare to cancer and non-cancer conditions, 
data from the EORTC QLQ-C30 were graphed and compared to these groups in Figure 11. In 
comparison to the general population, scores of global QOL and QOL domain scores reported in 
this study are consistently lower than in the general population as can be seen in panel (a) in 
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Figure 11. This relationship also holds for most functioning domains when comparing to general 
cancer populations. Particularly physical, role and social functioning appear to be the domains the 
most affected, with the confidence intervals not including the mean functioning scores of 
normative cancer and non-cancer populations. Comparable or slightly higher levels of overall 
QOL and emotional functioning to those found in non-malignant conditions are reported. This 
study also demonstrates significant impairments regarding the symptoms pain, fatigue and sleep 
problems relative to cancer and non-malignant population data. The severity of dyspnoea again 
 
Figure 11: Norm comparison of QOL and symptom data from this study to the 
general and cancer population 






Abbreviations: AP: appetite loss, CI: confidence interval, CF: cognitive functioning, CO: constipation, DI: diarrhoea, 
DY: dyspnoea, EF: emotional functioning, FA: fatigue, FI: financial difficulties, NV: nausea/vomiting, PA: pain, PF: 
physical functioning, QL: overall quality of life, RF: role functioning, SF: social functioning, SL: sleep problems. 
 
Studies providing norm populations: General population in Hjermstad et al. (1998) (711), general Swedish population in 
Michelson et al. (2000) (712), general Dutch population in van de Poll-Franse et al. (2011) (713), non-malignant long-
term disease in van de Poll-Franse et al. (2011) (713), post-SCT patient data in Kopp et al. (2005) (714), general cancer 
population in Fayers et al. (1998) (715) 
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exceeds the one found in all cancer and in non-cancer normative comparison data. Overall, the 
previously observed considerable decrements in QOL and functioning and symptom scores (496) 
have also been observed in this study. 
Contrasting with the results from the symptom prevalence analysis, impairment of cognitive 
functioning seems to be lower than the prevalence reported based on the MyPOS item “problems 
remembering”. This discrepancy can potentially be explained by the different definitions of 
cognitive functioning measured in the MyPOS and the EORTC subscale. The QLQ-C30 focuses 
more on aspects of concentration, whereas the MyPOS asks about subjective problems with recall 
or memory (384). Both aspects are a legitimate part of cognitive dysfunction but represent 
different concepts. One qualitative study (482), focusing on perceived cognitive impairment in 
multiple myeloma reported various problems with memory, recall and lack of concentration 
contributing to diminished role functioning and interference with personal and professional life. 
Inconsistencies in definitions and measurement of cognitive phenomena have been shown to 
affect prevalence and severity estimates (716,717). 
Table 8 presents a comparison of results from this study with pooled data from all myeloma 
studies containing QOL data from the EORTC QLQ-C30, split by disease stage, newly diagnosed, 
mixed (all types) and advanced disease, and contrasting autologous stem cell transplant samples 
(ASCT) with the chemotherapy treatment group. ASCT samples present with consistently lower 
symptom burden (except for short-term side effects of the procedure itself, like diarrhoea). The 
longest prospective longitudinal study including multiple myeloma ASCT patients tracked 
symptoms and QOL over three years (31). All patients recovered quickly, as early as the second 
month after SCT with role and social functioning taking longer to reach baseline levels. This 
study showed that QOL in this group reached baseline levels early on and remained stable over 
long time periods. However, a different impact of ASCT has been described by Frick et al. (2004) 
(30,32) and Hjermstad (2004) (718). The finding of comparably lower burden is interesting as 
reviews usually conclude that the group of SCT patients is more burdened than those treated with 
second or third-line chemotherapeutical regimes (719-721). Differences between the ASCT and 
non-ASCT groups could be explained by differences in measurement time points. QOL could 
have been measured later in the disease trajectory in stable phases than in the non-ASCT 
population. Other confounding variables could be age and comorbidity. High-dose therapy with 
ASCT is considered the front-line treatment and standard care in younger and fitter patients (220). 
Older patients with comorbid conditions and a poor performance status are not subjected to high-
dose therapy with the initial therapy consisting of thalidomide or bortezomib in combination with 
an alkalyting agent or a steroid (71). However, these therapies produce less durable remissions. 
QOL has been shown to increase with length of time off chemotherapy (83). This study showed 
QOL impairment levels more similar to the non-ASCT population. The comparison between 
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ASCT and non-ASCT groups was not possible in this PhD study since not enough patients were 
undergoing this procedure during the study period. 
Table 8: Comparison of quality of life results from this study with existing studies (EORTC QLQ-
C30 instruments) 
Symptoms/QOL This study Meta-analysis Subsamples meta-analysis 
 Mean (95% CI) n Mean (95% CI)   
Fatigue 41.3 (36.6–46.3) 6197 43.3 (32.7–53.8)   
Newly diagnosed 45.0 (28.2–61.8) 3762 45.9 (26.2–65.6) ASCT 42.2 (24.3-60.0) 




Advanced 42.7 (32.6–52.7) 750 40.2 (13.4–66.9)   
Nausea / vomiting 5.1 (2.9–7.4) 2545 8.0 (3.8–12.3)   
Newly diagnosed 5.0 (3.1–13.1) 1239 2.6 (0.5–4.6) ASCT 7.9 (3.3–12.5) 




Advanced 8.7 (2.4–14.9) 186 8.5 (1.3–15.8)   
Pain 28.8 (21.1–32.4) 5964 36.0 (26.4–45.6)   
Newly diagnosed 26.7 (10.6–42.8) 3762 45.6 (27.7–63.5) ASCT 32.5 (16.5–48.5) 




Advanced 30.7 (21.0–40.3) 750 38.7 (16.0–61.4)   
Breathlessness 26.7 (21.1–32.4) 2479 25.3 (14.3–36.2)   
Newly diagnosed 40.0 (12.9–67.1) 1173 26.1 (11.6–40.7) ASCT 26.2 (12.0–40.4) 




Advanced 26.7 (16.9–36.4) 186 23.8 (15.0–32.7)   
Sleep problems 29.3 (22.8–35.8) 2989 31.2 (17.7–44.7)   
Newly diagnosed 20.0 (3.3–36.7) 1173 29.4 (12.7–46.2) ASCT 28.9 (9.4–48.3) 




Advanced 25.3 (12.6–38.1) 285 25.0 (17.6–32.4)   
Appetite loss 15.4 (10.2–20.6) 2877 17.6 (9.5–25.8)   
Newly diagnosed 16.7 (4.1–29.2) 1239 12.0 (7.8–16.3) ASCT 16.7 (7.7–25.7) 




Advanced 24.0 (12.4–35.6) 186 20.6 (0.9–40.3)   
Constipation 16.1 (10.2–22.0) 2530 10.5 (4.2–16.7)   
Newly diagnosed 20.0 (5.6–34.4) 1224 18.0 (12.0–24.1) ASCT 8.5 (1.7–15.2) 




Advanced 28.0 (15.0–40.9) 186 14.7 (0.0–29.3)   
Diarrhoea 8.4 (4.9–11.9) 2530 12.5 (7.7–17.4)   
Newly diagnosed 10.0 (6.1–13.9) 1173 7.9 (0.9–14.9) ASCT 13.0 (7.7–18.3) 




Advanced 9.3 (3.0–15.6) 186 8.3 (0.5–16.2)  10.3 (1.4–19.3) 
General QOL 63.3 (58.9–67.6) 6704 56.7 (47.9–65.6   
Newly diagnosed 53.3 (37.6–69.1) 7845 55.1 (43.4–66.8) ASCT 53.0 (37.7–68.4) 
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Symptoms/QOL This study Meta-analysis Subsamples meta-analysis 
 Mean (95% CI) n Mean (95% CI)   
Physical 67.1 (62.5–71.7) 6042 61.6 (51.9–71.3)   
Newly diagnosed 62.7 (46.6–78.8) 1526 52.2 (23.0–81.3) ASCT 65.8 (47.2–84.4) 




Advanced 64.0 (54.4–73.6) 186 59.4 (18.9–99.8)   
Role 63.6 (57.6–69.5) 3164 53.5 (36.7–68.4)   
Newly diagnosed 60.0 (38.8–81.2) 1526 52.2 (23.0–81.3) ASCT 49.6 (25.5–73.7) 




Advanced 60.7 (49.5–71.9) 186 59.4 (27.9–90.8)   
Emotional 77.4 (72.6–82.1) 3597 69.7 (59.7–79.8)   
Newly diagnosed 73.3 (53.1–93.6) 1526 74.3 (52.6–96.0) ASCT 71.1 (53.5–88.7) 




Advanced 79.7 (70.7–88.7) 619 57.0 (20.1–93.9)   
Cognitive 78.6 (73.9–83.2) 3085 78.4 (67.9–88.9)   
Newly diagnosed 73.3 (57.2–89.4) 1526 77.2 (55.0–99.4) ASCT 82.5 (65.4–99.7) 




Advanced 76.0 (66.9–85.1) 186 76.1 (53.2–99.1)   
Social 67.0 (61.0–73.1) 3318 66.6 (54.2–78.9)   
Newly diagnosed 58.3 (33.0–83.6) 1526 66.6 (44.6–88.5) ASCT 66.6 (54.2–78.9) 




Advanced 64.0 (51.0–76.9) 186 65.4 (30.9–99.9)   
Financial 10.6 (5.4–15.9) 2148 23.7 (14.7–32.7)   
Newly diagnosed 3.3 (0.2 – 6.4) 542 16.5 (0.9–32.0) ASCT 26.0 (15.3–36.7) 




Advanced 10.7 (0.4–20.9) 154 8.8 (6.1–11.5)   
Disease symptoms 24.4 (20.4–28.3) 3698 32.5 (19.1–46.0)   
Newly diagnosed 29.4 (18.5–40.4) 2606 30.8 (5.4–56.2)   
Mixed  319 42.6 (6.9–78.3)   
Advanced 23.1 (16.1–30.1) 619 25.7 (1.2–50.1)   
Side effects 15.4 (12.9–17.9) 3085 26.0 (14.1–37.8)   
Newly diagnosed 18.0 (5.1–30.9) 2147 20.2 (0.7–39.7)   
Mixed  319 38.4 (4.4–72.4)   
Advanced 16.9 (12.4–21.5) 619 19.3 (1.7–36.9)   
Body image 20.9 (15.3–26.4) 745 48.4 (24.2–72.6)   
Newly diagnosed 30.0 (6.3–53.7) 240 80.0 (76.2–83.8)   
Mixed  319 58.3 (21.7–94.8)   
Advanced 16.0 (7.9–24.1) 186 23.4 (15.3–31.6)   
Future perspect. 36.4 (31.1–41.6) 899 49.6 (30.4–68.9)   
Newly diagnosed 37.8 (16.8–58.7) 240 42.3 (38.9–45.7)   
Mixed  319 51.6 (19.5–83.7)   
Advanced 33.8 (25.8–41.8) 186 46.6 (15.1–78.2)   
 
In the cross-sectional study the three MyPOS subscales (except for the Healthcare support 
subscale) and the MyPOS total score differed significantly between disease phase. Severity or 
impairment was highest in the progressive, advanced or relapsed phase, followed by newly 
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diagnosed patients, with lowest values reported in stable phase. The same pattern was seen in the 
EORTC subscales global QOL, physical functioning and role functioning. The QLQ-MY20 
subscale ‘Side effects of treatment’ departed from this pattern with post-hoc tests showing the 
highest amount of side effects in the stable phase, possibly demonstrating the time lag and 
chronicity of accumulating treatment toxicities. The first regression model also revealed disease 
phase to be significantly associated with the total MyPOS score. This relationship between 
disease duration, symptom burden, and treatment side effects was also observed in a smaller, 
cross-sectional European cohort study (593). All these variables, together with treatment status 
and bone pain among symptoms were found to be strong predictors of global health status.  
However, disease phase does not equal time since diagnosis as was demonstrated in a small Dutch 
survivorship study in myeloma. Length of survivorship had no impact on the global health 
subscale of the EORTC QLQ-C30, nor its subscales (381). A study by a UK research group used 
a similar definition of phase as this PhD study (83), although the authors divided phase into 
treatment-free intervals and lines of treatment and did not distinguish at all between phases on and 
off-treatment beyond second-line treatment. The EORTC QLQ-C30 physical, role, emotional and 
social functioning; the QLQ-MY20 future perspectives; side effects and body image subscales all 
demonstrated significantly positive associations with the first treatment-free interval (83). Despite 
these significant relationships, QOL variables did not exhibit large differences between treatment 
phases and the later stage, which might be an artefact of the grouping that the authors used. A 
third study supporting the finding of fluctuant QOL per disease phase was conducted by Boland 
and coauthors (2013) (593) involving advanced, but stable patients. The authors defined this 
phase as being in a later treatment-free interval after a prior median of three lines of treatment. A 
median of 5.5 years from diagnosis markedly compromised physical functioning was found 
together with fatigue and pain as the dominating symptom that significantly differed to early 
disease (593). Later disease stage was also characterised by greater symptom burden, reduced 
body image and greater impairment in future perspectives. A possible explanation is that 
especially in later relapses, many patients will have accumulated complications or side effects of 
previous treatment regimens that will impair QOL (68). 
The finding of more advanced disease being associated with poorer HRQOL scores has not been 
unequivocally reported in the haematological cancer literature. The relationship holds true for 
non-Hodgkin lymphoma patients (722,723), but in Hodgkin lymphoma the reverse finding of 
relapsed patients not reporting worse HRQOL than those remaining disease-free has also been 
reported (722,723). In mixed haematological cancer samples, usually more advanced disease 
stage, coupled with being on-treatment and having a poorer performance status, are accompanied 
by poorer HRQOL functioning scores (93,724). Our finding of a high symptom burden in patients 
newly diagnosed with myeloma (which, according to our definition, entails patients waiting for 
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treatment to begin, being on treatment or receiving maintenance treatment after first-line 
treatment) is also new. It demonstrates that palliative care cannot focus on the later stages of 
disease alone but makes the early integration of palliative care and supportive care for a variety of 
problems and unmet needs important. A network meta-analysis of baseline QOL data from six 
bortezomib randomised controlled trials in myeloma published this year reported similar mean 
EORTC global health scores across newly diagnosed, early and late disease phases (725). 
Unexpectedly, functioning subscales were higher in the later stages, indicating a better perceived 
health status. In addition, symptom scores, including pain, were similar or lower in the later 
versus earlier stages. Similarly to our study, this suggests a better symptom control with more 
advanced disease. Also, newly diagnosed patients tended to have more fatigue and greater loss of 
appetite, a result that was also found in this PhD study, with higher fatigue severity, 
breathlessness, disease symptoms and more problems with future perspectives reported at 
baseline. Other possible explanations for this finding could be adaptation and response shift 
processes (299,726-728), influencing the perception of burden and impact on QOL. A possible 
sample bias could be present in Robinson et al.’s (2006) (725) study due to pooling data from 
bortezomib studies and including baseline data from clinical trials only. These inconsistent results 
point towards the difficulty of basing need on a survival/prognosis model. A high symptom 
burden and amount of QOL impairment can be present from the beginning of disease and needs to 
be addressed. These findings also point towards different trajectories over time and a potentially 
heterogeneous population of myeloma sufferers. To understand this heterogeneity and risk of 
deterioration, following individuals over time as they progress through different phases of disease 
is needed. 
Longitudinal evidence to date is mainly derived from clinical trials, which either only include 
newly diagnosed but transplant-ineligible patients (365,366,370-373) or relapsed/refractory 
patients (23,375-377,729). From this data, no typical trajectory of QOL can be determined, as 
patients represent a selected group, and low compliance and possible selection bias regarding age 
and comorbidity are likely to occur (147,148,730). The second group of studies providing 
information on the course of symptoms and QOL over time include those in ASCT samples. 
Sherman et al. (2009) (35) compared data from stem cell collection with post-transplantation 
QOL and reported patients recovering with less pain and fatigue, but worsening levels of anxiety, 
depression and general well-being. Pillay et al. (2015) (731) compared the course of 
psychological symptoms 2-3 weeks post transplantation to 3 months post-SCT, at which point the 
proportion of anxiety and depression and general QOL scores dropped below the baseline level. 
Four studies focused on experiences during ASCT and followed the course of symptoms over this 
usually 28-day long period (29,378,690,731-734). They all reported the highest prevalence of 
symptoms at point of nadir with subsequent recovery of levels. This PhD study is the only study 
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presenting symptom prevalence over an eight months period in multiple myeloma. Overall, the 
general decrease in symptom prevalence reported in the studies above was also observed in this 
study. However, baseline levels well exceeded levels reported in SCT studies. For example, pain 
(67.6%), breathlessness (56.7%) and fatigue (83.6%) were considerably higher at baseline than in 
the SCT population, with the exception of the prevalence of fatigue in Sherman et al.’s (2009) 
(35) study. At 8 months, these rates reduced to 42.4% for pain, 39.1% breathlessness and 52.5% 
for fatigue. The last comparable time point to SCT studies was at 2-3 months post-baseline. 
Sherman (35) reported a prevalence of 30.9% for pain. Anderson and co-authors (2007, 2011) 
(29,734) reported a prevalence of 8% for breathlessness. Similarly to the elevated levels of 
psychological symptoms and their rise over time described in reviews and studies of symptom 
burden in haematology/SCT populations (35,719,735,736), we observed a rising prevalence for 
anxiety and depression. Psychological distress has been shown to be associated with a high or 
very high level of unmet supportive care needs in haematology and myeloma (90,526). Thus, the 
sample in this study seems to experience a decrease in symptom burden but not as pronounced as 
those reported in SCT samples. However, psychological distress becomes a much greater issue 
over time. It should be borne in mind that the comparison to SCT samples is a comparison to a 
mixed cancer population, containing a maximum of 30% patients with multiple myeloma. This 
sample, however, contained a mixture of myeloma only patients at different points in their disease 
trajectory, some of which were several years post-SCT. This leads to a symptom profile that is 
characterised by a blend of disease-related and short- and long-term toxicities of treatment, 
including organ dysfunction, comorbid disease and other complications.  
In palliative care, knowing the pattern of illness in terms of understanding the trajectories of 
functioning, symptoms and concerns informs patient-centred care and underpins service provision 
at the end of life (565,737). High levels of symptoms and other problems show areas that need to 
be addressed and help focus care on needs, thereby shifting from a diagnosis-oriented/treatment-
oriented focus of slowing the progression of disease towards a more patient-centred model of care 
that includes much greater recognition of the extent to which symptoms and concerns impact on 
patients’ QOL. Recognising drivers of psychosocial, practical and social consequences of some of 
these symptoms and their impact on functioning would promote assessment and intervention 
beyond disease-orientated and pharmacological interventions in multiple myeloma, including 
more and appropriate psychosocial assessment and support. For multiple myeloma, this 
information is largely missing, with the main evidence on HRQOL stemming from clinical trial 
evaluations (738). Large observational cohort studies that investigate changes in patient-reported 
outcomes over the disease course, thereby spanning multiple therapeutic interventions and 
trajectories (725), are missing. In this study, we tried to partly fill this gap by following a 
naturalistic, prospective multi-centre group of patients as they progressed from diagnosis and 
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initial therapy to later stages (359). Ideally, follow-up should be long enough the see the 
progression across the whole disease and treatment course, from diagnosis to advanced disease, 
capturing multiple therapies, treatment-free intervals and the use of supportive care services. 
Population trajectories have implications for the provision of care to a population as a whole. 
They might indicate areas of greater need where resources should be focused, also showing areas 
for proactive targeting of intervention to alleviate symptoms early. Some of this work has been 
conducted in multiple myeloma regarding the beneficial role of early exercise interventions to 
address fatigue (488,739,740). However, mean trajectories can obscure subgroups of QOL 
impairments and persisting symptoms. Individual trajectories have implications for care provision 
for the individual patient. Therefore, the aim of this study was to understand the considerable 
heterogeneity in QOL and functioning trajectories in this large sample of MM patients. When 
graphing the mean QOL trajectory for the whole group and overlaying this picture with the 
individual trajectories, it became apparent that analysing the mean trajectory would mask 
important between-subject variation and probably lead to wrong conclusions regarding 
influencing factors.  
Therefore, an approach combining the multivariate, longitudinal analysis of trajectories with 
cluster analysis was used to understand the heterogeneity and to split the sample into groups or 
classes of common QOL experience. Groups of QOL experience seemed to follow a stable 
course, either characterised by a high or a low level of QOL throughout the trajectory (class 2, 
stable, good QOL and class 3, stable poor QOL). A rising/declining trajectory of improving QOL 
(class 1) and deteriorating QOL (class 4) was found in addition. Progressive decline was confined 
to a few patients only, the class of poor but stable QOL experience was larger (n = 24). 
Trajectories of fluctuant decline were not identified in this research. Other than in the cross-
sectional analysis in which duration of illness or disease phase influenced poor QOL, these results 
highlight that there is a group of patients that consistently are more poorly or show a rapidly 
declining trajectory. A comparison to other longitudinal studies is hindered by the fact that the 
only other observational longitudinal study in myeloma (381) only included two time points, one 
year apart, and only described mean change in QOL and its domains, not exploring heterogeneity 
within the sample. 
Analogous to a seminal study by Murray et al. (2002) (737), we wanted to better understand how 
the overall trajectory of QOL in these classes related to aspects of QOL functioning and thus 
graphed physical, role, emotional and social functioning as well as side effects of treatment for 
each class (see chapter 6). For the classes improving QOL, stable good QOL and deteriorating 
QOL the trajectory of QOL seemed to be largely determined by the level of physical functioning, 
with social functioning and role functioning following this course as well. Only the class of stable, 
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poor QOL showed a remarkably fluctuant course of QOL domains with all functioning aspects 
first showing improvement and then returning to baseline levels around four to six months. This 
points towards domain scores possibly indicating overall risk of deterioration in QOL, a fact that 
was explored in the regression analyses. 
 
8.1.2 Risk factors for poor and deteriorating HRQOL in multiple myeloma  
After identifying the group of myeloma patients with a poor QOL, the last step in the modelling 
consisted of considering risk factors for experiencing poor or deteriorating QOL. A two-step 
procedure was followed. Firstly, a model of independently associated factors was built from the 
large, multi-centre cross-sectional dataset using the MyPOS, EORTC global QOL scale, and EQ-
5D Index (UK norm) as dependent variables. The rationale for including different dependent 
variables in this step was to follow a wide definition of poor quality of life and integrating results 
from the meta-analyses (see chapter 2.2.2.3). The three measures represented different methods of 
capturing QOL, one being a global rating, one a generic utility measure and the MyPOS being a 
multidimensional questionnaire with a focus on palliative care aspects in multiple myeloma. 
Consistency of independent factors between the models was proposed as a method of internal 
validation (613,624). Models were built using Altman’s recommendations (741) for prioritising 
variables. First univariate linear regression models tested each of the symptoms. Bivariate 
analyses were conducted to determine the socio-demographic, disease and treatment history 
variables to enter into the model. Those symptoms found significant were combined in a 
multivariate model which was then trimmed to exclude those that lost significance. The second 
step consisted of hierarchical regression procedures, adjusting for general symptom level and 
entering variables step-wise into the model. For the longitudinal study, the risk model was built 
differently by using not a QOL outcome per se as the independent variables, but focusing on the 
combined classes of those patients with stable poor QOL and deteriorating QOL found in the 
trajectory analysis. Instead of validating the model from the cross-sectional analysis by using the 
same significant predictor variables and testing their magnitude, the model was validated by 
essentially building a new exploratory model and comparing the predictors to the cross-sectional 
analysis. This was necessary because of the change in outcome (class membership and no linear 
dependent variable). Again, bivariate associations were tested first and those variables found to be 
significant entered into a multivariable logistic regression.  
The regression model in the cross-sectional analysis showed a mediating influence of general 
symptom level only for the outcome palliative care concerns/total MyPOS. Symptoms predicted 
all three outcomes, but of the ones entered only pain showed consistent associations with all three 
outcomes. Fatigue was found to be a significant predictor variable in the EORTC QLQ-C30 
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global QOL model; dry mouth/mouth problems was associated with higher palliative care 
concerns. Psychological symptoms exhibited a consistent relationship with all outcome variables. 
ECOG performance status of 3 or higher was independently associated with the EQ-5D index 
score. The amount of variance explained in the models was lowest in the model of global QOL 
(51.4%) and highest in the model of palliative care concerns (MyPOS) (88%). All socio-
demographic variables, disease and treatment characteristics (age, gender, ethnicity, educational 
level (as an indicator of socio-economic status), working status, type of myeloma, ISS stage, 
comorbidity, lines of treatment, treatment intensity) needed to be removed from the model due to 
non-significance. Once entered into the multivariate models, the explanatory power of symptom 
and functioning variables let these variables drop from the model. At the bivariate level in the 
cross-sectional analysis, age, being on treatment, working status and type of myeloma (light chain 
disease versus IgA or IgG myeloma) were found significant. Of these, only stage of disease and 
age remained in the multivariate model. In the longitudinal regression model, only phase of illness 
remained significant in the final model. Overall, results from the longitudinal study confirmed the 
results from the initial exploratory analysis. However, it should be noted that there is a common 
element between the two parts of the study since baseline data from the longitudinal survey was 
included in the secondary analysis. Overall, although the outcome variable was changed between 
the two models, common variables working as risk factors for poor or deteriorating QOL 
emerged: general symptom level, presence of pain and fatigue (and possibly mucositis), 
performance status and psychological/mental health status. Interestingly, when defining classes of 
QOL trajectories the influence of phase of illness was obliterated, meaning that poor or 
deteriorating QOL was not bound to a specific disease phase. This also highlights the fact that 
poor or deteriorating QOL can be present in newly diagnosed patients, a result found in the 
descriptive analysis. Support for this view comes from studies with radiation or chemotherapy 
patients in which fatigue was present even before the begin of treatment and persisting at even 
higher than baseline rates for years (34,35,742). It also means that identifying patients that need 
palliative care involvement cannot rely on factors such as disease phase or functional status (as 
was the case in the initial proposal by Lynn and Lunney (157)) alone. 
Support for the role of symptoms in predicting poor QOL and at-risk groups comes from a large 
population-based study of mixed cancer patients, among them 120 myeloma patients (743). 
Multivariate modelling revealed fatigue to be correlated with poor performance status, having 
active disease and feeling sad and irritable (743). Particularly the role of pain cannot be 
overstated. It has consistently been shown to be a strong determinant for QOL, particularly in 
myeloma (744). Recent Italian studies (501) into the nature of pain experienced by 
haematological cancer patients illustrate that sources of pain are manifold, with pain mechanisms 
not only involving bone pain or neuropathic pain, but even incident pain being aetiologic for 38% 
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of all pain syndromes. Bone lesions and bone involvement cause the majority of pain syndromes 
(501). They can increase bone resorption, leading to skeletal complications (pathologic fractures, 
spinal cord compression, hypercalcaemia and severe bone pain), and thus may substantially 
reduce functional independence and QOL. They have been shown to be related to survival in 
multiple myeloma and other diseases (745-747). Mucositis has been identified as a critical risk 
factor for infections and is a major driver of analgesic and total parenteral nutrition use 
(91,496,502), also increasing nutritional risk, a factor identified as a major driver of QOL in the 
meta-analysis of predictors of QOL (see chapter 2.2.2.3). 
The strong interrelationships in this study have also been established in other studies, particularly 
between overall QOL, greater symptom burden and poorer outcomes (483,748,749). Symptoms 
appear in clusters, of which the two most common are: pain – fatigue – physical functioning 
(90,365,750-752) and pain – fatigue – depression (598). It has been hypothesised that particularly 
pain and fatigue can have a common underlying cause (744,753,754), since adequate pain control 
has been shown to reduce fatigue (365). Similar interrelationships are reported in the wider cancer 
literature in prospective studies of oncological patients with advanced cancer (755). Hwang et al. 
(2003) (756) demonstrated correlations between fatigue, dyspnoea, pain, lack of appetite, 
depression and irritability. Positive correlations of fatigue with performance status and negative 
correlations with depression and haemoglobin levels were described in elderly cancer (757) and 
haemato-oncological patients (758). Fatigue and pain seem to have high correlations throughout 
the disease course in multiple myeloma (381,752). This can be partly explained by the chronicity 
of this condition with frequent relapses after remission or partial remission, leading to an 
accumulation of disease- and treatment-related problems. 
Symptoms have a considerable impact on aspects of QOL. In a study of 379 patients receiving 
chemotherapy, almost all fatigued patients said symptoms prevented a normal life and changed 
their daily routine (759). The presence of symptoms influenced physical functioning and physical 
activity in particular (760-763), decreased functional ability leading to lower QOL (764,765) and 
negative effects on mood and psychological health in as little as seven days (766). The role of 
performance status has recently been demonstrated in a network meta-analysis of six bortezomib 
trials in multiple myeloma, with performance status persistently influencing global health status 
across all disease stages (725). Poor physical function can result in increased dependence, 
restricting family life and role functioning (743,767). However, performance status and physical 
functioning cannot explain differences in QOL alone. As seen in the regression analysis, symptom 
variables and psychological distress showed higher beta coefficients than performance status or 
physical functioning. There is a role for performance status to be used as a stratification variable 
to indicate the need for screening of general symptom level, symptom burden and mental health. 
Previous research suggested that physical activity may be an important intervention in the group 
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of multiple myeloma to decrease overall symptom and fatigue levels (739,768-770). Expanding 
supportive care interventions to include exercise seems warranted since a population-based study 
showed that all physical activity levels declined from pre-diagnosis levels soon after diagnosis 
and completion of first-line treatment with long-term consequences for physical functioning later 
in the disease trajectory (771). 
In this study, clinically relevant anxiety and/or depression at baseline emerged as an important 
predictor for poor QOL. This is relevant since only one quarter of all participants presented with 
clinically relevant psychological distress. Psychological distress, coupled with the symptoms pain 
and fatigue and functioning therefore represents an important screening and assessment variable 
to indicate possible palliative care needs. Higher anxiety and depression in general have been 
linked to higher supportive care needs in the literature (529,772). Rates of anxiety and depression 
are particularly high among individuals with multiple myeloma (90), in part higher than in the 
wider cancer literature (773,774). It has been proposed that pain, fatigue and depression/anxiety 
form a symptom cluster, but no strong evidence for a cause and effect relationship has been 
provided to date (775). Pain is associated with anxiety/depression, when comparing cancer 
patients with pain to those without (776,777). Ahles and co-authors (1983) (776,777) found pain 
to be related to pain-specific anxious mood and global distress. Pain and its treatment may cause 
fatigue directly or indirectly through stress responses. In multiple myeloma and other 
haematological disease, strong associations between depression and high levels of fatigue and, to 
a lesser extent, between anxiety, fatigue and comorbidity have been reported (778). This 
relationship also holds true in studies of bone marrow transplantation patients (779). Associations 
may be due to mood disturbances resulting from the psychological impact of cancer and/or the 
neurotoxic effects of cancer (780). Since not all participants in this study experienced this triad of 
symptoms, it is likely that such a symptom cluster is not universally present but that the link of 
these symptoms indicates a higher impact on QOL in general, possibly by symptoms influencing 
functioning and mood factors leading to inefficient coping or making the individual more 
susceptible to the debilitating influence of these symptoms on well-being. Some authors argue 
that the high correlations between these measures represent an artefact and highlight problems 
with discriminant validity because of the considerable overlap between these entities 
(339,340,356,781,782). What was not possible in this analysis was the investigation of whether 
psychological factors function as stable predictors or whether they are responsive to treatment 
(see section 8.5.1). The regression analyses highlight the need to treat these symptoms since they 
can compromise the timing or completion of treatment regimes, either as dose-limiting adverse 
effects or because they reduce patients’ compliance and willingness to adhere to treatment (783). 
The failure to complete the optimal schedule reduces the chance of remission and length of 
remission (86,784). 
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One drawback of the predictive model built to indicate risk of deterioration or poor QOL in 
multiple myeloma is the lack of biomedical variables that could be taken into account. One of the 
candidates for investigation is anaemia. In multiple myeloma patients, anaemia is present in about 
half of myeloma patients at diagnosis (205) and in most patients during the course of disease, 
either caused by cancer or its treatment, which can induce fatigue (161). Haemoglobin 
concentrations are associated with the type of tumour, the extent of disease, response to treatment 
and relapse, all of which can have an impact on QOL and suggesting an independent relationship 
of haemoglobin and QOL. However, this relationship remains uncertain and recent studies in 
myeloproliferative disorders and in myeloma patients have shown that oftentimes, haemoglobin 
levels provided little insight into levels of QOL (161,785-788). For example, the change in mean 
QOL scores was modest in trials of epoetin alpha (185,494,789-791). Fatigue levels often 
indicated larger changes in the global QOL EORTC QLQ-C30 scale, as large as four times the 
magnitude of a clinically meaningful difference, when compared to anaemia as an explanatory 
variable (767). Elucidating the role of anaemia as a predictor might have important implications 
since the haemoglobin level at disease onset is an important factor on which treatment decisions 
are based. However, patient-reported outcomes rather than the degree of anaemia may more 
accurately reveal the effects of disease burden on QOL functioning. Similarly, monitoring of 
cytokines has been proposed, among them interleukin (IL)-1, tumour necrosis factor (TNF)-alpha 
and various other (792,793). Cytokines like IL-6 have been related to disease activity in multiple 
myeloma (188). IL-6 has been shown to correlate with pain, physical functioning, sleep problems, 
and appetite loss in advanced disease (593,794). Wang and co-authors (2015) (379), in a recent 
longitudinal study of myeloma SCT patients, demonstrated that elevated baseline levels of TNF-a 
predicted membership in the high-symptom group. They found cytokines to be related to the 
severity of symptoms, whereas treatment-related factors such as maintenance therapy and tumour 
response were not related (190). This is contrary to a study that reported a relation between 
cytokines and a poor response to chemotherapy, therefore suggesting IL-6 and others markers as 
screening measures that could identify a subset of patients with a high risk of treatment failure 
(783). Other biomedical factors linked to QOL and survival are albumin and creatinine clearance 
rate, mainly due to their relationship to renal involvement which can be a factor affecting survival 
in myeloma (725). However, since these variables are confounded with disease complications like 
osteolytic lesions, their appropriateness for screening has been described as limited (183). The 
same is true for C-reactive protein (CRP) values that may be confounded with haematological 
disease factors and a chronic non-infectious inflammation process (183). 
In general, although some studies in myeloma demonstrated a relationship between baseline 
values and symptoms/QOL, correlation coefficients were generally of low to moderate strength. 
The meta-analysis of factors being associated with QOL presented in chapter 2.2.2.3 synthesised 
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these studies and came to a similar conclusion. Much of the evidence also focuses on early disease 
stages with the predictive power of these variables needing to be established in later stages. A 
major critique of biomarkers has been around their lack of adequate sensitivity and specificity, 
concluding that they are not suitable as predictive factors for survival, disease progression, 
response to treatment and QOL in particular (191). Thus, although counterintuitive at first, 
biomedical factors may show lower predictive power than symptoms and individual psychological 
factors (795), a finding that has been observed in both regression analyses. However, future 
studies should focus on the link between traditionally proposed targets for monitoring, like 
disease progression and response to treatment, and QOL. 
One surprising finding was that comorbidity did not reveal any sizable influence on HRQOL. 
Comorbidity in particular has been suggested as one of the main factors driving mortality in MM 
and has been included in recent models of prognosis in palliative care. For multiple myeloma, a 
number of comorbidity indices have been tested (95,206-209,702). The Charlson comorbidity 
index, assessing 19 comorbid conditions, is the one most frequently used. Other indices are the 
Freiburg comorbidity index, including patients’ Karnofsky performance and renal and lung 
disease status (206). Comorbidity has been linked to mortality in myeloma (796), particularly in 
the presence of renal disease, dementia or cardiovascular and pulmonary disease and most likely 
due to patients receiving less-intensive treatments. Comorbidities associated with organ failure or 
cognitive function are associated with poorer prognosis (199,214,797-800), especially among 
patients in HSCT transplant population (702,801,802). Patients with a high number of 
comorbidities more often report lower levels of health-related quality of life (803), a result that 
was not observed in this study. This is striking as these differences between patients with 
comorbidity and those without have been reported as profound, at least twice the magnitude of the 
minimal important difference in general health, pain and physical functioning (804). Vissers et al. 
(2013) (805) reported that comorbidity explained up to 20% of the variance in pain and fatigue, 
with comorbidity explaining more variation than sociodemographic and cancer characteristics. 
However, again patient-reported variables like psychological status might exert a stronger link to 
deteriorating and poor QOL. 
The findings of this study generally point towards the need for basing risk stratification in 
myeloma not only on disease or treatment characteristics. To date, prognostic risk stratification in 
myeloma is solely based on disease characteristics assessed at diagnosis, ISS or chromosomal 
abnormalities (806). Linking these prognostic indices to HRQOL has been challenging (245,807-
809). Some initiatives in myelodysplastic syndromes produced risk scores composed of traditional 
biomedical indices and symptom scores (presence of fatigue) (810). Chow and colleagues 
developed and validated a predictive model for survival in advanced cancer patients including 
disease variables and Karnofsky performance status, symptom severity and QOL variables (146). 
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An integration of these variables to potentially indicate need for supportive/palliative care should 
be validated in later disease stages. Some recent models in palliative care tried to emulate these 
findings and developed frailty scores that contain patient-reported outcomes (dyspnoea, anorexia), 
performance status and white blood cell abnormalities (183). The Palliative Prognostic Index 
(146,811), the Palliative Prognostic Score (204) and the Palliative Performance Scale 
(203,217,812) all contain symptom information. However, their applicability to the 
haematological discipline remains to be tested since these tools were designed to indicate short-
term mortality of one month. Multiple myeloma is characterised by a long disease trajectory. 
Another proposal is to recognise frailty as an important predictive factor in multiple myeloma, 
integrating dependency, comorbidities, disease-specific variables and patient-reported outcomes 
into a frailty score (95, 694). The data from this study provides an argument for incorporating 
patient-reported outcomes in these scores. Particularly symptoms and psychological factors were 
identified as important screening and monitoring variables. These variables, together with 
physical functioning, have been linked to mortality in multiple myeloma (22,23,242,813). 
Hypothesising a mediating mechanism by controlling physical symptoms, thus reducing 
depression and increasing social support and influencing treatment decision making has been 
proposed in Temel and co-authors seminal study as the reason for why the early integration of 
palliative care was associated with a survival advantage in this advanced cancer cohort (172,277). 
This is another argument for including HRQOL and symptom status variables into risk scores. In 
the next section, I will therefore focus on the assessment of these variables using the Myeloma 
Patient Outcome Scale. 
 
8.1.3 Longitudinal validity and reliability of the MyPOS  
The Myeloma Patient Outcome Scale was developed after an initial systematic review revealed 
that existing questionnaires in the field were either developed solely or primarily for research 
purposes and were not covering all the issues important to myeloma patients (359). However, the 
issue of developing a new questionnaire in light of the abundance of HRQOL tools, generic and 
some disease-specific, that are already available in haematology and multiple myeloma needs to 
be argued carefully. One approach recognising the wealth of development and field-test work was 
to modify an existing questionnaire rather than design a new tool. Therefore, the most successful 
items from existing questionnaires such as the Palliative Care Outcome Scale (POS) and the 
EORTC QLQ-MY20 were picked and subjected to cognitive testing involving a large sample of 
patients with different disease stages (384). This was supplemented with extensive qualitative 
interviews and focus groups to understand how individuals with myeloma define QOL and what 
symptoms and problems impact on QOL (357). 
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Table 9: Comparison of the content and domain coverage of the main myeloma-specific quality of life 
and symptom questionnaires 
QOL domain 
Myeloma Patient 
Outcome Scale (384) 
EORTC QLQ-
MY20 (221,310) 
M. D. Anderson 
Symptom Inventory – 
Multiple myeloma 
(690) 




Pain Pain Pain 
Breathlessness Breathlessness Breathlessness 
Fatigue/Weakness Fatigue Fatigue 
Nausea Nausea Nausea 
Vomiting Vomiting Vomiting 
Poor appetite Lack of appetite Lack of appetite 
Constipation Constipation Constipation 
Sore/dry mouth Dry mouth 
Dry mouth, Sore 
mouth 
Drowsiness Drowsiness Drowsiness 
Diarrhoea Diarrhoea Diarrhoea 
Tingling  Tingling  Numbness or tingling 
Remembering Remembering Remembering 
– Trouble sleeping Disturbed sleep 
– – Muscle weakness 
– – Rash 
– Concentrating Paying attention 
– Bone aches Bone aches 
– Thirst – 
– Restlessness – 
– Indigestion – 


















Social/ participatory function 
Quality time with 
friends/family 
Social activities – 
Spiritual concerns Feeling at peace – – 







Libido/ sexual function Worry about sex life – – 
Role function/Work life Usual activities – Work 
Financial concerns 





Leisure activities Hobbies/Leisure Hobbies/Leisure Enjoyment of life 
Body image Physical appearance Body image  
Quality of health care 
Knowledge/skills  
Care and respect 
– – 
Information about disease and 
treatment 
Information as wanted 
Advice as needed 
Practical concerns 
– – 
Support/ coping mechanisms Coping with illness – – 
Thinking about the future 
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Three specific features of the MyPOS are highlighted below, (a) its high content validity, (b) the 
issue of scaling impact/evaluation instead of severity/intensity, and (c) the use of open questions 
within a standardised assessment instrument. Table 9 compares the content and domain coverage 
of the three main myeloma-specific questionnaires, the MyPOS (384), the EORTC QLQ-MY20 
(221,310) and the M.D. Anderson Symptom Inventory – Multiple myeloma (690), a tool that was 
developed post 2012 and was therefore not included in the systematic review of measures (359). 
Use of qualitative interviews with all stakeholders, but patients in particular, was recently 
advocated by both the FDA (636) and within the COSMIN guidelines for measure development 
(640). The MyPOS was built entirely from patient interviews, with clinicians not being involved 
in the item development or item selection. It is the only measure of three to have done so. When 
comparing coverage of symptoms among the three measures it is apparent that the MyPOS has the 
shortest list of items. Despite its brevity, these symptoms were identified by participants in our 
qualitative study as the most important ones. They correspond to a core set of symptoms that have 
been considered in other studies as well. The National Cancer Institute proposed a similar list for 
inclusion in clinical trials as the minimum set of symptoms (814). More importantly, since the 
MyPOS was also developed with the intention to cover issues important to patients with more 
advanced disease, the list of included items covers those that are named in studies of commonly 
held concerns among palliative care patients (259,574,815-817). In fact, these 12 symptoms are 
covered by the most common QOL and symptom assessment tools but not all contain peripheral 
neuropathy and memory problems that are included in the MyPOS as important toxicities of 
treatment (404). Moreover, unlike the MDASI-MM and the EORTC-QLQ-MY20, the MyPOS 
contains more items regarding worry about the future, information needs, coping processes but 
also adaptation processes that the prolonged disease trajectory of myeloma asks of individuals. 
These issues have been also highlighted as important in recent qualitative studies focusing on the 
advanced myeloma population (385,480,482). Particularly in the studies of Steinhauser and 
Singer (259,815-817), symptom control was given consistently the highest priority. 
This might be related to the fact that the MyPOS, as a QOL tool suitable for use in clinical 
practice, was designed to probe beyond a simple assessment of symptom status (intensity or 
severity of a symptom) and instead asks for an evaluation of symptom impact. Therefore, the 
MyPOS is a QOL instrument and not a health status assessment, the latter being a construct that 
does not capture all aspects of QOL (295,314,315). A few definitions of QOL particularly 
highlight this aspect of evaluation, among them the definitions by Calman, Campbell et al. and 
Frisch (295). These all explicitly refer to internal standards affecting such evaluations. Ferrans 
(2005, 2007) (295,518), who developed the distinction between health status and health 
evaluation/impact measures, defines QOL as the satisfaction with those aspects of life that are 
important to the individual. Asking a patient’s evaluation of components of each domain of QOL 
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requires additional cognitive processing and has the potential of becoming taxing for individuals 
with cognitive impairment (518). However, evaluating the impact rather than severity has been 
one of the defining features of the POS, the measure upon which the MyPOS was built and of 
which it is now a module. The symptom items on the POS are preceded by the statement “Please 
indicate how much you were affected over the past three days by the following symptoms” (512). 
The original scale then specified effects on functioning and/or concentration as qualifiers to 
further probe impact. The issue of scaling impact versus severity is partly related to the QOL 
model/theory employed. This might also be one argument against Fayers’ theory (339,340,356) of 
distinguishing between QOL items and symptom items in the evaluation of HRQOL measures. He 
sees symptoms as causal indicators, sufficient to cause a change in QOL. Aspects like anxiety and 
depression are seen as effect indicators, reflecting the level of QOL. While his theory has a sound 
basis, evidence from our qualitative study points towards a less stringent relationship between 
symptoms and QOL. We found that the inter-relationship between symptoms and QOL sometimes 
matched Fayers’ description, but that it could also be mediated by his so-called effect indicators 
(357). In the initial factor analysis of the MyPOS (384), the functioning items loaded with the 
symptom items, also pointing towards a different relationship of QOL and symptoms. 
The MyPOS has been revised since, on the basis of cognitive interviews with palliative care 
patients that contested the double-barrelled nature of the scale (818). In the revised version of the 
POS, the Integrated Palliative Care Outcome Scale (IPOS) (819), the scale was changed to only 
contain the preceding statement followed by a scale of severity. In keeping with the format of the 
IPOS, we adapted the MyPOS accordingly. The resulting changes in the endorsement of items, 
problems with scaling seen in the Rasch analysis and in the assignment of items to scales in the 
exploratory and confirmatory factor analyses point towards this being an issue of contestation 
with possible further revisions being necessary. 
Recently, there has been a move towards increased development of needs measures arguing that 
this type of questionnaire is better suited for use in clinical practice to help the clinician recognise 
the problems experienced by the patient that require help (820). Work to convert the EORTC 
QLQ-C30 into a needs measures, using the item of fatigue as an example found a high correlation 
between fatigue intensity and fatigue burden (r = 0.91) (820), pulling the distinction between 
health status and health evaluation into question. However, needs questionnaires often contain a 
list of items and domains and ask the patient to indicate how much help they want with a 
particular issue or ask them to rank needs in their importance (521). This approach looses the 
dimensionality with which domains should be covered in QOL questionnaires. It also requires a 
full set of possible unmet needs. An issue of greater concern is the narrowness inherent in the 
concept of need. According to Bradshaw’s (1972) definition (532), a need is the possibility to 
benefit from healthcare. This narrows a questionnaire to probing only those needs that can be 
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potentially met by an intervention. As indicated in multiple studies (821,822), this can result in 
important aspects not being included in the questionnaire, like items about sexual concerns, 
satisfaction with healthcare and family/caregiver burden.  
The third strength of the MyPOS lies in its semi-individualised nature. Open questions at its 
beginning and below the symptom list invite identification of the most important problem(s) and 
additional symptoms. This allows adding those symptoms not covered by the core set of 
symptoms, yet keeping the questionnaire reasonably short. In comparison, the MyPOS contains 
the shortest list of symptoms with less items being devoted to symptoms than in the EORTC 
QLQ-MY20 and the MDASI-MM (see Table 9). Using qualitative methods to complement 
standardised questions has been advocated as a way to better capture the totality of the patient’s 
experience (823). This approach partially circumvents the problem of individualised measures 
regarding difficulties in administration and scoring and the strain this can put on individuals 
experiencing a high disease and symptom burden (316). In a postal survey of cancer patients from 
three UK Cancer registries, open questions were completed by 32% (824). We found an even 
higher percentage of 56% across all five time points in our study. One of the issues and additional 
symptoms named the most frequently was sleep problems. The issue of sleep disruption and 
disorders is well-known in haematological and SCT patients (825). One could consider possibly 
adding this symptom to the core set of symptoms in the MyPOS. 
How a change in the wording of the scale and thereby altering the dimensions that are assessed 
can affect factor analytical results became apparent in the longitudinal psychometric analysis of 
the MyPOS. Whereas in the initial factor analysis symptoms loaded with functioning items onto 
one subscale (384), after reformatting the questionnaire and making it a module of the POS, the 
subsequent change in the scaling of the symptom items also changed the loading of items onto 
subscales. This underscores the difference between severity and evaluative scaling (518). 
Although the Rasch model fitted the data well, there were areas of potential improvements (see 
Table 10). Three out of 33 items did not fit the Rasch model, the three being item 12, Tingling in 
the hands and feet, item 24, Worry about sex life, and item 33, “Do you have enough information 
about the future?”. Although these three items show fit residuals within the agreed optimum of +/- 
2.5 (668), they most likely misfitted due to a high amount of missing data (item 24, worry about 
sex life, in particular had a high proportion of participants not answering this item). On a 
theoretical basis, they should stay in the MyPOS because they have been shown to be important 
areas of concern in myeloma, as is the case with the items about peripheral neuropathy and worry 
about the future/information needs that have been identified as causing a high proportion of unmet 
needs in this population (90). 
8 Integration of findings and discussion 
272 
 
Table 10: Summary of hypotheses and results of longitudinal validity of the MyPOS 
Hypotheses/ Domain Empirical 
support 
Commentary 
Objective a) Construct validity   
Structural validity   
A1) Confirming the three-factor 
structure of the MyPOS 
+ Three-factor structure confirmed. Functioning 
items now loading onto Emotional Response 
subscale. Fit indices show satisfactory model 
fit. 
A2) After confirmation of 
subscale structure, evaluation of 
fit to the Rasch model for each 
subscale. 
+ Fit to the Rasch model for all three subscales 
(RMSEA < 0.2).  
Scaling assumptions   
A3) Determining the individual 
item fit for each subscale of the 
MyPOS to identify misfitting and 
redundant items. 
+/– Overall 30/33 items marginal – good fit 
Misfitting items according to graphical fit: 
- (12) Tingling in hands/feet 
- (24) Worry about sex life 
- (33) Information about the future 
Redundant items: 
- Nausea – Vomiting 
- Feeling at peace – Depression 
- Sharing feelings – Family anxiety 
- Hobbies – Usual activities 
- Worry illness worsening – Anxiety 
- Contacting doctors – Knowledge of staff 
- Contacting doctors – Doctors showing respect 
A4) Determining floor and 
ceiling effects of individual items 
and subscales 
+/– 9/33 items problematic 
Emotional response subscale and Healthcare 
support subscale show floor effects (not enough 
subjects in the sample to cover worse emotional 
problems or dissatisfaction with healthcare). 
A5) Determining validity of 
response options/scaling 
– 21/33 disordered thresholds 
10 items: Problems to distinguish between a 
moderate, severe and overwhelming problem 
11 items: Problems discriminating between ‘not 
at all’ and ‘slight’. 
Objective b) Reliability   
B1) Determining internal 
consistency reliability from 
factor and Rasch analyses. 
+/– Person separation index (correction for 
Cronbach’ alpha in Rasch analysis): 
- Symptoms subscale 0.80 - good 
- Emotional response 0.83 - good 
- Healthcare support 0.13 - poor 
Cronbach’s α ≥ 0.79 
B2) Determining test-retest 
reliability and its subcomponents 
via Generalizability coefficients. 
+ 
+/– 
Reliability of screening: R 0.55 to 0.73 - good 
Reliability of discrimination: R < 0.50 - poor 
Test-retest reliability: R > 0.90 - excellent 
Individual change: R 0.42 to 0.68 - moderate 
B3) Determining item invariance 
over time via differential item 
functioning analysis in Rasch 
model. 




- Worry about infections 
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Objective c) Responsiveness   
C1) Determining the minimal 
importance difference (MID) via 
the anchor-based approach 
+/– Change scores for improved, stable and 
deteriorated patients in the expected direction, 
but some misclassification and small numbers 
in improved/deteriorated categories. 
MID for MyPOS total score, improvement: 2.5 
MID for MyPOS total score, deterioration: 4.5 
Non-significant AUC for Healthcare support 
C2) Determining the MID via the 
distribution-based approach 
+ Larger MIDs for total MyPOS score (8.4) and 
subscale scores (0.8 to 6.2). 
Objective d) Acceptability   
D1) Exploring the acceptability 
of the MyPOS. 
+/– 46% MyPOS feasible tool for monitoring 
23.9% concerns regarding acceptability, due to 
duplicate measurement (patients in clinical 
trials) or symptom monitoring through clinical 
team. 
 
However, the redundant items that were detected by response-residual analysis represent possible 
targets for revision. These redundancies mainly concern items in the emotional response and the 
healthcare support subscales. Some, like the high correlation between the item “depression” and 
“feeling at peace” are known in the literature and, in fact, both items have been evaluated for their 
ability to diagnose depression in palliative patients (826). For some of these redundant items, 
there are clinical arguments to keep them as separate items, such as the items nausea, vomiting, 
and depression and feeling at peace. The latter, in particular, taps into a different aspect of 
spiritual well-being that is otherwise not represented by other items in the MyPOS. However, 
items about family, usual activities and the items in the healthcare support subscale could be 
possible targets for reduction. 
Items in the Healthcare Support subscale caused the most concern from a psychometric 
perspective. Despite the considerable floor effect seen in those items in the initial validation of the 
MyPOS, it was opted to keep them in the questionnaire on clinical grounds (384). However, in 
this second validation of the MyPOS, the healthcare support subscale as a whole showed 
psychometric shortcomings both in traditional and Rasch analyses (see Table 10). These items 
were among the misfitting items, showing redundancy and low reliability coefficients, possibly a 
result of the small number of items in this subscale. Satisfaction can be defined as the extent to 
which an individual’s expectation regarding the quality of healthcare and the quality of 
information provision are met (827). This definition is not substantially different to the one for 
QOL that Calman (296) provided, defining QOL as the gap between an individual’s experiences 
and expectations. In general, patient’s satisfaction is related to the extent to which general and 
condition-specific needs are met. The evaluation of satisfaction with care can be argued to be 
important and clinical relevant because of the consequences of dissatisfaction. Satisfied patients 
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have been reported to show better compliance with treatment (828), to take a more active role in 
their treatment (829) and to not change healthcare providers as much (830). 
Patient satisfaction has traditionally been assigned a centrality in patient outcomes (831). 
Donabedian (1966), in his definition of outcomes to judge the quality of healthcare (448), sees 
patient satisfaction as an outcome of equal importance to HRQOL. However, there is also the 
opposite view that HRQOL is distinct from satisfaction. Patient satisfaction is regarded an 
experience measure since it is not only influenced by preceding healthcare but much more 
affected by personality, socioeconomic background and immutable characteristics of the 
individual (832). It is thus not considered to be an outcome measure. However, depending on the 
definition of QOL that guides the development of a measure, these seemingly more distal aspects 
can be nonetheless regarded as influencing QOL, as is the case in the model by Wilson & Cleary 
(330). In this model, characteristics of both the individual and the environment simultaneously 
influence biological and physiologic variables and, through a causal chain linking these elements 
to symptom status, functional status, general health perceptions, affect overall quality of life 
(833). We extended this model in our qualitative work by showing that factors of environment 
and the individual not only influenced the first point in the causal chain, but also influenced every 
single component forming HRQOL, therefore acting as a lens (357). A link between satisfaction 
and HRQOL has also been shown in SCT survivors (833). The authors reported a high and 
unexpected level of HRQOL in these survivors, despite ongoing physical and psychosocial 
morbidities, a result that was echoed in both the cross-sectional and longitudinal parts of this 
research. These patients have also reported higher levels of satisfaction with medical care (834) 
and it was hypothesised that this high level of satisfaction and the reported high level of QOL can 
be explained by a common mechanism of these patients being more accepting of residual effects 
which leads to response shift (299). Thus, from a theoretical perspective, there are arguments both 
for keeping or removing these items from the MyPOS. 
The main problem observed in the items of the Healthcare Support subscale of the MyPOS, their 
unreliability (835-837) and the high undifferentiated levels of satisfaction, are problems often 
described since the introduction of patient satisfaction surveys into healthcare (838,839). A meta-
analysis in 1990 reported a level of satisfaction as high as 80% (840). This led to a general 
critique of satisfaction surveys regarding their lack of theoretical underpinning and the poor 
methodology behind their measurement (838,841). Interestingly, several qualitative studies have 
shed light on the finding of high satisfaction, providing explanations beyond those of an 
acquiescence response bias in respondents (842). Expressions of satisfaction can also indicate 
negative experiences and perceptions (556,843), as for some participants, being satisfied with 
healthcare meant health care being seen as ‘adequate or average’ and not meaning that certain 
aspects could not be improved (556). In contrast, being very satisfied with a service meant that the 
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service was outstanding and better than average (556). This suggests a continuum from satisfied 
to very satisfied, a fact that is not captured at all in the response levels on the MyPOS. The Rasch 
analysis in our validation work also suggested such an extension of the upper level of the scale 
because of a non-matching level of satisfaction in participants and the level of discrimination in 
measurement that the scale allows for each satisfaction item. Of course, the second explanation of 
those participants in the study representing a biased sample towards those that are satisfied could 
also be a possible reason for the floor effect observed in this validation. Williams et al. (1998) 
(843) explained high levels of satisfaction with a perception of culpability. Ferrell (1992) (834) 
reported feelings of indebtedness to their clinical teams in SCT survivors, leading to more 
apparently satisfied patients taking part in this research. 
Overall, there are arguments both for removing and keeping this subscale. As shown above, these 
arguments centre around clinical reasons, arguing that dissatisfaction with quality of care is 
important information (311) and that population-based or routine usage of questionnaires might 
attenuate the acquiescence response bias inherent in research using convenience samples. On the 
other hand, these items have repeatedly shown poor psychometric properties and do not satisfy the 
agreed standards for quality of outcome measures (640). For example, items tapping the domain 
of treatment satisfaction or relationship with the physician were removed from the initial versions 
of both the FACT questionnaire, leading to its four-domain core version, the FACT-G (844), and 
the EORTC QLQ-MY20, previously containing four satisfaction items (310). Since its extension 
in the number of items, the MyPOS is a comparably long instrument, although it is still a shorter 
measure than the EORTC QLQ-MY20 (which is combined with the core module, the C-30 (310)) 
and only a few items longer than the MDASI-MM (690) (see Table 9). Nonetheless, shortening 
the MyPOS would aid its clinical utility. Regarding the removal of the healthcare support 
subscale, the loss of information could possibly be compensated by keeping items on information 
provision and having enough information about the future (items 28 and 33), depression and 
anxiety (items 14 and 16). Appropriate information provision has been linked to satisfaction and a 
higher sense of control and coping and overall better HRQOL (845). Dissatisfaction, contrarily, is 
associated with higher levels of anxiety and depression (846,847). The relationship between 
anxiety/depression can be bidirectional, with inadequate information provision either making 
cancer patients more anxious or depressed or depression and anxiety in cancer patients hindering 
active information seeking or perception of such information (848-850). Dissatisfaction with 
information provision might be caused by misunderstandings regarding information needs on the 
side of the haematologist or time constraints leading to unanswered questions (851,852). All of 
these aspects could possibly be indicated by low levels of satisfaction with information in the 
MyPOS.   
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As a last point in the discussion of the MyPOS, a comparison to another generic palliative care 
measure, the EORTC QLQ-C15-PAL, is warranted because of the similarities between the 
measures (853). Both the MyPOS and the QLQ-C15-PAL have been developed from already 
existing scales, with similar aims (to provide short measures for the more seriously ill population) 
and both using new psychometric methods to do so (395,853-855). However, shortening the 
QLQ-C30 to its variant for palliative care has resulted in obliterating the social function, cognitive 
function, role function and financial difficulties scales plus the diarrhoea item (853). These are all 
aspects shown to be of particular importance in our qualitative work and the cognitive interviews 
(357,384). Also, the MyPOS aims towards measuring HRQOL in the whole spectrum of myeloma 
patients ranging from newly diagnosed to patients with advanced and refractory disease. The 
focus of the QLQ-C15-PAL lies on application in the palliative care setting. However, its 
advantages include a higher infrastructure around the EORTC measures, involving extensive 
validation data (858-861), availability of data for norm comparison (711-715), translation and 
cultural adaptation work (854,862), provision of MIDs and interpretation of cores 
(368,382,383,863-865), and the recent development of guidelines for the clinical use of their 
instruments (401). When considering the applicability of a measure, these aspects aiding its use in 
routine clinical practice need to be taken into account. However, the MyPOS offers items that are 
applicable in the spectrum of myeloma disease and can be used for longitudinal monitoring, as 
shown in this psychometric analysis (the validity of the minimal important difference that was 
derived in this study has been presented in chapter 7 and will be further discussed in section 
8.3.3.) The Rasch analysis allowed the identification of items most suitable for such a purpose. 
Together with the results from the regression analyses, a model of monitoring in multiple 
myeloma involving PRO parameters can be built. 
 
8.1.4 Integration: Symptom burden, longitudinal changes of QOL and self-
monitoring of quality of life in multiple myeloma   
Figure 12 presents an overview of the PhD project and shows how the different sub-studies 
interlink and integrate to help understand who within the multiple myeloma population is 
experiencing poor quality of life and how these individuals can be identified using individual 
patient-monitoring and assessment. Describing and understanding the trajectories of health-related 
quality of life and symptoms in multiple myeloma was accompanied by building a model of 
predictors in several stages. First, systematic literature reviews served to identify potential 
explanatory variables and their respective strength of association with the outcome HRQOL were 
analysed in a meta-analysis. The secondary analysis of a large cross-sectional dataset served to 
build the first regression models and identifying those variables that explain enough variance in 
the final model to warrant inclusion. This model was subsequently validated, albeit with the 
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different outcome variable of membership in the class of poor/deteriorating QOL trajectory and 
thus combining information from the course of QOL in myeloma with information on risk factors 
for deterioration. This was complemented by identifying items from a psychometric point of view 
that are best suited for use in longitudinal monitoring. This analysis tried to answer the same 
question, but used a measurement quality approach to help identify targets for monitoring in 
myeloma. 
Figure 12: Overview of the PhD research study and integration of findings from different sub-studies 
 
When looking at the combined results of the meta-analysis, the cross-sectional study and the 
measurement and predictive models from the longitudinal study, it is apparent that those variables 
that emerged as targets for monitoring in multiple myeloma are very similar to the ones proposed 
as influencing QOL most strongly in Osborne and co-authors’ model of quality of life (357). 
Their theoretical model sought to represent relationships between clinical, functioning, 
psychological and health service variables and used Wilson and Cleary’s theory of QOL (330) to 
posit causal relationships between the different domains. The model was derived from patient 
interviews and focus groups. It is argued that the influence of biological and clinical factors on 
QOL is less strong than from aspects more proximal to QOL. Even symptoms are seen to not 
directly influence the outcome, but via a mediated pathway of affecting aspects of functioning 
(330). This signifies that changes in emotional status, functioning and sometimes symptoms can 
lead to direct changes in QOL, whereas biological status and treatment factors do not exhibit this 
direct influence. This relationship was certainly found in this PhD study, both in the cross-
sectional data and the longitudinal analysis. It was demonstrated that accumulated symptom 
burden, mental health and performance status variables indicate who experienced a deterioration 
or poor QOL trajectory. The psychometric analysis also identified emotional functioning and 
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coping items as good items for monitoring, thus pointing towards the role of illness adaptation on 
outcomes. This is contrary to other models (358) that postulate a preponderance of disease- and 
treatment-related variables on quality of life in myeloma. This study, however, has shown that 
monitoring should involve patient-reported outcomes since these are more sensitive to capturing 
deterioration in patient’s HRQOL than are biological factors. 
The model of predictors and monitoring variables has several further applications. Previous 
research has highlighted the need for guidelines for HRQOL measurement in MM (359). This 
model could inform the development of such guidelines for screening and monitoring. It could 
also be used to identify targets for early intervention, particularly the early integration of palliative 
care into myeloma care. These aspects are discussed in the sections 8.4 and 8.5, after highlighting 
methodological limitations and contributions of this work. 
 
8.2 Strengths and limitations of the study  
8.2.1 Strengths and limitations relating to the secondary analysis  
Secondary analysis of quantitative datasets is a well-established methodology, yielding many 
benefits but also having implications for the type of analyses possible. My analysis was limited by 
the measures used to collect the data and the limited demographic and clinical data, particularly 
on biomedical variables such as haemoglobin, albumin, CRP and beta2-microglobulin. However, 
the dataset for combination with baseline data from the longitudinal survey that was used for the 
cross-sectional analysis originated from the initial validation study of the MyPOS (384), and 
extensive biomedical variables were not important to collect for that purpose. These 
characteristics, as well as variables acting as mediating factors, as shown in the model of QOL in 
multiple myeloma (see section 2.2.1), would have enabled me to explore the data with more 
sophistication, taking more explanatory and confounding factors into account. This might be one 
of the reasons that the regression analysis on the cross-sectional dataset only yielded an adjusted 
R2 of 51.4% for the dependent variables global QOL (EORTC QLQ-C30). Adding these aspects 
would have allowed an analysis of how psycho-spiritual factors and coping mediated the impact 
of biological factors and symptoms on QOL, thus validating the model empirically. 
The secondary analysis used to build the initial model of predictors was cross-sectional in nature. 
This might explain the differences seen between the two regression analyses in the size and 
importance of explanatory variables and their regression coefficients. However, combining the 
two datasets for building an initial model of independent predictors yielded a much higher sample 
size, thereby circumventing problems regarding power of analysis. Secondary analysis of datasets 
always needs to bridge the gap between being confined regarding variables included in the 
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dataset, since the data was collected for a different purpose, and – under economic and resource 
perspectives - lifting the full potential of a dataset (551,561). 
A major drawback of the statistical analysis of independently associated factors, both in the 
secondary analysis dataset and the longitudinal model, was the multicollinearity of the factors. 
Multicollinearity describes the fact that two or more independent variables are highly correlated 
(which can be the case with PROs), thus leading to incorrect model selection and making it 
difficult to disentangle the influence of a single variable (866,867). Further testing the stability of 
the final multivariable model is highly recommended, but this was beyond the scope of this thesis. 
An approach of controlling multi-collinearity statistically has been followed by one study within 
cancer QOL research (16,868). A bootstrap model accounting for multicollinearity among several 
PRO predictor variables was subsequently successfully validated in several studies with solid 
cancer patients. 
 
8.2.2 Strengths and limitations relating to the longitudinal study of changes of QOL 
Piloting was done on a small number of patients that were not purposefully sampled. The sample 
size was below the recommended target of 10 patients (869). This might have biased views 
towards higher acceptability of methods used for monitoring than normally present in the 
myeloma population. Some of the issues that were raised in the pilot interviews questioned the 
content validity of the MyPOS and scaling issue. So, while most of the relevant quality of life 
issues were included in this measure, some symptoms were reported as missing. Participants also 
commented on the scaling of the MyPOS symptom items and pointed towards some redundancy 
between the MyPOS, the EORTC QLQ-MY20 and the Hospital Anxiety and Depression Scale. 
However, since these measures were included based on hypotheses regarding the mediating nature 
of anxiety and depression and with the aim to cover potential aspects and influencing factors on 
HRQOL in the broadest possible way, the suite of measures was not further reduced for the 
longitudinal study.  
Participants in the small pilot study also pointed towards problems with recall and time frames in 
the included measures, acknowledging the fluctuation in symptoms and problems depending on 
chemotherapy and maintenance treatment cycles. The time frame was not altered in keeping with 
the time frames used in the initial validation of the MyPOS. Validation of this aspect was not 
within the merit of this study, but it is certainly an area that needs to be explored. Guidance on 
this issue of time frames and recall periods is rare (583,870-872). Ideally, piloting should involve 
a sufficient number of patients and caregivers. Caregivers were not included in the pilot study. 
The longitudinal study was designed such to include information on caregiver burden and the 
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caregiver’s perception of the patient’s health status only every four months. This time interval 
between measurement points was chosen to minimise burden. However, I did not know whether it 
was adequate for capturing changes in the patient’s and caregiver’s condition. A pilot study can 
test whether the planned data collection strategies will work and whether methods of recruitment 
result in acceptable consent rates as well as determining the acceptability and selection of the 
most appropriate measures (819,869). This pilot work did not fulfil all of these objectives, mainly 
due to time constraints. More extensive piloting could have helped design the accompanying 
caregiver survey in a different way, so that data collection on those participants ceasing to send 
questionnaires would have been possible. 
For the longitudinal survey, inclusion criteria were very broad, thus resulting in a potentially 
wider and more representative sample of patients to be included, but also biasing the sample 
towards those patients not suffering from neutropenia. The sample was also biased towards the 
more stable phases of multiple myeloma since we mainly recruited patients from outpatient 
clinics. Hospices and other inpatient palliative care facilities were not included in the sampling 
frame. An alternative would have been to stratify the sample and require a number of patients in 
each disease severity/phase stratum. This would have resulted in a more balanced sample and 
allowed the study of mortality. The second possibility would have been to stratify by performance 
status. However, this would have necessitated including some measure of activities of daily 
living, such as the Barthel Index (873). In the end it was decided to not include stratification 
criteria for eligibility to arrive at as natural a sample as possible.  
A further limitation in this study is the lack of information on the characteristics of non-
participants, patients who were invited to take part in the study but refused. In addition, the 
denominator population is not known. Describing the study population and the denominator 
population are essential elements in the study design to judge the representativeness (external 
validity) and the amount of selection bias likely to have occurred (874,875). Selection bias first 
occurs when those that take part in a study show different characteristics than those that refused, 
as likely happened in this longitudinal study which oversampled patients in the stable phases of 
disease at the end of treatment or post stem cell transplantation. A qualitative study suggested that 
the feature of a sample biased towards stable phases might be a result of cancer patient’s 
willingness to take part in longitudinal research which is highest after initial diagnosis and 
treatment when patients are emotionally coping and are not experiencing significant physical side 
effects of the treatment (586). A second selection bias is introduced through gatekeeping of 
clinical staff members that performed the screening in the participating centres (876-878). We 
provided extensive training and standard operating procedures before the start of the study to all 
study site personnel and in particular to those research nurses identifying and approaching patients 
for inclusion in the study. However, gatekeeping is still likely to have occurred as evidenced by 
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the sample biased towards patients not overly distressed by symptoms and psychological 
problems. Another bias is apparent in the slightly lower mean age that was observed in this study. 
The mean age of participants was 68.5 years, whereas the mean age of diagnosis is 73 for the UK 
(55). This lack of older patients has been described as a problem in clinical trials of 
haematological disease patients (145) and other conditions (147,148). However, the mean age in 
this study is higher than the mean age reported in clinical trials of myeloma. Overall, selection 
bias has occurred, but the comparably older sample included in this longitudinal research and the 
high proportion of comorbid disease in our sample supports the population perspective (145,230).  
Ideally, results should be set in relation to the total population served in the recruitment sites. 
There are two ways to overcome the problem of not having information on the denominator 
population. We could have asked the research staff at each site to record details of all patients 
potentially eligible. Since this is a time-consuming process, alternatively we could have collected 
minimal demographic patient data from those patients that refused to participate. However, the 
ethics committee did not allow such data collection from non-participants. Another way to reduce 
and understand the problem of selection bias is to obtain information on the characteristics of the 
denominator population by performing an audit of all recruiting sites. This approach was hindered 
by the fact that in some hospitals demographic and clinical information from the patient records 
was not available in electronic format. For this study, to indirectly judge the amount of selection 
bias, we compared the demographic and clinical information to other population studies in the 
literature (90,381,593).  
Recruitment into this study, contrary to anticipation and experiences in the field of palliative care, 
was surprisingly fast and satisfactory. This was possible by using the support of research nurses 
and research personnel at each site through the infrastructure provided by the National Institute of 
Health Research who has created National Cancer Research Networks to aid clinical research 
within the NHS (488). Although setting up the longitudinal survey as a portfolio study resulted in 
a large sample to be recruited, the bias in participating centres towards tertiary care shows that the 
population from which the sample was drawn does not represent the population of all multiple 
myeloma patients in the UK. Particularly community hospitals and hospices are underrepresented. 
Although the multi-site recruitment helped accrue a large sample of patients that partly 
counteracted the influence of attrition on the findings, there are concerns about differences in care 
delivery at the participating sites. While analysing the treatment information, for instance, it 
became apparent that choice of second- and third-line treatments was centre-dependent and 
largely driven by participation of these centres in clinical trials. This variation between centres 
was also observed regarding supportive therapies that patients received, ultimately introducing a 
bias and influencing outcomes between sites (517). 
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Caution is required when interpreting the estimates from the regression analysis, owing to the risk 
of a biased sample. Although care was taken to consecutively recruit patients in the services, in 
practice those physically better or easier to approach may have been oversampled. There is also 
some survivorship bias (719) with those patients that have a higher number of QOL-related 
problems being more likely to drop out of the study. Attrition from the study was moderate with a 
final 52.5% of those initially recruited returning the last set of questionnaires eight months after 
beginning the study. This attrition rate is below the one observed in many longitudinal studies in 
palliative care patients (574,878,879) and also comparable to attrition observed in the most recent 
clinical trials in multiple myeloma (365,374). Delforge et al. (2012) (365) and Dimopoulos et al. 
(2014) (374) reported a slightly higher retention rate of 62%, respectively, but their follow-up was 
determined by the duration of cycles of chemotherapy treatment that was trialed in these studies. 
Tang & McCorkle (2002) (583) reviewed published QOL studies and noted attrition rates ranging 
from 27 to 91.4% with an average of 53.6% drop-outs within an average duration of a study of 
45.7 days. This rate is comparable to the attrition rate that was observed in our study over a period 
of 240 days. Attrition due to death was not observed as often as anticipated when planning the 
study. The main reasons for attrition were questionnaire fatigue and deterioration of the patient, 
either due to multiple myeloma or due to other comorbid conditions. For a substantial number of 
withdrawn participants, information on the reasons for withdrawal was not available, despite 
telephone follow-up. Thus, the small numbers in the trajectory class of poor and deteriorating 
QOL patients can be attributed to losing patients with worsening HRQOL to follow-up and 
estimates of change as well as regression coefficients are less stable due to the small sample size 
in this group (323). 
To counteract attrition, I used a number of strategies recommended to promote retention of 
participants in the study (877). Mechanisms such as personalisation of letters and study 
communication, thoughtful messaging to make research more relevant, telephone calls and 
telephone reminders when sending out questionnaires and when questionnaires were not returned, 
re-sending questionnaires when participants failed to return them and use of incentives with each 
questionnaire were built into the study to maximise response rates. The method of data collection 
influences the type of sample that can feasibly be recruited and the characteristics of recruited 
participants. Postal questionnaires were chosen for reasons of resources, practicability and to 
obtain data from a multi-site, national sample. The alternative use of face-to-face interviews or 
interviews over the telephone would have ensured a more personal relationship between 
participants and researcher, would have resulted in more timely completion of questionnaires and 
higher completeness of data and might have made it easier to recruit and retain participants for 
whom English is not the primary language (878,880). Nevertheless, these methods are no 
guarantee for higher response and retention rates and increase resources and cost considerably for 
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a longitudinal study of over 200 participants (530,881). Also, although they have proven to be 
successful in some palliative care studies, they are no recipe for avoiding attrition (878). Views of 
patients regarding the time point of being approached, the mode of data collection and method of 
follow-up are mixed, and there are no consistent preferences that ensure good participation. For 
example, Shipman and co-authors (2008) (585) concluded that face-to-face interviews are 
preferred over postal data collection, whereas Sherman et al. (2005) (878) and Riopelle et al. 
(2011) (880) concluded the feasibility of telephone follow-up. Postal surveys have been 
successfully applied in longitudinal studies within palliative care (587,882,883) and, lately, in 
registry-based longitudinal monitoring of cancer patients (381,586). In this study, the mode of 
data collection did not result in an overly large attrition rate and can therefore be recommended 
for future studies.  
Another aspect that reduced the validity of the findings and their generalisability was the issue of 
missing data (583). Missing data reduces the number of patients available for analysis and 
particularly challenge the multivariate analysis of the data, as many of these techniques assume 
complete data and univariate and multivariate normality (884,885). Missing data can occur at the 
institutional level, at the individual patient level and at the individual questionnaire level (886). 
The first two parts have been discussed above, handling of missing data from missing forms and 
missing items will be discussed next. In general, in longitudinal studies and particularly in those 
in palliative care research, it is impossible to avoid missing data (887). Moinpour (1997) observed 
that this most compelling setting for QOL research guarantees missing data (888). Hence, the 
Morecare statement (542) recommended to assume high rates of attrition and missingness in any 
palliative care data set and to classify reasons for attrition accordingly (ADD – due to death, ADI- 
due to illness, AaR – at random). The present study was characterised mainly by the types ADI 
and AaR. This means that a proportion of missing data at follow-up was most likely missing not 
at random (MNAR) (320), as missing values depended on current or future values. The missing 
data in this study thus represents non-ignorable missing data.  
Strategies to reduce missing data were largely successful and overall level of missing data was 
low. Missing data was of the non-response type (889,890), i.e. singe items missing. Following 
recommendation from Hopwood et al. (1994) (891), we tabulated the amount of missing data for 
each MyPOS item at each time point to graphically portray the size of the problem. Further, we 
used several imputation methods for missing data in a sensitivity analysis which entailed simple 
imputation methods (last observation carried forward and median/mean imputation) and multiple 
imputation. Simple imputation methods have been criticised in the literature for yielding 
unreliable results. It has been argued that imputation yields a decrease in variability of that 
particular variable (892). Instead, multiple imputation and Markov Chain models are 
recommended (610,888,893-898). With the multiple imputation method, varied values are 
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calculated for a missing value with the sets of imputations repeatedly drawn under one model for 
missingness and resulting in a combined summary statistic (892). However, even those methods 
have been criticised for producing invalid results in the presence of missing data not at random 
(MNAR). The sensitivity analysis yielded similar results with different imputation techniques and 
the complete case analysis. Three studies of HRQOL in palliative care affirm this finding. In the 
studies by Ahlner-Elmquvist et al. (2009) (899), Petersen et al. (2009) (900) and Riopelle et al. 
(2011) (880), non-response did not lead to the underestimation of symptomatology or 
overestimation of QOL/well-being and different imputation techniques did not result in 
substantial changes to the results of these studies. Nevertheless, problems with validity and non-
ignorable missing data can affect particularly those parts of the sample with more advanced 
disease. Mor (1986) (901) reported that non-responders in a study of pain and mood states were 
consistently sicker and more likely to suffer from severe symptoms. Likewise, Hopwood et al. 
(1994) (899,891) showed that for lung cancer patients, clinician’s assessment of functional status 
was a predictor for dropout, with only 31% of those with poor functional status finishing the 
study. Twisk (2002) (892) has demonstrated that in a longitudinal situation, using more refined 
multiple imputation methods did not result in different point estimates than the single imputation 
methods. Rather, the author recommends using generalised linear models for accounting for 
missing data in the analysis or alternative approaches for non-linear data (GEE, generalised 
estimating equation models) that should be tried in a further analysis of the dataset. 
Another area of concern is the timing of data collection in this study. Data collection took place 
bi-monthly to capture changes, but balancing frequent assessments with participant burden was 
also important to keep participants in the study. Monthly intervals, although in many respect 
preferable for assessment of more short-term changes associated with treatment side effects and 
fluctuant symptoms, would have probably obtained smaller changes and data on adaptation 
processes in patients. In addition, the follow-up period of eight months was not long enough to 
study long-term adverse effects or long-term changes in patients’ coping mechanisms. The 
follow-up period was much shorter than in some prospective observational research in SCT 
samples (31,34,35,378,734,902) that followed participants one year to three years. However, since 
more measurement time points were captured within the eight months, this study provides more 
information on changes in QOL than other observational research in myeloma (381). 
Longitudinal research needs to have three elements to be successful: a theoretical model of 
change, together with a temporal design and a statistical model that represents or operationalises 
the theoretical model of change (590). Ideally, the model of change includes a comprehensive 
statement about the nature of the change phenomenon and the shape of change (linear, quadratic, 
other forms), as well as the periodicity and/or cyclical nature. The temporal design (timing, 
frequency, spacing of observations) is one of the components of a longitudinal design that can 
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have the largest impact on the results (591). While this importance of timing assessments has been 
stated repeatedly in the literature, its empirical study has not received much attention. Only two 
studies could be found focusing on the issue of timing QOL assessment (903,904). Due to lack of 
data on QOL and symptom trajectories in multiple myeloma, the definitions of a model of change 
in advance was not possible. The lack of certain QOL problems might be due not only to the 
oversampling of stable patients but also to the mismatch between timing of assessment and recall 
period of questions with the cyclical nature of patients’ treatment-related side effects. The choice 
of measurement interval can be a determinant for whether an effect is large enough to be detected 
(591). 
Some authors have defined theoretical models that differentiate cancer-related symptoms, acute 
side effects, chronic side effects and symptoms not related to cancer in their periodicity (871). 
These models state that the typical side effects in chemotherapy are cyclical in nature, but 
depending on the treatment, a continuous low level of acute side effects during the treatment cycle 
is also possible. Added to this are chronic side effects, side effects with a constant or slowly 
progressing severity, like peripheral neuropathy in multiple myeloma. The model could explain 
some of the low prevalence rates seen in the data of this study or could explain the lack of 
problems, i.e. change in mastery of illness, since these aspects of HRQOL might be more trait-like 
and prone to more stability, necessitating longer assessment periods (833). Klee (2000) (871), 
together with other authors (870,872,905), postulates different time frames to capture these 
cyclical symptoms and side effects. In this study, longer assessment periods would have been 
possible during the stable phases, switching to shorter intervals to obtain information on change in 
patients with advanced disease or approaching death. Alternative ways of capturing data could 
have helped with this issue. Online or electronic versions of questionnaires have shown to benefit 
compliance and recall, also allowing more dynamic assessment of PROs (636,906-910). Online 
platforms have been successfully used to measure chemotherapy-related side effects (911-914). 
Electronic data collection was suggested by some participants in the qualitative part of the 
longitudinal survey. However, using this more dynamic approach to the study of change was not 
possible in this study, mostly due to logistics. Also, participants in the pilot study argued against 
changing time frames, preferring fixed intervals so that they could anticipate the next 
questionnaire and arguing that changes occurred across longer periods, saying that monthly data 
collection would place too great a burden on respondents and not allowing them to experience a 
sense of normalcy in between. In this study, I tried to ensure a sufficient number of assessment, 
but the bi-monthly data collection means that sensitivity to change was partly lost. Also, recall 
bias might have occurred since any response process relying on cognitive processing and 
retrospective estimates is less reliable (915).  
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Similar to the cross-sectional secondary analysis, some explanatory variables are missing from the 
regression model in the longitudinal study. Next to biological factors, more information on 
treatment variables would have helped to determine if QOL changes noted were secondary to 
these treatments. The lack of physiological measures as independent variables is a drawback and 
makes it difficult to compare this research to other studies in multiple myeloma. However, as 
already mentioned in section 8.2.1, this data was not available in a reliable and valid format in all 
participating sites. For example, it was not possible to obtain ISS staging for all patients in the 
study, due to lack of data on beta2-microglobulin and albumin. Treatment data would have helped 
to understand the pattern of acute and chronic side effects of treatment, but there was not enough 
homogeneity in the treatment population to do this. The inclusion of functional assessments in the 
repeated data collection would have helped to understand changes in HRQOL. The assessment of 
the ECOG performance status has been included only at baseline and not in follow-up. 
Assessments over the phone during reminder phone calls could have been used to obtain such 
data. Alternatively, indices of activities of daily living or the Karnofsky performance status could 
have been included in the informal caregivers’ assessment which would have provided this 
information for at least part of the sample.  
The analysis of trajectories, despite using a novel technique for explaining the heterogeneity that 
mean trajectory analysis cannot represent, can be critiqued for not modelling change in predictors. 
Independent variables in the regression analysis did not represent this temporal perspective as 
variables were taken at baseline but time-varying variables were not included. Furthermore, since 
prospective QOL information was used mainly for classification of participants into classes of 
QOL changes, rather than including QOL as a time-varying dependent variables as is possible in 
general linear models, the analysis did not model predictors of change in QOL.  
Part of the wider project was the inclusion of caregivers to collect longitudinal data on change of 
their quality of life, their views on the quality of life and situation of their partner or parent (by 
collecting the proxy version of the POS), and caregiver burden. This data was meant to serve as a 
proxy for deteriorating patients, to allow data collection for those that became too sick or 
burdened to take part. However, caregivers often stopped returning questionnaires when patients 
withdrew from the study. Therefore it was not possible to use the caregiver data to inform 
imputation of missing data in this study. The analysis of the caregiver data is beyond the scope of 
this thesis but will be analysed and integrated with the results from the longitudinal survey in a 
future publication. 
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8.2.3 Strengths and limitations relating to the psychometric assessment of 
longitudinal validity and reliability 
The selection bias already described in the previous section also affected the validation of the 
MyPOS questionnaire. It is unlikely that participants who find questionnaires difficult and 
unwelcome have taken part in this study. The acquiescence bias manifested itself in the floor 
effect that was observed in satisfaction items. The nature of the recruitment process through 
research nurses working in the recruiting sites and having a long relationship with patients, 
particularly given the fact that many patients with multiple myeloma can only receive treatment in 
the UK by participating in clinical trials of new chemotherapeutical agents (i.e. pomalidomide) 
(82), and potential gatekeeping by healthcare professionals makes it unlikely that dissatisfied 
patients were included in the survey. The MyPOS is intended as a questionnaire for routine 
collection of HRQOL in clinical practice. The validity of these questions needs to be studied in a 
consecutive, routine sample that is free from this bias. 
Longitudinal validity and responsiveness assessment either follow an anchor-based or 
distribution-based approach (916). As anchors, transition ratings, usually regarding the global 
health or QOL status of the individual, are used. The quality of the anchor, since it is used in a 
diagnostic approach and a receiver-operating characteristic curve analysis, is determining the 
quality of the minimal important difference (MID) analysis. As an external criterion it should 
ideally be free from measurement error (672). However, the amount of misclassification that was 
seen in Table 5 in chapter 7, ranging from 56.7% in the Symptoms subscale to 94.2% in the 
Healthcare Support subscale, points towards the global rating of change (GRC) not being free 
from measurement error. This means that the GRC does not represent a true gold standard and 
that measurement error is present when classifying patients into groups of importantly improved 
and importantly deteriorated change (1207). In such situations, it is possible to construct 
confidence intervals and the area under the curve within ROC analysis using bootstrap 
(1208,1209) or Bayesian Markov-Chain models (1209). However, these approaches have not been 
employed within anchor-based responsiveness analysis and are not currently recommended 
(672,1210). 
The anchor that was used in this study only measured change on three levels – improved, stable or 
deteriorated. In comparison to the global transition ratings used by Osoba (1998) (368,865) with 
five to seven categories, the anchor in this study most likely lacked sensitivity and discriminatory 
power. The MID depends on the definition of important change, which in itself is operationalised 
in the number and labels on the GRC (672). In the Deyo and Centor method (478) that was 
followed here, the change score on the MyPOS is compared, dividing the population into persons 
who are minimally importantly changed and those who are not. In studies following this method, 
different definitions of minimal importance in the anchor have been proposed as either “a little 
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worse/better” (676,677,1211) to “moderate improvement” (1212) or even “much worse/better” 
(1213,1214). To date, little research has focused on the amount of “importance” in the change 
(672,1215). De Vet and other authors (323,687,1216) –rather than considering a slight 
improvement to be the minimally important change – have proposed to use only “much 
improved” patients as the anchor for change. The greater the number of levels on the anchor and 
the smaller the difference between adjacent levels, the smaller the MID will be with the inherent 
risk of not exceeding the random measurement error (1217). Because of these reasons, the GRC in 
this study consisted of only three levels – improved, no change or deteriorated. This was thought 
to help with obtaining clear ratings of change from the individual patient. However, in following a 
crude approach the analysis forewent capturing the granularity of change and allowing sub-
analyses of small changes versus moderate to large changes. Future responsiveness analyses need 
to explore the optimal number of response levels on the GRC and use cognitive interviewing 
techniques to understand the standard that is used by patients to make comparisons in their quality 
of life over time on these anchors. 
In general, the transition question did not match the concept of multi-dimensional QOL as 
measured in the MyPOS. It asked for a global assessment of whether the overall quality of life 
had changed since the participant first completed the questionnaire. Therefore, the anchor might 
also be subject to recall bias and response shift (726,917-919) since it asked for a comparison to 
the baseline assessment instead of the previous assessment. The global rating scale of change 
asked about change in the same multidimensional construct that the MyPOS is measuring (672). 
Since its adaptation to the general IPOS format, the MyPOS presents items on disease-related 
quality of life, but also contains items regarding palliative care concerns. It cannot be determined 
whether the global rating of change asking about the change in quality of life is interpreted by 
patients in such a way that change in the same construct that the MyPOS is measuring is assessed. 
This hampers the analysis of responsiveness since anchor-based approaches using ROC analysis 
rely on the validitiy and reliability of the anchor chosen. This is a well-described limitation in the 
literature (672,1218).  
The original transition rating designed by Osoba for assessing responsiveness of the EORTC 
QLQ-C30 (865,869) involved the Subjective Significance Questionnaire. This was developed not 
as patient self-report, but to be conducted as an interview. This approach, although followed by 
Kvam et al. (2010a,b, 2011) (368,382,383) when determining the MIDs for the EORTC QLQ-
C30 and EQ-5D, would have been too time-consuming and resource-intensive. To aid the analysis 
of responsiveness different anchors could have been explored. Also, it would have been possible 
to obtain clinician ratings of change for triangulation with patients’ ratings. Suitable alternative 
anchors include (920): status on a measure of function, physical examination, change in disease 
severity, response to treatment, and health care utilization. In comparison to the use of a global 
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rating of change as an anchor, these anchors have the drawback of not representing direct ratings 
of important change from the patient’s perspective. However, the patient’s viewpoint is what 
PROs attempt to express and capture.  
It was also not possible to derive an MID for individual symptoms and to test the prognostic 
significance of cut-off scores for individual symptoms on the MyPOS. To address some of the 
limitations regarding the anchor-based approach (672), we have followed the approach to test the 
validity of the anchor by examining correlations between global ratings and baseline and post-
baseline QOL as measured on the MyPOS, as recommended by de Vet and co-authors (2011) 
(478). Spearman’s Rho of the GRC with the changes in the total MyPOS and subscale scores 
ranged from 0.23 (Symptom subscale) to 0.59 (Emotional response subscale) at baseline and from 
0.26 (Symptoms and Emotional Response) to 0.41 (Total MyPOS score) at follow-up. These 
moderate correlation coefficients point towards a statistically significant correlation between the 
GRC rating and the score changes, which is deemed necessary to accept the validity of the rating 
score (682,1216,1219). However, some of these correlations between the global rating scale and 
subscales of the MyPOS also highlight that the phrasing of the GRC might have precluded this 
scale to validly assess change in aspects such as symptoms and some functioning aspects in 
patients.  
Distribution-based methods for obtaining MIDs were contrasted with the anchor-derived 
estimates (916). Within the latter approach, distributional characteristics of the sample express the 
observed change to a standardised metric, for example effect sizes. The disadvantage of 
distribution-based methods lies in their inability to provide an indication as to the importance of 
observed changes (916). Following Crosby et al.’s (2003) (672) recommendations, we combined 
anchor-based and distribution-based approaches and checked how well estimates from both 
approaches align. The distribution-derived MIDs are well above the anchor-based MIDs, 
highlighting the likely high misclassification when using the anchor-based MIDs in this sample. 
Finally, we also related the anchor-based MID to the standard error of measurement (SEM), thus 
checking that obtained MIDs exceeded the imprecision of the instrument (682). The SEM for the 
total MyPOS was 6.9, and 3, 5 and 1 for the subscales Symptoms, Emotional Response and 
Healthcare Support, respectively. The estimated MIDs for the MyPOS do not exceed the SEM for 
the total score or the subscales. Therefore, MID estimates are likely biased and should be 
determined with an alternative anchor or GRC scale in the future.  
In the Rasch analysis, it would have been beneficial to do more extensive testing of the 
unidimensionality assumption of each subscale. This was partly checked by re-running the 
confirmatory factor analysis. These tests should have been supplemented with procedures 
available within the analysis (i.e. principal component analysis (663,668)). Before proceeding to 
8 Integration of findings and discussion 
290 
 
more advanced longitudinal applications, revising items with reversed thresholds in category 
probability curves, revising items showing poor fit and using differential item functioning (DIF) 
analysis to check item bias would have elucidated areas for further revision of the MyPOS. 
Although the use of the Generalizability approach for assessment of test-retest reliability 
represents a novel approach to the measurement of change in palliative care, interpretation of the 
reliability indices is difficult. Guidelines for the interpretation of the size of the derived indices, 
particularly the one for within-person change, are needed. I followed standard guidelines 
(640,921,922), but experience with these indices is lacking. The framework of Generalizability 
theory assumes frequent measurement. The approach that was followed in this analysis was 
originally developed for daily measurement of emotions via diaries. The timing of assessments in 
this study, every two months, benefitted trait-like change in HRQOL (870). It would be beneficial 
to test this framework in a situation with more frequent measurements of QOL. For reliability 
testing, only stable patients were considered that self-identified as stable in the global transition 
rating. The misclassification that might have occurred in the anchor was already mentioned above. 
All analyses of longitudinal validity and reliability were performed on non-imputed, complete 
case data. For the derivation of the MID and test-retest reliability, two analyses were performed – 
contrasting time point 5 (the last available time point) with baseline and contrasting time point 2 
with baseline. The latter comparison formed the basis for deriving the MIDs following the anchor-
based and distribution-based approach and for deriving test-retest and further reliability estimates 
according to Generalizability theory. This was necessary because of small numbers with complete 
data in time point 5, pointing towards the attrition of over 40%. It was decided to not impute 
missing data despite the complete case analysis being biased towards those participants with a 
higher quality of life and less disease-related deterioration. Despite efforts to ascertain reasons for 
withdrawing from the study, the mechanism of missing data (see classification and discussion of 
multiple imputation methods for longitudinal data in section 8.2.2.) was not known for most of 
withdrawn participants and in the absence of further clinical data, missing data could not be 
imputed in a valid way. This highlights that longitudinal validation of the MyPOS was only 
performed  on those with better quality of life and not those more severely ill or in a later disease 
phase. 
One of the limitations of the assessment of the acceptability and utility of longitudinal monitoring 
was the limited data quality. Questions about these aspects were asked in an open-ended nature in 
the third questionnaire. Participants were provided with open questions regarding the suitability of 
the MyPOS for longitudinal monitoring, their willingness to self-complete such measures 
frequently before clinic visits and a question regarding preferences for data presentation. 
However, these questions were asked in a survey and were not explored in-depth with 
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participants. Studying these aspects in a routine care environment using qualitative interviews 
would yield richer data. This is an area for further research. 
 
8.2.4 Ethical issues 
Unusually high participation rates in bone marrow transplantation studies, as high as 86-100%, 
have often been observed (923-925). However, the myeloma population, subjected to frequent 
treatments with a high impact on QOL, represents a vulnerable population and researchers need to 
be sensitive in their approach to potential participants who may sacrifice autonomy because of a 
sense of indebtedness. To minimise coercion, the initial approach was led by research nurses at 
participating centres who were usually not a member of the participant’s primary care team at the 
hospital. 
It is recommended that in longitudinal studies continuing consent is taken from participants (926), 
seeing informed consent as an on-going process in the potentially distressing situation that 
answering questions about their well-being or lack thereof constitutes for patients (927). The issue 
of repeated consent was of lesser concern in this study since participants could choose to not 
return their questionnaire. However, continuing telephone contacts and reminder calls were of 
greater concern and I continually checked with participants that they were still willing to continue 
with the study. 
In addition, researcher intervention in the presence of high levels of symptoms or psychological 
distress was mandated by the distress protocol in this study. The distress protocol was activated 
twice during the course of the study, once because of suicidal ideation mentioned by one 
participant and another time when a patient mentioned a serious side effect from the anti-cancer 
treatment. Both cases were brought to the attention of the clinical staff caring for these patients at 
the participating sites immediately. However, since data was collected in a postal way on 
standardised forms with not all participants taking the opportunity to qualify their status by 
making use of the additional comments field at the end of each questionnaire booklet, some 
instances of distress could have been missed. All the participants in the study were under regular 
follow-up in their hospitals. 
Overall, completing questionnaires containing personal questions about emotional and sexual 
well-being repeatedly every two months was not perceived as overly distressing by most 
participants. However, a few comments in the open-ended questions on the MyPOS and the 
additional comments section at the end of the questionnaire indicated that for some participants, 
completing a questionnaire about their well-being served as a reminder of their disease and 
mortality.  However, this situation is not avoidable. The ethics committee reviewing the study did 
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not voice concerns regarding this aspect. Rather, they advised to increase the sample size to allow 
for valid estimates to be obtained and not waste resources by conducting a study that is under-
powered (see Appendix A, Correspondence with the Research Ethics Committee: approval and 
amendments). 
 
8.3 Methodological contributions 
8.3.1 Recruitment and retention of participants in a longitudinal palliative care 
study 
This thesis has developed longitudinal techniques and developed successful ways of keeping 
participants engaged with the study. There is still a dearth of longitudinal population-based 
studies in haematology and in multiple myeloma specifically. Those studies that recruit a 
population-based sample either utilise cancer registries for identifying potential participants (381) 
or follow patients undergoing stem cell transplantation (29,34,35,378,496,928,929). Despite the 
sample in this study being weighted towards stable phases, one quarter to one third of participants 
experienced advanced disease, relapsed and refractory disease. I managed to keep these 
participants engaged with the study over the period of eight months, despite the fact that most of 
these participants were not recruited by myself personally and that postal surveys have a lower 
participation and retention rate than interview-based studies (880). The need for longitudinal 
studies has been recognised in palliative care research (930), but studies employing this 
methodology have traditionally reported problems with recruitment and retention of participants 
(574,931). 
In the methodological literature, recruitment/enrolment and retention as well as minimisation of 
missing data are often treated as separate entities with different strategies proposed for these 
phases of research. Strategies identified to overcome difficulties with ascertainment and 
enrolment comprise using clinical criteria and medical record review instead of physician 
prognostication, and personalised recruitment letter content from the patient’s personal physician 
with personalised brochure/information leaflet content (932). The UK National Cancer 
Survivorship Initiative commissioned a study to understand when best to approach cancer patients 
for inclusion in longitudinal monitoring of PROs (586). In this interview study with patients and 
clinicians, optimal time points for recruitment were perceived to be after initial treatment had 
finished, provided that patients were coping emotionally and were not suffering from significant 
side effects of treatment. A qualitative study to understand participation in a longitudinal postal 
cohort survey recommended providing clear information about the study and explanations of the 
likely benefits. The neutrality of the survey and its origination from a reputable source were 
further determinants of participation (933). Some randomised trials have tested different aspects 
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of survey design to enhance retention and completeness of data, among them strategies like 
shortening lengthy questionnaires (934), sending full reminder packs (934), using a different 
mode of contact for follow-up and reminder phone calls or phone interviews (935). Recent 
systematic reviews of 481 RCTs evaluating 110 different methods of increasing response rates to 
any survey found factors such as incentives, personalised letters, pre-questionnaire contact and 
reputable source (university rather than governmental or commercial organisation) being effective 
(936,937). General ways of enhancing participation and thus retention in an intervention trial in 
palliative care employed strategies such as systematic tracking and phone calls, minimising 
respondent burden and maintaining interviewer-respondent dyads over time (880). 
In this study, rather than treating enrolment, retention and minimising missing data as separate 
entities, the researcher developed an overall strategy to engage participants and keep them 
engaged with the study. Especially given the fact that recruitment was performed by the research 
nurses at the different sites, a strategy building rapport and personal relationships was thought to 
be of primary importance for the success of the study. The fact that many research nurses in the 
participating sites also worked as clinical nurse specialists meant that they already had a personal 
relationship with the patients, a fact that has helped recruitment and enrolment. The researcher 
then called each participant after receiving the first questionnaire, explaining further about the 
study and getting to know the participant. Every study communication, particularly the letters 
accompanying questionnaires and reminder packs, was personalised. The researcher kept a log 
book of phone conversations and significant events about the participant’s wellbeing and used this 
information when contacting participants. Each questionnaire that was sent to participants came 
with a pen and a little sweet, following advice from Bowling (2000) (580). Rather than giving 
monetary incentives, the sweet was perceived as a little treat and some participants even took the 
trouble of calling the researcher to request certain sweets to be sent with the next questionnaire. If 
questionnaires were returned with incomplete questions, the participant was called and asked 
about the reasons for the missing item or pages. The questionnaires in the questionnaire pack were 
preceded by instructions for completion and highlighting the importance of complete data and 
correctly completed questionnaires. If questionnaires were not returned after a reminder and a full 
questionnaire pack had been sent, the researcher or one of the research nurses contacted the 
participant by phone to ask about reasons for withdrawal from the study. Recruiting patient and 
caregiver dyads certainly helped keeping participants interested in the study. Some informal 
caregivers commented that they valued being asked their views and that they convinced their 
partners to continue with the study even if that participant felt inclined to withdraw because of 
deteriorating disease. 
The overall strategy of personal contact and keeping this contact over a period of eight months 
with each participant has likely helped to maximise and maintain follow-up. Especially the 
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methods of personalised letters, sending out letters with a hand-written greeting and signature plus 
a photograph of the study team at King’s College London, telephone contact both initially and 
after completion of questionnaires in case of missing data or potential withdrawal and sending out 
questionnaires with a pen and a sweet proved particularly successful. Although this approach to 
longitudinal monitoring is time-consuming and resource-intensive, it does help to overcome the 
barriers associated with longitudinal research in palliative care and particularly it helps remedy 
the low retention rate and high level of missing data reported in palliative care research (574,931) 
and observational haematological research (95,381). These techniques should be considered in 
future studies. Recommendations for handling missing data usually focus on statistical imputation 
methods, but rarely name strategies to minimise them at the level of data collection (938). 
Strategies to overcome missing data recommended by researchers entail using interviewer-based 
questionnaires as mode of administration (880). In this study, rather than using phone interviews, 
we used postal surveys but with a telephone follow-up call if questionnaires were returned 
incomplete. This is a practical strategy seldom used in research which could be explored further. 
 
8.3.2 Latent growth mixture models for modelling heterogeneity in palliative care  
This study made a methodological contribution to palliative care research by being the first within 
the context of longitudinal studies in advanced cancer to employ latent growth mixture modelling 
and latent class analysis to QOL data. Advanced illness is a continuing and chronic experience 
with the impact of various clinical, disease- and treatment-related factors developing over time. 
The ability to model change and explore trajectories of QOL using advanced statistical techniques 
depends on large enough datasets. Therefore, the methods developed to maximise recruitment and 
retention in this study directly helped to bring a higher sophistication to the longitudinal analysis 
than normally possible in palliative care research. Longitudinal studies in advanced disease are 
usually limited by small numbers and a high volume of missing data (931), however, more 
descriptive and older analytic methods such as repeated measures ANOVA or simply computing 
rates of change, thereby presupposing only linear trajectories over time, have been shown to be 
outdated and producing biased and misleading results (939). Small sample sizes have often 
limited longitudinal analyses to descriptive graphing of results only (155,587). While exploratory 
and confirmatory graphical analysis is certainly valuable in its own right and recommended as a 
first step to longitudinal analysis for screening raw data and understanding possible inter-
relationships in the data (940,941), failure to use analytical techniques can result in non-detection 
of important covariates and confounding factors. Other outdated methods that have been used in 
recent longitudinal palliative care studies are: change scores (as a single number per subject 
indexing change instead of treating change as a continuous variable) (574), repeated measures 
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analysis of variance and analysis of covariance (942). In the former approach, the problem of 
analysing longitudinal data is essentially bypassed by summarising change for each subject with a 
single numeric value that is then used in further regression analyses. A major drawback of this 
method is that coefficients are assumed to have equal reliability, even in the situation of 
incomplete data (386). Similarly, repeated measures AN(C)OVA requires evenly spaced repeated 
observations and complete data across subjects and time points, an assumption that rarely holds in 
palliative care research (542). Also, within-subject data over time results in auto-correlation of 
observations which also violates the assumption of non-correlated error in ANOVA (386,943). 
Given these drawbacks, newer, advanced techniques of longitudinal analysis are recommended, of 
which the two most common approaches are random-coefficient models (944) and generalised 
estimation equation models (GEE) (945). Random-coefficient models, also named mixed-effect 
models, estimate a straight regression line (if linearity is assumed, otherwise other rates of change 
can also be modelled, i.e. quadratic or cubic change) for each subject in the sample. Covariates 
are then added to the model, of which there are two types: subject-level fixed (constant) 
covariates (e.g. demographic or clinical variables, coping styles) and within-subject time-varying 
random covariates (e.g. time-varying biochemical variables, symptoms) (594,946). Added to this 
can be interaction terms between the covariates. However, these models work by essentially 
estimating an average rate of change for the whole group (i.e. a mean trajectory of change). 
Advantages of this method are its flexibility in terms of handling imbalanced data (with different 
time points per subjects and variation in the timing/spacing of observations) and missing data. 
This is achieved by usually employing maximum likelihood estimators which correct for certain 
types of missing data (missing completely at random and missing at random) (947). Recently, this 
method of longitudinal analysis has been used to describe trajectories of physical symptoms, 
coping styles and quality of life and their interrelationships in the last year of life of ovarian 
cancer patients (948). In this study from the Australian Ovarian Cancer group, a mixed effect 
model including time to death as fixed effect and coping styles as random effects was fitted to 
each of the 16 subscales of the FACT. The coping variables higher optimism and lower 
helplessness emerged as significant predictors for better QOL at the end of life (948). 
A different approach to longitudinal analysis was followed by Spichiger et al. (2011) (573) in 
their prospective study of symptom prevalence and its changes in patients with advanced cancer. 
They used a model of generalised estimation equations with the number of symptoms as outcome 
variables, time as main predictor variable and controlling for depression as measured by the 
HADS-D as a confounding factor. GEE models (600) approach longitudinal analysis using a top-
down approach (386), unlike random coefficient models which focus on individual subjects, and 
then average processes of change. GEE models directly estimate the changes in the dependent 
variable over time (600). Their advantage over random effects models is the ability to estimate 
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non-normally distributed dependent variables. Although both methods are powerful methods for 
longitudinal analysis of change, they assume that subjects are drawn from a single population and 
that a single trajectory of change can adequately approximate and represent an entire population. 
It is therefore also assumed that covariates affecting the trajectory of change influence each 
individual in the sample in the same way. Within the mixed effect framework, methods can be 
used to separate out between- and within-subject relations, but heterogeneity in trajectories is not 
modelled (386). However, describing an entire population with known heterogeneity like the type 
of myeloma disease, stage of disease and treatments received using a single trajectory estimate 
likely results in an oversimplification of the complex pattern of change among members of 
different groups in the sample.  
In this study, the focus was on understanding the heterogeneity of QOL trajectories and 
particularly understanding who experienced a poor outcome in terms of poor HRQOL and high 
symptom burden. The aim was then to identify variables that indicated who was at risk of 
experiencing low QOL in multiple myeloma. Consequently, instead of following a conventional 
approach of estimating a single average trajectory, estimation of variance and assuming a uniform 
influence of covariates on the variance and growth parameters (949), the aim of the study called 
for modelling heterogeneity in the sample. The goal was to classify individuals into distinct 
groups based on their individual QOL trajectories over time, thereby identifying groups or classes 
of individuals with a distinct pattern. Such an analysis produced groups in which individuals 
within one group were more similar than individuals between groups (949). Latent class growth 
analysis (LGCA) can be understood as a person-centred approach to longitudinal analysis rather 
than being variable-centred, in which the goal is to identify significant predictors and describing 
interrelationships between and among independent and dependent variables. This analysis 
produces separate trajectory models for each class of subjects, each with its unique covariate 
influences (608). 
Variability in symptom trajectories has traditionally been modelled in child development studies. 
Latent class growth analysis and growth mixture modelling (GMM) have only been recently 
introduced into longitudinal descriptive research in cancer and wider healthcare. Kroemeke 
(2016) (950) studied the association between distinct patterns of depression and coping variables 
in myocardial infarction over a period of 6 years. She found four latent classes of depressive 
trajectories. Membership in the chronic depressive trajectory class was associated with negative 
coping strategies. By testing a model of four trajectories of depressive symptoms over time, 
chronic high symptoms, rising moderate symptoms, fluctuating symptoms (decreasing – then 
increasing) and low stable/decreasing trajectories, she was able to explain the inconclusive results 
seen in research to this date (950). This study showed that classes of trajectories help elucidate 
inconsistent results that stem from studies using mean symptoms scores for the entire sample, 
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particularly in a scenario where subgroups exist, each with a different level of symptoms within 
an overall heterogeneous sample of patients. However, given that it is likely that patients adjust to 
the disease, its impact on their HRQOL and treatment-related effects over time depending on 
personal and other characteristics, cognitive appraisal and coping, the presence of one common 
trajectory of symptoms over time is an unlikely situation. LGCM and GMM analysis allow the 
description of homogeneous subgroups whose trajectory can be characterised by intercept (low, 
middle or high level of symptoms), slope (decreasing, increasing, fluctuating or stable trajectory) 
or both (combination of severity and shape of trajectory). GMM models can serve the function of 
testing a certain theory of change (590), such as the stress and coping model (343). 
Latent mixture growth modelling was also successfully employed in Parkinson’s disease (606). 
The research group had first analysed mean trajectories of generic and disease-specific QOL in 
this condition, using both the EQ-5D and the Parkinson’s Disease Questionnaire for modelling. A 
multi-level mixed model, a variant of a random coefficients model (597,951), was used to 
estimate the mean trajectory of change and to explore predictors of change. The authors 
subsequently wanted to model the considerable heterogeneity in individual trajectories both on the 
generic and the disease-specific outcome measure. Also, since the assumptions of mechanisms of 
missingness and equal variances and covariances of the outcome variable over time were violated 
in their initial analysis, they re-analysed trajectories of QOL. This analysis demonstrates the 
feature of LGCM of accounting for missing data in the dependent variable through the full-
information maximum likelihood method under a missing at random assumption (952). The only 
study in cancer research using such an approach studied patterns of change in supportive care 
needs and psychological distress over a period of 8 months post completion of initial treatment in 
breast cancer patients (953). Four trajectory classes were identified, among them two indicating 
high or increasing needs and psychological distress. Predictors of coping variables and treatments 
received helped predict class membership. The study was the first to study trajectories of 
supportive care needs.  
Compared to these examples, this study is the first to employ the technique of LGCM to study 
HRQOL over time in multiple myeloma and thus among advanced cancer patients. It utilises this 
new approach to understand the considerable heterogeneity in individual trajectories, to combine 
person-centred techniques of identifying homogeneous groups of trajectories (601), and also 
circumvents some of the problems around handling of missing data and non-evenly spaced 
observations over time that characterise random coefficient and GEE models (954). It allows the 
study of how predictors differently affect only certain types of trajectories. Other than Klotsche et 
al. (2011) (606) and Brédart et al. (2014) (953), in this study only predictors for deteriorating and 
poor QOL were modelled, using logistic regression analysis. Subsequent studies could examine 
predictors for the remaining two latent classes. This is further discussed in section 8.5.1. 




8.3.3 Psychometrics for monitoring quality of life 
Similarly to bringing new approaches to the analyse of change in HRQOL over time into 
palliative care, another methodological contribution concerned two new techniques of 
psychometric analysis for understanding the longitudinal validity and reliability of the Myeloma 
Patient Outcome Scale.  
The aspects of QOL and palliative care concerns, particularly aspects such as symptoms and 
psychological distress or coping variables, are dynamic processes with constant change. 
Monitoring QOL thus has the potential to provide high-resolution information about evolving 
processes of adaptation and progression of symptom burden. However, frequent measurement as 
it occurs in the context of individual patient-monitoring can place substantial demands on 
participants. This burden should be minimised by the use of shorter questionnaires, yet this 
approach sacrifices reliability through diminishing redundancy with which a domain of interest is 
measured. This might also restrict the conceptual range of the measure. Since the measurement of 
change came into the focus of psychometrics (955,956), unreliability of measures has been shown 
to diminish statistical power that can lead to biased influences (957). This is of concern when 
measures are used in clinical monitoring, were relatively small variations need to be detected 
when studying intra-individual change. Through the loss of power this issue also affects clinical 
trials and detecting between-person differences in outcome measures (649). The usual approach is 
to use longer measures for the study of change, a strategy that is not favourable in palliative care 
where shorter measures are preferred due to the sometimes quite considerable level of impairment 
and fatigue that patients experience (316). 
Since this study used the MyPOS over a comparably long period of eight months, this 
measurement framework provided the opportunity to study the reliability of the measure using 
Generalizability theory (GT) (659). Generalizability theory is a new extension of classical test 
theory, using analysis of variance to decompose the variance of a set of scores into multiple 
effects and their interactions plus an error component (656). Generalizability extends the 
reliability estimates within classical test theory. Reliable indices of measurement consistency 
range from 0 to 1. Essentially, reliability estimates such as coefficient alpha (958) or intraclass 
correlation coefficients (ICCs) gleaned from test-retest reliability analyses try to quantify the 
amount of random measurement error. The reasoning behind this assumption is that in classical 
test theory (CTT), a person’s true score is always constant. Observed scores vary from one 
measurement occasion to the next. If there is little variability in observed scores, each observed 
score is close to the true score that is unknown. Reliability is high if the correlation between 
observed and true scores is high. 
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Although coefficient alpha is perhaps the most widely used reliability index, its use has been 
contested for a long time. Even Cronbach reflected 50 years after its invention that it may be a 
useful but certainly a limited tool for practice (959). As becomes apparent from the description 
above, CTT treats all error as random measurement error. Cronbach himself introduced a theory 
of generalisability in 1972 (659) that makes it possible to assess multiple sources of measurement 
error in order to pinpoint these sources of error, disentangle them and estimate each one 
individually (656,659,960). Cranford et al. (2006) (651) used the GT approach to decompose the 
item variance into the different components item variance, time variance, person variance, and the 
interaction terms (person by time variance, item by time variance, person by item variance), and 
error. From these components they estimated four types of reliability. Among them are types of 
alpha coefficients for a person on a single day and for persons over multiple days, but GT also 
allows assessing the precision of the measurement of systematic change in a person. The typical 
palliative care patient experiences constant variation over time. Classical reliability indices cannot 
take this variation into account. They treat it as error which diminishes the reliability of the 
measure. The new approach represents a solution for this dilemma and allows the estimation of 
reliability even in an environment of constant change. Cranford’s approach is not the only one 
available, other authors have used other forms of GT (960) to develop different methods of 
assessing within-person change (651,660,961-963). However, Cranford’s method provides two 
indices that are of particular importance for assessing a measure’s suitability for individual 
patient-monitoring: the estimate of reliability of measurement on a single day and the estimate of 
reliability of change. These indices essentially capture how much trust a clinician can place in the 
interpretation of scores of a patient when s/he sees that person in clinic and whether the measure 
can capture the change in the patient’s condition that is happening over time, thus providing an 
estimate of sensitivity of the measure. This was therefore used in determining the suitability of the 
MyPOS for monitoring. 
It is also possible to marry GT approaches with item response theory, either by using embedded or 
sequential designs. In a sequential design GT is first used to identify important sources of 
variation which are then further understood by diagnosing aberrant persons or items that exhibit 
floor or ceiling effects (964). In this study, I did not follow such an approach but rather performed 
a Rasch analysis of the MyPOS subscales, together with using the new psychometric approaches 
for sensitivity and responsiveness analyses. However, the two methods still interlink in producing 
a general assessment of the measure’s suitability for monitoring QOL in multiple myeloma. As 
such, in this study I tried to show that psychometrics can help assess the clinical utility, namely 
the measure’s suitability for routine clinical use. Psychometric evaluation to support clinical use is 
a relatively under-developed conceptual field. Evidence of validity, reliability and responsiveness 
is requested by both practitioners and the community to form a judgement on the instrument’s 
8 Integration of findings and discussion 
300 
 
appropriateness (965,966). However, the exact psychometric criteria for the application in clinical 
practice are ill-defined. Recent guidelines (287,640,641) mainly define the psychometric 
methodology for supporting research applications. Only one conceptual paper could be located 
that proposed criteria for individual patient-monitoring regarding (i) the interpretability of scores, 
(ii) assessing the full range of underlying constructs across different age groups, diagnoses, 
severity and comorbidity, (iii) minimal floor and ceiling effects, (iv) reproducibility and minimal 
measurement error over time for individual patients, and (v) sensitivity to clinical change (649). 
The authors also recommended more stringent benchmarks for measurement errors for 
longitudinal use of measures (649). Moreover, evidence to support the psychometric properties of 
outcome measures is often gleaned from clinical trials, rather than using observational studies that 
can provide a better representation of the ‘messiness’ of clinical data (436). Particular attention is 
placed on measurement precision and sensitivity to change in this context (649). 
Rasch analysis offers one solution to address these shortcomings. In Rasch analysis (662) a 
measurement model is defined which allows summating scores into an overall score per 
unidimensional subscale. The Rasch model assumes that the response to an item is only defined 
by two factors; the person’s ability to answer the item and the item difficulty (662,967). The 
probability of a given response is a logistic function of the relative distance between the item 
difficulty (item location) and the respondent’s location (person ability) on a linear scale (968). In 
health care, person’s ability can be thought of as the person’s level of a certain symptom, i.e. pain 
or anxiety, whereas item difficulty is the level of pain or anxiety severity that is expressed by the 
item. Transferred to QOL measurement, responses in a QOL tool such as the MyPOS are only 
determined by the health status or quality of life of the person and the level of QOL or health 
status impairment represented by the item. A questionnaire that meets this requirement exhibits 
certain features that overcome some of the problems associated with the CTT approach. First, 
questionnaires constructed under the Rasch model have interval scaling properties. Rasch analysis 
provides estimates of measurement sensitivity and scale discrimination and also reflects the fact 
that precision and scale discrimination are not constant across all levels of a given score 
distribution. Especially QOL measures with comparably fewer distinct levels on the scale tend to 
yield skewed distributions and floor and ceiling effects (283). In Rasch analysis, it is possible to 
understand the reasons for these floor or ceiling effects and thus reasons for the mismatch of the 
ability level demonstrated by the sample and the difficulty level represented by the QOL scale. 
This is because Rasch analysis allows disentangling scale statistics from the particular sample 
from which they were derived (665,969). Thus, obtained statistics in Rasch analysis are sample-
independent and indicate which items can be used in which type of sample, i.e. certain items are 
fitted to persons with a comparably low level of QOL whereas some are appropriate for those 
experiencing minimal symptom burden or psychological problems. This also improves reliability 
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of the scale (666) and even allows the direct comparability of scores from different QOL 
questionnaires through equating different measures with one another (283). A future application 
of Rasch analysis could involve equating a total score on the MyPOS with a total score on the 
EORTC QLQ-MY20, for example. 
CTT is the paradigm under which the MyPOS was constructed and evaluated. The Rasch analysis 
of this measure revealed important areas for revision. It helped to understand the considerable 
floor effect that was seen in the health care satisfaction items, demonstrating that the sample was 
ill-matched to the level of difficulty of the items. It also showed that some items on the MyPOS 
were not suitable for individual patient-monitoring. Particularly some items of physical symptoms 
and the emotional response scale did not exhibit a Guttman pattern (970). Some items also 
demonstrated item bias by showing differential item functioning (971). DIF shows instances of 
the scale not working in the same way for all groups being assessed. This means it tests if the 
items of the scale are invariant across all possible levels of QOL severity and invariant across the 
clinically relevant groups in which they are used (i.e. groups of different stage of myeloma 
disease) (972). This type of analysis was used in a way initially proposed by Hobart (2009) (661) 
to evaluate responsiveness. He also proposed to use DIF analysis to understand test-retest 
reliability but since I used GT analysis in this study, which provided a more fine-grained 
approach, Rasch analysis was only used to understand sensitivity to change and responsiveness of 
the MyPOS. This approach addresses almost all the parameters for the adequate psychometric 
analysis of individual monitoring as proposed by McHorney & Tarlov (1995) (649). 
Cited as a major drawback for the clinical applicability of QOL scales, the interpretation of the 
significance of differences or changes in the score in a particular QOL domain (687,973) have 
posed a challenge to developers of health status measurement scales for a long time. Individual 
patient-monitoring of QOL poses the challenge of focusing on change data at the individual 
person level, a challenge that cannot be addressed by employing methods of CTT (283,974). The 
added value of Rasch analysis in this study stems from its ability to disentangle the potentially 
confounding variables of the performance of the scale with persons’ level of QOL, as described 
above. In addition, Rasch-based estimates provide individualised standard errors, thus providing 
statistics at the level of the individual patient. In CTT, significant change for any one individual is 
often treated as a simple function of the magnitude of change in the sample used to derive the 
minimal important difference (636,672,687,920,974-976). Rather, Rasch analysis shows that the 
significant change in individuals also depends on their location on the continuum at all 
measurement time points (661). Often, measurement precision and presence of floor and ceiling 
effects can make the derivation of the MID impossible. Rasch analysis, not relying on group-level 
variance of scores or standard error as the denominator, is able to detect differences by using the 
standard error of scores for individuals (661). It thus provides a framework to understand which 
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items are suitable for individual patient-monitoring, an objective defined for this study. This 
approach to constructing or revising scales is relatively new to health services research and the 
validation of HRQOL questionnaires. Research groups around Jeremy Hobart (661,663,977), 
Alan Tennant (668) and Richard Siegert (978) have used Rasch methods for scales in palliative 
care or non-cancer conditions at the end of life (interstitial lung disease, multiple sclerosis (979)). 
Although the Rasch measurement model addresses many of the shortcomings of a classical test 
theory approach to responsiveness, the high level of statistical and measurement knowledge it 
presupposes on part of the reader makes it difficult to translate its benefits to practitioners who are 
the ultimate addressees when arguing the clinical applicability of a QOL scale in monitoring. 
However, this thesis shows that it can be used to provide solutions to some of the taxing issues 
regarding validation of the scales in a field such as palliative care. 
 
8.4 Clinical recommendations: Improving QOL assessment and 
palliative care involvement in multiple myeloma 
8.4.1 The use of MyPOS in research  
This thesis set out to study the clinical applicability of a measure of QOL and palliative care-
related concerns in multiple myeloma. Specifically in the validation I focused on measurement 
characteristics showing that the MyPOS is suitable for longitudinal use as it occurs during patient-
monitoring or in clinical trials. Only recently has PRO use been advocated in clinical trials by the 
FDA and the EMEA in their guidance documents (287,637,980). The industry-sponsored PRO 
use centres around inclusion in phase II and phase III clinical trials (981). However, a review of 
trials registered on clinicaltrials.gov has shown that only 12-15% of protocols for phase III studies 
incorporate some form of PRO assessment (982). This incorporation, almost exclusively as 
secondary endpoints, is largely driven by the potential for securing a labelling claim in the USA 
or in providing arguments for reimbursement in Europe (981). This perspective disregards the fact 
that regulators and payers are only two of the stakeholders, with clinicians and patients being the 
key stakeholders. Moreover, the number of RCTs including PRO as an endpoint is still much 
lower in haematological trials than in trials of solid cancer patients (24,983). At the point of the 
review in 2009, only 15 clinical trials that included QOL outcomes in myeloma could be located. 
These outcomes are often published separately to the main findings (82,365,366,374), which 
makes linkage of information on progression-free survival and potential QOL benefits or 
treatment-related toxicities difficult. This practice is in stark contrast to the situation of patients 
with multiple myeloma who represent a group with incurable disease with an impact on patient’s 
wellbeing over a prolonged period of time. QOL data can be most informative in diseases where 
treatment-related toxicities are of interest or treatments are expected to be more palliative than 
8 Integration of findings and discussion 
303 
 
others (888). In myeloma, prolongation of the progression-free interval is often considered as the 
primary outcome with patient-reported QOL assessments being relegated to second place 
(24,983). Failure to include PRO assessments in advanced stage, however, can result in 
misjudgement of the effects of a trial (554). Recognition of this complexity underscores the 
importance of including information on HRQOL in clinical trials in multiple myeloma and 
haematology. 
The use of the MyPOS as a disease-specific QOL assessment tool particularly targeted at later 
disease stages is recommended as at least a secondary endpoint in clinical trials. Its potential 
value lies in capturing additional treatment effects, providing valuable information on the patient 
experience and adverse effects of treatments. Studies in haematological cancers (22,23) show a 
linkage of physical functioning/fatigue and survival. HRQOL information thus may provide 
additional information for predicting prognosis and outcome in clinical trials. Finally, the MyPOS 
could be used to understand interactions and trade-offs among symptoms (288). 
Certain features of the MyPOS support its use in this context. Three free-text questions about 
main problems/concerns and three free-text fields about additional symptoms could help identify 
the most concerning symptom or problem in patients, an approach that is put forward as a new 
way to analyse longitudinal data in palliative care (574). In addition, the free-text format can 
provide additional information on why certain items are missing. This is particularly valuable in 
the context of palliative care where one methodological concern centres on the often high amount 
of missing data (520,542). The MyPOS assembles the most important symptoms, derived from 
extensive patient interviews (357). In clinical trials, it can provide a brief assessment of the most 
important tumour-specific symptoms in myeloma, either shifting the focus to symptomatology in 
trials of anti-myeloma therapy or helping to promote the evaluation of supportive care 
interventions through providing an outcome measure that can detect differences in trials focusing 
on unmet needs in multiple myeloma. Symptoms as outcomes could then be used in combination 
with other outcomes as composites. This was attempted in two studies, one with advanced non-
small cell lung cancer patients, combining an improvement in one or more symptoms with a 
specified improvement in performance status to be defined as a positive clinical response 
(984,985). Guidance regarding PRO instruments in research states that shorter recall periods are 
preferred since longer periods of one to four weeks may increase measurement error through 
recall bias. The MyPOS with its time frame of asking about the previous three days therefore 
might improve capturing changes in symptoms over time in trials. The two validation studies of 
the MyPOS have shown that its psychometric features support this use. Information from physical 
symptoms and emotional functioning items can be aggregated into two unidimensional subscales, 
as supported by the results from factor analyses and Rasch modelling. Deriving an MID for the 
MyPOS will aid sample size calculation and valid interpretation of important differences. The 
8 Integration of findings and discussion 
304 
 
MID makes it possible to report the magnitude of treatment, which constitutes a much more 
powerful approach than selecting a thresholds arbitrarily or dichotomising data, as often done in 
the absence of MID information (920). 
The MyPOS is a new disease-specific questionnaire. In comparison to the EORTC QLQ-MY20 
(221,310), the myeloma-specific QOL questionnaire developed by the EORTC group, the MyPOS 
has the drawback of not having the same history of use. The generic EORTC QLQ-C30 has a 
wide-spread application in clinical trials, being used in 75% of RCTs in haematological cancer 
(986), and representing, together with the MY20, the most commonly used tool in clinical trials in 
multiple myeloma (359). The EORTC and likewise the FACT group in the United States have had 
fifty years of facing the challenges of implementing QOL into research, addressing measurement 
challenges by providing modular assessments of QOL, cultural adaptation of questionnaires, 
developing guidelines for protocol development with QOL as endpoints, and, most recently, 
providing guidelines for use of QOL in clinical practice in addition to clinical research (401,987). 
Rather than suggesting the MyPOS being suitable for all clinical research, it has a specific place 
in RCTs including the more advanced stages of multiple myeloma, as an additional measure. 
Besides this use, other applications in research consist of more descriptive explorations of reasons 
for treatment non-adherence or discontinuation. Withdrawal or non-adherence is often related to 
toxicity which can be documented in the MyPOS. Its integration can also serve the purpose of 
understanding intermediate and ancillary study endpoints or variables. Following the model of 
QOL (357), the MyPOS contains items representing intermediate and more distal variables 
impacting on QOL and thus provides the opportunity for modelling these pathways. 
 
8.4.2 The clinical use of MyPOS (screening, assessment, monitoring) 
With increasing survival rates in haematology and a greater variety of treatments available for 
multiple myeloma, questions about long-term effects of treatment and best supportive care emerge 
for patients. To answer these questions, QOL knowledge and QOL assessment need to be 
integrated into clinical practice. This is one of the areas in which both parts of this thesis, the 
further development of the MyPOS as a tool for monitoring QOL in patients with multiple 
myeloma and the development of a model of predictors for poor QOL. The intention is to provide 
a framework for clinical evaluation of QOL, for patient education and for deriving interventions 
to maintain or restore QOL and to focus on those patients who might benefit from palliative care 
involvement being at high risk of multiple symptoms (93). 
Survival prediction models have been largely based on disease characteristics, biochemical 
variables, and performance status (146). The current study shows that for the outcome poor QOL, 
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factors with predictive power are not those associated with disease or treatment characteristics but 
patients’ self-reported symptoms and functioning. Patient’s self-reported aspects of health status 
have been demonstrates as useful for estimating survival in cancer patients (166,192,223,241,988-
991). The model of predictors could be used as a conceptual model to develop a PRO 
measurement strategy of when monitoring HRQOL is particularly beneficial for patients. The 
model also demonstrates the need for proactive symptom management and better symptom 
control in multiple myeloma (in particular pain, fatigue, breathlessness, emotional problems) early 
in the course of the disease and in later stages. Screening and supportive care interventions (in 
particular psychological services) are warranted, as is an awareness among clinicians of the 
emotional distress and concerns about the future and compromised physical functioning in 
myeloma patients. 
Patient-reported outcomes are characterised by a flexibility that makes them ideal for their 
repeated application essential for longitudinal monitoring. PROs also provide the patient’s view of 
their functioning and areas of concern. Greenhalgh (2009) (38) in her theoretical framework of the 
application of PRO in clinical practice, describes four areas of application, depending on two 
dimensions – the level of data aggregation and whether the application involves data use within 
the encounter between clinician and patient or not. Among the application of use of PRO data 
from individual patients, she describes screening, monitoring and – if data is reviewed by a group 
of clinicians - facilitating communication within multidisciplinary team meetings. Group-level 
aggregated data, if used in the encounter between clinician and patient, can provide decision aids 
for patients when considering PRO scores and toxicity profiles before selecting a new treatment 
or when weighing different treatment options. This application has been studied in breast cancer 
patients (992-994), but – with more data emerging from clinical trials and even from long-term 
surveillance data of anti-cancer therapy – could also be applied to multiple myeloma. Decision 
materials are provided in the form of Patient Decision Aids (430,433), enabling patients to make 
informed decisions between treatment options, by presenting all options and information in 
patient information leaflets. The other form is a professional decision support system (995) in 
which evidence-based choices with incorporation of QOL information are presented to clinicians. 
Treatment decision making in myeloma would be greatly enhanced by the ability to balance 
QOL-related impact of treatment with traditional outcomes such as survival time, durability of 
remission, toxicity of treatment and symptom palliation (85). This can only be achieved by 
collecting QOL data in clinical practice to aid post-marketing surveillance of treatment benefits 
(450). 
The last quadrant defines PRO use at the population level for assessing quality of care and even 
deriving PRO-based benchmarks. This approach has been used successfully in elective surgery in 
the United Kingdom (438) and in palliative care in Australia (442-444). Similarly to Greenhalgh 
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(2005) (427), Osoba (2002) (996) and Sutherland & Till (1993) (431) define levels of decision 
making when applying PROs in clinical practice, distinguishing between a micro, a meso and a 
macro level. The micro level corresponds to Greenhalgh’s (427) first quadrant of screening and 
monitoring of an outcome, the macro level corresponds to the population application. The meso 
level is the application of PROs in clinical trials which was covered in the previous section. Yet 
another framework of PRO use in clinical care contrasts cross-sectional with longitudinal 
applications (997). Cross-sectional applications are assessment, screening and shared decision 
making, whereas longitudinal applications are symptom management, outcome assessment and 
quality improvement. For example, the MyPOS can be used to identify the necessity for a formal 
patient evaluation or supportive care intervention when screening symptom burden and palliative 
care-related concerns. A similar application relies on tracking symptoms and treatment effects 
over time and identifying opportunities for improved symptom management or palliative care 
involvement in myeloma. Longitudinal MyPOS data also is the prerequisite for outcome 
assessment (448) and quality improvement through audit, service evaluation and benchmarking 
(316,997).  
When considering the clinical applicability of the MyPOS, the initial focus needs to be on its 
wide-spread use for screening and monitoring. Screening is the one-off application of an 
assessment instruments to potentially identify troublesome symptoms and problems (664), 
ultimately leading to interventions to treat the problem and decreasing its severity. Monitoring is 
the regular, ongoing assessment of the individual patient to check whether a treatment is working 
or to aid the early detection of disease progression or development of further symptoms (38). The 
rationale for screening is the detection of problems that would go undetected otherwise (145). The 
underreporting of symptoms is a phenomenon that has long been described in the literature (998-
1000). For example, a study in specialist palliative care estimated the amount of symptoms to be 
undetected without systematic screening as high as 66% (1001). Disconcordance between 
physicians and patients results in underestimation of symptom severity in 60% of symptom 
dimensions. Overestimation of 77% has been described when comparing caregiver and patient 
ratings (1002). Several reasons for the under-detection and the disconcordance between patient 
self-report and clinician assessment of symptoms have been proposed. Patients may consider 
symptoms not severe enough to warrant medical attention or may perceive a symptom as 
inevitable with no treatment available (703,1001). Clinicians may judge a symptom as uncommon 
or may feel that they have nothing to offer as treatment and thus not inquire about the presence of 
certain problems such as fatigue or sexual functioning (1003).  
The process of screening is resource-intensive. First, patients need to be made familiar with the 
tool and the process needs to be explained to them. Staff may be needed to collect the instrument. 
Above-threshold values must be monitored by clinicians and results must be formatted for 
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clinicians to be readily interpretable for decision making. Results of PROs such as the MyPOS 
need to inform treatment decisions – either to stop or modify the current plan of therapy or add 
supportive care interventions (450). Ideally, assessment should be considered a longitudinal 
activity. Baseline information could be followed by periodic assessment during and at completion 
of therapy, at follow-up visits and through treatment-free intervals into later stages of disease 
(1004). However, this continuity of assessment would require patients being followed through 
different settings and care providers, something which is not readily achievable in myeloma care. 
Incorporating MyPOS screening routinely into haematological care could promote a new patient-
centredness in health care, seeing PROs not as adjuncts or added tasks to usual care (555). It can 
be used to identify the most pressing issues that the patient wants help with and such information 
can guide resource allocation, care planning and patient referrals (1005-1007). This would require 
PROs like the MyPOS being used to organise health care. Patients would be screened repeatedly 
when well or sick and not at one point in time as is current practice in the UK with the assessment 
of supportive care needs (96). Systems could be built in such a way that electronic, web-based 
screening is combined with feedback and guidance as well as access with information about wider 
resources like self-help for patients.  
Both the model of predictors developed in results chapters 5 and 6 and the development work of 
the MyPOS may inform what the essential issues are that need to be screened or monitored using 
PROs. Ideally, screening and monitoring should involve symptoms indicating progression of 
disease and side effects of treatment, performance status, degree of psychosocial or spiritual 
distress, personal goals and expectations, information needs and understanding of the 
disease/concerns about the future (1008). All these aspects, except performance status, are 
covered by the MyPOS. Especially the presence of symptoms such as pain or fatigue, the general 
symptom level, Eastern Cooperative Oncology Group performance status of 2 or above and 
potentially information about disease stage could form screening criteria. For patients who meet 
these initial criteria, palliative care involvement might be warranted, with additional assessments 
and review by an advisory palliative care team or other forms of models of palliative care being 
provided to myeloma patients (267). From the prevalence figures seen in the cross-sectional 
analysis in chapter 5, screening of sexual well-being and financial difficulties is also important. 
Sexual concerns and financial issues are two aspects that are readily sidestepped by oncologists in 
patient consultations (821,822,1008). Forbat and co-authors (2012) (822) found that when sexual 
functioning was raised by the patient, the oncologists were apt in finding medical explanations 
which did not result in a discussion of how to manage the emotional side of these issues. 
Education and training as well as development of resources that patients can access via the 
internet or through patient charities can help with these two problems in particular (1009). 
Regarding screening of symptoms, there has been a debate in the literature around the value of a 
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common set of symptoms versus more targeted screening of specific symptoms indicating risk 
(510,1010). The MyPOS offers both these options by providing a list of common and frequent 
symptoms in multiple myeloma, both disease- and treatment-related, with the option of adding 
additional symptoms that patients find troublesome. 
Screening and monitoring in myeloma can learn from approaches that have already been tried in 
psychosocial care. Information on the trajectory of QOL in multiple myeloma together with the 
model of predictors could inform risk-targeted assessment at transition points in the disease 
trajectory. This could be combined with a layered model of screening in stages that is common for 
distress screening in oncology (360). The National Comprehensive Cancer Network (NCCN) in 
their guidelines recommend a simple screening tool, the Distress Thermometer (DT), for initial 
screening of psychological or spiritual distress in cancer (647,1011). A cut-off point is defined to 
help identify those patients with significant distress. What follows is a staged model of further 
assessment and management, depending on the level of psychological distress. With mild distress, 
the NCNN recommends management by the primary care team with information and relaxation 
exercises being provided to the patient. Moderate to severe distress should involve proactive 
referral for further assessment and treatment by a mental health professional or social worker. The 
highest levels of distress need to be evaluated by a psychiatrist (360,647,1011-1013). A similar 
model of screening/assessment in levels is proposed for symptom assessment in advanced cancer 
(1014). Level 1 consists of screening of important domains such as common symptoms and 
cognitive impairment. Level 2 explores more symptom dimensions and mobility. Level 3 involves 
psychosocial variables and should be combined with daily follow-up and review of physical and 
psychosocial distress (1014). While this model of screening tries to confine comprehensive 
screening to the higher stages of distress, it may still be too elaborate for assessing the breadth of 
symptoms important in multiple myeloma, given that multiple symptom dimensions need to be 
assessed in level 2 (1014). The model of distress screening proposed by the NCNN better suits the 
needs of identifying symptoms that are clinically significant and thereby identifying patients that 
would benefit from further assessment and care (1012,1015). Rather than proposing an initial 
screening only comprising one question or an abbreviated scale, such as recommended by the 
NCNN (647) and Kirkova (1014), screening following a multi-symptom approach with a 
moderate level of detail, as in the MyPOS, might provide a more detailed picture, yet allowing a 
focus on the most important problems. This study has shown that self-assessment is possible even 
in those myeloma patients with poor performance status, thus making self-report feasible in this 
scenario (1016,1017). 
As a way to potentially relieve clinical services from resource-intensive regular comprehensive 
screening as part of the routine care of patients, such evaluation could be targeted to at-risk groups 
at different points in the disease trajectory when patients are most at risk of developing a poor 
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outcome (93). Zabora (2015) (360) suggested linking clinical with psychosocial challenges in 
multiple myeloma and establishing comprehensive screening at these transition points. The 
authors recommend screening at first diagnosis, even in asymptomatic patients, screening during 
active treatment, at point of entering remission, during each subsequent relapse and when the 
refractory stage is reached (93,360). This screening could be combined with information from the 
predictor models to target those patients with poor performance status in particular. From this 
longitudinal study and the high prevalence of problems found even in stable phases of myeloma 
disease, I would like to recommend at least one regular assessment time point during each 
treatment-free interval or, alternatively, to provide patients with the facility to self-complete the 
MyPOS with alerts being sent to the clinic. The fact that patients are classified as asymptomatic or 
stable, according to their disease activity, does not mean that they are not distressed or are 
experiencing symptoms, a fact that is overlooked when assuming that trajectories of psychosocial 
concerns follow trajectories of disease activity and severity. Among others, this was shown in a 
recent study with newly diagnosed multiple myeloma patients in which over 50% of patients 
expressed preferences for psychosocial interventions at the point of diagnosis (1018). This result 
has been echoed in studies with HSCT and other cancer populations (1019,1020) as well as in this 
PhD study. 
When thinking about the clinical applicability of the MyPOS in screening and monitoring, 
screening and monitoring physical symptom burden, caregiving burden and psychosocial distress 
in informal caregivers needs to be mentioned as well. It is important for clinicians to screen at 
least for emotional distress and information needs as well as readiness to manage illness-specific 
problems in caregivers (1021). Offering psychosocial support to family members of patients with 
multiple myeloma at multiple points in their disease trajectory is recommended by the NICE 
guidance (96), but it is not explained how such support should be targeted and delivered.  
Overall, the questions and problems arising from resource-intensive screening point towards a 
change in existing models of follow-up care in multiple myeloma. First, the increase in numbers 
of patients being followed puts pressure on clinics. Face-to-face hospital appointments with 
intervals between appointments increasing over time is a static model of follow-up. Concerns 
have been expressed about the effectiveness of this model of care (1022). Second, this model has 
been shown to be ineffective in detecting recurrence, whereas recent research has demonstrated 
that symptom screening could detect relapse in lung cancer early (645,646). Third, one argument 
for clinic-based follow-up is maintaining contact with the clinical care team. However, shorter 
consultation times result in information and psychosocial needs remaining unmet (1023,1024). 
Rather than follow-up through primary care or telephone follow-up, eHealth applications of 
monitoring could be combined with open-access clinics where patients can drop by on demand 
(475,1025,1026). Electronic patient-monitoring can help the integration of PROs like the MyPOS 
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in regular assessment of myeloma patients. Web-based systems offer a number of features that 
allow an easy integration into existing workflows and provide reliable, reproducible and high 
quality data (411,420,427,432,1027-1032). This prospective use of QOL information would allow 
remote monitoring with PROs such as MyPOS being completed at home, alarms being sent out to 
clinics if scores are above-threshold, patients being reviewed by the clinicians if problems arise, 
indicators and alarms being set according to risk models of QOL in multiple myeloma and 
clinicians being provided with immediate scoring results for the patients, allowing subsequent 
further diagnostic assessments (1033). Such an integrated system could offer further features. 
Next to its primary purpose, providing a measurement feedback system to patients and clinicians 
with multiple outcome scores, such a system could have built-in personalised advice and 
reference to supportive care services (1034). In this way, the multi-step model of distress 
screening and management could be incorporated into an eHealth application for QOL, by 
providing the first or lowest step on the ladder in the form of additional information, links to web-
based help and guidance as those offered by patient-led charities like Myeloma UK or the NHS, 
and even offer specific self-help interventions (i.e. relaxation exercises) (1034-1036).  
Several systems of electronic PRO data collection have been tested over recent years 
(189,453,473). The first and most prominent system was developed at the Memorial Sloan 
Kettering Cancer Center to monitor adverse events during chemotherapy in advanced cancer 
patients (42,404). The most recent RCT, published in 2016, used electronic PRO collection by 
sending weekly e-mail prompts to patients between visits. Physicians were made available 
symptom profiles during the consultation and nurses received e-mail alerts when scores indicated 
severe or worsening symptoms. The trial showed a HRQOL benefit in the intervention group, 
together with less frequent admissions to the emergency room or the hospital and longer time of 
patients on chemotherapy (43). This system mainly focused on chemotherapy-related toxicities. 
Similar systems have been built for monitoring other patient groups, i.e. general health (1037), 
child behaviour and development (1038,1039), general oncology (455,586,1040), and the general 
outpatient setting (42,463,469,1037,1041). Within palliative care, a few initiatives have centred 
on developing a core set of measures for monitoring palliative care patients. Amy Abernethy has 
developed an electronic system, the Patient Care Monitor (1042), to address under-identification 
of symptoms and distress in oncology clinics. An Australian initiative has built a system to 
monitor rural palliative care patients via the telephone (460,462). The only system that could be 
located using tracking of symptoms and mental health in hospice patients was a system using 
web-based reporting from home in hospice at home patients (465). In Canada, a national system 
using repeated assessments of ESAS symptom scores improved predictions of death in cancer 
patients (990). A new study using electronic patient-reported outcomes for monitoring in the UK 
links electronic and data collection via mail with cancer registries (470).  
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Most of these projects have not been evaluated in RCTs. Exceptions are the study by Basch et al. 
(2016) (43) and a study in HSCT patients testing a system of PRO collection with results being 
provided in form of a graphical summary to clinicians before the patient’s clinic visit (467). Also, 
some of these systems do not provide a fully-integrated workflow with some still requiring 
manual PRO collection. Integration of clinical data into PRO reports is seldom achieved. Another 
key difference between systems is the feedback loop. Some provide PRO data to patients and 
clinicians, some only provide the clinician with the PRO information the patient has entered 
(473). Systems most widely differ in the incorporation of educational materials and giving 
guidance and promoting self-help in patients for addressing symptoms outside clinical 
interactions. This feature, one of the main benefits of electronic monitoring and easily achievable, 
is the one that is used least often (1043-1045). These aspects should be built into a system of 
using the MyPOS for electronic monitoring. The MyPOS offers some features that are desirable in 
this context, namely the potential for personalisation by adding additional symptoms to the scale. 
The identification of main problems and concerns at the beginning of the measure offers an 
opportunity for further personalisation and for tailoring information and guidance to the 
individual patient. At the same time it has been shown in the psychometric analysis that the 
MyPOS is robust and sensitive enough to detect changes over time to be used for monitoring, with 
the potential to define cut-off values for alerts to clinics that the patient needs to be reviewed by 
the clinical team, thus allowing a new model of follow-up care (1046).  
Lastly, I would like to focus on one potential feature that an electronic patient-reported outcome 
system could offer. This addresses a gap often cited as a barrier to clinicians using PROs in 
clinical practice (40,400,1047,1048) - the paucity of linking assessment to suggested action by 
providing guidelines of PRO-linked interventions (40,90,1049). Only one group so far has 
incorporated guidelines for treatment and intervention of QOL-related problems into their system, 
the Patient Viewpoint (1048). When viewing patient results, doctors or nurses can click on a link 
labelled “What can I do” that takes them to recommendations emphasising the need for further 
assessment and evaluation, as well as pharmacological treatments and referrals to other members 
of the multi-disciplinary team (1048). The authors provide consensus recommendations for eight 
symptoms, two psychosocial issues, problems with various aspects of functioning including 
sexual function, overall QOL and information needs. Some of these recommendations could be 
transferred to myeloma-related problems, some recommendations regarding issues particular to 
this disease group would need to be developed for an electronic PRO collection system of the 
MyPOS. Since the MyPOS is a module of the Palliative care Outcome Scale, some 
recommendations could be taken from the set of guidelines produced for five common problems 
as seen on the POS (1050). This would result in a fully integrated system, a streamlined 
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application of regular assessment, patient-empowering information provision and guidance a well 
as recommendations for actions linked to identified QOL-related problems. 
 
8.4.3 Recommendations for the integration of haematology and early palliative care 
involvement in the care of multiple myeloma 
Assessment in form of screening and monitoring and, in particular, the use of the MyPOS for such 
a purpose can also aid the better integration of palliative care into general haematological care of 
patients with multiple myeloma. This view is supported by recent guidelines published by the 
NCCN in America (647,1051,1052) and the slightly older NICE guidance for the UK (96). These 
guidelines call for routine screening and early intervention at regular intervals with re-assessment 
indicated by an overall change in function. They further recommend the integration of palliative 
care into the general care for haematological cancer patients, even those undergoing treatment, if 
they meet screening criteria (647,1052,1053). However, one should note that despite targets for 
palliative care screening being the same as those in oncology, in palliative care symptom 
management is not pursued with the explicit purpose of allowing more active cancer treatment. It 
rather serves the identification of needs and concerns that will help in alleviating symptoms and 
optimising QOL (1008). 
This study has demonstrated the high prevalence of symptoms in a sample of multiple myeloma 
patients at different stages of disease. Fatigue, pain and breathlessness were the symptoms with 
the highest prevalence of 88, 72 and 61%, respectively. Other problems, particularly anxiety, 
depression and worry about worsening of the disease, were as common. This highlights the 
problem described in the literature for almost all haematological disease patients and HSCT 
populations, namely the generally high and complex symptoms that persist even in treatment-free 
intervals (83,593,734,1054) and the challenge this poses for continued care. By contrast to many 
other haematological malignancies, myeloma has many potential complications including bone 
disease and the severe and complex pain resulting from it, a generally high level of comorbid 
disease due to the advanced age of patients and disease complications such as renal failure (1051). 
Moreover, myeloma displays features of some non-cancer conditions with a prolonged illness 
trajectory extending years due to the introduction of novel agents, also resulting in accumulation 
and multiplicity of treatment- and comorbidity-related toxicities and other health problems (706). 
Such pathways are now associated with long-term follow-up which can result in interruptions in 
the continuity of care and patients expressing unmet needs for supportive care and symptom 
control (90). Lack of continuity of care is especially problematic at the end of first-line treatment 
at which point patients leave tertiary care and are followed-up in the community (90). 
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The symptom burden of haemato-oncological patients has been shown to be comparable to those 
with advanced solid tumours (93,234,1015). However, the pattern of symptom prevalence and 
their severity can be different which has implications for the model of care (93). Some new care 
models including wider supportive care have been proposed in recent years to address the high 
amount of unmet needs experienced by HSCT and haematological cancer patients throughout the 
disease trajectory (88). These survivorship care plans contain schedules for follow-up and review 
in clinics, review of symptoms and treatment-related toxicities, supportive care as in blood 
product support or maintenance chemotherapy and psychosocial and nutritional support, if needed 
(998). Several different models of monitoring patients in cancer survivorship care have been 
described and tested, some instituting specialist and multi-disciplinary or oncology-led outpatient 
clinics (1055-1060), some proposing models integrated in primary care or collaborative models 
between primary and specialist care by sharing specialist nurses with primary care practices 
(474,1055,1058-1062). However, high-quality evidence regarding the effectiveness of these 
models of follow-up care is still lacking (998). On the one hand, survivorship care includes the 
components of coordination of care, monitoring, prevention and screening as well as psychosocial 
support and information provision that are needed to address the unmet needs of patients with 
multiple myeloma (90,385,482). On the other hand, despite myeloma patients formally falling 
within the definition of survivors when living beyond five years with their disease (477), the 
incurable nature of their disease makes the use of the language of survivorship difficult. This 
could foster wrong hope in patients with myeloma.  
However, one aspect from survivorship models could be implemented in routine myeloma follow-
up. This is the use of multi-disciplinary teams that manage the multi-dimensional symptoms and 
concerns of patients (477). This and other studies showing a spectrum of QOL-related problems 
(381,593,803) highlight the range of resources that are needed to offer comprehensive care with 
an ongoing multidisciplinary approach (593). Multi-disciplinary team (MDT) meetings have been 
the preferred model of care in complex and chronic conditions for many years (434). However, 
MDTs in oncology care are different. They usually consist of a different mix of professions than 
is common in chronic conditions or palliative care. MDTs in cancer specifically deal with only 
one type of cancer, often including specialists for diagnosis like radiologists and histopathologists. 
Their organisation and composition is left to local discretion and regular review is the exception 
with many patients being discussed only when first entering the service or at point of diagnosis 
(1063). These MDTs focus on diagnosis and curative treatment rather than the minimisation and 
optimal management of symptoms throughout the cancer pathway (434). Consequently, there has 
been little empirical support for their effectiveness (1063,1064). However, truly multi-
professional and inter-disciplinary team meetings could offer a way to address the need for 
complex and comprehensive long-term care in multiple myeloma and other haematological cancer 
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patients, by using PROs such as the MyPOS to detect and screen for areas of concern and discuss 
a care approach to address these areas of unmet need. This would require a restructuring of team 
meetings and changing the attitude towards these MDTs, the inclusion of nurse specialists and the 
wider psychosocial team within facilities, possibly also comprising specialists for non-
pharmacological treatment of symptoms in myeloma such as physiotherapists and occupational 
therapists (1015,1040,1065). 
Evidence that haematological cancer patients receive less specialist palliative care in hospitals and 
referral to home care or hospice services has been accumulating for some time 
(137,152,158,159,706,1066). A large gap exists in the access to palliative care for multiple 
myeloma. Different barriers to the integration of both specialities have been proposed at the level 
of the patient, the illness, clinicians and the health care system (140). Among reasons pertaining 
to the system are the level of generalist palliative care skills and funding shortages of integrated 
models (694). Clinician-led barriers centre on attitudes and the reluctance or inability to define the 
palliative status and predict the time to death in this patient group 
(93,105,130,158,162,261,264,1066,1067). Given that there is no commonly agreed definition of a 
palliative care patient (1068), their might be disagreement about the suitability of myeloma 
patients for palliative care. The disease trajectory of multiple myeloma also makes it impossible to 
reliably predict survival early on and deterioration can happen quickly. As such, myeloma 
resembles trajectories of non-malignant disease which are characterised as having entry-reentry 
patterns with frequent hospitalisation, exacerbations of disease resulting in declining functional 
status but intermittent stabilisation phases (694). Also, multiple myeloma patients are usually 
burdened by two or more comorbid diseases, which may add cumulatively to their under-
representation in specialist end-of-life (EOL) care (1069,1070). Attitudinal barriers in clinicians 
can go hand in hand with attitudinal barriers in patients. On the one hand, in the few studies 
examining advance care planning in the HSCT and haematological population (132,1071), it has 
been shown that most patients want honest information regarding the risk of death when obtaining 
information about the benefits and harms of chemotherapy (132). On the other hand, the sickest 
patients with the highest chance of dying were the least likely to perceive their poor prognosis. 
Referral to palliative care services has been described by some patients as leading to the feeling of 
being abandoned by their clinical team (138,162). Haematologists may feel that a referral to 
palliative care indicates that treatment is no longer aimed at curing and causing a sense of 
hopelessness in the patient (132,160).  
Therefore, unique care models might be needed for the integration of palliative care into general 
haematological oncology (160,1072). There are different templates of integration, particularly for 
early involvement of palliative care, some of which have been tested in the stem-cell 
transplantation setting (161,263,1073,1074). A link between the two specialties would greatly 
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benefit patients and staff. Haematological clinical staff needs to be skilled up in generalist 
palliative care provision and palliative care specialists are in need for training in the unique issues 
faced by haematological cancer patients (261).  
To foster the integration of palliative care with haematological care, it helps to distinguish 
between generalist palliative care and specialty palliative care (1075). This distinction is akin to 
the model of levels of distress management proposed by the NCCN (647), whereby different 
levels of need are met by different and more extensive skill-sets in the professionals (1075,1076). 
Generalist palliative care comprises basic symptom management of physical and psychological 
symptoms, communication regarding cancer prognosis and goals of treatment as well as advance 
care planning (1075). Specialist palliative care (SPC), however, is reserved for complex or 
refractory symptoms, communication issues and conflict management between patients, family 
members and healthcare professionals. While this model recognises that oncological teams can 
deliver palliative care – given that they receive specific training by palliative care specialists – it 
also recognises the fact that SPC involvement has its place not just at the end of life in 
haematological care, but potentially earlier on. This would require a paradigm shift in the 
perception of oncologists about the adequate timing of palliative care. Currently, a 
prognosis/survival model dictates when referrals to SPC are made (151), which disregards the 
needs-based approach that Quill and Abernethy (2013) have proposed in their model of 
generalist/specialist palliative care provision (1075). 
Overall, referral to palliative care is highly heterogeneous. This situation is not helped by the 
absence of palliative care in treatment guidelines of multiple myeloma and other haematological 
cancers (1077). Palliative care was only mentioned twice in the latest National Comprehensive 
Cancer Network guidelines for multiple myeloma and non-Hodgkin lymphoma and not at all in 
the guidelines for Hodgkin lymphoma and several types of leukemia (96). The situation in the UK 
is different, possibly aided by guidelines for supportive care which are symptom-focused and 
encompass end of life care as well recommendations towards multidisciplinary collaboration with 
specialists in palliative medicine and appropriate interdisciplinary referral (126). This might result 
in the higher rate of specialist palliative care referrals seen in myeloma patients in the UK (137). 
Hui et al. (2015) (265) have suggested rebranding the term palliative care into supportive care 
which they advise might overcome the stigma associated with this discipline. However, given that 
supportive care is in itself a technical term within myeloma care, usually comprising pain 
management, management of bone disease, fatigue, anaemia, infectious complications and 
nutritional and psychologic support during therapy to enable patients the completion of their 
chemotherapeutical regime (87-89,701), rebranding does not seem to be a solution to this 
problem. Rather, thinking about models of care, clinical pathways and bringing a health 
services/population perspective to haematological care could help overcome attitudinal and other 
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barriers regarding the integration of palliative care. A few successful examples of pilot projects 
exist. In response to the high prevalence of invasive medical interventions at the end of life in 
haematological cancer patients and the high incidence of hospital deaths in this group, 
comprehensive programmes based on multidisciplinary home care services coordinated with 
haematological wards and hospices, have shown to have had an impact on patient and family 
satisfaction and the time spent in hospital in the last days of life (501,1072,1078-1082). An Italian 
initiative has worked to develop integrated care plans including care pathways for terminally ill 
and dying patients and enabling home care both for patients undergoing high-intensity treatment 
as well as palliative patients (1072). 
These examples demonstrate that an integration of the principles of palliative care with 
haematological care is possible. For more patients of this neglected group getting access to the 
speciality, I suggest two changes to the current practice: defining new risk models for 
identification of suitable patients, thereby moving from survival prediction at time of diagnosis to 
a monitoring approach, and early, temporary integration of palliative care instead of a sequential 
model of haematological and end of life care. Current routine monitoring and prognostic risk 
stratification comprises a considerable number of clinical and laboratory findings, among them 
biomarkers for disease staging and chromosomal abnormalities, which carry prognostic 
information for survival (806,1083,1084). Many of these prognostic tools are scored at diagnosis, 
but less so after disease progression (139). With every treatment cycle and line of treatment, 
response to treatment, measured by changes in the Myeloma-protein component level, is 
evaluated (1085). However, M-protein level is a surrogate marker with considerable measurement 
error (26,205), its evaluation is confined to end of treatment/routine follow-up and its usefulness 
for indicating the need of palliative care involvement is limited (139,230). In recent years, 
answers to the questions of prognostication and suitable indicators for the need of palliative care 
have been developed, particularly for non-cancer conditions in which prognostication and the 
definition of a palliative care patient are equally contested and difficult (694). These indicators 
centre very much on performance status, sometimes combined with other signs and symptoms. 
Among them, the most widely used are (202): the Palliative Prognostic index (204,812,1086-
1090), combining performance status with oral intake, oedema, breathlessness at rest and 
delirium, the Charlson Comorbidity Index (195-200), deriving risk of mortality from a weighted 
score of comorbidities, and the Glasgow prognostic index (1091), combining serum CRP and 
albumin levels into an inflammation-based prognostic score (thus it is often used in the 
chemotherapy setting). One recent study from the National Hospice Organization has found that 
Karnofsky Performance Status together with the presence of five symptoms indicated a median 
survival of 6 weeks (1092), although a change in performance status that is not reversible has 
been shown to be an equally potent indicator for palliative care involvement in cancer patients 
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(1092-1097). The problem with this array of possible indices is their focus on the end of life. 
Their aim is to identify patients with a survival of 3 months or less (202). They have only been 
validated in palliative care populations and thus have limited generalisability to other settings. 
Given that some patients with myeloma show compromised general mobility early on in their 
disease trajectory, caused by spinal lesions and myeloma bone disease, performance status may be 
of limited usefulness for prognostication (47,87,90,92,379,499,598,701,750).  
There is a call for prognostic models that integrate biological and patient-related aspects, in 
particular joint predictive models of biomarkers and longitudinal PRO data (1098). This 
recognition of complexity and the need to honour the patient perspective stems from evidence that 
has accumulated over the past 20 years. It has been shown that symptoms and aspects of QOL 
carry prognostic significance for survival that often exceed the strength of association of clinical 
biomarkers (229). Among the symptoms, fatigue and drowsiness are emerging as main factors, 
being associated with survival in over 50% of studies (16,225-229,767). This has been found for 
solid cancer patients (223,238-240,1099,1100) as well as haematological disease patients 
(164,241,810,1101). In our systematic review, we likewise found a higher absolute association of 
symptoms and patient-reported outcomes than for biomarkers or demographic factors. Tracking 
aspects of QOL over time therefore has the potential to provide a more relevant way of 
identifying who might benefit from palliative care in multiple myeloma. From a clinical 
perspective, the results from this study suggest that patients with poor performance status, high 
symptom burden and the presence of fatigue or pain could be considered as potentially benefit 
from palliative care programs. These aspects could be monitored using above-threshold values of 
the MyPOS. 
To meet the demand for palliative care in haematology, new models of co-management and early 
integration need to be developed. Evidence for the feasibility and effectiveness of early 
integration has been emerging in recent years for solid tumours. Three RCTs have tested different 
models of outpatient early palliative care and showing effects on a number of physical and 
psychological symptoms, QOL and even prolonged survival of metastatic lung cancer patients 
(172-174,277). Less stringent evidence from retrospective and prospective cohort studies 
investigated different models of outpatient collaborative oncology and palliative care (1102-
1104). One also needs to bear in mind that the existing few studies had considerable variability in 
setting (i.e. stand-alone clinic versus integrated clinics versus home-based palliative care 
provision), timing (upon referral or simultaneous care), and the number and types of interventions 
within palliative care that were delivered (1102-1104). It is currently unknown which model of 
integration works best. None of these studies included haematological cancer patients, therefore 
the transferability of this model needs to be researched. Only two retrospective studies including 
leukemia patients could be located that tried a collaborative model of care between 
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haematological cancer care and the palliative sector (143,153). Preliminary effects shown were 
symptom alleviation, advance care planning, home care provision and hospice referrals and 
bereavement care for family members (143,153). 
Currently, the predominant model of care is the “solo practice” model as defined by Bruera and 
Hui (2010) (248). In this model, palliative care provision is completely separate from oncological 
care and the haematological team provides all disease management and supportive/palliative care. 
The first level of integration exists when interdisciplinary care is provided by referral to 
supportive and palliative care services as needed. However, the main responsibility remains with 
the haematologists, referral to palliative care happens too late (1105) and results in patients being 
seen only at the end of life. The lack of interaction among the different specialists can result in 
adverse events for the patient (248). The step to a fully integrated model between primary 
specialist and palliative care team is taken when multidisciplinary team meetings are held with 
palliative care consultants present and seen as full members of the primary care team (248). 
Different approaches to achieving this level of integration range from embedded clinics 
(277,1106), to outpatient palliative care clinics within oncology (172,174,1107,1108), inpatient 
palliative care advisory teams (1109), and combined patient care rounds or MDT meetings (1106)  
To routinely involve palliative care, ongoing communication between the specialties is needed 
(162). Universal screening criteria both for inpatient and outpatient settings (178,1110) could help 
identify patients earlier on in the disease trajectory. At a minimum, standardised assessment of 
palliative care needs and concerns is needed, for example using the MyPOS or similar tools, to 
accomplish the management and treatment of the identified symptoms and problems 
(275,277,1111). This would require addressing the attitudinal barriers and provide training to 
foster haematologist’s willingness to base their treatment decisions on patient’s QOL and be open 
to such co-management models (515). If early integration is achieved, potential effects would be 
the reduction in patients with multiple myeloma seen too late in their disease strategy. Also, early 
involvement could lessen the stigma of equating palliative care with end of life care (1112). 
Instead, patients and their families could develop a longstanding relationship with the palliative 
care team, similar to the trust they develop to their haematological care team (277). Developing 
this therapeutic collaboration can prepare the ground for difficult conversations regarding advance 
care planning, weighing the benefits and harms of treatment options and achieving clarity 
regarding the patient’s goals (277) Some authors also see the major benefit of early palliative care 
referral in the psychosocial support provided even to newly diagnosed patients (153). 
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8.4.4 Training, resource and policy implications 
Significant barriers still prevent the early integration of palliative care into the continuum of 
haematological cancer care. Some of these include the lack of payment models to support a co-
management model (1112). Others are the considerable lack of trained professionals (277). 
Treatment and the profile of side effects are complex in haematology and the special needs of 
haematological cancer patients at the end of life regarding management of infections and bleeding 
have been listed as barriers to integration (151,153,707,1113,1114). In an integrated and 
interdisciplinary model of care, haematologists and palliative care could learn from each other, 
both regarding aspects of tumour biology and anticancer treatment and knowledge about 
management of complex symptoms and psycho-spiritual care (154). This would involve 
broadening oncology training to communication skills programs (1115) and allowing rotation of 
registrars across the disciplines.  
Tied into this aspect is the general training of the workforce that is needed to fully implement 
patient-reported outcome measures in clinical practice. Among the systematic reviews on PROs, 
none covers the process of implementation of outcome measures into clinical practice (37,417-
423,966). But if PROs like the MyPOS or others are envisioned to guide care and be used for 
routine screening and monitoring of patients in oncological practice, an implementation strategy is 
needed to change processes of care. Implementing PROs into routine practice is an issue of the 
organisation rather than the individual. Several systematic reviews of qualitative research have 
highlighted barriers to routine use that need to be addressed (37,417-423,966). These stress the 
need for a set of implementation strategies covering education, audit and management of change 
within the organisation. Such an implementation also requires resources at the outset, clinician 
input into the system, and planning feedback that patients and clinicians receive from the system, 
the format and the additional time that data collection and documentation will take (453,1116). 
Grol (1997) (1117) proposed a model for implementing changes comprising the elements (a) 
educational – sustainable training provided to a changing workforce, (b) epidemiological – 
provision of evidence-based guidelines of how to react to uncovered problems through screening, 
and (c) marketing – designing the system involving all stakeholders, but patients and their 
families in particular. Some of the international organisation, for example the International 
Society for Quality of Life Research (ISOQOL), have recognised the need for routine 
implementation of PROs and provided guidelines for their implementation (400). They also stress 
the need for a high-facilitation model of implementation since PRO use in clinical practice is 
resource-intensive.  
This points towards the fact that changing care and aiding the integration of palliative care into 
haematological practice requires a population perspective. As shown above, effective 
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dissemination relies on new information infrastructures and technologies and the redesign of care 
and thus should not be left to individual organisations. There are several examples of nationwide 
initiatives that promoted an integrated system of introducing PROs into clinical practice, offering 
consistent training and facilitation, and using data to inform patient care and/or provide 
benchmarks and metrics for overall performance of services. The most prominent of these 
examples is the Palliative Care Outcomes Initiative in Australia (422-424), running as a national 
program that utilises PROs in palliative care. A similar but less sophisticated system exists since 
2007 in Ontario, Canada (1118). All cancer centres including homecare services systematically 
collect data on performance status and the Edmonton Symptom Assessment Scale in outpatients 
with cancer. Contrary to the Australian initiative, this system contains province-wide information 
on general oncological cancer outpatients and thus focuses on patients further upstream. Yet a 
different way is followed in England. The UK PROMs programme introduced a generic health 
status assessment via the EQ-5D into elective surgery (438). Rather than directly benefitting 
patients by developing programmes of how to improve PROs of patients and promote quality 
improvement of providers, the system relies solely on benchmarks with the aim to provide data 
regarding which services perform best, so that consumers can select the best quality 
(442,443,1119). 
All these systems envision change by following a top-down approach of changing health care by 
changing processes. A different model of introducing routine monitoring into myeloma care could 
follow the approach of putting monitoring into the hands of the patient. Such an approach is 
gradually being developed by Myeloma UK, a patient-led charity operating in Scotland and 
England. They have recently developed an online platform onto which patients log on to track 
their treatments and progression of their disease. Currently this system does not contain PRO 
information. During a conference held at the Cicely Saunders Institute in March 2016, this subject 
was discussed with Myeloma UK representatives, service users and clinicians from both 
haematology and palliative care. The introduction of PROs and promotion of patient-led 
monitoring could provide a bottom-up approach to the implementation of PROs. However, it 
should be borne in mind that such a system needs to fulfil considerable security requirements, as 
every electronic patient record does, and guidelines for clinicians on how to react to certain QOL 
problems, based on evidence, are still needed.  
A third approach, next to performance measurement and patient-led monitoring, could be the 
coupling of PROs with nationwide cancer registries. This approach has been used in the 
Netherlands (1120) in the Eindhoven Cancer Registry, which compiles data of all individuals 
newly diagnosed with cancer in the Netherlands. The EORTC QLQ-C30 is collected routinely on 
these patients and they are followed into survivorship or until death. The generic QOL module is 
supplemented with disease-specific or domain-specific questionnaires, i.e. satisfaction with 
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information provision (1121). There have been numerous outputs from this cancer registry-based 
monitoring, also focusing on or involving multiple myeloma (381,503,805,1120-1122). Its 
strength relies on flexibility of data collection, which is either achieved by using a web-based 
system or via postal surveys. The general population is also surveyed at regular intervals to 
provide the facility of comparing to population norms. Through the registry, a direct link to 
clinical data is possible. This data can then be used to identify patients at high risk for poor 
physical and mental health as well as enabling the analysis of mechanisms leading to specific 
outcomes (1120). In the United Kingdom, a cancer registry specifically focusing on haemato-
oncological patients has formed surveying the population of newly diagnosed haematological 
patients in two adjacent UK Cancer networks (145). So far, this group yet needs to integrate PRO 
data. Their current emphasis is on haemato-pathology laboratory parameters, prognostic factors, 
treatment and response to treatment history and socio-demographic details. This registry has taken 
efforts of setting up the infrastructure necessary to support monitoring and it would be interesting 
to see whether they can incorporate the PRO perspective in population-based monitoring. 
Following the monitoring idea and the nationwide initiatives to promote patient outcome 
measures that recent health policy has promoted, the MyPOS could be used in such a system to 
measure quality indicators of haematological care, but also to indicate the state of integration 
between the disciplines of palliative care and general oncological care. The number of potential 
stakeholders has broadened in recent years to not only include policy makers, regulators and 
physicians, but also patients and their representatives. Their views on the effects of treatment 
should be included, particularly when health care is predominantly concerned with the treatment 
of chronic or palliative conditions where improving life quality rather than cure is the aim (435). 
Both sides, health care and service commissioners as well as patient representatives have called 
for including outcome measures into metrics, to provide information about the quality of services 
(439). The availability of such metrics, such as the quality indicators utilised in the Australian 
Palliative Care Outcomes Collaborative, would allow policy makers to set goals for the quality of 
healthcare provision, and patients and referring physicians to recognise services with good care 
provision. Avedis Donabedian in 1966 (448,829) split the elements of quality into the three 
parameters structure, process and outcome. Outcome is defined as “a change in the health status 
that can be attributed to preceeding health care” (p. 167). While structure and process variables, 
such as the presence of a palliative care advisory teams or the numbers of times a palliative care 
physician or nurse has seen a patient with multiple myeloma, are useful in describing prerequisites 
to quality, only outcomes can capture this quality. Hence, outcome measures like the MyPOS can 
be used to capture aspects of quality and, if routinely implemented, could help compare the 
quality of haematological services in meeting the needs of haematological cancer patients. Current 
indicators of the integration of palliative care with general oncology still focus mainly on 
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structure and process variables. For example, presence of in- and outpatient services (structure) 
and routine screening and documentation of palliative care needs in patients’ notes (process) are 
used (1123). However, for quality to be judged outcomes over time need to be assessed. Possible 
benchmarks could include reduction in high symptom levels or congruence of preferred and 
achieved place of death in haematological cancer patients (275,1106,1112,1123). Other 
benchmarks could include staying symptom-free and thus focusing healthcare professionals on the 
prevention of symptoms and problems (442,443). Overall, for these metrics to reflect patient 
experience, outcome measures need to be integrated routinely into health care. 
 
8.5 Areas for future research 
This study highlighted the course of palliative care-related concerns in multiple myeloma, and, for 
the first time, described the longitudinal symptom burden using new statistical and psychometric 
approaches. The integration of methodological aspects of assessing and measuring quality of life 
with screening for palliative care-related problems suggests a number of further areas for research 
regarding both the further development of the MyPOS and using the measure in clinical practice. 
 
8.5.1 Further development of the MyPOS 
The psychometric analysis of the MyPOS, both within a classical test theory and a Rasch analysis 
framework, supported the overall validity and reliability of the tool. However, problems with 
floor effects, suboptimal targeting and scaling (disordered response categories) were observed. In 
order to support the utility of the questionnaire in longitudinal applications and clinical trials, 
these shortcomings should be addressed by revising the scale. Since its initial validation, the 
MyPOS has been converted partially to fit the format of the Palliative Care Outcome Scale (512), 
a tool that has undergone several revisions to its scaling, the most recent one during cognitive 
interview testing prior to forming the Integrated Palliative Care Outcome Scale (IPOS) (818,819). 
Although this modularised approach addresses some of the challenges facing questionnaires, 
particularly the aspect of standardisation, it resulted in disregarding the participants’ preference of 
an evaluative response scale that they indicated during the cognitive interviews in the 
development phase of the MyPOS. Further exploration of the floor effects could entail testing the 
MyPOS in a larger sample of inpatients and patients at the end of life as well as in patients with 
pre-stages of myeloma or newly diagnosed myeloma patients in the watch-and-wait group (360). 
The former two groups are likely experiencing a higher symptom burden than participants in the 
present study. The latter group might represent a group with low disease and treatment-related 
symptom burden. This would allow an exploration of whether the MyPOS validly reflects quality 
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of life concerns at the extremes of its scale. During this exploration, further study of the issue of 
recall and timing would allow addressing the combination of stable and fluctuating or state-and 
trait-like items in one questionnaire. Since participants in the longitudinal survey as well as in the 
piloting interviews voiced concerns regarding the time frame of the questions, different recall 
periods could be studied and contrasted against each other. This has been successfully 
implemented for fatigue, for which an equivalence of a seven-day to a four-week time frame has 
been demonstrated (437) by the absence of differential item functioning within Rasch analysis. 
However, the study of equivalence and impact of different time frames is one of the largest 
measurement challenges in PROs and QOL tools. Stull et al. (2009) (870) have provided a 
heuristic model for selecting recall periods for symptoms, psychological states, global life 
satisfaction and psychological traits which could act as a conceptual framework for the MyPOS. 
Given the higher incidence of multiple myeloma in people with African descent, its cultural 
adaptation and accurate translation into different languages would aid its utility both in the United 
Kingdom as well as worldwide. The EORTC and FACT working groups faced a similar 
challenge, and provided translation guidelines for their tools (1124,1125). Similarly, since the 
spectrum of multiple myeloma reaches from indolent forms to advanced and relapsed disease, and 
the application of the MyPOS measure is particularly recommended in a palliative care 
population, proxy or caregiver versions of the tool should be developed. Both the original POS 
and the newly developed IPOS have staff-rated and caregiver-rated versions available. Therefore, 
the development and validation work would be minimal, with approximately 10 patients for 
cognitive interviews and small samples for validity and reliability testing (869). Proxy versions 
address the difficulty of collecting outcomes data from physically compromised patients and 
support the monitoring of the whole spectrum of disease severity. However, although caregiver 
and patients can be close in assessment, there are known inaccuracies such as over- and 
underestimation of the severity of physical and psychological symptoms (1126), as demonstrated 
for the symptom drowsiness in the IPOS (819). 
One of the main barriers to the use of PROs in clinical practice is the lack of demonstration of 
their responsiveness to change and indicating what constitutes a clinically important change on 
the scale (323,1127). Establishing an MID for the MyPOS, both the total score and its subscales, 
will also foster the use of the MyPOS in clinical trials. However, as this is the first study to 
establish the minimal important change for a measure of the POS family, the MID estimates need 
to be validated in larger studies. Triangulation, the use of multiple methods to determine the MID, 
is recommended, typically yielding a range of values which need to be narrowed (1128-1130). We 
tried to follow this approach by providing both anchor-derived and distribution-derived MIDs for 
the MyPOS. Further research should focus on the problems with the global change rating scale 
that was used as the anchor in the present study. For instance, violation of the monotonicity 
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assumption in form of patients reporting they were better on the global change question but 
reporting a rise in their total MyPOS score needs to be understood and addressed. Furthermore, 
uncertainty exists regarding the comparability of MIDs derived from observational studies versus 
those established in clinical trials (1128). It is known that the MID can vary according to the 
impact of interventions and sample characteristics (1131). A larger database can address its 
generalisability. This will be harder to establish for the MyPOS as it is for larger QOL consortia 
like the EORTC and the FACIT group who can integrate data from over 10,000 patients collected 
in RCTs (1132). However, should it be possible to use the MyPOS as an instrument for routine 
monitoring of QOL issues in haematology clinics, the resulting large dataset might provide a 
source for such an analysis. Further validation of the MID should make use of the new 
psychometric methods to compute change on the standardised latent construct scale (1133). Since 
Rasch modelling allows the construction of a measure that is both free of influences from the 
sample and the scale (662,968,1134), its application for establishing MIDs is particularly 
promising and can yield generally applicable MIDs. IRT analysis can also be used to first evaluate 
the validity of the global change/transition question used as an anchor in responsiveness analyses 
(323). This was recently employed in a responsiveness analysis of the FACT-G (323). The use of 
Rasch modelling/IRT also plays a role in understanding response shift, one of the measurement 
errors that beset longitudinal studies of PROs (918). Differential item functioning analysis can 
reveal changes in patients’ standards and definitions of QOL and Rasch scaling analysis can help 
understand the change in the relative importance of domains as patients adapt to changing long-
term experiences (918). Methods have been proposed for using the new psychometric methods to 
study response shift and adaptation processes (728). 
An integration of the above mentioned proposed adaptations of the MyPOS – establishing a proxy 
version, cultural adaptation, using the MyPOS for monitoring and establishing a large database to 
study its longitudinal validity – could be achieved by converting the MyPOS and its core measure 
IPOS into a multi-level PRO item bank. An item bank constitutes a hierarchical collection of 
calibrated and standardised items that provide an operational definition of a latent construct (i.e. 
quality of life). An item bank therefore covers all relevant domains and all relevant severity levels 
of this construct. It provides a basis for designing the best set of questions for a particular 
application and therefore makes possible the derivation of short forms or the dynamic selection of 
targeted questions based on the characteristics of the patients (i.e. disease severity, study or 
assessment aim) (1135). The latter can be accomplished by developing a computer-adaptive test 
(CAT) based on the item bank, a procedure in which the computer determines the next most 
informative question based on the prior responses of the patient and the respondent’s latent trait 
level that is revealed in these responses (1136). Item banks and CAT are envisioned to be the 
future of assessment and screening (1137), as they allow to measure with greater precision by 
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means of shorter questionnaires (345,1116). Both the EORTC and the US National Institute of 
Health have developed or are currently developing item banks across diseases, either − such as in 
the case of the EORTC – converting their established standard EORTC core questionnaire into an 
item bank, or building one as is the case with the Patient-Reported Outcomes Measurement 
System (PROMIS) (397,398,520,1031). Particularly the PROMIS system makes use of the feature 
of Rasch analysis and IRT to provide equivalent scores for different instruments and establishing 
the validity of single items instead of complete questionnaires. This makes it possible to compare 
QOL results across samples and studies (661) and tailor content, yet using standardised scores 
(997,1138). It is even possible to customise item banks further, as evidenced by a computerised 
pilot version of the Schedule for the Evaluation of Individual Quality of Life (SEIQOL) (1139), 
one of the individualised QOL measures. 
Establishing a POS/MyPOS item bank would benefit the routine collection and utilisation of these 
PRO data in clinical data and bridge the gap to its clinical utility. Chang (2007) (1135) has 
proposed the introduction of item banks and CAT as aspects of an integrated clinical decision 
support system for PROs, also consisting of clinical practice guidelines and predictive models 
based on large databases. The strategy for developing an item bank should follow the general item 
bank development approach as followed by PROMIS and the EORTC, including literature 
searches and conceptualisation, formulation of new items/operationalisation, expert and patient 
evaluations in Delphi studies, field-testing and cognitive testing of items, and lastly psychometric 
analyses and item calibration (397,398,410). This would establish the first item bank built to 
support palliative clinical practice. 
 
8.5.2 Validation of the risk model and further observational research 
Assessment and measurement of QOL in clinical practice ideally help identify those patients at 
risk of developing a poor outcome. In this study, the focus was on developing a multivariable 
prognostic model. In two regression analyses, important factors and predictors were identified. 
Although development occurred in two stages, first in the secondary analysis of a cross-sectional 
sample of myeloma patients and then in the longitudinal survey, relative weights of each predictor 
and a full validation of the model’s predictive performance (i.e. calibration and discrimination) in 
new participants is yet to be achieved. Moons, Altman and colleagues (1140) propose a three-
stage process for the validation of risk models. Development, in addition to establishing 
predictors, entails assigning relative weights to each predictor, optimising the model and 
correcting for overfitting (635). Validation studies should occur in mostly broad samples of new 
participants from various institutions to test the model’s predictive performance (calibration and 
discrimination, i.e. does the model correctly identify those at risk and correctly reject those not at 
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risk) (14,629). The last stage consists of impact studies, in which the clinical utility of the 
prognostic model for decision making is studied (14). Validation should be done on different and 
larger datasets than those used for developing the model (629,1141). 
For the MyPOS and the proposed classes of QOL experience, this should be done focusing on a 
sample which is followed up for a longer period than eight months, also to allow the combination 
of PRO and survival data in this cohort. This would necessitate solving the challenge of recruiting 
more ill patients, particularly inpatients, stem cell transplant patients and those hospitalised with 
advanced and relapsed/refractory myeloma disease. This would allow collecting data from 
subjects that are palliative rather than only from survivors or relatively well, stable patients (95). 
It can also proof difficult to reach subjects who do not usually respond to QOL survey, but may 
have poorer QOL outcomes or are dissatisfied with the healthcare service they received (1142). 
Care must also be taken to not rely on treatment-defined samples of younger patients but 
achieving a true population-based sample (145). Establishing proxy versions of the MyPOS, as 
proposed in the previous section, would also help in this situation. Longer and more extensive 
follow-up can allow subanalyses of dose-intensity and treatment type, establishing the long-term 
toxicity of treatment and the chronicity of symptoms and their treatment-related or disease-related 
nature (509,698). For this aetiologic research, potential biologic correlates of the mechanisms 
underlying symptom and QOL burden, particularly albumin, haemoglobin, and biomarkers of 
inflammatory processes (190,379,785), should be collected. However, given their rather short-
term importance during acute therapies such as ASCT (379), their role for indicating longer-term 
poor outcomes is yet to be established.  
Relating QOL information to survival and establishing the predictive power of the MyPOS for 
survival in myeloma could underscore the validity and equivalence of PRO information as 
outcomes. So far, only treatment response and disease activity are being monitored in myeloma 
on a regular basis, but have proven limited usefulness for indicating the need for palliative care 
referral. QOL needs to be established as a similarly reliable and valid indicator for progression of 
illness and palliative care need in the haematological cancer population. While symptom measures 
have been shown to be predictors of cancer survival in solid tumours (146,1143), this evidence is 
lacking for multiple myeloma or restricted to studies examining symptom scores recorded at 
baseline or at enrolment in a clinical trial (22,23,242). Predictive models that take into account 
more heterogeneous, larger, non-treatment defined samples are needed.  
Further to these suggestions for extending the longitudinal study, new areas for observational 
research, particularly regarding palliative care involvement in multiple myeloma care, should also 
be considered. As established in the meta-analyses of place of death and specialist palliative care 
involvement in multiple myeloma and other haematological cancer (137,152,159,706), 
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haematological cancer patients are missing out on palliative care. But there is also a general lack 
of information on those patients that receive specialist palliative care and their preferences. We 
know that large proportions of patients want to die at home, but whether this proportion is 
comparable in haematological cancer patients and whether multiple myeloma patients maintain 
their preferences as the illness progresses, is not well understood (112,151,1144). Next to 
preferences for place of death, preferences for place of care may also change over time. Multiple 
myeloma, with its potentially long disease trajectory from indolent, pre-forms to advanced stages 
constitutes a good model for studying patient factors that help predict changes in preferences and 
to study advance care planning (152). This would also promote information provision and help 
guide resources for better quality of death and dying in myeloma (151). Linked to the study of 
preferences is the study of transitions in care in this patient cohort. For achieving early and good 
quality involvement of palliative care, the quality of existing hospice and home care programmes 
needs to be described. There is scope for using mortality follow-back surveys to evaluate the 
quality of end of life care from the caregivers’ perspective (105). This would also provide insights 
into how myeloma patients might want to receive specialist palliative care – as part of oncological 
care, as a stand-alone intervention and in which setting (homecare, hospice, hospital) (161). This 
information could help support haematologists in their complex decision making processes when 
patients reach the advanced refractory stage of treatment (1145). 
Disproportionally little attention has been paid to informal caregivers of multiple myeloma 
patients. So far, only one study measured their unmet needs and contrasted them with those of 
their partners with advanced multiple myeloma (90). In the haematopoietic transplant population a 
study has looked at long-term effects of 177 transplant survivors and their partners a median of 
six to seven years post-transplant (1146). Partners reported increased fatigue, cognitive problems, 
depressive symptoms and lower emotional, social and spiritual well-being, highlighting the 
adverse effects that informal caregivers suffer. It is unknown how far the evidence from 
caregivers of solid tumour patients with advanced disease can be extrapolated to multiple 
myeloma. Although multiple myeloma affects the whole family and caregivers assume 
responsibility in the daily care of their partners like in other cancers, the situation of myeloma 
sufferers and their families might be unique as caregivers might be subject to psychosocial 
fatigue, a process described in a recent qualitative study by Zabora et al. (2015) (360) in which 
stressors from years of medical caregiving, from the indolent, watch-and-wait period to the 
advanced stages, culminate and result in psychological and social strain. 
Research is needed to describe the burden of caregiving in this population, to characterise the 
caregiving experience, particularly across the myeloma disease continuum. Caregiving intensity 
might vary, based on a number of treatment-, disease- and patient-related factors, as well as the 
level of disease burden in the elderly caregiver (1147). Ideally, a study should follow caregivers 
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over time and assess their views on their health and caregiving burden at the same time intervals 
during which the patient is surveyed. Given that multiple myeloma afflicts the elderly and their 
informal caregivers therefore also constitute an elderly population, attention should be paid to the 
caregivers’ disease burden. Multiple myeloma often presents with a prolonged illness trajectory, 
characterised by patients experiencing a high level of uncertainty and fear of relapse (360,361). It 
would be interesting to see whether trajectories of physical, emotional, social and spiritual 
wellbeing match those of patients or whether transitions occur at different time interval to 
patient’s status. A different avenue for research consists of contrasting patient’s assessment with 
the caregiver’s assessment of the patient’s situation and understanding the factors that influence 
the agreement between the two perspectives. 
Caregiver burden is partly a result of the responsibilities of caregiving, involving direct care, 
indirect care and the changes to normal routines and employment as a result of these 
responsibilities (1148). Yet, in multiple myeloma nothing is known about the actual amount of 
caregiving and the different tasks that informal caregivers perform when caring for their partners. 
This could be accomplished by incorporating self-report data about care activities, for instance 
through tools like the Client Receipt Service Inventory (CSRI) (1149-1151). The CSRI provides 
information about service utilisation by collecting retrospective information about the services 
received. In addition, it records the different tasks that informal caregivers perform, thus allowing 
the estimation of informal care costs. It is a validated tool and has been used in a range of research 
studies including in mental health, community care of older people and dementia (1150,1151). 
The study of unmet needs represents another fruitful avenue for study, with the potential to design 
interventions that directly address unmet needs and provide targeted care and support for informal 
caregivers. Two recent studies in HSCT populations have identified unmet needs in caregivers 
including managing concerns for cancer recurrence, finding information about financial support 
and benefits, strategies to maintain the caregiver’s own health, sexuality and balancing the needs 
of the patient with the caregivers’ own needs (1152,1153). These unmet needs could be further 
investigated in caregivers of myeloma patients. Specific assessment instruments like the Carer 
Support Needs Assessment Tool (1154) encompass multidimensional needs of family caregivers 
and have a special focus on end-of-life care, another gap present in the literature on informal 
caregivers in multiple myeloma. The longitudinal description of unmet needs would eventually 
indicate when during the disease trajectory informal caregivers are at the highest risk of 
experiencing strain and would benefit from support. The implementation of such tools in routine 
clinical care can help oncologists and palliative care providers to better identify the needs of 
unpaid carers and to design and offer interventions (1155,1156). 
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8.5.3 Using MyPOS to foster integration of haematological and palliative care in 
multiple myeloma 
8.5.3.1 Early identification and early palliative care for patients with multiple myeloma 
The new definition of palliative care by the World Health Organisation highlights the need for 
early identification and impeccable assessment as elements of good palliative care (266). In fact, 
timely referral of lung cancer and advanced solid tumour patients to palliative care has shown the 
potential of incorporating patient and family wishes into care plans, improving quality of life and 
reducing aggressive interventions in the last months of life with patients being able to die in their 
preferred place of care (172-174). Evidence supports the efficacy of palliative care for improving 
clinical outcomes and quality of care (1157), reducing hospital costs (272,1158) and reducing the 
aggressiveness of care in terms of hospitalisation rates, invasive procedures and intensive care 
admissions (1159). 
All these outcomes would benefit patients with multiple myeloma and their caregivers. Yet, most 
patients who could potentially benefit from palliative care are not identified or are identified late 
in their disease process, despite higher inpatient mortality and at least comparable if not higher 
unmet needs (9). The significantly later access to PC services in haematology has been described 
in several case series and studies with aggressive lymphoma, leukemia and myeloma patients 
(101-104,112,126,130,137,151,243,710,1015,1160-1164). The WHO estimates that only 1 in 10 
who needs palliative care receives it (111). Reasons for the low referral rates are manifold. The 
current system of referrals relies entirely on physicians, however, most have been slow to 
integrate palliative care into their practices (1165-1167). Reasons for delayed or lack of referral 
might include a perceived lack of palliative care needs among these patients by the 
haematologists, the possibility of cure in the advanced disease setting or the blurring between 
curative and palliative treatments in haematological cancer patients, general uncertainty in the 
disease trajectory, a strong sense of responsibility to provide care, stigma or lack of understanding 
what palliative care is and the lack of randomised controlled trials of early palliative care in 
haematology (103,139,141-143). Moreover, there are special considerations to care provision at 
the end of life in haematological cancer patients, due to the invasive nature of their treatments, the 
speed of change to a terminal event, the need for blood products and the fact that patients 
sometimes show signs of recovery even when close to death (138). Communication between 
providers and variation in referral criteria or in the perception of what constitutes a palliative care 
patient have also been proposed as chief barriers to the provision of palliative care services 
(1067,1168-1171).  
Some of these issues, particularly regarding the speed of change and the lack of an easily 
recognisable advanced phase of illness, are comparable to the situation in non-malignant disease 
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(694). To help remedy the under-identification and late referral of haematological cancer patients, 
it would be possible to learn from solutions proposed in the context of non-cancer disease. A 
number of tools for the systematic identification of palliative care patients have been developed in 
recent years. These tools either focus on the systematic identification in primary care or in the 
emergency department or intensive care unit (179,1172-1174). They are intended to facilitate 
shifting the provision of palliative care from the last days of life to earlier phases, during which 
palliative care would be provided concomitantly with disease-modifying treatments. This enables 
timely modification of goals of care and the anticipation of needs (1175). Early integration shifts 
the delivery of palliative care from a cross-sectional to a longitudinal model, beginning at the time 
of a life-limiting diagnosis and continuing over the illness trajectory (1176). However, although 
most of these tools consider patient factors such as functional performance status or presence of 
comorbid illness, only a few incorporate a genuine needs-based approach to screening by 
recording symptom burden (1172,1173). The consensus statement on referral criteria for palliative 
care in the hospital setting does not consider a full symptom screening either, albeit mentioning 
admission due to difficult to control symptoms alongside the surprise question, frequent 
admissions, complex care requirements and decline in functioning as primary criteria for referral 
(1110). Though symptom burden is included, self-report measures are not considered in the 
assessment, with a clinician usually making an informal assessment of overall symptom burden. 
But the presence of symptoms is regarded as a trigger equal to factors such as healthcare resource 
use and living situation (1173). This is questionable as it has been shown that single criteria alone, 
such as the surprise question or performance status, are not specific enough and may identify too 
many patients, and they do not reflect and capture the complexity of need (106,694,1177,1178). 
For effective identification of myeloma patients in need for palliative care, a shift in 
prognostication from prognosis/survival models to needs-based models, identifying those at risk 
of deterioration for proactive assessment and care planning, is needed (1173). Screening criteria 
should rely on self-reported, systematically assessed symptom burden. Assessment should be 
multidimensional in nature, incorporating those aspects important to patients and their caregivers 
(1179). These features are offered by the MyPOS. What is lacking is a set of criteria for its items 
that could be used to screen for appropriate referral to SPC in multiple myeloma patients. This 
study would need to establish the diagnostic validity of these cut-off criteria in a large 
haematological/multiple myeloma population. Additionally, for those referred to SPC according 
to these criteria, the appropriateness of each referral to SPC should be determined. Three sets of 
cut-off criteria on the MyPOS should be developed to determine the level of SPC that is needed, 
(a) a one-off consultation with SPC due to low palliative care needs, (b) medium amount of 
contact with the SPC team due to a moderate number of palliative care needs, and (c) a high 
amount of contact with the SPC team due to a high and complex palliative care needs. 
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Similar routine screening procedures have already been developed for distress screening in 
general oncological practice. Since the National Comprehensive Cancer Network in the USA 
(647) and the National Institute for Clinical Excellence in the UK (1180) designated the Distress 
Thermometer as the main instruments in their guidelines, it is now the most widely implemented 
clinical tool for screening in psychosocial oncology. A similar process could be designed for 
incorporating the MyPOS into standard oncological practice. Also, new technology in form of 
touch-screen computers installed in outpatient clinics could help this process, as already piloted in 
several UK clinics in the Imparts project (1181). The set of diagnostic criteria could be obtained 
in a prospective study among multiple myeloma patients in outpatient clinics. However, since the 
main aim would be to obtain valid and reliable criteria, a sample of consecutive patients needs to 
be screened for the criteria to be generalizable. This poses interesting demands on the recruitment 
process. Ideally, the MyPOS should be implemented as a routine screening tool for all patients in 
clinics and recruitment should follow an opt-out approach. Several demographic and clinical 
characteristics could be taken into account when designing the set of criteria for the MyPOS. 
These screening criteria could either consist of a cut-off value for subscales of the MyPOS or 
could consider particularly high values on a set of items (i.e. levels “3 – severe” and “4 – 
overwhelmingly” on the MyPOS scale). For instance, instead of defining a value on one subscale, 
one could design a criterion of at least two scores of “4” or at least three scores of “3” on the 
whole MyPOS or among the physical or the psychological items. 
To determine the optimal cut-off points on the MyPOS for appropriate referrals to the palliative 
care consultation service, an external, standard criterion needs to be defined. This could either 
consist of a palliative care clinician’s rating of appropriateness of SPC for each patient, or – in a 
longitudinal study – survival. However, this again poses problems, as both these criteria represent 
those barriers that were identified as needing to be overcome for timely referral of haematological 
cancer patients to palliative care. In the absence of a clear definition of what constitutes a 
palliative care patient (1068), this situation cannot easily be remedied. All potential external 
criteria, even the ESAS for which cut-off criteria have been defined (1182,1183) and the surprise 
question to determine prognosis (1184), carry a potentially substantial amount of measurement 
bias and cannot therefore be considered gold standards. This poses challenges for the evaluation 
of the diagnostic validity of these cut-off criteria since ROC curve analysis and generalised linear 
models procedures for determining the set of criteria with the smallest amount of misclassification 
rely on a criterion that is unbiased by measurement error. Also, determining the appropriate cut-
off score to use on the MyPOS depends on the clinical importance of false positives versus false 
negatives. One could argue that it is more important that every patient with multiple myeloma 
who possibly has a need for palliative care interventions be identified (531) – which would argue 
for favouring sensitivity over specificity. This approach might result in a potentially large 
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population of multiple myeloma needing attention from SPC services, thus putting the service 
under considerable strain. Therefore, an economic evaluation should be performed alongside this 
validation study.  
A possible alternative solution would be to develop training for haematology doctors and nurses 
to deliver general palliative care. This longitudinal study has demonstrated that advanced disease 
and palliative care need are not dependent on phase of illness or biological factors. Rather, 
symptom burden, even during the early phases of illness indicate that patients can profit from 
symptom alleviation and psychosocial interventions. Information needs, also regarding the end of 
life, are high in this cohort and need to be addressed (1185). A shared care model is proposed for 
facilitating the integration of palliative care and haematological care, whereby general palliative 
care consists of alleviation of pain and other symptoms, psychosocial care of anxiety and 
depression and general discussions regarding prognosis, care plans and end of life care. Specialist 
palliative care services could be involved on a short-term basis for the care of complex and 
refractory symptoms and side effects in myeloma. The following model (Figure 13), partly based 
on Hui and co-authors’ (2015) views on early integration of palliative care in general oncological 
care (260) highlights some of the SPC contributions to generalist palliative care in haematology. 
The upper row represents generalist palliative care issues, the lower row represents contributions 
of SPC to the care of myeloma patients. 
Figure 13: Research opportunities of generalist and specialist palliative care in multiple myeloma 
(based on (260)) 
 Early or advanced multiple 
myeloma 
Advanced and refractory 
myeloma 
Disease and cancer 
treatment-related issues 
Secondary supportive care to 
cancer treatment (addressing 
toxicities in MM treatment) 
Management of treatment-
related side effects  
Cancer treatment decisions at 
the end of life 
Supportive care issues 
Physical, emotional, spiritual 
concerns 
Unmet needs, particularly 
information needs and sexual 
concerns 
Advance care planning 
End of life care issues in 
patients with cancer  
Palliative home care 
 
An intervention to support such an approach would be the routine use of the MyPOS for 
monitoring of symptoms and palliative care concerns in myeloma patients. Some recent studies in 
general oncology and HSCT populations using website-based systems have shown how this 
application can be successfully linked to patient education and offering personalised supportive 
care through these websites (43,189,467,569,1186-1188). The self-care element combined with 
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patient education has the potential to foster self-efficacy and empower patients (421,1189-1191). 
Trials have shown the feasibility of building a monitoring system using the internet even in older 
populations (43). Monitoring applications can either be built as patient-led systems, in which 
patients monitor their QOL themselves, or as clinician-led systems, in which monitoring is linked 
to an alert system notifying the clinic of the need to review the patient, thus providing early 
identification and further treatment of symptoms and problems. In the last part of this section, I 
would like to propose this latter approach for a complex intervention study. However, designing 
an intervention that puts monitoring into the hands of the patients, together with appropriate 
support for self-help and further interventions also represents a fruitful way of enhancing the 
clinical utility of PROs such as the MyPOS. 
 
8.5.3.2 Complex intervention of monitoring HRQOL and palliative care needs in multiple 
myeloma using the MyPOS 
Instead of just introducing the measure into practice I would like to propose combining MyPOS 
monitoring with a training component for oncology staff (1160) and a restructuring of the 
multidisciplinary team meeting process in haematology, thereby addressing some of the 
shortcomings that have been identified to hamper the evaluation of routine outcome assessment in 
clinical practice. According to Greenhalgh (2005) (427), PROs can be applied at the individual 
patient or the group level. At the individual level, screening and monitoring with feedback only 
provided to the health care professional (HCP) directly involved in the care of the patient is the 
most widely studied model. No intervention study to date has addressed the gap of implementing 
outcome measures as tools to structure the process of care planning in multi-disciplinary team 
meetings (MDTs) (426). This study would also need to address shortcomings in trials of outcome 
measures, namely implementation approaches that foster sustainable, local ownership, training in 
the use of PROs and continued training for health care professionals, provision of management 
guidelines, and thus providing a whole-systems approach to implementation (472). 
Two reasons in particular have led researchers and clinicians to campaign for the wide-spread and 
routine use of PROs in clinical care. First, disconcordance between patient-reported and clinician-
reported symptoms and the unreliability of symptom assessment has been observed. Basch et al. 
(2006, 2009) (44,412) report that cancer patients detected symptoms sooner and with a higher 
severity than oncologists and that clinicians who independently graded adverse events within 
minutes of each other reached modest levels of agreement at best (413). Systematic 
underreporting of symptoms by clinicians, in terms of frequency, severity, incompleteness, and 
general heterogeneity in the methods of reporting have also been observed in other studies in 
oncology (414,1192). Second, next to the improvement of accuracy in the assessment of 
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symptoms, PROs are hypothesised to help the issue of clinician’s reluctance to address QOL 
issues in consultations (427), an issue that was highlighted by clinicians participating in the focus 
group for development of the MyPOS (384). In particular, they valued the MyPOS as an 
“icebreaker” to discuss difficult or embarrassing questions such as emotional and sexual 
functioning with patients. Systematic introduction of PROs into clinical care may enable 
clinicians to discuss these issues and bring about a change in attitudes, so that they view QOL as 
clinically important enough to initiate changes in treatment (427). 
Despite recommendations, the routine use of PROs in palliative care has been slow to implement 
and their wide-spread use is yet to be achieved (37,472). The majority of available evidence, both 
from cancer and in palliative care, focuses on the one-off application. Twelve systematic reviews 
exist (37,416-424,26,453,966). They conclude tentative evidence regarding the effectiveness of 
PROs to improve quality of care, with contradicting results depending on the patient population 
and outcomes that are studied. Particularly in palliative care (37), the introduction of PROs has 
not yielded the impact on patient outcomes that investigators had hoped for. While there is a 
strong effect for their impact on processes of care, both in form of better recognition of 
symptoms, better communication regarding QOL issues and more actions taken as a result 
(37,416,418,427,1193), the evidence for their influence on outcomes shows minimal to moderate 
effects (37). The lack of impact of PROs has been attributed to both their method of use as well as 
to implementation factors of the intervention (427). Without further elements of the intervention 
(e.g. training and clinical management guidelines) addressing changes in staff attitudes and 
behaviour, it is unlikely that the simple introduction of a screening measure leads to changes in 
clinician attitudes and behaviour and ultimately to changes in patient care (427). Reviews of 
facilitators and barriers during the implementation of outcome measures into routine care also 
point towards the importance of a thorough model of implementation that takes into account the 
organisational background and interpersonal relationships between team members for the 
intervention as a backdrop to be successful (416,472,1194,1195). 
Providing PROs for screening purposes with results discussed by doctors alone misses the reality 
of clinical care and the opportunity to make use of the multidisciplinary team meetings that are 
also slowly implemented in haematological care. MDTs in cancer care are composed differently 
than MDTs in palliative care. Their focus often is on diagnosis and curative treatment decisions 
rather than consisting of an inter-disciplinary, multi-professional team to discuss symptom 
alleviation and adaptation to advanced illness, as is the case for palliative care (434). However, 
with the introduction of outcome measures such as the MyPOS and incorporation of this 
information to plan care, it could be possible to alert clinicians to the wider, multidimensional 
spectrum of unmet needs in the multiple myeloma population and help teams to plan care and to 
refer patients appropriately to supportive, psychosocial or palliative care services if needed. 
8 Integration of findings and discussion 
335 
 
MDTs are the preferred model of service delivery in palliative care and neurorehabilitation (434) 
and have been shown to enhance decision making, coordination of care and clinical outcomes 
(1063). Only a small number of qualitative or non-randomised studies has studied introduction of 
PROs in MDTs, using information from PROs as a determinant of clinical decisions (1196-1198). 
These studies solely originated from the discipline of rehabilitative medicine. Only one study 
within palliative care could be located (437). 
Routine use of PROs such as the MyPOS in haematological MDTs could yield many potential 
benefits for myeloma patients, i.e. improved symptom identification, patient-centred care plans, 
better communication within teams and between care providers, the patient and their caregivers, 
as well as enhancing quality of care (1199). If PROs are thoroughly implemented in MDT 
meetings with appropriate training provided to all clinicians, this intervention could potentially 
help with designing better care plans for patients reflecting the multi-dimensional nature of unmet 
needs, and making the process of clinical decision making a shared process (427). 
Evaluating this intervention would need to follow the Medical Research Council’s framework for 
complex interventions (1200). As the introduction of PROs change clinician behaviour and 
processes of care, the introduction of the MyPOS is a complex intervention. It affects other care 
processes (427) and a number of intermediate outcomes need to be achieved before more distal 
outcomes like patient health status can be affected. Establishing its effectiveness can only succeed 
if the active ingredients have been identified (1201). This entails determining elements that lead to 
successful implementation, both in form of incorporation of PROs / change in existing processes 
of care and in form of training. Careful qualitative modelling of team processes in MDTs is 
necessary to understand the mechanisms underlying successful change (434,1202), before such an 
intervention can be evaluated. Therefore, qualitative phases should precede a feasibility 
study/phase II trial to test the feasibility of evaluating the introduction of the MyPOS into routine 
clinical care. Only then can a full phase III efficacy RCT be successful. Moreover, since the 
intervention targets care processes with the risk of carry-over and contamination bias, an RCT 
would need to employ a cluster design (1203) with implications for costs through sample size and 
increase in number of recruiting centres not feasible until best methods of implementation have 
been determined. 
The feasibility study should also explore the best outcomes to evaluate such an intervention. 
Greenhalgh (2005) (427) has pointed out that often outcomes too distal are chosen, without an 
understanding of the intermediate processes that need to occur for distal outcomes to be affected. 
Santana et al. (2014) (1199) have proposed a cascade of processes and outcomes that can be 
affected by the introduction of PROs in clinical practice. They define communication and patient 
engagement/activation as processes most proximal to the intervention, followed by shared 
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decision making, changed patient management, patient and clinician satisfaction, to most distal 
outcomes such as patient adherence and outcomes in the form of health care use, health 
status/HRQOL and survival. Reviews of the effectiveness of PROs in clinical practice (37,416-
424,426,453,966) also highlighted that choice of outcome measures to evaluate the intervention 
are not guided by a theoretical model of what is affected in what way by the intervention. For the 
introduction of the MyPOS in MDTs in haematology, this aspect needs to be modelled both in the 
qualitative phase I work and the phase II feasibility study. Some qualitative work exploring team 
processes after introduction of PROs has been undertaken in neurorehabilitation (434), identifying 
meeting structure organisation and model of service delivery as the external constraints, and 
leadership and team/social climate as mediating processes. Another study exploring how these 
teams use measurement tools highlighted that although the tools led to a better identification of 
patient’s problems and also were used externally, to justify and demonstrate the effectiveness of 
their care to managers and external agencies like social care services, the interpretation of the 
scores to guide clinical decisions was hampered by the clinician’s lacking familiarity with the 
tools and divergent professionals perspectives on what constitutes an important score 
(37,43,436,1204,1205). The intervention therefore needs to address this need for training. 
Development, planning of the training, the choice of the training approach, the content of the 
training and delivery as well as supporting materials and duration of training sessions, lastly the 
sustainability of training effects with staff turn-over should be decided upon. I propose for the 
training intervention to combine problem-based interactive learning elements with small group 
interactive learning practice and the possible introduction of dedicated “outcome champions” 
within each organisation to support the introduction of PROs in team meetings. The training 
element would thus combine elements of train the trainer, focus on team processes, 
communication and problem solving strategies, incorporate clinical management guidelines for 
frequent HRQOL problems in multiple myeloma and refresher webinars for maintenance of skills. 
Both the phase II and phase III stages of evaluation should incorporate qualitative components, 
particularly non-participant observation of team meetings, to understand the above described team 
processes and whether the intervention is having an effect on these processes. 
However, despite this intervention addressing several of the shortcomings identified by 
Greenhalgh in the evaluation studies of PROs (427), it will prove challenging to obtain a large 
enough number of centres to participate in this multi-centre study. While the feasibility study can 
follow a quasi-experimental design, possibly using a pre-post study with a patient cohort being 
followed before the introduction of outcome measures and a second cohort of consecutive patients 
after the introduction of the MyPOS, the phase III study will need to employ a cluster randomised 
design with enough centres participating to account for the intracluster correlation of observations 
and the lower power associated with such a design (1203). However, since haematology 
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constitutes a discipline relatively naïve regarding routine use of patient-reported outcome 
measures this trial could be successful. The aspect of long-term sustainability of these changed 
processes of care requires the use of implementation methods (1206). 
 
8.6 Conclusion 
This observational study to describe the longitudinal trajectories of QOL in multiple myeloma 
provides a major contribution towards the understanding of the persistent and severe QOL and 
palliative care-related problems and concerns in this patient group. It illustrates the high burden of 
symptom prevalence and psychological distress experienced by those patients in all stages of 
myeloma disease, from newly diagnosed into the advanced, refractory disease stages. People with 
multiple myeloma rarely receive adequate support for the wider symptom, psychological and 
other multidimensional problems and they are not accessing specialist palliative care services. 
This study was the first to identify and describe four QOL trajectories within the heterogeneous 
group of myeloma patients. While there are two groups experiencing good and stable or 
improving QOL, there are also subgroups with a chronically low level of QOL or deteriorating 
QOL.  
Experiencing a trajectory of poor QOL was not related to the disease phase or staging variables of 
the disease, like the International Staging System. This points towards the need to base advanced 
support for these patients not on a model of prognosis but on one of palliative care need. 
Predictors for experiencing a trajectory of poor or deteriorating QOL were general symptom level, 
pain or fatigue and psychological distress (anxiety and depression). In order to identify these 
patients early and to adequately refer them to palliative and supportive services, symptom burden 
and psychological distress therefore present as targets for routine assessment. In an extensive 
psychometric analysis of the Myeloma Patient Outcome Scale, a newly developed myeloma-
specific QOL tool to measure these aspects of symptom burden and psychological distress, items 
were evaluated for their longitudinal measurement properties to support such individual patient-
monitoring. By changing the model of care for myeloma patients, via the early integration of 
palliative and supportive care services with routine screening procedures using PROs in the wider 
myeloma population, barriers to palliative care access in this haematological patient group could 
be addressed. Further research is needed to test the generalisability and clinical applicability of 
this prognostic model in routine clinical care. 
As well as identifying the targets for routine patient-monitoring, this study also presented 
methodological contributions to longitudinal research and psychometric analysis. These include 
methods of longitudinal follow-up and the successful application of a new type of longitudinal 
analysis that combines cluster analysis with mixed effects modelling, the latent growth curve 
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analytical approach. This approach allows the identification of subgroups of homogeneous 
trajectories within a sample characterised by heterogeneity. This heterogeneity would otherwise 
be obscured when using analytical approaches that focus on the average trajectory for a group of 
patients. The second methodological contribution consists in defining and evaluating more 
stringent psychometric criteria for the application of monitoring individuals, an approach that has 
not yet been developed in classical and new psychometric test theory. The Rasch measurement 
model alongside with new approaches to determine the responsiveness of change and to assess 
different forms of longitudinal reliability were applied to the psychometric analysis of the 
MyPOS.  
Overall, this study has shown that longitudinal description of QOL trajectories can identify 
important targets for monitoring and intervention in the group of patients with multiple myeloma. 
There is scope to generalise these findings to other more chronic, yet incurable haematological 
conditions increasingly afflicting elderly patients. Whether the proposed model of predictors can 
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Professor Irene Higginson 
Head of Department 
Department of Palliative Care, Policy and Rehabilitation 
Cicely Saunders Institute 
London SE5 9PJ 
Dr Andrew Hilson 
Chair, NRES Committee London - Central 
Skipton House 
80 London Road 
London SE1 6LH 
 
7th November 2013 
 
Dear Dr Hilson, 
 
Re: Quality of life in multiple myeloma (MyCare): Longitudinal experience and potential 
use of information on quality of life for patient self-monitoring and patient care 
REC Ref No:  13/LO/1140 
IRAS Project ID: 129254 
 
Thank you for your letter dated 9th October, and for your helpful suggestions.  We have addressed 
each issue below: 
 
i. The Committee commented that although they are satisfied with the consenting process, the 
Researcher is to ensure that patients who are willing to complete the Questionnaire at the 
clinic are taken to an appropriate area to do so and should not be done in the clinic. 
 
We will make sure to take those participants that are willing to complete the questionnaire at the 
clinic to the Cicely Saunders Institute which is located directly opposite King’s College Hospital. 
On the ground floor of the building there are dedicated private therapy rooms available in the 
Macmillan Cancer Support centre which will be available for the participants to complete the 
questionnaire in privacy. At the other participating sites (i.e. Guy’s and St Thomas’ NHS 
Foundation Trust) appropriate areas might not be available and researchers will give participants 
recruited at those sites the questionnaires to complete at home only. This will be reflected in the 
standard operating procedures for these sites. 
 




ii. The Committee asks the Researcher to add information about the distress protocol to the 
Information Sheet explaining what it is and how it will be used if required. Similarly, the 
Researcher is asked to add information about the distress protocol for the focus group. 
 
We have added this information to the Patient Information Sheets for all three phases (see section 
‘What are the disadvantages or risks of taking part?’). We have added information on the distress 
protocol for the focus groups, but only for the focus group held with patients. A distress protocol 
for the focus group with health care professionals is not in place.  
 
iii. The Committee asks the Researcher to confirm whether five or seven participants are 
required for the pilot study. 
 
We will maximally sample seven participants for the pilot study. This number will be sufficient to 
capture views about the feasibility of the design and approaches used in the study from a variety 
of patients with different characteristics.  
 
iv. The following amendments should be made to the Patient Information Sheet: The Committee 
notes that the word treatment is frequently used but thinks it should be more carefully 
considered as the aim of this study is to see how to improve the wellbeing and the care of the 
patients, not improve their treatment. The Researcher is therefore asked to change the word 
to assessment. 
 
We have changed the word treatment to the word assessment in all Participant Information sheets. 
This was done for the sections ‘What is the purpose of the study?’ and the section ‘What are the 
potential benefits of taking part?’. The word treatment in the section ‘What will happen if I decide 
not to take part?’ was changed to care as it was felt to be a more appropriate substitute for 
treatment in this context than the word ‘assessment’. 
 
v. The Committee asks the Researcher to spell out in the Information Sheet that participants 
will be expected to monitor their own changes. 
 
We have changed the relevant section in the Information Sheet for the focus group with patients. 
It is only then that we will ask participants their opinions on monitoring their own changes in 
quality of life. During the longitudinal study with patients and carers (phase II), changes in quality 
of life will be assessed by the answers given in the questionnaires.  
 
vi. The Committee asks the Researcher to spell out the frequency of the Questionnaires and to 
ensure that both the patients and their carers are aware of the level of commitment that is 
required for the study. 
 




We have amended the Study Information Sheet for phase II, longitudinal survey, for both patients 
and carers. Please see the changes made to both sheets in section ‘What will happen to me if I 
decide to take part?’. We have spelled out how often participants will receive questionnaires in 
total and we have described further what the questionnaires will contain. Amendments on this 
subject were also made in the consent forms for phase II patient survey and phase II carer survey. 
The total number of questionnaires patients or carers will receive is now stated in the consent 
forms. 
 
vii. The committee asks the Researcher to amend the section in the Information Sheet that says 
“some find it convenient to complete the Questionnaire”, the Committee believes the word 
“convenient” is inappropriate. 
 
The section in the Information Sheet for phase I, Pilot QOL survey, was amended. The passage of 
text has been substituted with “at a place and time of your choice (for example your home or a 
private room in our research institute)”.  
 
viii. The Committee asks the Researcher to add a paragraph that explains why access to medical 
records is required, who will have access to the records and what the records will be used 
for. This should be reflected in the Consent Form. 
 
This paragraph was added to the Information Sheets for phase I, Pilot QOL survey, phase II (both 
patient and carer survey), and phase II (patient focus group). In the section ‘What will happen to 
me if I decide to take part’ it describes that access to the medical records is needed to understand 
possible treatment factors that could have an influence on quality of life, that records will be 
viewed by the researchers or research nurses working on the project, and which information will 
be viewed. The section in the relevant consent forms for all three phases has been amended. 
 
ix. The following amendments should be made to the Consent Form Sheet: The Committee asks 
the Researcher to ensure that amendments made to the Information Sheets are reflected in 
the Consent Form where appropriate. 
 
The amendments made to the Information Sheets with regard to access to medical records and the 
frequency of questionnaires in the longitudinal patient and carer survey (phase II) are now 
reflected in the Consent Form. 
 




All changes to the Information Sheets and Consent Forms have been highlighted in red colour. 
We enclose the supporting documents which have been amended since the meeting of 25th 
September, and thank you for reviewing the amended versions.  The table below lists all the 
documents enclosed with new dates and version numbers. 
 
Document Version Date 
Participant Information Sheet: Phase I-Pilot QOL Survey 2 07/11/2013 
Participant Information Sheet: Phase II-Longitudinal QOL 
Survey Carer Version 
2 07/11/2013 
Participant Information Sheet: Phase II – Longitudinal QOL 
Survey Patient version 
2 07/11/2013 
Participant Information Sheet: Phase III – Clinician Focus group 2 07/11/2013 
Participant Information Sheet: Phase III – Patient Focus Group 2 07/11/2013 
Participant Consent Sheet: Phase 1-Pilot QOL Survey 2 07/11/2013 
Participant Consent Sheet: Phase II-Longitudinal QOL Survey 
Carer Version 
2 07/11/2013 
Participant Consent Sheet: Phase II – Longitudinal QOL Survey 
Patient version 
2 07/11/2013 
Participant Consent Sheet: Phase III – Clinician focus group 2 07/11/2013 
Participant Consent Sheet: Phase III – Patient focus Group 2 07/11/2013 
 
Many thanks once again for your helpful comments and suggestions.  I hope you find these 






Professor Irene Higginson 
Head of Department and Professor of Palliative Care and Policy. 

























Cicely Saunders Institute 
Bessemer Road 
London SE5 9PJ 
FAO:  Noel Graham 
National Research Ethics Service (NRES) 
3
rd
 Floor, Barlow House 






 April 2014 
 
Dear Noel Graham, 
 
Re: Longitudinal Quality of life in multiple myeloma, REC Ref: 13/LO/1140 
 
The above study was approved by the Central London REC on 9
th
 November 2013. I am writing to 
inform you of a non-substantial amendment. 
 
We are about to open phase II of the study, which involves giving participants a selection of quality of 
life and other questionnaires that they fill in every 2 months, 5 times in total. The questionnaires 
have been approved by the REC in November 2013. To keep burden to a minimum for participating 
patients and their family member, we will not give all approved questionnaires at all times.  
 
By combining these questionnaires into booklets, we have prepared 6 questionnaire booklets for use 
in our two participant groups (5 for patients with multiple myeloma and 1 for their family member).  
We have standardised the layout and formatting of the questionnaires throughout the booklets for 
clarity. The piloting of the questionnaires in phase I of our research has also prompted us to make 
minor changes to the time frames that questionnaires ask about (4 months instead of 3 months).  
 
In addition, we have made a change to the questionnaire that asks about demographic details for 
patient participants. We have taken out one question (about the current/previous occupation) and 
would like to add one question about any other illnesses the participant might have. 
 
This has been discussed with Will Bowen (R+D, King’s College Hospital) and Keith Brennan (Sponsor 
and Director of Research Management, King’s College London), who agree that this constitutes a 
minor amendment. 
 
In enclose the following revised documents for your information: 
 
• Questionnaire booklet for patients, time point 1 (Version 1, 14/4/2014) 
• Questionnaire booklet for patients, time point 2 (Version 1, 14/4/2014) 




• Questionnaire booklet for patients, time point 3 (Version 1, 14/4/2014) 
• Questionnaire booklet for patients, time point 4 (Version 1, 14/4/2014) 
• Questionnaire booklet for patients, time point 5 (Version 1, 14/4/2014) 
• Questionnaire booklet for family members (Version 1, 14/4/2014) 
• Demographic data collection form – patients (Version 2, 16/4/2014) 
 
I would be grateful if you could acknowledge receipt of these new documents at you earliest 
convenience, so that King’s College Hospital R+D unit can upload them onto the CSP for use by our 
collaborators. 
 
Also, Simon Connolly from the South London CLRN also asked us to draw attention to the documents 
that have been approved by the REC in the Favourable opinion letter from 13/11/2013. In the list of 
approved documents both versions 1 of the participant consent form and participant information 
sheet for all three phases (which were the initial version before REC review) and versions 2 of these 
documents (version with requested changes made by the ethics committee). Could I please ask you 
to re-issue that letter with approval for version 1 of these documents removed. Otherwise there will 
be confusion for our collaborating centres which version to use.  
 
Documents that need to be removed from the list of approved documents are: 
 
• Participant Consent Form: Phase 1 – Pilot QOL Survey, Version 1, 16 July 2013 
• Participant Consent Form: Phase II – Longitudinal Survey Patient, Version 1, 16 July 2013 
• Participant Consent Form: Phase II – Longitudinal Survey Carer, Version 1, 16 July 2013 
• Participant Consent Form: Phase III – Patient focus group, Version 1, 16 July 2013 
• Participant Consent Form: Phase III – Clinician focus group, Version 1, 16 July 2013 
• Participant Information Sheet: Phase 1 – Pilot QOL Survey, Version 1, 16 July 2013 
• Participant Information Sheet: Phase II – Longitudinal QOL Survey Patient, Version 1, 16 July 
2013 
• Participant Information Sheet: Phase II – Longitudinal QOL Survey Carer, Version 1, 16 July 
2013 
• Participant Information Sheet: Phase III – Patient focus group, Version 1, 16 July 2013 
• Participant Information Sheet: Phase III – Clinician focus group, Version 1, 16 July 2013 
 
I would be grateful if you could remove these versions 1 from the list of approved documents, so that 
only version 2 of these documents has approval.  
 





Department of Palliative Care, Policy and Rehabilitation 
King’s College London 
 
Cc:  Professor Irene Higginson, Chief Investigator and Head of Department of Palliative Care, Policy 
and Rehabilitation, Cicely Saunders Institute, King’s College London, Bessemer Road, London, SE5 9PJ. 
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Appendix D.1: Consent form, phase I ‘Pilot survey’ 
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Appendix D.2: Consent form, Phase II ‘Patient Quality of Life Survey’ 
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Appendix D.3: Consent form, phase II ‘Caregiver Quality of Life Survey’ 
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Appendix D.4: Information leaflet, phase I ‘Pilot Quality of Life Survey’ 
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Appendix D.5: Information leaflet, phase II ‘Patient Quality of Life Survey’ 
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Appendix D.6: Information leaflet, phase II ‘Caregiver Quality of Life Survey’ 
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Appendix F.1: Example questionnaire booklet from the Patient QOL Survey 
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Appendix F.2: Example questionnaire booklet for Caregiver QOL Survey 
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